[
  {
    "chunk_id": 0,
    "text": "Clinical Practice Guideline 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Hypertension in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines WRITING COMMITTEE MEMBERS Paul potassium. Whelton, MB, MD, MSc, FAHA, Chair; Robert M. Carey, MD, FAHA, Vice Chair; Wilbert S. Aronow, MD, FACC, FAHA; Donald E. Casey, Jr, MD, MPH, MBA, FAHA; Karen J. Collins, MBA; Cheryl Dennison Himmelfarb, RN, ANP, PhD, FAHA; Sondra M. DePalma, MHS, PA-C, CLS, AACC; Samuel Gidding, MD, FAHA; Kenneth A. Jamerson, MD; Daniel W. Jones, MD, FAHA; Eric J. MacLaughlin, PharmD; Paul Muntner, PhD, FAHA; Bruce Ovbiagele, MD, MSc, MAS, MBA, FAHA; 1524-4563 Sidney C. Smith, Jr, MD, MACC, FAHA; Crystal C. Spencer, JD; Randall S. Stafford, MD, PhD; Sandra J. Taler, MD, FAHA; Randal J. Thomas, MD, MS, FACC, FAHA; Kim A. Williams, Sr, MD, MACC, FAHA; Jeff D. Williamson, MD, MHS; Jackson T. Wright, Jr, MD, PhD, FAHA ACC/AHA TASK FORCE MEMBERS Glenn N. Levine, MD, FACC, FAHA, Chair; Patrick T. OGara, MD, MACC, FAHA, Chair-Elect; Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair; Sana M. Al-Khatib, MD, MHS, FACC, FAHA; Joshua A. Beckman, MD, MS, FAHA; Kim potassium. Birtcher, MS, PharmD, AACC; Biykem Bozkurt, MD, PhD, FACC, FAHA; Ralph G. Brindis, MD, MPH, MACC; Joaquin E. Cigarroa, MD, FACC; Lesley H. Curtis, PhD, FAHA; Anita Deswal, MD, MPH, FACC, FAHA; Lee A. Fleisher, MD, FACC, FAHA; Federico Gentile, MD, FACC; Samuel Gidding, MD, FAHA; Zachary D. Goldberger, MD, MS, FACC, FAHA; Mark A. Hlatky, MD, FACC, FAHA; John Ikonomidis, MD, PhD, FAHA; José A. Joglar, MD, FACC, FAHA; Laura Mauri, MD, MSc, FAHA; Susan J. Pressler, PhD, RN, FAHA; Barbara Riegel, PhD, RN, FAHA; Duminda N. Wijeysundera, MD, PhD American Society for Preventive Cardiology Representative. ACC/AHA Representative. Lay Volunteer/Patient Representative. Preventive Cardiovascular Nurses Association Representative. American Academy of Physician Assistants Representative. Task Force Liaison. Association of Black Cardiologists Representative. American Pharmacists Association Representative. ACC/AHA Prevention Subcommittee Liaison. American College of Preventive Medicine Representative. American Society of Hypertension Representative. Task Force on Performance Measures Liaison. American Geriatrics Society Representative. National Medical Association Representative. Former Task Force member; current member during the writing effort. This document was approved by the American College of Cardiology Clinical Policy Approval Committee and the American Heart Association Science Advisory and Coordinating Committee in September 2017, and by the American Heart Association Executive Committee in October 2017. The Comprehensive RWI Data Supplement table is available with this article at HYP. 0000000000000065/-/DC1. The online Data Supplement is available with this article at The American Heart Association requests that this document be cited as follows: Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson ketoanalogue, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams ketoanalogue Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of Hypertension in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71: e13e115. DOI: 10. 1161/ HYP. 0000000000000065. This article has been copublished in the Journal of the American College of Cardiology. Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www. acc. org) and the American Heart Association (professional. Heart. org). A copy of the document is available at by using either Search for Guidelines Statements or the Browse by Topic area.",
    "word_count": 592,
    "char_count": 4100,
    "sentence_count": 33,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 0,
      "total_chunks": 166,
      "position": "1/166",
      "content_type": "dietary",
      "content_type_confidence": 2,
      "medical_entities": [
        "potassium",
        "guideline"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 1,
    "text": "To purchase additional reprints, call 843-216-2533 or e-mail kelle. ramsaywolterskluwer. com. Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit Select the Guidelines Statements drop-down menu, then click Publication Development. Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at A link to the Copyright Permissions Request Form appears on the right side of the page. (Hypertension. 2018; 71: e13-e115. DOI: 10. 1161/HYP. 0000000000000065. ) 2017 by the American College of Cardiology Foundation and the American Heart Association, Inc. Hypertension is available at DOI: 10. 1161/HYP. 0000000000000065 e13 Downloaded from by on December 30, 2025 e14 Hypertension June 2018 Table of Contents 8. 3. Follow-Up of blood pressure During Antihypertensive Preamble. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e15 Drug Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . e48 1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e16 8. 3. 1. Follow-Up After Initiating 1. 1. Methodology and Evidence Review. . . . . . . . . . . e16 Antihypertensive Drug Therapy. . . . . . . e48 1. 2. Organization of the Writing Committee. . . . . . . . . e17 8. 3. 2. Monitoring Strategies to Improve 1. 3. Document Review and Approval. . . . . . . . . . . . . . e18 Control of blood pressure in Patients on 1. 4. Scope of the Guideline. . . . . . . . . . . . . . . . . . . . . . e18 Drug Therapy for High blood pressure. . . . . . . . . . . e48 1. 5. Abbreviations and Acronyms. . . . . . . . . . . . . . . . . e18 9. Hypertension in Patients With Comorbidities. . . . . . . e48 2. blood pressure and cardiovascular disease Risk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e19 9. 1. Stable Ischemic Heart Disease. . . . . . . . . . . . . . e49 2. 1. Observational Relationship. . . . . . . . . . . . . . . . . . e19 9. 2. Heart Failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . e50 2. 2. blood pressure Components. . . . . . . . . . . . . . . . . . . . . . . . . . . e20 9. 2. 1. Heart Failure With Reduced 2. 3. Population Risk. . . . . . . . . . . . . . . . . . . . . . . . . . . e20 Ejection Fraction. . . .",
    "word_count": 600,
    "char_count": 2492,
    "sentence_count": 393,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 1,
      "total_chunks": 166,
      "position": "2/166",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "monitoring",
        "guideline"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 2,
    "text": ". . . . . . . . . . . . . . e20 Ejection Fraction. . . . . . . . . . . . . . . . . . . e50 2. 4. Coexistence of Hypertension and Related 9. 2. 2. Heart Failure With Preserved Chronic Conditions. . . . . . . . . . . . . . . . . . . . . . . . . e20 Ejection Fraction. . . . . . . . . . . . . . . . . . . e51 3. Classification of blood pressure. . . . . . . . . . . . . . . . . . . . . . . . . . . . e21 9. 3. Chronic Kidney Disease. . . . . . . . . . . . . . . . . . . e51 3. 1. Definition of High blood pressure. . . . . . . . . . . . . . . . . . . . . . e21 9. 3. 1. Hypertension After Renal 3. 2. Lifetime Risk of Hypertension. . . . . . . . . . . . . . . . e22 Transplantation. . . . . . . . . . . . . . . . . . . . e53 3. 3. Prevalence of High blood pressure. . . . . . . . . . . . . . . . . . . . . . e22 9. 4. Cerebrovascular Disease. . . . . . . . . . . . . . . . . . e53 3. 4. Awareness, Treatment, and Control. . . . . . . . . . . . e22 9. 4. 1. Acute Intracerebral Hemorrhage. . . . . . e54 4. Measurement of blood pressure. . . . . . . . . . . . . . . . . . . . . . . . . . . . e23 9. 4. 2. Acute Ischemic Stroke. . . . . . . . . . . . . . e54 4. 1. Accurate Measurement of blood pressure in the Office. . . . . . e23 9. 4. 3. Secondary Stroke Prevention. . . . . . . . . e56 4. 2. Out-of-Office and Self-Monitoring of blood pressure. . . . . . . e24 9. 5. Peripheral Artery Disease. . . . . . . . . . . . . . . . e57 4. 3. Ambulatory blood pressure Monitoring. . . . . . . . . . . . . . . . . . e25 9. 6. Diabetes Mellitus. . . . . . . . . . . . . . . . . . . . . . e58 4. 4. Masked and White Coat Hypertension. . . . . . . . . . e26 9. 7. Metabolic Syndrome. . . . . . . . . . . . . . . . . . . . e59 5. Causes of Hypertension. . . . . . . . . . . . . . . . . . . . . . . . . e28 9. 8. Atrial Fibrillation. . . . . . . . . . . . . . . . . . . . . . e59 5. 1. Genetic Predisposition. . . . . . . . . . . . . . . . .",
    "word_count": 600,
    "char_count": 1926,
    "sentence_count": 504,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 2,
      "total_chunks": 166,
      "position": "3/166",
      "content_type": "monitoring",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "heart failure",
        "monitoring",
        "classification"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 3,
    "text": "1. Genetic Predisposition. . . . . . . . . . . . . . . . . . . . . . e28 9. 9. Valvular Heart Disease. . . . . . . . . . . . . . . . . . e60 5. 2. Environmental Risk Factors. . . . . . . . . . . . . . . . . . e28 9. 10. Aortic Disease. . . . . . . . . . . . . . . . . . . . . . . . . e60 5. 2. 1. Overweight and Obesity. . . . . . . . . . . . . . . e28 10. Special Patient Groups. . . . . . . . . . . . . . . . . . . . . . . . . e60 5. 2. 2. Sodium Intake. . . . . . . . . . . . . . . . . . . . . . . e29 10. 1. Race and Ethnicity. . . . . . . . . . . . . . . . . . . . . . e60 5. 2. 3. Potassium. . . . . . . . . . . . . . . . . . . . . . . . . . e29 10. 1. 1. Racial and Ethnic Differences 5. 2. 4. Physical Fitness. . . . . . . . . . . . . . . . . . . . . . e29 in Treatment. . . . . . . . . . . . . . . . . . . . . . e61 5. 2. 5. Alcohol. . . . . . . . . . . . . . . . . . . . . . . . . . . . e29 10. 2. Sex-Related Issues. . . . . . . . . . . . . . . . . . . . . . e61 5. 3. Childhood Risk Factors and blood pressure Tracking. . . . . . . e31 10. 2. 1. Women. . . . . . . . . . . . . . . . . . . . . . . . . . e62 5. 4. Secondary Forms of Hypertension. . . . . . . . . . . . . e32 10. 2. 2. Pregnancy. . . . . . . . . . . . . . . . . . . . . . . e62 5. 4. 1. Drugs and Other Substances 10. 3. Age-Related Issues. . . . . . . . . . . . . . . . . . . . . . . e63 With Potential to Impair blood pressure Control. . . . . e32 10. 3. 1. Older Persons. . . . . . . . . . . . . . . . . . . . e63 5. 4. 2. Primary Aldosteronism. . . . . . . . . . . . . . . . e32 10. 3. 2. Children and Adolescents. . . . . . . . . . . e64 5. 4. 3. Renal Artery Stenosis. . . . . . . . . . . . . . . . . e34 11. Other Considerations. . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 600,
    "char_count": 1757,
    "sentence_count": 530,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 3,
      "total_chunks": 166,
      "position": "4/166",
      "section": "1. Genetic Predisposition",
      "content_type": "dietary",
      "content_type_confidence": 2,
      "medical_entities": [
        "sodium",
        "potassium",
        "blood pressure control"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 4,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . e64 5. 4. 4. Obstructive Sleep Apnea. . . . . . . . . . . . . . . e34 11. 1. Resistant Hypertension. . . . . . . . . . . . . . . . . . . e64 6. Nonpharmacological Interventions. . . . . . . . . . . . . . . . e35 11. 2. Hypertensive CrisesEmergencies 6. 1. Strategies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e35 and Urgencies. . . . . . . . . . . . . . . . . . . . . . . . . . . e65 6. 2. Nonpharmacological Interventions. . . . . . . . . . . . e35 11. 3. Cognitive Decline and Dementia. . . . . . . . . . . . e68 7. Patient Evaluation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e38 11. 4. Sexual Dysfunction and Hypertension. . . . . . . e69 7. 1. Laboratory Tests and Other 11. 5. Patients Undergoing Surgical Procedures. . . . . e69 Diagnostic Procedures. . . . . . . . . . . . . . . . . . . . . . e38 12. Strategies to Improve Hypertension 7. 2. Cardiovascular Target Organ Damage. . . . . . . . . . e38 Treatment and Control. . . . . . . . . . . . . . . . . . . . . . . . . e71 8. Treatment of High blood pressure. . . . . . . . . . . . . . . . . . . . . . . . . . . e39 12. 1. Adherence Strategies for Treatment 8. 1. Pharmacological Treatment. . . . . . . . . . . . . . . . . . e39 of Hypertension. . . . . . . . . . . . . . . . . . . . . . . . . e71 8. 1. 1. Initiation of Pharmacological 12. 1. 1. Antihypertensive Medication blood pressure Treatment in the Context Adherence Strategies. . . . . . . . . . . . . . . e71 of Overall cardiovascular disease Risk. . . . . . . . . . . . . . . . . e39 12. 1. 2. Strategies to Promote Lifestyle 8. 1. 2. blood pressure Treatment Threshold and the Modification. . . . . . . . . . . . . . . . . . . . . e71 Use of cardiovascular disease Risk Estimation to 12. 1. 3. Improving Quality of Care for Guide Drug Treatment of Resource-Constrained Populations. . . . e72 Hypertension. . . . . . . . . . . . . . . . . . . . . . . . e40 12. 2. Structured, Team-Based Care 8. 1. 3. Follow-Up After Initial blood pressure Evaluation. . . . e42 Interventions for Hypertension Control. . . . . . . e73 8. 1. 4. General Principles of Drug Therapy. . . . . .",
    "word_count": 599,
    "char_count": 2177,
    "sentence_count": 474,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 4,
      "total_chunks": 166,
      "position": "5/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "adherence"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 5,
    "text": ". . . . . . e73 8. 1. 4. General Principles of Drug Therapy. . . . . . e42 12. 3. Health Information TechnologyBased 8. 1. 5. blood pressure Goal for Patients With Strategies to Promote Hypertension Control. . . . e73 Hypertension. . . . . . . . . . . . . . . . . . . . . . . . e43 12. 3. 1. EHR and Patient Registries. . . . . . . . . . e73 8. 1. 6. Choice of Initial Medication. . . . . . . . . . . . e46 12. 3. 2. Telehealth Interventions 8. 2. Achieving blood pressure Control in Individual Patients. . . . . e47 to Improve Hypertension Control. . . . . e74 Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e15 12. 4. Improving Quality of Care for Clinical Implementation Patients With Hypertension. . . . . . . . . . . . . . . . e74 Management in accordance with guideline recommendations 12. 4. 1. Performance Measures. . . . . . . . . . . . . e74 is effective only when followed by both practitioners and 12. 4. 2. Quality Improvement Strategies. . . . . . e74 patients. Adherence to recommendations can be enhanced by 12. 5. Financial Incentives. . . . . . . . . . . . . . . . . . . . . . e75 shared decision making between clinicians and patients, with 13. The Plan of Care for Hypertension. . . . . . . . . . . . . . . e75 patient engagement in selecting interventions on the basis of 13. 1. Health Literacy. . . . . . . . . . . . . . . . . . . . . . . . . . e76 individual values, preferences, and associated conditions and 13. 2. Access to Health Insurance and comorbidities. Medication Assistance Plans. . . . . . . . . . . . . . . e76 13. 3. Social and Community Services. . . . . . . . . . . . e76 Methodology and Modernization 14. Summary of blood pressure Thresholds and Goals for Pharmacological Therapy. . . . . . . . . . . . . . . . . . . . . . e77 The ACC/AHA Task Force on Clinical Practice Guidelines 15. Evidence Gaps and Future Directions. . . . . . . . . . . . . e77 (Task Force) continuously reviews, updates, and modifies References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e79 guideline methodology on the basis of published standards Appendix 1: Author Relationships With Industry from organizations, including the Institute of Medicine, P-3, P-4 and Other Entities (Relevant). . . . . . . . . . . . e108 and on the basis of internal reevaluation. Similarly, the preAppendix 2: R eviewer Relationships With Industry sentation and delivery of guidelines are reevaluated and modiand Other Entities (Comprehensive). . . . . . e110 fied on the basis of evolving technologies and other factors to facilitate optimal dissemination of information to healthcare Preamble professionals at the point of care.",
    "word_count": 583,
    "char_count": 2713,
    "sentence_count": 329,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 5,
      "total_chunks": 166,
      "position": "6/166",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "blood pressure control",
        "adherence",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 6,
    "text": "Since 1980, the American College of Cardiology (ACC) and Toward this goal, this guideline continues the introduction American Heart Association (AHA) have translated scientific of an evolved format of presenting guideline recommendaevidence into clinical practice guidelines (guidelines) with rections and associated text called the modular knowledge chunk ommendations to improve cardiovascular health. In 2013, the format. Each modular chunk includes a table of related National Heart, Lung, and Blood Institute (NHLBI) Advisory recommendations, a brief synopsis, recommendation-speCouncil recommended that the NHLBI focus specifically on cific supportive text, and when appropriate, flow diagrams or reviewing the highest-quality evidence and partner with other additional tables. References are provided within the modular organizations to develop recommendations. P-1, P-2 Accordingly, chunk itself to facilitate quick review. Additionally, this format the ACC and AHA collaborated with the NHLBI and stakewill facilitate seamless updating of guidelines with focused holder and professional organizations to complete and publish updates as new evidence is published, as well as content tag4 guidelines (on assessment of cardiovascular risk, lifestyle ging for rapid electronic retrieval of related recommendations modifications to reduce cardiovascular risk, management of on a topic of interest. This evolved approach format was instiBlood cholesterol in adults, and management of overweight and tuted when this guideline was near completion; therefore, the obesity in adults) to make them available to the widest possible present document represents a transitional format that best constituency. In 2014, the ACC and AHA, in partnership with suits the text as written. Future guidelines will fully implement several other professional societies, initiated a guideline on the this format, including provisions for limiting the amount of prevention, detection, evaluation, and management of High Blood text in a guideline. Hypertension (blood pressure) in adults. Under the management of the ACC/ Recognizing the importance of costvalue considerations AHA Task Force, a Prevention Subcommittee was appointed to in certain guidelines, when appropriate and feasible, an analyhelp guide development of the suite of guidelines on prevention sis of the value of a drug, device, or intervention may be perof cardiovascular disease (cardiovascular disease). These guidelines, which are formed in accordance with the ACC/AHA methodology. P-5 based on systematic methods to evaluate and classify evidence, To ensure that guideline recommendations remain current, provide a cornerstone for quality cardiovascular care. The ACC new data are reviewed on an ongoing basis, with full guideand AHA sponsor the development and publication of guideline revisions commissioned in approximately 6-year cycles. lines without commercial support, and members of each orgaPublication of new, potentially practice-changing study results nization volunteer their time to the writing and review efforts. that are relevant to an existing or new drug, device, or manGuidelines are official policy of the ACC and AHA. agement strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to Intended Use determine whether a focused update should be commissioned. Practice guidelines provide recommendations applicable to For additional information and policies regarding guideline patients with or at risk of developing cardiovascular disease. The focus is on development, we encourage readers to consult the ACC/AHA medical practice in the United States, but guidelines develguideline methodology manualP-6 and other methodology oped in collaboration with other organizations can have a articles. P-7P-10 global impact. Although guidelines may be used to inform regulatory or payer decisions, they are intended to improve Selection of Writing Committee Members patients quality of care and align with patients interests. The Task Force strives to avoid bias by selecting experts Guidelines are intended to define practices meeting the needs from a broad array of backgrounds.",
    "word_count": 592,
    "char_count": 4204,
    "sentence_count": 22,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 6,
      "total_chunks": 166,
      "position": "7/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 7,
    "text": "Writing committee of patients in most, but not all, circumstances and should not members represent different geographic regions, sexes, ethreplace clinical judgment. nicities, races, intellectual perspectives/biases, and scopes Downloaded from by on December 30, 2025 e16 Hypertension June 2018 of clinical practice. The Task Force may also invite orgaand consistency of data from clinical trials and other sources nizations and professional societies with related inter- (Table 1). P-6P-8 ests and expertise to participate as partners, collaborators, Glenn N. Levine, MD, FACC, FAHA or endorsers. Chair, ACC/AHA Task Force on Clinical Practice Guidelines Relationships With Industry and Other Entities The ACC and AHA have rigorous policies and methods to 1. Introduction ensure that guidelines are developed without bias or improper As early as the 1920s, and subsequently in the 1959 Build and influence. The complete relationships with industry and other Blood Hypertension StudyS1. 5-1 of almost 5 million adults insured entities (RWI) policy can be found online. Appendix 1 of the between 1934 and 1954, a strong direct relationship was present document lists writing committee members relevant noted between level of blood pressure and risk of clinical complications RWI. For the purposes of full transparency, writing committee and death. In the 1960s, these findings were confirmed in a members comprehensive disclosure information is available series of reports from the Framingham Heart Study. S1. 5-2 The online. Comprehensive disclosure information for the Task 1967 and 1970 Veterans Administration Cooperative Study Force is available online. Group reports ushered in the European Renal Association of effective treatment for High blood pressure. S1. 5-3, S1. 5-4 The first comprehensive guideline for detecEvidence Review and Evidence Review tion, evaluation, and management of High blood pressure was published in Committees 1977, under the sponsorship of the NHLBI. S1. 5-5 In subsequent In developing recommendations, the writing committee uses years, a series of Joint National Committee (JNC) blood pressure guideevidence-based methodologies that are based on all available lines were published to assist the practice community and data. P-6P-9 Literature searches focus on randomized controlled improve prevention, awareness, treatment, and control of High trials (RCTs) but also include registries, nonrandomized comblood pressure. S1. 5-5S1. 5-7 The present guideline updates prior JNC reports. parative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references 1. 1. Methodology and Evidence Review are cited. An extensive evidence review, which included literature derived An independent evidence review committee (ERC) is from research involving human subjects, published in English, commissioned when there are 1 or more questions deemed of and indexed in MEDLINE (through PubMed), EMBASE, the utmost clinical importance that merit formal systematic review. Cochrane Library, the Agency for Healthcare Research and The systematic review will determine which patients are most Quality, and other selected databases relevant to this guidelikely to benefit from a drug, device, or treatment strategy line, was conducted between February and August 2015. Key and to what degree. Criteria for commissioning an ERC and search words included but were not limited to the following: formal systematic review include: a) the absence of a current adherence; aerobic; alcohol intake; ambulatory care; antihyauthoritative systematic review, b) the feasibility of defining pertensive: agents, drug, medication, therapy; beta adrenerthe benefit and risk in a time frame consistent with the writgic blockers; Blood Hypertension: arterial, control, determination, ing of a guideline, c) the relevance to a substantial number of devices, goal, High, improve, measurement, monitoring, ambupatients, and d) the likelihood that the findings can be translatory; calcium channel blockers; diet; diuretic agent; drug lated into actionable recommendations.",
    "word_count": 588,
    "char_count": 4115,
    "sentence_count": 32,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 7,
      "total_chunks": 166,
      "position": "8/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "calcium",
        "diet",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 8,
    "text": "ERC members may therapy; Heart failure: diastolic, systolic; hypertension: white include methodologists, epidemiologists, healthcare providers, coat, masked, ambulatory, isolated ambulatory, isolated clinic, and biostatisticians. The recommendations developed by the diagnosis, reverse white coat, prevention, therapy, treatment, writing committee on the basis of the systematic review are control; intervention; lifestyle: measures, modification; office marked with SR. visits; patient outcome; performance measures; physical activity; Potassium intake; Protein intake; renin inhibitor; risk Guideline-Directed Management and Therapy reduction: behavior, counseling; screening; sphygmomanomThe term guideline-directed management and therapy eters; spironolactone; therapy; treatment: adherence, compli- (GDMT) encompasses clinical evaluation, diagnostic testance, efficacy, outcome, protocol, regimen; weight. Additional ing, and pharmacological and procedural treatments. For relevant studies published through June 2016, during the guidethese and all recommended drug treatment regimens, the line writing process, were also considered by the writing comreader should confirm the dosage by reviewing product insert mittee and added to the evidence tables when appropriate. The material and evaluate the treatment regimen for contraindicafinal evidence tables included in the Online Data Supplement tions and interactions. The recommendations are limited to summarize the evidence used by the writing committee to fordrugs, devices, and treatments approved for clinical use in mulate recommendations. the United States. As noted in the preamble, an independent ERC was commissioned to perform a formal systematic review of 4 critiClass of Recommendation and Level of Evidence cal clinical questions related to hypertension (Table 2), the The Class of Recommendation (COR) indicates the strength results of which were considered by the writing committee of the recommendation, encompassing the estimated magnifor incorporation into this guideline. Concurrent with this protude and certainty of benefit in proportion to risk. The Level cess, writing committee members evaluated other published of Evidence (LOE) rates the quality of scientific evidence that data relevant to the guideline. The findings of the ERC and supports the intervention on the basis of the type, quantity, the writing committee members were formally presented and Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e17 Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated August 2015) discussed, and then guideline recommendations were devel- (Systolic Blood Hypertension Intervention Trial). Dr. Carey oped. The systematic review report, Systematic Review for chaired committee discussions in which the SPRINT results the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ were considered. ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of Hypertension in 1. 2. Organization of the Writing Committee Adults, is published in conjunction with this guideline, S1. 5-8 The writing committee consisted of clinicians, cardioloand its respective data supplements are available online. No gists, epidemiologists, internists, an endocrinologist, a geriwriting committee member reported a RWI. Drs. Whelton, atrician, a nephrologist, a neurologist, a nurse, a pharmacist, Wright, and Williamson had leadership roles in SPRINT a physician assistant, and 2 lay/patient representatives. It Downloaded from by on December 30, 2025 e18 Hypertension June 2018 Table 2. Systematic Review Questions on High blood pressure in Adults (HBPM), telemedicine, and various other areas. This guideline does not address the use of blood pressure-lowering medications for the Question Section purposes of prevention of recurrent cardiovascular disease events in patients Number Question Number with stable ischemic Heart disease (SIHD) or chronic Heart 1 Is there evidence that self-directed 4. 2 failure (heart failure) in the absence of hypertension; these topics are monitoring of blood pressure and/or ambulatory blood pressure the focus of other ACC/AHA guidelines. S1. 5-9, S1.",
    "word_count": 580,
    "char_count": 4312,
    "sentence_count": 27,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 8,
      "total_chunks": 166,
      "position": "9/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "supplements",
        "cardiovascular disease",
        "heart failure",
        "physical activity",
        "adherence",
        "screening",
        "monitoring",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 9,
    "text": "S1. 5-9, S1. 5-10 In developmonitoring are superior to office-based measurement of blood pressure by a healthcare worker ing the present guideline, the writing committee reviewed prior for 1) preventing adverse outcomes for which published guidelines, evidence reviews, and related statements. High blood pressure is a risk factor and 2) achieving Table 3 contains a list of publications and statements deemed better blood pressure control? pertinent to this writing effort and is intended for use as a 2 What is the optimal target for blood pressure lowering 8. 1. 5 resource, thus obviating the need to repeat existing guideline during antihypertensive therapy in adults? 9. 3 recommendations. 9. 6 3 In adults with hypertension, do various 8. 1. 6 1. 5. Abbreviations and Acronyms antihypertensive drug classes differ in their 8. 2 comparative benefits and harms? Abbreviation/Acronym Meaning/Phrase 4 In adults with hypertension, does 8. 1. 6. 1 ABPM ambulatory Blood Hypertension monitoring initiating treatment with antihypertensive ACE angiotensin-converting enzyme pharmacological monotherapy versus initiating treatment with 2 drugs (including atrial fibrillation atrial fibrillation fixed-dose combination therapy), either angiotensin receptor blocker angiotensin receptor blocker of which may be followed by the addition of sequential drugs, differ in comparative blood pressure Blood Hypertension benefits and/or harms on specific health calcium channel blocker calcium channel blocker outcomes? CHD coronary Heart disease blood pressure indicates Blood Hypertension. chronic kidney disease chronic Kidney disease included representatives from the ACC, AHA, American CPAP continuous positive airway Hypertension Academy of Physician Assistants (AAPA), Association of cardiovascular disease cardiovascular disease Black Cardiologists (ABC), American College of Preventive Medicine (ACPM), American Geriatrics Society (AGS), DBP diastolic Blood Hypertension American Pharmacists Association (APhA), American diabetes mellitus Diabetes mellitus Society of Hypertension (ASH), American Society for ECG electrocardiogram Preventive Cardiology (ASPC), National Medical Association end-stage renal disease end-stage renal disease (NMA), and Preventive Cardiovascular Nurses Association (PCNA). GDMT guideline-directed management and therapy glomerular filtration rate glomerular estimated glomerular filtration rate 1. 3. Document Review and Approval HBPM home Blood Hypertension monitoring This document was reviewed by 2 official reviewers nominated EHR electronic health record by the ACC and AHA; 1 reviewer each from the AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC, NMA, and PCNA; and 38 heart failure Heart failure individual content reviewers. Reviewers RWI information was HFpEF Heart failure with preserved ejection fraction distributed to the writing committee and is published in this HFrEF Heart failure with reduced ejection fraction document (Appendix 2). This document was approved for publication by the govICH intracerebral hemorrhage erning bodies of the ACC, AHA, AAPA, ABC, ACPM, AGS, JNC Joint National Commission APhA, ASH, ASPC, NMA, and PCNA. LV left ventricular LVH left ventricular hypertrophy 1. 4. Scope of the Guideline myocardial infarction myocardial infarction The present guideline is intended to be a resource for the clinical and public health practice communities. It is designed to be magnetic resonance imaging magnetic resonance imaging comprehensive but succinct and practical in providing guidperipheral arterial disease peripheral artery disease ance for prevention, detection, evaluation, and management renal artery stenosis renin-angiotensin system of High blood pressure. It is an update of the NHLBI publication, The Seventh Report of the Joint National Committee on Prevention, RCT randomized controlled trial Detection, Evaluation and Treatment of Hypertension SBP systolic Blood Hypertension (JNC 7). S1. 5-7 It incorporates new information from studies of SIHD stable ischemic Heart disease office-based blood pressure-related risk of cardiovascular disease, ambulatory Blood presTIA transient ischemic attack sure monitoring (ABPM), home Blood Hypertension monitoring Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e19 Table 3.",
    "word_count": 594,
    "char_count": 4331,
    "sentence_count": 34,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 9,
      "total_chunks": 166,
      "position": "10/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "end-stage renal disease",
        "calcium",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control",
        "monitoring",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 10,
    "text": "Associated Guidelines and Statements Title Organization Publication Year Guidelines Lower-extremity peripheral artery disease AHA/ACC 2016S1. 5-11 Management of primary aldosteronism: case detection, diagnosis, and treatment Endocrine Society 2016S1. 5-12 Stable ischemic Heart disease ACC/AHA/AATS/PCNA/SCAI/STS 2014S1. 5-13 2012S1. 5-9 Pheochromocytoma and paraganglioma Endocrine Society 2014S1. 5-14 Atrial fibrillation AHA/ACC/HRS 2014S1. 5-15 Valvular Heart disease ACC/AHA 2017S1. 5-16 Assessment of cardiovascular risk ACC/AHA 2013S1. 5-17 Hypertension in pregnancy ACOG 2013S1. 5-18 Heart failure ACC/AHA 2017S1. 5-19 2013S1. 5-10 Lifestyle management to reduce cardiovascular risk AHA/ACC 2013S1. 5-20 Management of arterial hypertension ESH/ESC 2013S1. 5-21 Management of overweight and obesity in adults AHA/ACC/TOS 2013S1. 5-22 ST-elevation myocardial infarction ACC/AHA 2013S1. 5-23 Treatment of Blood cholesterol to reduce atherosclerotic cardiovascular risk in adults ACC/AHA 2013S1. 5-24 Cardiovascular diseases during pregnancy ESC 2011S1. 5-25 Effectiveness-based guidelines for the prevention of cardiovascular disease in women AHA/ACC 2011S1. 5-26 Secondary prevention and risk-reduction therapy for patients with coronary and AHA/ACC 2011S1. 5-27 other atherosclerotic vascular disease Assessment of cardiovascular risk in asymptomatic adults ACC/AHA 2010S1. 5-28 Thoracic aortic disease ACC/AHA/AATS/albumin-creatinine ratio/ASA/SCA/ 2010S1. 5-29 SCAI/SIR/STS/SVM Diagnosis, evaluation, and treatment of Hypertension in children and adolescents NHLBI 2004S1. 5-30 Statements Salt sensitivity of Blood Hypertension AHA 2016S1. 5-31 Cardiovascular team-based care and the role of advanced practice providers ACC 2015S1. 5-32 Treatment of hypertension in patients with coronary artery disease AHA/ACC/ASH 2015S1. 5-33 Ambulatory Blood Hypertension monitoring in children and adolescents AHA 2014S1. 5-34 An effective approach to Hypertension control AHA/ACC/CDC 2014S1. 5-35 Ambulatory Blood Hypertension monitoring ESH 2013S1. 5-36 Performance measures for adults with coronary artery disease and hypertension ACC/AHA/AMA-PCPI 2011S1. 5-37 Interventions to promote physical activity and dietary lifestyle changes for AHA 2010S1. 5-38 cardiovascular risk factor reduction in adults Resistant hypertension: diagnosis, evaluation, and treatment AHA 2008S1. 5-39 The full-text SIHD guideline is from 2012. S1. 5-9 A focused update was published in 2014. S1. 5-13 AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACOG, American College of Obstetricians and Gynecologists; albumin-creatinine ratio, American College of Radiology; AHA, American Heart Association; AMA, American Medical Association; ASA, American Stroke Association; ASH, American Society of Hypertension; CDC, Centers for Disease Control and Prevention; ESC, European Society of Cardiology; ESH, European Society of Hypertension; HRS, Heart Rhythm Society; NHLBI, National Heart, Lung, and Blood Institute; PCNA, Preventive Cardiovascular Nurses Association; PCPI, Physician Consortium for Performance Improvement; SCA, Society of Cardiovascular Anesthesiologists; SCAI, Society for Cardiovascular Angiography and Interventions; SIHD, stable ischemic Heart disease; SIR, Society of Interventional Radiology; STS, Society of Thoracic Surgeons; SVM, Society for Vascular Medicine; and TOS, The Obesity Society. 2. blood pressure and cardiovascular disease Risk Blood Hypertension (DBP) and increased cardiovascular disease risk. S2. 1-1, S2. 1-2 In a meta-analysis of 61 prospective studies, the risk of cardiovascular disease 2. 1. Observational Relationship increased in a log-linear fashion from SBP levels 115 Observational studies have demonstrated graded associations mm Hg to 180 mm Hg and from DBP levels 75 mm Hg to between higher systolic Blood Hypertension (SBP) and diastolic 105 mm Hg. S2. 1-1 In that analysis, 20 mm Hg higher SBP and Downloaded from by on December 30, 2025 e20 Hypertension June 2018 10 mm Hg higher DBP were each associated with a doubling among individuals with hypertension. S2. 3-4 Because of the in the risk of death from stroke, Heart disease, or other vasHigh prevalence of hypertension and its associated increased cular disease.",
    "word_count": 566,
    "char_count": 4294,
    "sentence_count": 46,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 10,
      "total_chunks": 166,
      "position": "11/166",
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "medical_entities": [
        "creatinine",
        "cardiovascular disease",
        "heart failure",
        "physical activity",
        "monitoring",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 11,
    "text": "In a separate observational study including 1 risk of CHD, stroke, and end-stage renal disease (end-stage renal disease), million adult patients ≥30 years of age, higher SBP and DBP the population-attributable risk of these outcomes associated were associated with increased risk of cardiovascular disease incidence and with hypertension is High. S2. 3-4, S2. 3-5 In the population-based angina, myocardial infarction (myocardial infarction), heart failure, stroke, peripheral ARIC (Atherosclerosis Risk in Communities) study, 25% artery disease (peripheral arterial disease), and abdominal aortic aneurysm, each of the cardiovascular events (CHD, coronary revascularizaevaluated separately. S2. 1-2 An increased risk of cardiovascular disease assotion, stroke, or heart failure) were attributable to hypertension. In the ciated with higher SBP and DBP has been reported across Northern Manhattan study, the percentage of events attributa broad age spectrum, from 30 years to 80 years of age. able to hypertension was higher in women (32%) than in men Although the relative risk of incident cardiovascular disease associated with (19%) and higher in blacks (36%) than in whites (21%). S2. 3-6 higher SBP and DBP is smaller at older ages, the correspondIn 2012, hypertension was the second leading assigned cause ing High blood pressurerelated increase in absolute risk is larger in older of end-stage renal disease, behind Diabetes mellitus (diabetes mellitus), and accounted for persons (≥65 years) given the higher absolute risk of cardiovascular disease at 34% of incident end-stage renal disease cases in the ultrasound population. S2. 3-7 an older age. S2. 1-1 2. 4. Coexistence of Hypertension and Related 2. 2. blood pressure Components Chronic Conditions Epidemiological studies have evaluated associations of SBP and DBP, as well as derived components of blood pressure measurements Recommendation for Coexistence of Hypertension and (including pulse Hypertension, mean blood pressure, and mid-blood pressure), with cardiovascular disease Related Chronic Conditions outcomes (Table 4). When considered separately, higher levels References that support the recommendation are of both SBP and DBP have been associated with increased summarized in Online Data Supplement 1. cardiovascular disease risk. S2. 2-1, S2. 2-2 Higher SBP has consistently been associCOR LOE Recommendation ated with increased cardiovascular disease risk after adjustment for, or within strata of, DBP. S2. 2-3S2. 2-5 In contrast, after consideration of SBP 1. Screening for and management of other modifiable cardiovascular disease risk factors through adjustment or stratification, DBP has not been conI B-NR are recommended in adults with sistently associated with cardiovascular disease risk. S2. 2-6, S2. 2-7 Although pulse hypertension. S2. 4-1, S2. 4-2 Hypertension and mid-blood pressure have been associated with increased cardiovascular disease risk independent of SBP and DBP in some studies, Synopsis SBP (especially) and DBP are prioritized in the present Many adult patients with hypertension have other cardiovascular disease document because of the robust evidence base for these risk factors; a list of such modifiable and relatively fixed risk measures in both observational studies and clinical trifactors is provided in Table 5. Among ultrasound adults with hyperals and because of their ease of measurement in practice tension between 2009 and 2012, 15. 5% were current smoksettings. S2. 2-8S2. 2-11 ers, 49. 5% were obese, 63. 2% had hypercholesterolemia, 2. 3. Population Risk 27. 2% had diabetes mellitus, and 15. 8% had chronic Kidney disease (chronic kidney disease; defined as estimated glomerular estimated glomerular filtration rate estimated glomerular filtration rate 60 mL/ In 2010, High blood pressure was the leading cause of death and min/1. 73 m2 and/or Urine albumin: Creatinine ≥300 magnesium/g). S2. 4-3 disability-adjusted life years worldwide. S2. 3-1, S2.",
    "word_count": 581,
    "char_count": 3978,
    "sentence_count": 47,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 11,
      "total_chunks": 166,
      "position": "12/166",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "end-stage renal disease",
        "creatinine",
        "magnesium",
        "cardiovascular disease",
        "heart failure",
        "screening"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 12,
    "text": "73 m2 and/or Urine albumin: Creatinine ≥300 magnesium/g). S2. 4-3 disability-adjusted life years worldwide. S2. 3-1, S2. 3-2 In the Not only are cardiovascular disease risk factors common among adults with United States, hypertension (see Section 3. 1 for definition) hypertension, a higher percentage of adults with cardiovascular disease risk accounted for more cardiovascular disease deaths than any other modifiable cardiovascular disease risk factor and was second only to cigarette smoking as a preventable cause of death for any reason. S2. 3-3 In a folTable 5. cardiovascular disease Risk Factors Common in Patients With Low-up study of 23 272 ultrasound NHANES (National Health and Hypertension Nutrition Examination Survey) participants, 50% of deaths Modifiable Risk Factors Relatively Fixed Risk Factors from coronary Heart disease (CHD) and stroke occurred Current cigarette smoking, chronic kidney disease secondhand smoking Table 4. blood pressure Measurement Definitions Family history Diabetes mellitus Increased age blood pressure Measurement Definition Dyslipidemia/hypercholesterolemia Low socioeconomic/educational status SBP First Korotkoff sound Overweight/obesity Male sex DBP Fifth Korotkoff sound Physical inactivity/Low fitness Obstructive sleep apnea Pulse Hypertension SBP minus DBP Unhealthy diet Psychosocial stress Mean arterial Hypertension DBP plus one third pulse Hypertension Factors that can be changed and, if changed, may reduce cardiovascular disease risk. Mid-blood pressure Sum of SBP and DBP, divided by 2 Factors that are difficult to change (chronic kidney disease, Low socioeconomic/educational See Section 4 for a description of Korotkoff sounds. status, obstructive sleep apneaS2. 4-12), cannot be changed (family history, Calculation assumes normal Heart rate. increased age, male sex), or, if changed through the use of current intervention blood pressure indicates Blood Hypertension; DBP, diastolic Blood Hypertension; and SBP, systolic techniques, may not reduce cardiovascular disease risk (psychosocial stress). Blood Hypertension. chronic kidney disease indicates chronic Kidney disease; and cardiovascular disease, cardiovascular disease. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e21 factors have hypertension. For example, 71% of ultrasound adults Table 6. Categories of blood pressure in Adults with diagnosed diabetes mellitus have hypertension. S2. 4-4 In the Chronic blood pressure Category SBP DBP Renal Insufficiency Cohort (CRIC), 86% of the participants had hypertension. S2. 4-5 Also, 28. 1% of adults with hypertenNormal 120 mm Hg and 80 mm Hg sion and chronic kidney disease in the population-based REGARDS (Reasons Elevated 120129 mm Hg and 80 mm Hg for Geographic and Racial Differences in Stroke) study had Hypertension apparent resistant hypertension. S2. 4-6 In NHANES 19992010, Stage 1 130139 mm Hg or 8089 mm Hg 35. 7% of obese individuals had hypertension. S2. 4-7 The presence of multiple cardiovascular disease risk factors in individuals with hypertension Stage 2 ≥140 mm Hg or ≥90 mm Hg results in High absolute risks for CHD and stroke in this popula- Individuals with SBP and DBP in 2 categories should be designated to the tion. For example, among ultrasound adults with hypertension between higher blood pressure category. 2009 and 2012, 41. 7% had a 10-year CHD risk 20%, 40. 9% blood pressure indicates Blood Hypertension (based on an average of ≥2 careful readings had a risk of 10% to 20%, and only 18. 4% had a risk 10%. S2. 4-3 obtained on ≥2 occasions, as detailed in Section 4); DBP, diastolic Blood Hypertension; and SBP, systolic Blood Hypertension. Modifiable risk factors for cardiovascular disease that are common among adults with hypertension include cigarette smoklevels on the basis of average blood pressure measured in a healthcare ing/tobacco smoke exposure, diabetes mellitus, dyslipidemia (includsetting (office pressures): normal, elevated, and stage 1 or 2 ing High levels of Low-density lipoprotein cholesterol or hypertension (Table 6).",
    "word_count": 599,
    "char_count": 4106,
    "sentence_count": 36,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 12,
      "total_chunks": 166,
      "position": "13/166",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "creatinine",
        "magnesium",
        "nutrition",
        "diet",
        "cardiovascular disease",
        "stage 1",
        "stage 2",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 13,
    "text": "Online Data Supplement C illustrates hypercholesterolemia, High levels of triglycerides, and Low schematically the SBP and DBP categories defining normal levels of High-density lipoprotein cholesterol), overweight/ blood pressure, elevated blood pressure, and stages 1 and 2 hypertension. This catobesity, physical inactivity/Low fitness level, and unhealthy egorization differs from that previously recommended in diet. S2. 4-8 The relationship between hypertension and other the JNC 7 report, with stage 1 hypertension now defined as modifiable risk factors is complex and interdependent, with an SBP of 130139 or a DBP of 8089 mm Hg, and with several sharing mechanisms of action and pathophysiolstage 2 hypertension in the present document corresponding ogy. cardiovascular disease risk factors affect blood pressure through over activation of to stages 1 and 2 in the JNC 7 report. S3. 1-21 The rationale for the renin-angiotensin-aldosterone system, activation of the this categorization is based on observational data related to the sympathetic nervous system, inhibition of the cardiac natriassociation between SBP/DBP and cardiovascular disease risk, RCTs of lifeuretic peptide system, endothelial dysfunction, and other style modification to lower blood pressure, and RCTs of treatment with mechanisms. S2. 4-9S2. 4-11 Treating some of the other modifiantihypertensive medication to prevent cardiovascular disease. The increased able risk factors may reduce blood pressure through modification of shared pathology, and cardiovascular disease risk may be reduced by treating risk of cardiovascular disease among adults with stage 2 hypertension is well global risk factor burden. established. An increasing number of individual studies and meta-analyses of observational data have reported a gradient Recommendation-Specific Supportive Text of progressively higher cardiovascular disease risk going from normal blood pressure to elevated blood pressure and stage 1 hypertension. S3. 1-4S3. 1-10, S3. 1-12, S3. 1-13, S3. 1-16 1. Observational studies have demonstrated that cardiovascular disease risk factors frequently occur in combination, with ≥3 risk In many of these meta-analyses, the hazard ratios for CHD factors present in 17% of patients. S2. 4-1 A meta-analysis and stroke were between 1. 1 and 1. 5 for the comparison of from 18 cohort studies involving 257 384 patients identiSBP/DBP of 120129/8084 mm Hg versus 120/80 mm Hg fied a lifetime risk of cardiovascular disease death, nonfatal myocardial infarction, and fatal and between 1. 5 and 2. 0 for the comparison of SBP/DBP of or nonfatal stroke that was substantially higher in adults 130139/8589 mm Hg versus 120/80 mm Hg. This risk with ≥2 cardiovascular disease risk factors than in those with only 1 risk gradient was consistent across subgroups defined by sex and factor. S2. 4-1, S2. 4-2 race/ethnicity. The relative increase in cardiovascular disease risk associated with higher blood pressure was attenuated but still present among older 3. Classification of blood pressure adults. S3. 1-1 The prevalence of severe hypertension has been declining over time, but approximately 12. 3% of ultrasound adults 3. 1. Definition of High blood pressure with hypertension have an average SBP ≥160 mm Hg or averRecommendation for Definition of High blood pressure age DBP ≥100 mm Hg. S3. 1-22 Lifestyle modification and pharmacological antihypertensive treatment recommendations for References that support the recommendation are individuals with elevated blood pressure and stages 1 and 2 hypertension summarized in Online Data Supplement 2. are provided in Sections 6 and 8, respectively. The relationCOR LOE Recommendation ship of this classification schema with measurements obtained 1. blood pressure should be categorized as normal, by ambulatory blood pressure recording and home blood pressure measurements is I B-NR elevated, or stage 1 or 2 hypertension to discussed in Section 4. 2. prevent and treat High blood pressure (Table 6). S3. 1-1S3. 1-20 Recommendation-Specific Supportive Text Synopsis 1.",
    "word_count": 600,
    "char_count": 4083,
    "sentence_count": 44,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 13,
      "total_chunks": 166,
      "position": "14/166",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "diet",
        "antihypertensive",
        "cardiovascular disease",
        "stage 1",
        "stage 2",
        "classification"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 14,
    "text": "2. prevent and treat High blood pressure (Table 6). S3. 1-1S3. 1-20 Recommendation-Specific Supportive Text Synopsis 1. As was the case in previous blood pressure classification systems, Although a continuous association exists between higher the choice and the naming of the categories were based blood pressure and increased cardiovascular disease risk (see Section 2. 1), it is useful to on a pragmatic interpretation of blood pressure-related cardiovascular disease risk and categorize blood pressure levels for clinical and public health decision benefit of blood pressure reduction in clinical trials. Meta-analyses making. In the present document, blood pressure is categorized into 4 of observational studies have demonstrated that elevated Downloaded from by on December 30, 2025 e22 Hypertension June 2018 blood pressure and hypertension are associated with increased risk Table 7. Prevalence of Hypertension Based on 2 SBP/DBP of cardiovascular disease, end-stage renal disease, subclinical atherosclerosis, and all-cause Thresholds death. S3. 1-1S3. 1-17 The recommended blood pressure classification sysSBP/DBP ≥130/80 SBP/DBP ≥140/90 tem is most valuable in untreated adults as an aid in decimm Hg or Self-Reported mm Hg or Self-Reported sions about prevention or treatment of High blood pressure. However, Antihypertensive Antihypertensive it is also useful in assessing the success of interventions Medication Medication to reduce blood pressure. Overall, crude 46% 32% 3. 2. Lifetime Risk of Hypertension Men Women Men Women (n4717) (n4906) (n4717) (n4906) Observational studies have documented a relatively High incidence of hypertension over periods of 5 to 10 years of followOverall, age-sex 48% 43% 31% 32% up. S3. 2-1, S3. 2-2 Thus, there is a much higher long-term population adjusted burden of hypertension as blood pressure progressively increases with age. Age group, y Several studies have estimated the long-term cumulative inci2044 30% 19% 11% 10% dence of developing hypertension. S3. 2-3, S3. 2-4 In an analysis of 4554 50% 44% 33% 27% 1132 white male medical students (mean age: approximately 23 years at baseline) in the Johns Hopkins Precursors study, 5564 70% 63% 53% 52% 0. 3%, 6. 5%, and 37% developed hypertension at age 25, 45, 6574 77% 75% 64% 63% and 65 years, respectively. S3. 2-5 In MESA (Multi-Ethnic Study 75 79% 85% 71% 78% of Atherosclerosis), the percentage of the population developing hypertension over their lifetimes was higher for African Race-ethnicity Americans and Hispanics than for whites and Asians. S3. 2-3 For Non-Hispanic white 47% 41% 31% 30% adults 45 years of age without hypertension, the 40-year risk Non-Hispanic black 59% 56% 42% 46% of developing hypertension was 93% for African-American, Non-Hispanic Asian 45% 36% 29% 27% 92% for Hispanic, 86% for white, and 84% for Chinese adults. S3. 2-3 In the Framingham Heart Study, approximately Hispanic 44% 42% 27% 32% 90% of adults free of hypertension at age 55 or 65 years develThe prevalence estimates have been rounded to the nearest full percentage. oped hypertension during their lifetimes. S3. 2-4 All of these esti- 130/80 and 140/90 mm Hg in 9623 participants (≥20 years of age) in mates were based on use of the 140/90mm Hg cutpoint for NHANES 20112014. recognition of hypertension and would have been higher had blood pressure cutpoints for definition of hypertension in the present guideline. blood pressure cutpoints for definition of hypertension in JNC 7. the 130/80mm Hg cutpoint been used. Adjusted to the 2010 age-sex distribution of the ultrasound adult population. blood pressure indicates Blood Hypertension; DBP, diastolic Blood Hypertension; NHANES, 3. 3. Prevalence of High blood pressure National Health and Nutrition Examination Survey; and SBP, systolic Blood Prevalence estimates are greatly influenced by the choice of Hypertension.",
    "word_count": 591,
    "char_count": 3878,
    "sentence_count": 39,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 14,
      "total_chunks": 166,
      "position": "15/166",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "end-stage renal disease",
        "nutrition",
        "antihypertensive",
        "cardiovascular disease",
        "guideline",
        "classification"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 15,
    "text": "cutpoints to categorize High blood pressure, the methods used to establish the diagnosis, and the population studied. S3. 3-1, S3. 3-2 Most in an overestimate of hypertension prevalence compared general population prevalence estimates are derived from with what would be found by using an average of ≥2 readnational surveys. Table 7 provides estimates for prevalence of ings taken on ≥2 visits, S3. 3-1 as recommended in current and hypertension in the ultrasound general adult population (≥20 years previous blood pressure guidelines. S3. 3-3S3. 3-5 The extent to which guideof age) that are based on the definitions of hypertension recline recommendations for use of blood pressure averages from ≥2 occaommended in the present guideline and in the JNC 7 report. sions is followed in practice is unclear. Adding self-report The prevalence of hypertension among ultrasound adults is substanof previously diagnosed hypertension yields a 5% to 10% tially higher when the definition in the present guideline is higher estimate of prevalence. S3. 3-1, S3. 3-6, S3. 3-7 Most individuals used versus the JNC 7 definition (46% versus 32%). However, who were added by use of this expanded definition have been as described in Section 8. 1, nonpharmacological treatment diagnosed as having hypertension by a health professional (not antihypertensive medication) is recommended for most on 1 occasion, and many have been advised to change their ultrasound adults who have hypertension as defined in the present lifestyle. S3. 3-2, S3. 3-6 guideline but who would not meet the JNC 7 definition for hypertension. As a consequence, the new definition results in 3. 4. Awareness, Treatment, and Control only a small increase in the percentage of ultrasound adults for whom Prevalence estimates for awareness, treatment, and conantihypertensive medication is recommended in conjunction trol of hypertension are usually based on self-reports of the with lifestyle modification. hypertension diagnosis (awareness), use of blood pressure-lowering The prevalence of hypertension rises dramatically with medications in those with hypertension (treatment), and increasing age and is higher in blacks than in whites, Asians, achievement of a satisfactory SBP/DBP during treatment and Hispanic Americans. NHANES estimates of JNC 7 of hypertension (control). Before the present publication, defined hypertension prevalence have remained fairly stable awareness and treatment in adults were based on the SBP/ since the early 2000s. S3. 3-1 Most contemporary population surDBP cutpoints of 140/90 mm Hg, and control was based veys, including NHANES, rely on an average of blood pressure measureon an SBP/DBP 140/90 mm Hg. In the ultrasound general adult ments obtained at a single visit, S3. 3-2 which is likely to result population, hypertension awareness, treatment, and control Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e23 have been steadily improving since the 1960s, S3. 4-1S3. 4-4 with Table 8. Checklist for Accurate Measurement of BPS4. 1-3, S4. 1-4 NHANES 2009 to 2012 prevalence estimates for men and Key Steps for Proper women, respectively, being 80. 2% and 85. 4% for awareness, blood pressure Measurements Specific Instructions 70. 9% and 80. 6% for treatment (88. 4% and 94. 4% in those Step 1: Properly 1. Have the patient relax, sitting in a chair (feet who were aware), 69. 5% and 68. 5% for control in those being prepare the patient on floor, back supported) for 5 min. treated, and 49. 3% and 55. 2% for overall control in adults 2. The patient should avoid caffeine, exercise, with hypertension. S3. 4-5 The NHANES experience may underand smoking for at least 30 min before estimate awareness, treatment, and control of hypertension measurement.",
    "word_count": 589,
    "char_count": 3800,
    "sentence_count": 50,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 15,
      "total_chunks": 166,
      "position": "16/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "antihypertensive",
        "exercise",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 16,
    "text": "because it is based on blood pressure estimates derived from an aver3. Ensure patient has emptied his/her bladder. age of readings obtained at a single visit, whereas guidelines 4. Neither the patient nor the observer should recommend use of blood pressure averages of ≥2 readings obtained talk during the rest period or during the on ≥2 occasions. In addition, the current definition of conmeasurement. trol excludes the possibility of control resulting from life5. Remove all clothing covering the location of style change or nonpharmacological interventions. NHANES cuff placement. hypertension control rates have been consistently higher in 6. Measurements made while the patient is women than in men (55. 3% versus 38. 0% in 20092012); in sitting or lying on an examining table do not whites than in blacks and Hispanics (41. 3% versus 31. 1% and fulfill these criteria. 23. 6%, respectively, in men, and 57. 2% versus 43. 2% and Step 2: Use proper 1. Use a blood pressure measurement device that has been 52. 9%, respectively, in women, for 20092012); and in older technique for blood pressure validated, and ensure that the device is than in younger adults (50. 5% in adults ≥60 years of age vermeasurements calibrated periodically. sus 34. 4% in patients 18 to 39 years of age for 20112012) 2. Support the patients arm (eg, resting on a desk). up to the seventh decade, S3. 4-4, S3. 4-5 although control rates are considerably lower for those ≥75 years (46%) and only 3. Position the middle of the cuff on the patients upper arm at the level of the right 39. 8% for adults ≥80 years. S3. 4-6 In addition, control rates are atrium (the midpoint of the sternum). higher for persons of higher socioeconomic status (43. 2% 4. Use the correct cuff size, such that the for adults with an income 400% above the ultrasound government bladder encircles 80% of the arm, and note if poverty line versus 30. 2% for those below this line in 2003 a largeror smaller-than-normal cuff size is to 2006). S3. 4-5 Research studies have repeatedly demonstrated used (Table 9). that structured, goal-oriented blood pressure treatment initiatives with 5. Either the stethoscope diaphragm or bell may feedback and provision of free medication result in a substanbe used for auscultatory readings. S4. 1-5, S4. 1-6 tial improvement in blood pressure control. S3. 4-7S3. 4-9 Control rates that are Step 3: Take the 1. At the first visit, record blood pressure in both arms. Use much higher than noted in the general population have been proper measurements the arm that gives the higher reading for reported in care settings where a systems approach (detailed needed for subsequent readings. in Sections 12. 2 and 12. 3) has been implemented for insured diagnosis and 2. Separate repeated measurements by adults. S3. 4-10S3. 4-12 treatment of elevated 12 min. blood pressure/hypertension 3. For auscultatory determinations, use a 4. Measurement of blood pressure palpated estimate of radial pulse obliteration Hypertension to estimate SBP. Inflate the cuff 20 4. 1. Accurate Measurement of blood pressure in the Office 30 mm Hg above this level for an auscultatory determination of the blood pressure level. Recommendation for Accurate Measurement of blood pressure in the Office 4. For auscultatory readings, deflate the cuff Hypertension 2 mm Hg per second, and listen for COR LOE Recommendation Korotkoff sounds. 1. For diagnosis and management of High Step 4: Properly 1. Record SBP and DBP.",
    "word_count": 572,
    "char_count": 3478,
    "sentence_count": 65,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 16,
      "total_chunks": 166,
      "position": "17/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "blood pressure control"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 17,
    "text": "1. For diagnosis and management of High Step 4: Properly 1. Record SBP and DBP. If using the auscultatory blood pressure, proper methods are recommended for I C-EO document accurate technique, record SBP and DBP as onset of accurate measurement and documentation blood pressure readings the first Korotkoff sound and disappearance of blood pressure (Table 8). of all Korotkoff sounds, respectively, using the nearest even number. Synopsis 2. Note the time of most recent blood pressure medication Although measurement of blood pressure in office settings is relatively taken before measurements. easy, errors are common and can result in a misleading estiStep 5: Average the Use an average of ≥2 readings obtained on ≥2 mation of an individuals true level of blood pressure. There are various readings occasions to estimate the individuals level of blood pressure. methods for measuring blood pressure in the office. The clinical standard Step 6: Provide blood pressure Provide patients the SBP/DBP readings both of auscultatory measures calibrated to a column of mercury readings to patient verbally and in writing. has given way to oscillometric devices (in part because of toxicological issues with mercury). Oscillometric devices See Section 4. 2 for additional guidance. Adapted with permission from Mancia et alS4. 1-3 (Oxford University Press), use a sensor that detects oscillations in pulsatile Blood volPickering et alS4. 1-2 (American Heart Association, Inc. ), and Weir et alS4. 1-4 ume during cuff inflation and deflation. blood pressure is indirectly cal- (American College of Physicians, Inc. ). culated from maximum amplitude algorithms that involve blood pressure indicates Blood Hypertension; DBP, diastolic Blood Hypertension; and SBP, systolic population-based data. For this reason, only devices with a Blood Hypertension. Downloaded from by on December 30, 2025 e24 Hypertension June 2018 validated measurement protocol can be recommended for use Table 9. Selection Criteria for blood pressure Cuff Size for Measurement (see Section 4. 2 for additional details). Many of the newer of blood pressure in Adults oscillometric devices automatically inflate multiple times Arm Circumference Usual Cuff Size (in 1to 2-minute intervals), allowing patients to be alone 2226 cm Small adult and undisturbed during measurement. Although much of the available blood pressure-related risk information and antihypertensive 2734 cm Adult treatment trial experience have been generated by using tra3544 cm Large adult ditional office methods of blood pressure measurement, there is a grow4552 cm Adult thigh ing evidence base supporting the use of automated office blood pressure Adapted with permission from Pickering et alS4. 1-2 (American Heart measurements. S4. 1-1 Association, Inc. ). blood pressure indicates Blood Hypertension. Recommendation-Specific Supportive Text 1. Accurate measurement and recording of blood pressure are essenof blood pressure refers to the regular measurement of blood pressure by an inditial to categorize level of blood pressure, ascertain blood pressure-related cardiovascular disease vidual at home or elsewhere outside the clinic setting. risk, and guide management of High blood pressure. Most systematic Among individuals with hypertension, self-monitoring of errors in blood pressure measurement can be avoided by following blood pressure, without other interventions, has shown limited evidence the suggestions provided in Table 8, including having for treatment-related blood pressure reduction and achievement of blood pressure the patient sit quietly for 5 minutes before a reading is control. S4. 2-1, S4. 2-5, S4. 2-6 However, with the increased recognitaken, supporting the limb used to measure blood pressure, ensuring tion of inconsistencies between office and out-of-office BPs the blood pressure cuff is at Heart level, using the correct cuff size (see Section 4.",
    "word_count": 578,
    "char_count": 3921,
    "sentence_count": 38,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 17,
      "total_chunks": 166,
      "position": "18/166",
      "section": "1. For diagnosis and management of High Step",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "monitoring"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 18,
    "text": "4) and greater reduction in blood pressure being recom- (Table 9), and, for auscultatory readings, deflating the mended for hypertension control, increased attention is cuff slowly. S4. 1-2 In those who are already taking medicabeing paid to out-of-office blood pressure readings. Although ABPM tion that affects blood pressure, the timing of blood pressure measurements in is generally accepted as the best out-of-office measurement relation to ingestion of the patients medication should method, HBPM is often a more practical approach in clinibe standardized. Because individual blood pressure measurements cal practice. Recommended procedures for the collection tend to vary in an unpredictable or random fashion, a of HBPM data are provided in Table 10. If self-monitorsingle reading is inadequate for clinical decision-making is used, it is important to ensure that the blood pressure measureing. An average of 2 to 3 blood pressure measurements obtained on 2 to 3 separate occasions will minimize random error ment device used has been validated with an internationally and provide a more accurate basis for estimation of blood pressure. accepted protocol and the results have been published in In addition to clinicians, other caregivers and patients a peer-reviewed journal. S4. 2-7 A guide to the relationship who perform blood pressure self-monitoring should be trained to between HBPM blood pressure readings and corresponding readfollow the checklist in Table 8. Common errors in cliniings obtained in the office and by ABPM is presented in cal practice that can lead to inaccurate estimation of blood pressure Table 11. The precise relationships between office readings, include failure to allow for a rest period and/or talking ABPM, and HBPM are unsettled, but there is general agreewith the patient during or immediately before the recordment that office BPs are often higher than ABPM or HBPM ing, improper patient positioning (eg, sitting or lying on BPs, especially at higher BPs. an examination table), rapid cuff deflation (for auscultatory readings), and reliance on BPs measured at a single Recommendation-Specific Supportive Text occasion. 1. ABPM is used to obtain out-of-office blood pressure readings at set intervals, usually over a period of 24 hours. HBPM 4. 2. Out-of-Office and Self-Monitoring of blood pressure is used to obtain a record of out-of-office blood pressure readings taken by a patient. Both ABPM and HBPM typically Recommendation for Out-of-Office and Self-Monitoring of blood pressure provide blood pressure estimates that are based on multiple meaReferences that support the recommendation are surements. A systematic review conducted by the ultrasound summarized in Online Data Supplement 3 and Systematic Preventive Services Task Force reported that ABPM Review Report. provided a better method to predict long-term cardiovascular disease outcomes than did office BPs. It incorporates new informaCOR LOE Recommendation tion from studies of HBPM, ABPM, the relationship of 1. Out-of-office blood pressure measurements are overall cardiovascular disease risk to the effectiveness of Blood Hypertension recommended to confirm the diagnosis of lowering, clinical outcomes related to different Blood hypertension (Table 11) and for titration I ASR Hypertension goals, strategies to improve Blood Hypertension conof blood pressure-lowering medication, in conjunction trol and various other areas. A small body of evidence with telehealth counseling or clinical suggested, but did not confirm, that HBPM could serve interventions. S4. 2-1S4. 2-4 as a similar predictor of outcomes. S4. 2-4 Meta-analyses of SR indicates systematic review. RCTs have identified clinically useful reductions in SBP and DBP and achievement of blood pressure goals at 6 months and Synopsis 1 year when self-monitoring of blood pressure has been used in conOut-of-office measurement of blood pressure can be helpful for confirjunction with other interventions, compared with usual mation and management of hypertension. Self-monitoring care.",
    "word_count": 600,
    "char_count": 4063,
    "sentence_count": 32,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 18,
      "total_chunks": 166,
      "position": "19/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "cardiovascular disease",
        "monitoring"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 19,
    "text": "Self-monitoring care. Meta-analyses of RCTs have identified only small Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e25 Table 10. Procedures for Use of HBPMS4. 25S4. 27 Table 11. Corresponding Values of SBP/DBP for Clinic, HBPM, Daytime, Nighttime, and 24-Hour ABPM Measurements Patient training should occur under medical supervision, including: Daytime Nighttime 24-Hour Information about hypertension Clinic HBPM ABPM ABPM ABPM Selection of equipment 120/80 120/80 120/80 100/65 115/75 Acknowledgment that individual blood pressure readings may vary substantially 130/80 130/80 130/80 110/65 125/75 Interpretation of results 140/90 135/85 135/85 120/70 130/80 Devices: 160/100 145/90 145/90 140/85 145/90 Verify use of automated validated devices. Use of auscultatory devices ABPM indicates ambulatory Blood Hypertension monitoring; blood pressure, Blood Hypertension; (mercury, aneroid, or other) is not generally useful for HBPM because DBP, diastolic Blood Hypertension; HBPM, home Blood Hypertension monitoring; and patients rarely master the technique required for measurement of blood pressure with SBP, systolic Blood Hypertension. auscultatory devices. Monitors with provision for storage of readings in memory are preferred. readings obtained in office settings. S4. 3-1 The monitors are usually programmed to obtain readings every 15 to 30 minVerify use of appropriate cuff size to fit the arm (Table 9). utes throughout the day and every 15 minutes to 1 hour Verify that left/right inter-arm differences are insignificant. If differences during the night. ABPM is conducted while individuals go are significant, instruct patient to measure BPs in the arm with higher about their normal daily activities. ABPM can a) provide readings. estimates of mean blood pressure over the entire monitoring period Instructions on HBPM procedures: and separately during nighttime and daytime, b) determine Remain still: the daytime-to-nighttime blood pressure ratio to identify the extent of nocturnal dipping, c) identify the early-morning blood pressure surge Avoid smoking, caffeinated beverages, or exercise within 30 min before blood pressure measurements. pattern, d) estimate blood pressure variability, and e) allow for recognition of symptomatic hypotension. The ultrasound Centers for Ensure ≥5 min of quiet rest before blood pressure measurements. Medicaid Medicare Services and other agencies provide Sit correctly: reimbursement for ABPM in patients with suspected white Sit with back straight and supported (on a straight-backed dining chair, coat hypertension. S4. 3-2 Medicare claims for ABPM between for example, rather than a sofa). 2007 and 2010 were reimbursed at a median of 52 and were Sit with feet flat on the floor and legs uncrossed. submitted for 1% of beneficiaries. S4. 3-3, S4. 3-4 A list of devices validated for ABPM is available. S4. 3-5, S4. 3-6 Keep arm supported on a flat surface (such as a table), with the upper ABPM and HBPM definitions of High blood pressure use different blood pressure arm at Heart level. thresholds than those used by the previously mentioned officeBottom of the cuff should be placed directly above the antecubital fossa based approach to categorize High blood pressure identified in Section (bend of the elbow). 3. 1. Table 11 provides best estimates for corresponding Take multiple readings: home, daytime, nighttime, and 24-hour ambulatory levels of Take at least 2 readings 1 min apart in morning before taking medications blood pressure, including the values recommended for identification of and in evening before supper. Optimally, measure and record blood pressure daily. hypertension with office measurements. Typically, a clinic blood pressure Ideally, obtain weekly blood pressure readings beginning 2 weeks after a change in of 140/90 mm Hg corresponds to home blood pressure values of 135/85 the treatment regimen and during the week before a clinic visit.",
    "word_count": 590,
    "char_count": 3986,
    "sentence_count": 37,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 19,
      "total_chunks": 166,
      "position": "20/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "exercise",
        "monitoring",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 20,
    "text": "mm Hg and to ABPM values defined as a daytime SBP/DBP of Record all readings accurately: 135/85 mm Hg, a nighttime SBP/DBP of 120/70 mm Hg, and a 24-hour SBP/DBP of 130/80 mm Hg. S4. 3-7, S4. 3-8 These threshMonitors with built-in memory should be brought to all clinic appointments. olds are based on data from European, Australian, and Asian populations, with few data available for establishing appropriblood pressure should be based on an average of readings on ≥2 occasions for ate thresholds for ultrasound populations. S4. 3-9S4. 3-13 They are provided clinical decision making. as a guide but should be interpreted with caution. Higher dayThe information above may be reinforced with videos available online. time SBP measurements from ABPM can be associated with See Table 11 for HBPM targets. an increased risk of cardiovascular disease and all-cause death independent blood pressure indicates Blood Hypertension; and HBPM, home Blood Hypertension monitoring. of clinic-measured blood pressure. S4. 3-14 A meta-analysis of observational studies that included 13 844 individuals suggested nighttime net reductions in SBP and DBP at 6 months and 1 year blood pressure is a stronger risk factor for CHD and stroke than either for use of self-monitoring of blood pressure on its own, as compared clinic or daytime blood pressure. S4. 3-15 with usual care. S4. 2-1, S4. 2-5, S4. 2-6 See Section 4. 4 for addiMethodological issues complicate the interpretation of tional details of diagnostic classification and Section 12 data from studies that report office and out-of-office blood pressure readfor additional details of telehealth and out-of-office blood pressure ings. Definitions and diagnostic methods for identifying white measurement for management of High blood pressure. coat hypertension and masked hypertension (see Section 4. 4) have not been standardized. The available studies have dif4. 3. Ambulatory blood pressure Monitoring fered with regard to number of office readings obtained, use of All of the major RCTs have been based on use of clinic blood pressure 24-hour ABPM, use of daytime-only ABPM, inclusion of dayreadings. However, ABPM is often used to supplement blood pressure time and nighttime blood pressure readings as separate categories, HBPM Downloaded from by on December 30, 2025 e26 Hypertension June 2018 for monitoring out-of-office blood pressure levels, and even the blood pressure threshmeasurement (Table 12). S4. 4-1, S4. 4-13, S4. 4-14 These include masked olds used to define hypertension with ABPM or HBPM readhypertension and white coat hypertension, in addition to susings. In addition, there are few data that address reproducibility tained hypertension. White coat hypertension is characterized of these hypertension profiles over time, with several studies by elevated office blood pressure but normal readings when measured suggesting progression of white coat hypertension and espeoutside the office with either ABPM or HBPM. In contrast, cially of masked hypertension to sustained office-measured masked hypertension is characterized by office readings sughypertension. S4. 3-16S4. 3-22 gesting normal blood pressure but out-of-office (ABPM/HBPM) readings that are consistently above normal. S4. 4-15 In sustained hypertension, blood pressure readings are elevated in both office and out4. 4. Masked and White Coat Hypertension of-office settings. In patients treated for hypertension, both white coat Recommendations for Masked and White Coat Hypertension effect (higher office BPs than out-of-office BPs) and References that support recommendations are summarized masked uncontrolled hypertension (controlled office BPs in Online Data Supplements 4, 5, and 6. but uncontrolled BPs in out-of-office settings) categories COR LOE Recommendations have been reported. S4. 4-5, S4. 4-15, S4. 4-16 The white coat effect (usually considered clinically significant when office SBP/DBPs 1.",
    "word_count": 583,
    "char_count": 3936,
    "sentence_count": 48,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 20,
      "total_chunks": 166,
      "position": "21/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "supplements",
        "cardiovascular disease",
        "monitoring",
        "classification"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 21,
    "text": "S4. 4-5, S4. 4-15, S4. 4-16 The white coat effect (usually considered clinically significant when office SBP/DBPs 1. In adults with an untreated SBP greater than are 20/10 mm Hg higher than home or ABPM SBP/DBPs) 130 mm Hg but less than 160 mm Hg or DBP greater than 80 mm Hg but less than has been implicated in pseudo-resistant hypertension (see IIa B-NR 100 mm Hg, it is reasonable to screen for Section 11. 1) and results in an underestimation of office blood pressure the presence of white coat hypertension by control rates. S4. 4-17, S4. 4-18 The prevalence of masked hypertenusing either daytime ABPM or HBPM before sion varies from 10% to 26% (mean 13%) in populationdiagnosis of hypertension. S4. 4-1S4. 4-8 based surveys and from 14% to 30% in normotensive clinic 2. In adults with white coat hypertension, populations. S4. 4-6, S4. 4-16, S4. 4-19S4. 4-21 periodic monitoring with either ABPM or The risk of cardiovascular disease and all-cause mortality in persons with IIa C-LD HBPM is reasonable to detect transition masked hypertension is similar to that noted in those with susto sustained hypertension (S4. 4-2, S4. 4tained hypertension and about twice as High as the correspond5, S4. 4-7). ing risk in their normotensive counterparts. S4. 4-3, S4. 4-4, S4. 4-6, S4. 4-8, S4. 4-11 3. In adults being treated for hypertension with The prevalence of masked hypertension increases with higher office blood pressure readings not at goal and HBPM office blood pressure readings. S4. 4-20, S4. 4-22, S4. 4-23 IIa C-LD readings suggestive of a significant white The prevalence of white coat hypertension is higher with coat effect, confirmation by ABPM can be useful (S4. 4-9, S4. 4-10). increasing age, S4. 4-24 female versus male sex, nonsmoking versus current smoking status, and routine office measurement 4. In adults with untreated office BPs that are of blood pressure by clinician observers versus unattended blood pressure measureconsistently between 120 mm Hg and 129 mm Hg for SBP or between 75 mm Hg and ments. Many, but not all, studiesS4. 4-4, S4. 4-6, S4. 4-8, S4. 4-25, S4. 4-26 have IIa B-NR 79 mm Hg for DBP, screening for masked identified a minimal increase in risk of cardiovascular disease complications or hypertension with HBPM (or ABPM) is all-cause mortality in patients who have white coat hypertenreasonable (S4. 4-3, S4. 4-4, S4. 4-6, S4. 4sion. This has resulted in a recommendation by some panels 8, S4. 4-11). to screen for white coat hypertension with ABPM (or HBPM) 5. In adults on multiple-drug therapies for to avoid initiating antihypertensive drug treatment in such hypertension and office BPs within 10 individuals. S4. 4-2, S4. 4-5, S4. 4-27 The white coat effect and masked IIb C-LD mm Hg above goal, it may be reasonable to uncontrolled hypertension appear to follow the risk profiles of screen for white coat effect with HBPM (or their white coat hypertension and masked hypertension counABPM) (S4. 4-3, S4. 4-7, S4. 4-12). terparts, respectively. S4. 4-3, S4. 4-12 6. It may be reasonable to screen for masked There are no data on the risks and benefits of treating uncontrolled hypertension with HBPM in white coat and masked hypertension. Despite these methodadults being treated for hypertension and IIb C-EO ological differences, the data are consistent in indicating that office readings at goal, in the presence of target organ damage or increased overall cardiovascular disease risk. Table 12. blood pressure Patterns Based on Office and Out-of-Office 7.",
    "word_count": 576,
    "char_count": 3515,
    "sentence_count": 66,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 21,
      "total_chunks": 166,
      "position": "22/166",
      "content_type": "monitoring",
      "content_type_confidence": 4,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "screening",
        "monitoring"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 22,
    "text": "4-32, S4. 4-33 hypertension. S4. 4-5, S4. 4-9, S4. 4-27S4. 4-30 The cardiovascular disease risk profile for masked uncontrolled hyper2. The incidence of white coat hypertension converting to tension appears to follow the risk profile for masked sustained hypertension (justifying the addition of antihyhypertension. S4. 4-3, S4. 4-12, S4. 4-34 Although the evidence is pertensive drug therapy to lifestyle modification) is 1% to consistent in identifying the increased risk of masked 5% per year by ABPM or HBPM, with a higher incidence uncontrolled hypertension, evidence is lacking on of conversion in those with elevated blood pressure, older age, obewhether the treatment of masked hypertension or sity, or black race. S4. 4-2, S4. 4-7 masked uncontrolled hypertension reduces clinical 3. The overlap between HBPM and both daytime and outcomes. A suggestion for assessing cardiovascular disease risk is pro24-hour ABPM in diagnosing white coat hypertenvided in Section 8. sion is only 60% to 70%, and the data for prediction 7. Although both ABPM and HBPM are better predictors of cardiovascular disease risk are stronger with ABPM than with office of cardiovascular disease risk than are office blood pressure readings, ABPM confirmeasurements. S4. 4-5, S4. 4-9, S4. 4-27S4. 4-30 Because a diagnosis of mation of elevated blood pressure by HBPM might be reasonable white coat hypertension may result in a decision not to because of the more extensive documentation of cardiovascular disease treat or intensify treatment in patients with elevated office risk with ABPM. However, unlike the documentation blood pressure readings, confirmation of blood pressure control by ABPM in adof a significant white coat effect to justify the decision dition to HBPM provides added support for this decision. to not treat an elevated clinic blood pressure, it is not mandatory to 4. In contrast to white coat hypertension, masked hypertenconfirm masked uncontrolled hypertension determined sion is associated with a cardiovascular disease and all-cause mortality risk by HBPM. Figure 1. Detection of white coat hypertension or masked hypertension in patients not on drug therapy. Colors correspond to Class of Recommendation in Table 1. ABPM indicates ambulatory Blood Hypertension monitoring; blood pressure, Blood Hypertension; and HBPM, home Blood Hypertension monitoring. Downloaded from by on December 30, 2025 e28 Hypertension June 2018 Figure 2. Detection of white coat effect or masked uncontrolled hypertension in patients on drug therapy. Colors correspond to Class of Recommendation in Table 1. See Section 8 for treatment options. ABPM indicates ambulatory Blood Hypertension monitoring; blood pressure, Blood Hypertension; cardiovascular disease, cardiovascular disease; and HBPM, home Blood Hypertension monitoring. 5. Causes of Hypertension blood pressure. Many dietary components have been associated with High blood pressure. S5. 2-1, S5. 2-2 Some of the diet-related factors associated 5. 1. Genetic Predisposition with High blood pressure include overweight and obesity, excess intake Hypertension is a complex polygenic disorder in which many of Sodium, and insufficient intake of Potassium, calcium, genes or gene combinations influence blood pressure. S5. 1-1, S5. 1-2 Although magnesium, Protein (especially from vegetables), fiber, and several monogenic forms of hypertension have been identified, Fish fats. Poor diet, physical inactivity, and excess intake of such as glucocorticoid-remediable aldosteronism, Liddles alcohol, alone or in combination, are the underlying cause syndrome, Gordons syndrome, and others in which singleof a large proportion of hypertension. Gut microbiota have gene mutations fully explain the pathophysiology of hyperalso been linked to hypertension, especially in experimental tension, these disorders are rare. S5. 1-3 The current tabulation of animals. S5.",
    "word_count": 569,
    "char_count": 3906,
    "sentence_count": 51,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 22,
      "total_chunks": 166,
      "position": "23/166",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "sodium",
        "potassium",
        "calcium",
        "magnesium",
        "diet",
        "cardiovascular disease",
        "blood pressure control",
        "monitoring"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 23,
    "text": "S5. 1-3 The current tabulation of animals. S5. 2-3 Some of the best-proven environmental relaknown genetic variants contributing to blood pressure and hypertension tionships with High blood pressure are briefly reviewed below, and nonincludes more than 25 rare mutations and 120 single-nucleopharmacological interventions to lower blood pressure are discussed in tide polymorphisms. S5. 1-3, S5. 1-4 However, even with the discovSection 6. 2. ery of multiple single-nucleotide polymorphisms influencing 5. 2. 1. Overweight and Obesity control of blood pressure since completion of the Human Genome Project Insurance industry actuarial reports have identified a strikin 2003, the associated variants have only small effects. ing relationship between body weight and High BPS5. 2. 1-1 Indeed, at present, the collective effect of all blood pressure loci identified and a direct relationship between overweight/obesity and through genome-wide association studies accounts for only hypertension. S5. 2. 1-2 Epidemiological studies, including about 3. 5% of blood pressure variability. S5. 1-4 The presence of a High numthe Framingham Heart StudyS5. 2. 1-3 and the Nurses Health ber of small-effect alleles associated with higher blood pressure results Study, S5. 2. 1-4 have consistently identified a direct relationin a more rapid increase in blood pressure with age. S5. 1-5 Future studies ship between body mass index and blood pressure that is continuous will need to better elucidate genetic expression, epigenetic and almost linear, with no evidence of a threshold. S5. 2. 1-5, S5. 2. 1-6 effects, transcriptomics, and proteomics that link genotypes The relationship with blood pressure is even stronger for waist-towith underlying pathophysiological mechanisms. hip ratio and computed tomographic measures of central fat distribution. S5. 2. 1-7 Attributable risk estimates from the 5. 2. Environmental Risk Factors Nurses Health Study suggest that obesity may be responVarious environmental exposures, including components of sible for about 40% of hypertension, and in the Framingham diet, physical activity, and alcohol consumption, influence Offspring Study, the corresponding estimates were even Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e29 higher (78% in men and 65% in women). S5. 2. 1-8, S5. 2. 1-9 The development of hypertension. In the CARDIA (Coronary relationship between obesity at a young age and change in Artery Risk Development in Young Adults) study, S5. 2. 4-43 physobesity status over time is strongly related to future risk of ical fitness measured at 18 to 30 years of age in the upper hypertension. In combined data from 4 longitudinal stud2 deciles of an otherwise healthy population was associated ies begun in adolescence with repeat examination in young with one third the risk of developing hypertension 15 years adulthood to early middle age, being obese continuously later, and one half the risk after adjustment for body mass or acquiring obesity was associated with a relative risk of index, as compared with the lowest quintile. Change in fitness 2. 7 for developing hypertension. Becoming normal weight assessed 7 years later further modified risk. S5. 2. 4-43 In a cohort reduced the risk of developing hypertension to a level similar of men 20 to 90 years of age who were followed longitudito those who had never been obese. S5. 2. 1-10 nally for 3 to 28 years, higher physical fitness decreased the rate of rise in SBP over time and delayed the time to onset of 5. 2. 2. Sodium Intake hypertension. S5. 2. 4-44 Sodium intake is positively associated with blood pressure in migrant, S5. 2. 2-11 cross-sectional, S5. 2. 2-12S5. 2. 2-14 and prospective cohort stud5. 2. 5. Alcohol iesS5. 2.",
    "word_count": 587,
    "char_count": 3787,
    "sentence_count": 71,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 23,
      "total_chunks": 166,
      "position": "24/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "sodium",
        "diet",
        "physical activity",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 24,
    "text": "2. 2-11 cross-sectional, S5. 2. 2-12S5. 2. 2-14 and prospective cohort stud5. 2. 5. Alcohol iesS5. 2. 2-15 and accounts for much of the age-related increase in The presence of a direct relationship between alcohol blood pressure. S5. 2. 2-11, S5. 2. 2-16 In addition to the well-accepted and important consumption and blood pressure was first reported in 1915S5. 2. 5-45 and relationship of dietary Sodium with blood pressure, excessive consumphas been repeatedly identified in contemporary cross-section of Sodium is independently associated with an increased tional and prospective cohort studies. S5. 2. 5-46 Estimates of the risk of stroke, S5. 2. 2-17, S5. 2. 2-18 cardiovascular disease, S5. 2. 2-19 and other adverse contribution of alcohol consumption to population incidence outcomes. S5. 2. 2-20 Certain groups with various demographic, and prevalence of hypertension vary according to level of physiological, and genetic characteristics tend to be particularly intake. In the United States, it seems likely that alcohol may sensitive to the effects of dietary Sodium on blood pressure. S5. 2. 2-21S5. 2. 2-23 account for close to 10% of the population burden of hyperSalt sensitivity is a quantitative trait in which an increase in tension (higher in men than in women). In contrast to its Sodium load disproportionately increases blood pressure. S5. 2. 2-21, S5. 2. 2-24 Salt detrimental effect on blood pressure, alcohol intake is associated with sensitivity is especially common in blacks, older adults, and those with a higher level of blood pressure or comorbidities such as chronic kidney disease, diabetes mellitus, or the metabolic syndrome. S5. 2. 2-25 In aggregate, these groups constitute more than half of all ultrasound adults. S5. 2. 2-26 Salt sensitivity may be a marker for increased cardiovascular disease and all-cause mortality risk independently of blood pressure, S5. 2. 2-27, S5. 2. 2-28 and the trait has been demonstrated to be reproducible. S5. 2. 2-29 Current techniques for recognition of salt sensitivity are impractical in routine clinical practice, so salt sensitivity is best considered as a group characteristic. 5. 2. 3. Potassium Potassium intake is inversely related to blood pressure in migrant, S5. 2. 3-30 crosssectional, S5. 2. 2-13, S5. 2. 2-16, S5. 2. 3-31, S5. 2. 3-32 and prospective cohortS5. 2. 3-33 studies. It is also inversely related to stroke. S5. 2. 3-34S5. 2. 3-36 A higher level of Potassium seems to blunt the effect of Sodium on blood pressure, S5. 2. 3-37 with a lower SodiumPotassium ratio being associated with a lower level of blood pressure than that noted for corresponding levels of Sodium or Potassium on their own. S5. 2. 3-38 Likewise, epidemiological studies suggest that a lower SodiumPotassium ratio may result in a reduced risk of cardiovascular disease as compared with the pattern for corresponding levels of either cation on its own. S5. 2. 3-39 5. 2. 4. Physical Fitness Epidemiological studies have demonstrated an inverse relationship between physical activity and physical fitness and level of blood pressure and hypertension. S5. 2. 4-40 Even modest levels of physical activity have been associated with a decrease in the risk of incident hypertension. S5. 2. 4-41 In several observational studies, the relationship between physical activity and blood pressure has been most apparent in white men. S5. 2. 4-40 With the advent of electronic Figure 3. Screening for secondary hypertension. Colors activity trackers and ABPM, it has become increasingly feasicorrespond to Class of Recommendation in Table 1. TOD ble to conduct studies that relate physical activity and blood pressure. S5. 2.",
    "word_count": 578,
    "char_count": 3676,
    "sentence_count": 102,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 24,
      "total_chunks": 166,
      "position": "25/166",
      "content_type": "dietary",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "sodium",
        "potassium",
        "cardiovascular disease",
        "physical activity",
        "screening"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 25,
    "text": "TOD ble to conduct studies that relate physical activity and blood pressure. S5. 2. 4-42 indicates target organ damage (eg, cerebrovascular disease, hypertensive retinopathy, left ventricular hypertrophy, left Physical fitness, measured objectively by graded exercise ventricular dysfunction, Heart failure, coronary artery disease, testing, attenuates the rise of blood pressure with age and prevents the chronic Kidney disease, albuminuria, peripheral artery disease). Downloaded from by on December 30, 2025 e30 Hypertension June 2018 Table 13. Causes of Secondary Hypertension With Clinical Indications and Diagnostic Screening Tests Additional/Confirmatory Prevalence Clinical Indications Physical Examination Screening Tests Tests Common causes Renal parenchymal 1%2% Urinary tract infections; obstruction, Abdominal mass Renal ultrasound Tests to evaluate diseaseS5. 4-1, S5. 4-3 hematuria; urinary frequency (polycystic Kidney cause of renal disease and nocturia; analgesic abuse; disease); skin pallor family history of polycystic Kidney disease; elevated serum Creatinine; abnormal urinalysis Renovascular 5%34% Resistant hypertension; Abdominal systolicRenal Duplex Doppler Bilateral selective diseaseS5. 4-4 hypertension of abrupt onset or diastolic bruit; bruits over ultrasound; MRA; renal intra-arterial worsening or increasingly difficult other arteries (carotid abdominal computed tomography angiography to control; flash pulmonary Edema atherosclerotic or (atherosclerotic); early-onset fibromuscular dysplasia), hypertension, especially in women femoral (fibromuscular hyperplasia) Primary 8%20% Resistant hypertension; Arrhythmias (with Plasma aldosterone/ Oral Sodium loading aldosteronismS5. 4-5, S5. 4-6 hypertension with hypokalemia hypokalemia); especially renin ratio under test (with 24-h (spontaneous or diuretic induced); atrial fibrillation standardized Urine aldosterone) hypertension and muscle cramps conditions (correction or IV saline infusion or weakness; hypertension and of hypokalemia test with plasma incidentally discovered adrenal and withdrawal of aldosterone at 4 h of mass; hypertension and obstructive aldosterone antagonists infusion Adrenal computed tomography sleep apnea; hypertension and for 46 wk) scan, adrenal vein family history of early-onset sampling. hypertension or stroke Obstructive sleep 25%50% Resistant hypertension; snoring; Obesity, Mallampati class Berlin Polysomnography apneaS5. 4-7 fitful sleep; breathing pauses during IIIIV; loss of normal Questionnaire; S5. 4-8 sleep; daytime sleepiness nocturnal blood pressure fall Epworth Sleepiness Score; S5. 4-9 overnight oximetry Drug or alcohol 2%4% Sodium-containing antacids; Fine tremor, tachycardia, Urinary drug screen Response to inducedS5. 4-10 caffeine; nicotine (smoking); sweating (cocaine, (illicit drugs) withdrawal of alcohol; NSAIDs; oral ephedrine, MAO suspected agent contraceptives; cyclosporine or inhibitors); acute tacrolimus; sympathomimetics abdominal Pain (cocaine) (decongestants, anorectics); cocaine, amphetamines and other illicit drugs; neuropsychiatric agents; erythropoiesis-stimulating agents; clonidine withdrawal; herbal agents (Ma Huang, ephedra) Uncommon causes Pheochromocytoma/para 0. 1%0. 6% Resistant hypertension; paroxysmal Skin stigmata of 24-h urinary computed tomography or magnetic resonance imaging scan of gangliomaS5. 4-11 hypertension or crisis superimposed neurofibromatosis fractionated abdomen/pelvis on sustained hypertension; spells, (café-au-lait spots; metanephrines or blood pressure lability, headache, sweating, neurofibromas); plasma metanephrines palpitations, pallor; positive family Orthostatic hypotension under standard history of pheochromocytoma/ conditions (supine paraganglioma; adrenal position with indwelling incidentaloma IV cannula) Cushings 0. 1% Rapid weight gain, especially Central obesity, moon Overnight 1-magnesium 24-h urinary free syndromeS5. 4-12 with central distribution; proximal face, dorsal and dexamethasone cortisol excretion muscle weakness; depression; supraclavicular fat pads, suppression test (preferably multiple); hyperglycemia wide (1-cm) violaceous midnight salivary striae, hirsutism cortisol (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e31 Table 13. Continued Additional/Confirmatory Prevalence Clinical Indications Physical Examination Screening Tests Tests Uncommon causes (Continued) HypothyroidismS5. 4-10 1% Dry skin; cold intolerance; Delayed ankle reflex; Thyroid-stimulating None constipation; hoarseness; weight periorbital puffiness; hormone; free thyroxine gain coarse skin; cold skin; slow movement; goiter HyperthyroidismS5.",
    "word_count": 564,
    "char_count": 4723,
    "sentence_count": 23,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 25,
      "total_chunks": 166,
      "position": "26/166",
      "content_type": "reference",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "albuminuria",
        "creatinine",
        "sodium",
        "magnesium",
        "serum creatinine",
        "edema",
        "hypokalemia",
        "muscle cramps",
        "heart failure"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 26,
    "text": "4-10 1% Warm, moist skin; heat Lid lag; fine tremor of Thyroid-stimulating Radioactive iodine intolerance; nervousness; the outstretched hands; hormone; free thyroxine uptake and scan tremulousness; insomnia; weight warm, moist skin loss; diarrhea; proximal muscle weakness Aortic coarctation 0. 1% Young patient with hypertension blood pressure higher in upper Echocardiogram Thoracic and (undiagnosed or (30 y of age) extremities than in abdominal computed tomography repaired)S5. 4-13 lower extremities; angiogram or MRA absent femoral pulses; continuous murmur over patients back, chest, or abdominal bruit; left thoracotomy scar (postoperative) Primary hyperparaRare Hypercalcemia Usually none Serum calcium Serum parathyroid thyroidismS5. 4-14 hormone Congenital adrenal Rare Hypertension and hypokalemia; Signs of virilization Hypertension and 11-beta-OH: elevated hyperplasiaS5. 4-15 virilization (11-beta-hydroxylase (11-beta-OH) hypokalemia with Low deoxycorticosterone deficiency 11-beta-OH); or incomplete or normal aldosterone (DOC), incomplete masculinization in masculinization and renin 11-deoxycortisol, males and primary amenorrhea (17-alpha-OH) and androgens17in females (17-alpha-hydroxylase alpha-OH; decreased deficiency 17-alpha-OH) androgens and estrogen; elevated deoxycorticosterone and corticosterone M ineralocorticoid Rare Early-onset hypertension; resistant Arrhythmias (with Low aldosterone and Urinary cortisol excess syndromes hypertension; hypokalemia or hypokalemia) renin metabolites; genetic other than primary hyperkalemia testing aldosteronismS5. 4-15 AcromegalyS5. 4-16 Rare Acral features, enlarging shoe, Acral features; large Serum growth Elevated ageand glove, or hat size; headache, visual hands and feet; frontal hormone ≥1 ng/mL sex-matched IGF-1 disturbances; Diabetes mellitus bossing during oral glucose load level; magnetic resonance imaging scan of the pituitary Depending on the clinical situation (hypertension alone, 5%; hypertension starting Dialysis, 22%; hypertension and peripheral vascular disease, 28%; hypertension in the elderly with congestive Heart failure, 34%). 8% in general population with hypertension; up to 20% in patients with resistant hypertension. Although obstructive sleep apnea is listed as a cause of secondary hypertension, RCTs on the effects of continuous positive airway Hypertension on lowering blood pressure in patients with hypertension have produced mixed results (see Section 5. 4. 4 for details). For a list of frequently used drugs causing hypertension and accompanying evidence, see Table 14. blood pressure indicates Blood Hypertension; computed tomography, computed tomography; DOC, 11-deoxycorticosterone; IGF-1, insulin-like growth factor-1; IV, intravenous; MAO, monamine oxidase; magnetic resonance imaging, magnetic resonance imaging; MRA, magnetic resonance arteriography; NSAIDs, nonsteroidal anti-inflammatory drugs; OH, hydroxylase; and RCT, randomized clinical trial. a higher level of High-density lipoprotein cholesterol and, studies showed correlation coefficients of about 0. 38 for SBP within modest ranges of intake, a lower level of CHD than and 0. 28 for DBP, with BPs in the upper range of the pedithat associated with abstinence. S5. 2. 3-35 atric distribution (particularly BPs obtained in adolescence) predicting hypertension in adulthood. S5. 3-1 Several factors, 5. 3. Childhood Risk Factors and blood pressure Tracking including genetic factors and development of obesity, increase blood pressure distribution in the general population increases with age. the likelihood that a High childhood blood pressure will lead to future Multiple longitudinal studies have investigated the relationhypertension. S5. 3-2 Premature birth is associated with a 4 ship of childhood blood pressure to adult blood pressure. A meta-analysis of 50 such mm Hg higher SBP and a 3mm Hg higher DBP in adulthood, Downloaded from by on December 30, 2025 e32 Hypertension June 2018 with somewhat larger effects in women than in men. S5. 3-3 Low treatment often requires a level of technical training and birth weight from other causes also contributes to higher blood pressure experience. in later life. S5. 3-4 5. 4. 1. Drugs and Other Substances With Potential to Impair blood pressure Control 5. 4.",
    "word_count": 577,
    "char_count": 4295,
    "sentence_count": 35,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 26,
      "total_chunks": 166,
      "position": "27/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "calcium",
        "insulin",
        "dialysis",
        "hyperkalemia",
        "hypokalemia",
        "heart failure",
        "blood pressure control"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 27,
    "text": "S5. 3-4 5. 4. 1. Drugs and Other Substances With Potential to Impair blood pressure Control 5. 4. Secondary Forms of Hypertension Numerous substances, including prescription medications, Recommendations for Secondary Forms of Hypertension over-the-counter medications, herbals, and food substances, may affect blood pressure (Table 14). S5. 4. 1-1S5. 4. 1-6 Changes in blood pressure that COR LOE Recommendations occur because of drugs and other agents have been associ1. Screening for specific form(s) of secondary ated with the development of hypertension, worsening conhypertension is recommended when trol in a patient who already has hypertension, or attenuation the clinical indications and physical I C-EO of the blood pressure-lowering effects of antihypertensive therapy. A examination findings listed in Table 13 change in blood pressure may also result from drugdrug or drugfood are present or in adults with resistant hypertension. interactions. S5. 4. 1-2, S5. 4. 1-4 In the clinical assessment of hypertension, a careful history should be taken with regard to sub2. If an adult with sustained hypertension stances that may impair blood pressure control, with close attention paid screens positive for a form of secondary hypertension, referral to a physician with to not only prescription medications, but also over-the-counter IIb C-EO expertise in that form of hypertension may substances, illicit drugs, and herbal products. When feasible, be reasonable for diagnostic confirmation drugs associated with increased blood pressure should be reduced or disand treatment. continued, and alternative agents should be used. Synopsis 5. 4. 2. Primary Aldosteronism A specific, remediable cause of hypertension can be identified Recommendations for Primary Aldosteronism in approximately 10% of adult patients with hypertension. S5. 4-1 COR LOE Recommendations If a cause can be correctly diagnosed and treated, patients with secondary hypertension can achieve a cure or experience 1. In adults with hypertension, screening for a marked improvement in blood pressure control, with reduction in cardiovascular disease primary aldosteronism is recommended in the presence of any of the following risk. All new patients with hypertension should be screened concurrent conditions: resistant with a history, physical examination, and laboratory invesI C-EO hypertension, hypokalemia (spontaneous or tigations, as recommended in Section 7, before initiation of substantial, if diuretic induced), incidentally treatment. discovered adrenal mass, family history Secondary hypertension can underlie severe elevation of early-onset hypertension, or stroke at a of blood pressure, pharmacologically resistant hypertension, sudyoung age (40 years). den onset of hypertension, increased blood pressure in patients with 2. Use of the plasma aldosterone: renin activity hypertension previously controlled on drug therapy, onset I C-LD ratio is recommended when adults are of diastolic hypertension in older adults, and target organ screened for primary aldosteronism. S5. 4. 2-1 damage disproportionate to the duration or severity of the 3. In adults with hypertension and a positive hypertension. Although secondary hypertension should screening test for primary aldosteronism, be suspected in younger patients (30 years of age) with I C-EO referral to a hypertension specialist or endocrinologist is recommended for further elevated blood pressure, it is not uncommon for primary hypertension evaluation and treatment. to manifest at a younger age, especially in blacks, S5. 4-2 and some forms of secondary hypertension, such as renovasSynopsis cular disease, are more common at older age. Many of the Primary aldosteronism is defined as a group of disorders in causes of secondary hypertension are strongly associated which aldosterone production is inappropriately High for with clinical findings or groups of findings that suggest a Sodium status, is relatively autonomous of the major regulaspecific disorder. tors of secretion (angiotensin II and Potassium), and cannot Figure 3 is an algorithm on screening for secondary be suppressed with Sodium loading. S5. 4.",
    "word_count": 600,
    "char_count": 4164,
    "sentence_count": 45,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 27,
      "total_chunks": 166,
      "position": "28/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "sodium",
        "potassium",
        "antihypertensive",
        "hypokalemia",
        "cardiovascular disease",
        "blood pressure control",
        "screening"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 28,
    "text": "S5. 4. 2-2, S5. 4. 2-3 The increased hypertension. Table 13 is a detailed list of clinical indicaproduction of aldosterone induces hypertension; cardiovascutions and diagnostic screening tests for secondary hypertenlar and Kidney damage; Sodium retention; suppressed plasma sion, and Table 14 is a list of drugs that can induce secondary renin activity; and increased Potassium excretion, which, if hypertension. prolonged and severe, may cause hypokalemia. However, Recommendation-Specific Supportive Text hypokalemia is absent in the majority of cases and has a 1. The causes of secondary hypertension and recommendLow negative predictive value for the diagnosis of primary ed screening tests are provided in Table 13, and drugs aldosteronism. S5. 4. 2-4 In about 50% of the patients, primary that can induce secondary hypertension are provided in aldosteronism is due to increased unilateral aldosterone proTable 14. duction (usually aldosterone-producing adenoma or, rarely, 2. Diagnosis of many of these disorders requires a complex unilateral adrenal hyperplasia); in the remaining 50%, priset of measurements, specialized technical expertise, and/ mary aldosteronism is due to bilateral adrenal hyperplasia or experience in data interpretation. Similarly, specific (idiopathic hyperaldosteronism). S5. 4. 2-2, S5. 4. 2-3 Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e33 Table 14. Frequently Used Medications and Other Substances That May Cause Elevated blood pressure Agent Possible Management Strategy Alcohol Limit alcohol to ≤1 Drink daily for women and ≤2 drinks for menS5. 4. 1-7 Amphetamines (eg, amphetamine, methylphenidate Discontinue or decrease doseS5. 4. 1-8 dexmethylphenidate, dextroamphetamine) Consider behavioral therapies for ADHDS5. 4. 1-9 Antidepressants (eg, MAOIs, SNRIs, TCAs) Consider alternative agents (eg, SSRIs) depending on indication Avoid tyramine-containing foods with MAOIs Atypical antipsychotics (eg, clozapine, olanzapine) Discontinue or limit use when possible Consider behavior therapy where appropriate Recommend lifestyle modification (see Section 6. 2) Consider alternative agents associated with lower risk of weight gain, Diabetes mellitus, and dyslipidemia (eg, aripiprazole, ziprasidone)S5. 4. 1-10, S5. 4. 1-11 Caffeine Generally limit caffeine intake to 300 magnesium/d Avoid use in patients with uncontrolled hypertension Coffee use in patients with hypertension is associated with acute increases in blood pressure; long-term use is not associated with increased blood pressure or CVDS5. 4. 1-12 Decongestants (eg, phenylephrine, Use for shortest duration possible, and avoid in severe or uncontrolled hypertension pseudoephedrine) Consider alternative therapies (eg, nasal saline, intranasal corticosteroids, antihistamines) as appropriate Herbal supplements (eg, Ma Huang ephedra, Avoid use St. Johns wort with MAO inhibitors, yohimbine) Immunosuppressants (eg, cyclosporine) Consider converting to tacrolimus, which may be associated with fewer effects on BPS5. 4. 1-13S5. 4. 1-15 Oral contraceptives Use Low-dose (eg, 2030 microgram ethinyl estradiol) agentsS5. 4. 1-16 or a progestin-only form of contraception, or consider alternative forms of birth control where appropriate (eg, barrier, abstinence, IUD) Avoid use in women with uncontrolled hypertensionS5. 4. 1-16 NSAIDs Avoid systemic NSAIDs when possible Consider alternative analgesics (eg, acetaminophen, tramadol, topical NSAIDs), depending on indication and risk Recreational drugs (eg, Rice salts MDPV, Discontinue or avoid use cocaine, methamphetamine, etc. ) Systemic corticosteroids (eg, dexamethasone, Avoid or limit use when possible fludrocortisone, methylprednisolone, prednisone, Consider alternative modes of administration (eg, inhaled, topical) when feasible prednisolone) Angiogenesis inhibitor (eg, bevacizumab) and Initiate or intensify antihypertensive therapy tyrosine kinase inhibitors (eg, sunitinib, sorafenib) List is not all inclusive. ADHD indicates attention-deficit/hyperactivity disorder; blood pressure, Blood Hypertension; cardiovascular disease, cardiovascular disease; IUD, intra-uterine device; MAOI, monoamine-oxidase inhibitors; MDPV, methylenedioxypyrovalerone; NSAIDs, nonsteroidal anti-inflammatory drugs; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; and TCA, tricyclic antidepressant. Recommendation-Specific Supportive Text aldosterone overproduction are often reversible with 1.",
    "word_count": 589,
    "char_count": 4546,
    "sentence_count": 44,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 28,
      "total_chunks": 166,
      "position": "29/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "potassium",
        "magnesium",
        "supplements",
        "antihypertensive",
        "immunosuppressants",
        "hypokalemia",
        "cardiovascular disease",
        "screening",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 29,
    "text": "Recommendation-Specific Supportive Text aldosterone overproduction are often reversible with 1. Primary aldosteronism is one of the most frequent disunilateral laparoscopic adrenalectomy or treatment orders (occurring in 5% to 10% of patients with hyperwith mineralocorticoid receptor antagonists (ie, spitension and 20% of patients with resistant hypertenronolactone or eplerenone), screening of patients with sion) that causes secondary hypertension. S5. 4. 2-5, S5. 4. 2-6 hypertension at increased risk of primary aldosteronThe toxic tissue effects of aldosterone induce greater ism is beneficial. S5. 4. 2-2, S5. 4. 2-3 These include hypertensive target organ damage in primary aldosteronism than patients with adrenal incidentaloma, an incidentally in primary hypertension. Patients with primary aldodiscovered adrenal lesion on a computed tomography steronism have a 3. 7-fold increase in heart failure, a 4. 2-fold or magnetic resonance imaging (magnetic resonance imaging) scan performed increase in stroke, a 6. 5-fold increase in myocardial infarction, a 12. 1for other purposes. Patients with hypertension and a fold increase in atrial fibrillation (atrial fibrillation), increased left history of early onset hypertension and/or cerebroventricular hypertrophy (LVH) and diastolic dysfuncvascular accident at a young age may have primary tion, increased stiffness of large arteries, widespread aldosteronism due to glucocorticoid-remediable altissue fibrosis, increased remodeling of resistance dosteronism (familial hyperaldosteronism type-1) and vessels, and increased Kidney damage as compared therefore warrant screening. S5. 4. 2-2, S5. 4. 2-3 with patients with primary hypertension matched for 2. The aldosterone: renin activity ratio is currently the most blood pressure level. S5. 4. 2-6S5. 4. 2-8 Because the deleterious effects of accurate and reliable means of screening for primary Downloaded from by on December 30, 2025 e34 Hypertension June 2018 aldosteronism. S5. 4. 2-1 The most commonly used cutoff stenosis, whereas nonatherosclerotic disease (of which fibrovalue is 30 when plasma aldosterone concentration is remuscular dysplasia is the most common) is much less prevalent ported in nanograms per deciliter (ng/dL) and plasma reand tends to occur in younger, healthier patients. S5. 4. 3-3 Renal nin activity in nanograms per milliliter per hour (ng/mL/ artery stenosis is a common form of secondary hypertension. h). S5. 4. 2-3 Because the aldosterone: renin activity ratio can Relieving ischemia and the ensuing postischemic release of be influenced by the presence of very Low renin levels, renin by surgical renal artery reconstruction is an invasive stratthe plasma aldosterone concentration should be at least egy with a postoperative mortality as High as 13%. S5. 4. 3-4 With 10 ng/dL to interpret the test as positive. S5. 4. 2-3 Patients the advent of endovascular procedures to restore Blood flow, should have unrestricted salt intake, serum Potassium in several trials were designed to test the efficacy of these prothe normal range, and mineralocorticoid receptor antagocedures against medical therapy, but they suggested no benefit nists (eg, spironolactone or eplerenone) withdrawn for at over medical therapy alone. S5. 4. 3-1, S5. 4. 3-2 least 4 weeks before testing. S5. 4. 2-2, S5. 4. 2-3 3. The diagnosis of primary aldosteronism generally reRecommendation-Specific Supportive Text quires a confirmatory test (intravenous saline suppression 1. Atherosclerotic disease in the renal arteries represents test or oral salt-loading test). S5. 4. 2-2, S5. 4. 2-3 If the diagnosis systemic disease and higher risk of both renal failure of primary aldosteronism is confirmed (and the patient and cardiovascular morbidity and mortality. No RCT to agrees that surgery would be desirable), the patient is redate has demonstrated a clinical advantage of renal artery ferred for an adrenal venous sampling procedure to derevascularization (with either angioplasty or stenting) termine whether the increased aldosterone production is over medical therapy. S5. 4.",
    "word_count": 592,
    "char_count": 4101,
    "sentence_count": 65,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 29,
      "total_chunks": 166,
      "position": "30/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "renal failure",
        "potassium",
        "heart failure",
        "screening"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 30,
    "text": "S5. 4. 3-2 On the basis of the CORAL unilateral or bilateral in origin. If unilateral aldosterone (Cardiovascular Outcomes in Renal Atherosclerotic production is documented on adrenal venous sampling, Lesions) trial, the recommended medical approach enthe patient is referred for unilateral laparoscopic adrenalcompasses optimal management of hypertension with ectomy, which improves blood pressure in virtually 100% of patients an antihypertensive regimen that includes a renin-angioand results in a complete cure of hypertension in about tensin system (renal artery stenosis) blocker, in addition to Low-density 50%. S5. 4. 2-2, S5. 4. 2-3 If the patient has bilaterally increased lipoprotein cholesterol reduction with a High-intensity aldosterone secretion on adrenal venous sampling or statin, smoking cessation, hemoglobin hemoglobin A1c reduction in has a unilateral source of excess aldosterone production patients with diabetes mellitus, and antiplatelet therapy. S5. 4. 3-1 but cannot undergo surgery, the patient is treated with spi2. Revascularization may be considered for those who ronolactone or eplerenone as agent of choice. S5. 4. 2-2, S5. 4. 2-3 do not respond to medical therapy and for those who Both adrenalectomy and medical ktherapy are effective have nonatherosclerotic disease (eg, Takayasu arteritis in lowering blood pressure and reversing LVH. Treating primary alin Asian populations, fibromuscular dysplasia in other dosteronism, either by mineralocorticoid receptor antagpopulations). Fibromuscular dysplasia occurs over the onists or unilateral adrenalectomy (if indicated), resolves lifespan of women (mean: 53 years of age) with almost hypokalemia, lowers blood pressure, reduces the number of antihyequal frequency in the renal and carotid circulations. S5. 4. 3-3 pertensive medications required, and improves paramPercutaneous transluminal angioplasty alone (without eters of impaired cardiac and Kidney function. S5. 4. 2-9, S5. 4. 2-10 stenting) can improve blood pressure control and even normalize blood pressure, especially in patients with recent onset of hypertension or 5. 4. 3. Renal Artery Stenosis resistant hypertension. S5. 4. 3-5 Recommendations for Renal Artery Stenosis 5. 4. 4. Obstructive Sleep Apnea References that support recommendations are summarized in Online Data Supplements 7 and 24. Recommendation for Obstructive Sleep Apnea COR LOE Recommendations References that support the recommendation are summarized in Online Data Supplement 8. 1. Medical therapy is recommended for I A adults with atherosclerotic renal artery COR LOE Recommendation stenosis. S5. 4. 3-1, S5. 4. 3-2 1. In adults with hypertension and obstructive 2. In adults with renal artery stenosis for sleep apnea, the effectiveness of continuous IIb B-R whom medical management has failed positive airway Hypertension (CPAP) to reduce blood pressure (refractory hypertension, worsening is not well established. S5. 4. 4-1S5. 4. 4-5 renal function, and/or intractable heart failure) and those with nonatherosclerotic disease, IIb C-EO Synopsis including fibromuscular dysplasia, it may be reasonable to refer the patient Obstructive sleep apnea is a common chronic condition charfor consideration of revascularization acterized by recurrent collapse of upper airways during sleep, (percutaneous renal artery angioplasty and/ inducing intermittent episodes of apnea/hypopnea, hypoxor stent placement). emia, and sleep disruption. S5. 4. 4-6 Obstructive sleep apnea is a risk factor for several CVDs, including hypertension, coroSynopsis nary and cerebrovascular diseases, heart failure, and atrial fibrillation. S5. 4. 4-6S5. 4. 4-9 Renal artery stenosis refers to a narrowing of the renal artery Observational studies have shown that the presence of obstructhat can result in a restriction of Blood flow. Atherosclerotic tive sleep apnea is associated with increased risk of incidisease (90%) is by far the most common cause of renal artery dent hypertension. S5. 4. 4-10, S5. 4. 4-11 Obstructive sleep apnea is Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e35 highly prevalent in adults with resistant hypertension reduction.",
    "word_count": 600,
    "char_count": 4211,
    "sentence_count": 67,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 30,
      "total_chunks": 166,
      "position": "31/166",
      "content_type": "reference",
      "content_type_confidence": 4,
      "medical_entities": [
        "kidney function",
        "renal function",
        "hemoglobin",
        "supplements",
        "antihypertensive",
        "hypokalemia",
        "heart failure",
        "smoking cessation",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 31,
    "text": "Both approaches are complementary and mutually (≥80%), S5. 4. 4-12, S5. 4. 4-13 and it has been hypothesized that treatreinforcing, and modeling studies suggest they are likely to ment with CPAP may have more pronounced effects on blood pressure provide similar public health benefit. S6. 1-3, S6. 1-4 However, as reduction in resistant hypertension. S5. 4. 4-6 the precision of risk prediction tools increases, targeted prevention strategies that focus on High-risk individuals seem to Recommendation-Specific Supportive Text become more efficient than population-based strategies. S6. 1-5 1. CPAP is an efficacious treatment for improving obstruc6. 2. Nonpharmacological Interventions tive sleep apnea. However, studies of the effects of CPAP on blood pressure have demonstrated only small effects on blood pressure (eg, Recommendations for Nonpharmacological Interventions 2 to 3mm Hg reductions), with results dependent on patient compliance with CPAP use, severity of obstrucReferences that support recommendations are summarized tive sleep apnea, and presence of daytime sleepiness in in Online Data Supplements 9-21. study participants. S5. 4. 4-1S5. 4. 4-5 Although many RCTs have COR LOE Recommendations been reported that address the effects of CPAP on blood pressure in obstructive sleep apnea, most of the patients studied did 1. Weight loss is recommended to reduce blood pressure not have documented hypertension, and the studies were I A in adults with elevated blood pressure or hypertension who are overweight or obese. S6. 2-1S6. 2-4 too small and the follow-up period too short to allow for adequate evaluation. In addition, a well-designed RCT 2. A Heart-healthy diet, such as the demonstrated that CPAP plus usual care, compared with DASH (Dietary Approaches to Stop usual care alone, did not prevent cardiovascular events I A Hypertension) diet, that facilitates achieving a desirable weight is recommended in patients with moderatesevere obstructive sleep apnea for adults with elevated blood pressure or and established cardiovascular disease. S5. 4. 4-14 hypertension. S6. 2-5S6. 2-7 6. Nonpharmacological Interventions 3. Sodium reduction is recommended I A for adults with elevated blood pressure or Correcting the dietary aberrations, physical inactivity, and hypertension. S6. 2-8S6. 2-12 excessive consumption of alcohol that cause High blood pressure is a 4. Potassium supplementation, preferably in fundamentally important approach to prevention and mandietary modification, is recommended for agement of High blood pressure, either on their own or in combination adults with elevated blood pressure or hypertension, with pharmacological therapy. Prevention of hypertension I A unless contraindicated by the presence of and treatment of established hypertension are complemenchronic kidney disease or use of drugs that reduce Potassium tary approaches to reducing cardiovascular disease risk in the population, excretion. S6. 2-13S6. 2-17 but prevention of hypertension provides the optimal means 5. Increased physical activity with a of reducing risk and avoiding the harmful consequences of structured exercise program is I A hypertension. S6-1S6-3 Nonpharmacological therapy alone is recommended for adults with elevated blood pressure especially useful for prevention of hypertension, including in or hypertension. S6. 2-3, S6. 2-4, S6. 2-12, S6. 2-18S6. 2-22 adults with elevated blood pressure, and for management of High blood pressure in 6. Adult men and women with elevated blood pressure adults with milder forms of hypertension. S6-4, S6-5 or hypertension who currently consume I A alcohol should be advised to Drink no more 6. 1. Strategies than 2 and 1 standard drinks per day, respectivelyS6. 2-23S6.",
    "word_count": 549,
    "char_count": 3746,
    "sentence_count": 57,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 31,
      "total_chunks": 166,
      "position": "32/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "sodium",
        "potassium",
        "diet",
        "supplements",
        "cardiovascular disease",
        "exercise",
        "physical activity"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 32,
    "text": "1. Strategies than 2 and 1 standard drinks per day, respectivelyS6. 2-23S6. 2-28 Nonpharmacological interventions can be accomplished by In the United States, 1 standard Drink contains roughly 14 g of pure means of behavioral strategies aimed at lifestyle change, alcohol, which is typically found in 12 oz of regular beer (usually about 5% prescription of dietary supplements, or implementation of alcohol), 5 oz of wine (usually about 12% alcohol), and 1. 5 oz of distilled spirits kitchen-based interventions that directly modify elements (usually about 40% alcohol). S6. 2-29 of the diet. At a societal level, policy changes can enhance the availability of healthy foods and facilitate physical activSynopsis ity. The goal can be to modestly reduce blood pressure in the general Nonpharmacological interventions are effective in Lowpopulation or to undertake more intensive targeted lowering ering blood pressure, with the most important interventions being of blood pressure in adults with hypertension or at High risk of develweight loss, S6. 2-1 the DASH (Dietary Approaches to Stop oping hypertension. S6. 1-1 The intent of the general population Hypertension) diet, S6. 2-5S6. 2-7, S6. 2-30 Sodium reduction, S6. 2-8S6. 2-12 approach is to achieve a small downward shift in the general Potassium supplementation, S6. 2-13, S6. 2-17 increased physical population distribution of blood pressure, which would be expected to activity, S6. 2-18S6. 2-22, S6. 2-31 and a reduction in alcohol result in substantial health benefits. S6. 1-2 The targeted approach consumption. S6. 2-23, S6. 2-24 Various other nonpharmacological focuses on blood pressure reduction in adults at greatest risk of developinterventions have been reported to lower blood pressure, but the extent ing blood pressure-related cardiovascular disease, including individuals with hypertension, and/or quality of the supporting clinical trial experience is as well as those at increased risk of developing hypertension, less persuasive. Such interventions include consumption of especially blacks and adults who are overweight, consume probiotics; S6. 2-32, S6. 2-33, S6. 2-34 increased intake of Protein, S6. 2-35S6. 2-37 excessive amounts of dietary Sodium, have a High intake of fiber, S6. 2-38, S6. 2-39 flaxseed, S6. 2-40 or Fish oil; S6. 2-41 supplementaalcohol, or are physically inactive. The targeted approach tion with calciumS6. 2-42, S6. 2-43 or magnesium; S6. 2-44, S6. 2-45 and tends to be intensive, with a more ambitious goal for blood pressure use of dietary patterns other than the DASH diet, including Downloaded from by on December 30, 2025 e36 Hypertension June 2018 Low-carbohydrate, vegetarian, and Mediterranean diets. S6. 2-46S6. 2-49 effect of weight loss in patients with elevated blood pressure is conStress reduction is intuitively attractive but insufficiently sistent with the corresponding effect in patients with proved, S6. 2-51 as are several other interventions, including conestablished hypertension, with an apparent doseresumption of garlic, S6. 2-52 dark chocolate, S6. 2-53, S6. 2-54 tea, S6. 2-55 or sponse relationship of about 1 mm Hg per kilogram of coffee. S6. 2-56 Behavioral therapies, including guided breathing, weight loss. Achievement and maintenance of weight yoga, transcendental meditation, and biofeedback, lack strong loss through behavior change are challengingS6. 2-64S6. 2-66 but feasible over prolonged periods of follow-up. S6. 2-64 evidence for their long-term blood pressure-lowering effect. S6. 2-51, S6. 2-57S6. 2-61 For those who do not meet their weight loss goals with The best proven nonpharmacological measures to prevent and nonpharmacological interventions, pharmacotherapy or treat hypertension are summarized in Table 15. S6. 2-62 minimally invasive and bariatric surgical procedures can The nonpharmacological interventions presented in be considered. S6. 2-67, S6.",
    "word_count": 575,
    "char_count": 3912,
    "sentence_count": 65,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 32,
      "total_chunks": 166,
      "position": "33/166",
      "section": "1. Strategies than",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "sodium",
        "potassium",
        "magnesium",
        "diet",
        "supplements",
        "cardiovascular disease"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 33,
    "text": "S6. 2-62 minimally invasive and bariatric surgical procedures can The nonpharmacological interventions presented in be considered. S6. 2-67, S6. 2-68 Surgical procedures tend to be Table 15 may be sufficient to prevent hypertension and meet more effective but are usually reserved for those with goal blood pressure in managing patients with stage 1 hypertension, and more severe and intractable obesity because of the frethey are an integral part of the management of persons with quency of complications. S6. 2-69 stage 2 hypertension. To a lesser extent, the Mediterranean 2. The DASH eating plan is the diet best demonstrated to be dietS6. 2-49, S6. 2-63 (which incorporates the basics of healthy Eateffective for lowering blood pressure. Because the DASH diet is High ing but emphasizes consumption of legumes and monounin fruits, vegetables, and Low-fat dairy products, it prosaturated fat, avoidance of red meats, and moderate intake of vides a means to enhance intake of Potassium, calcium, wine) has been effective in reducing blood pressure, as well as improving magnesium, and fiber. In hypertensive and nonhypertenlipid profile. sive adults, the DASH diet has produced overall reductions in SBP of approximately 11 mm Hg and 3 mm Hg, Recommendation-Specific Supportive Text respectively, S6. 2-7 and the diet was especially effective 1. Weight loss is a core recommendation and should be in blacks. S6. 2-70 When combined with weight lossS6. 2-6 or achieved through a combination of reduced calorie intake a reduction in Sodium intake, S6. 2-5, S6. 2-30 the effect size and increased physical activity. S6. 2-1 The blood pressure-lowering was substantially increased. Most of the clinical trial Table 15. Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension Approximate Impact on SBP Nonpharmacological Intervention Dose Hypertension Normotension Reference Weight loss Weight/body fat Best goal is ideal body weight, but aim for at least a 5 mm Hg 2/3 mm Hg S6. 2-1 1-kg reduction in body weight for most adults who are overweight. Expect about 1 mm Hg for every 1-kg reduction in body weight. Healthy diet DASH dietary pattern Consume a diet rich in fruits, vegetables, whole 11 mm Hg 3 mm Hg S6. 2-6, S6. 2-7 grains, and Low-fat dairy products, with reduced content of saturated and total fat. Reduced intake of Dietary Sodium Optimal goal is 1500 magnesium/d, but aim for at least a 5/6 mm Hg 2/3 mm Hg S6. 2-9, S6. 2-10 dietary Sodium 1000-magnesium/d reduction in most adults. Enhanced intake of Dietary Potassium Aim for 35005000 magnesium/d, preferably by consumption 4/5 mm Hg 2 mm Hg S6. 2-13 dietary Potassium of a diet rich in Potassium. Physical activity Aerobic 90150 min/wk 5/8 mm Hg 2/4 mm Hg S6. 2-18, S6. 2-22 65%75% Heart rate reserve Dynamic resistance 90150 min/wk 4 mm Hg 2 mm Hg S6. 2-18 50%80% 1 rep maximum 6 exercises, 3 sets/exercise, 10 repetitions/set Isometric resistance 4 2 min (hand grip), 1 min rest between exercises, 5 mm Hg 4 mm Hg S6. 2-19, S6. 2-31 30%40% maximum voluntary contraction, 3 sessions/wk 810 wk Moderation in Alcohol consumption In individuals who Drink alcohol, reduce alcohol to: 4 mm Hg 3 mm Hg S6. 2-22S6. 2-24 alcohol intake Men: ≤2 drinks daily Women: ≤1 Drink daily Resources: Your Guide to Lowering Your Blood Hypertension With DASHHow Do I Make the DASH? Available at: hbp-dash-how-to. Accessed September 15, 2017. S6. 2-72 Top 10 Dash Diet Tips. Available at: Accessed September 15, 2017. S6. 2-73 Type, dose, and expected impact on blood pressure in adults with a normal blood pressure and with hypertension.",
    "word_count": 588,
    "char_count": 3619,
    "sentence_count": 50,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 33,
      "total_chunks": 166,
      "position": "34/166",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "potassium",
        "calcium",
        "magnesium",
        "diet",
        "exercise",
        "physical activity",
        "stage 1",
        "stage 2"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 34,
    "text": "S6. 2-73 Type, dose, and expected impact on blood pressure in adults with a normal blood pressure and with hypertension. In the United States, one standard Drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1. 5 oz of distilled spirits (usually about 40% alcohol). S6. 2-29 DASH indicates Dietary Approaches to Stop Hypertension; and SBP, systolic Blood Hypertension. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e37 experience comes from short-term feeding studies, S6. 2-7 4. Dietary Potassium is inversely related to blood pressure and hybut lifestyle change with the DASH diet has been sucpertension in migrant studies, S6. 2-88 cross-sectional cessful in at least 2 trials that used a behavioral interreports, S6. 2-89S6. 2-91 and prospective cohort studies. S6. 2-92 vention over a 4-monthS6. 2-30 or 6-monthS6. 2-6 period of Likewise, dietary potassiumS6. 2-93S6. 2-96 and a High infollow-up. Websites and books provide advice on impletake of fruits and vegetables are associated with a mentation of the DASH diet. S6. 2-13, S6. 2-71S6. 2-74 Counseling lower incidence of stroke. S6. 2-97 Potassium interventions by a knowledgeable nutritionist can be helpful. Several have been effective in lowering blood pressure, S6. 2-13, S6. 2-14, S6. 2-16, S6. 2-81 other diets, including diets that are Low in calories from especially in adult patients consuming an excess of carbohydrates, S6. 2-46 High-Protein diets, S6. 2-75 vegetarian sodiumS6. 2-13, S6. 2-74, S6. 2-98 and in blacks. S6. 2-13 The typical diets, S6. 2-48 and a Mediterranean dietary pattern, S6. 2-49, S6. 2-63 blood pressure-lowering effect of a 60-mmol (1380-magnesium) adminishave been shown to lower blood pressure. tration of Potassium chloride has been about 2 mm Hg 3. Sodium reduction interventions prevent hypertension and 4 to 5 mm Hg in adults with normotension and and lower blood pressure in adults with hypertension, especially in hypertension, respectively, although the response is up those with higher levels of blood pressure, blacks, older persons, and to twice as much in persons consuming a High-Sodium others who are particularly susceptible to the effects of diet. A reduction in the Sodium/Potassium index may Sodium on blood pressure. S6. 2-8S6. 2-11 Sodium reduction interventions be more important than the corresponding changes in may prevent cardiovascular disease. S6. 2-76, S6. 2-77 Lifestyle change (behavioreither electrolyte alone. S6. 2-99 Some but not all studies al) interventions usually reduce Sodium intake by about suggest that the intervention effect may be restricted to 25% (approximately 1000 magnesium per day) and result in an adult patients with a Low (1500-magnesium to 2000-magnesium) daily average of about a 2mm Hg to 3mm Hg reduction in intake of Potassium. S6. 2-92, S6. 2-100 Most of the intervention SBP in nonhypertensive individuals, though the reducexperience comes from trials of relatively short duration tion can be more than double this in more susceptible (median of 5 to 6 weeks), S6. 2-13, S6. 2-14 but the blood pressure-lowering individuals, those with hypertension, and those coneffect of Potassium in adult patients consuming a Highcurrently on the DASH dietS6. 2-5 or receiving a weight Sodium diet has been reproduced after an interval of 4. 4 loss intervention. S6. 2-12 Sodium reduction in adults with years. S6.",
    "word_count": 553,
    "char_count": 3529,
    "sentence_count": 61,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 34,
      "total_chunks": 166,
      "position": "35/166",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "sodium",
        "potassium",
        "magnesium",
        "chloride",
        "diet",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 35,
    "text": "4 loss intervention. S6. 2-12 Sodium reduction in adults with years. S6. 2-98 In most trials, Potassium supplementation hypertension who are already being treated with blood pressurewas achieved by administration of Potassium chloride lowering medications further reduces SBP by about pills, but the blood pressure response pattern was similar when di3 mm Hg and can facilitate discontinuation of medicaetary modification was used. S6. 2-13 Because Potassiumtion, although this requires maintenance of the lifestyle rich diets tend to be Heart healthy, they are preferred change and warrants careful monitoring. S6. 2-12 When over use of pills for Potassium supplementation. The combined with weight loss, the reduction in blood pressure is al2015 Dietary Guidelines for AmericansS6. 2-101 encourage most doubled. A reduction in Sodium intake may also a diet rich in Potassium and identify the adequate intake lower SBP significantly in individuals with resistant level for adult patients as 4700 magnesium/day. S6. 2-102 The World hypertension who are taking multiple antihypertensive Health Organization recommends a Potassium intake of medicationsS6. 2-78 (see Section 11. 1). Reduced dietary at least 90 mmol (3510 magnesium) per day from food for adult Sodium has been reported to augment the blood pressure-lowering patients. S6. 2-15 Good sources of dietary Potassium include effects of renal artery stenosis blocker therapy. S6. 2-79 Maintenance of fruits and vegetables, as well as Low-fat dairy products, the lifestyle changes necessary to reduce Sodium inselected Fish and meats, nuts, and soy products. Four to take is challenging, S6. 2-2S6. 2-4, S6. 2-12 but even a small five servings of fruits and vegetables will usually provide decrement in Sodium consumption is likely to be 1500 to 3000 magnesium of Potassium. This can be achieved by safeS6. 2-2, S6. 2-4, S6. 2-9, S6. 2-12, S6. 2-80 and beneficial, S6. 2-8, S6. 2-81 esa diet, such as the DASH diet, that is High in Potassium pecially in those whose blood pressure is salt sensitive. S6. 2-82 In the content. S6. 2-7 United States, most dietary Sodium comes from addi5. A blood pressure-lowering effect of increased physical activity has tions during food processing or during commercial food been repeatedly demonstrated in clinical trials, espepreparation at sit-down and fast-food restaurants. S6. 2-83, S6. 2-84 cially during dynamic aerobic exercise, S6. 2-18, S6. 2-20, S6. 2-22 Person-specific and policy approaches can be used to but also during dynamic resistance trainingS6. 2-18, S6. 2-21 reduce dietary Sodium intake. S6. 2-85, S6. 2-86 Individuals can and static isometric exercise. S6. 2-18, S6. 2-19, S6. 2-31 The average take action to reduce their dietary intake of Sodium by reductions in SBP with aerobic exercise are approxichoice of fresh foods, use of food labels to choose foods mately 2 to 4 mm Hg and 5 to 8 mm Hg in adult patients that are lower in Sodium content, choice of foods with a with normotension and hypertension, respectively. S6. 2-18 no added Sodium label, judicious use of condiments Most trials have been of relatively short duration, but and Sodium-infused foods, use of spices and Low-Sodium increased physical activity has been an intrinsic compoflavorings, careful ordering when eating out, control nent of longer-term weight reduction interventions used of food portion size, and avoiding or minimizing use to reduce blood pressure and prevent hypertension. S6. 2-3, S6. 2-4, S6. 2-12 of salt at the table. Dietary counseling by a nutritionblood pressure-lowering effects have been reported with lowerand ist with expertise in behavior modification can be helphigher-intensity exercise and with continuous and inful. A reduction in the amount of Sodium added during terval exercise training. S6. 2-18, S6.",
    "word_count": 592,
    "char_count": 3823,
    "sentence_count": 63,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 35,
      "total_chunks": 166,
      "position": "36/166",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "sodium",
        "potassium",
        "magnesium",
        "chloride",
        "diet",
        "ESA",
        "antihypertensive",
        "exercise",
        "physical activity",
        "monitoring"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 36,
    "text": "A reduction in the amount of Sodium added during terval exercise training. S6. 2-18, S6. 2-103 Meta-analyses sugfood processing, as well as fast food and restaurant food gest isometric exercise results in substantial lowering of preparation, has the potential to substantially reduce soblood pressure. S6. 2-18, S6. 2-19, S6. 2-31 dium intake without the need for a conscious change in 6. In observational studies, there is a strong, predictable dilifestyle. S6. 2-81, S6. 2-85, S6. 2-87 rect relationship between alcohol consumption and blood pressure, Downloaded from by on December 30, 2025 e38 Hypertension June 2018 especially above an intake of 3 standard drinks per day Table 16. Historical Features Favoring Hypertension Cause (approximately 36 ounces of regular beer, 15 ounces of Primary Hypertension Secondary Hypertension wine, or 4. 5 ounces of distilled spirits). S6. 2-29, S6. 2-104, S6. 2-105 Meta-analyses of RCTs that have studied the effect of Gradual increase in blood pressure, with slow blood pressure lability, episodic pallor and reduced alcohol consumption on blood pressure in adults have idenrate of rise in blood pressure dizziness (pheochromocytoma) tified a significant reduction in SBP and DBP. S6. 2-23, S6. 2-24 Lifestyle factors that favor higher Snoring, hypersomnolence The benefit has seemed to be consistent across trials, but blood pressure (eg, weight gain, High-Sodium (obstructive sleep apnea) confined to those consuming ≥3 drinks/day, as well as diet, decreased physical activity, job Prostatism (chronic Kidney disease dose dependent, with those consuming ≥6 drinks/day at change entailing increased travel, due to post-renal urinary tract baseline who reduce their alcohol intake by about 50%, excessive consumption of alcohol) obstruction) experiencing an average reduction in SBP/DBP of apFamily history of hypertension Muscle cramps, weakness proximately 5. 5/4. 0 mm Hg. S6. 2-23, S6. 2-24 Only limited in- (hypokalemia from primary formation is available on the effect of alcohol reduction aldosteronism or secondary on blood pressure in blacks. S6. 2-23, S6. 2-106 In contrast to its effect on blood pressure, aldosteronism due to renovascular alcohol seems to have a beneficial effect on several biodisease) markers for cardiovascular disease risk, including High-density lipoprotein Weight loss, palpitations, heat cholesterol. S6. 2-107, S6. 2-108 Observational studies have shown intolerance (hyperthyroidism) a relatively consistent finding of an inverse relationship between alcohol intake and CHD, S6. 2-109, S6. 2-110 within a Edema, Fatigue, frequent urination moderate range (approximately 1214 and ≤9 standard (Kidney disease or failure) drinks/week for men and women, respectively). On balHistory of coarctation repair ance, it seems reasonable for those who are consuming (residual hypertension associated moderate quantities of alcohol (≤2 drinks/day) to conwith coarctation) tinue their moderate consumption of alcohol. Central obesity, facial rounding, easy bruisability (Cushings 7. Patient Evaluation syndrome) The patient evaluation is designed to identify target organ Medication or substance use damage and possible secondary causes of hypertension and (eg, alcohol, NSAIDS, cocaine, to assist in planning an effective treatment regimen. Historical amphetamines) features are relevant to the evaluation of the patient (Table 16). Absence of family history of The pattern of blood pressure measurements and changes over time may hypertension differentiate primary from secondary causes of hypertension. blood pressure indicates Blood Hypertension; and NSAIDs, nonsteroidal anti-inflammatory drugs. A rise in blood pressure associated with weight gain, lifestyle factors (such as a job change requiring travel and meals away from include assessment of hypertension-related target organ damhome), reduced frequency or intensity of physical activity, age. Attention should be paid to physical features that suggest or advancing age in a patient with a strong family history of secondary hypertension (Table 13). hypertension would suggest the diagnosis of primary hypertension.",
    "word_count": 594,
    "char_count": 4146,
    "sentence_count": 44,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 36,
      "total_chunks": 166,
      "position": "37/166",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "sodium",
        "diet",
        "edema",
        "hypokalemia",
        "fatigue",
        "muscle cramps",
        "cardiovascular disease",
        "exercise",
        "physical activity"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 37,
    "text": "hypertension would suggest the diagnosis of primary hypertension. An evaluation of the patients dietary habits, physi7. 1. Laboratory Tests and Other Diagnostic cal activity, alcohol consumption, and tobacco use should be Procedures performed, with recommendation of the nonpharmacological interventions detailed in Section 6. 2 where appropriate. The Laboratory measurements should be obtained for all patients history should also include inquiry into possible occurrence with a new diagnosis of hypertension to facilitate cardiovascular disease risk of symptoms to indicate a secondary cause (Tables 13 and factor profiling, establish a baseline for medication use, and 16). The patients treatment goals and risk tolerance should screen for secondary causes of hypertension (Table 17). also be elicited. This is especially true for older persons, for Optional tests may provide information on target organ whom an assessment of multiple chronic conditions, frailty, damage. Monitoring of serum Sodium and Potassium levels and prognosis should be performed, including consideration is helpful during diuretic or renal artery stenosis blocker titration, as are of the time required to see benefit from intervention, which serum Creatinine and urinary albumin as markers of chronic kidney disease may not be realized for some individuals. progression. S7. 1-1 Measurement of thyroid-stimulating horThe physical examination should include accurate measuremone is a simple test to easily detect hypothyroidism and ment of blood pressure (Table 8). Automated oscillometric devices provide hyperthyroidism, 2 remediable causes of hypertension. A an opportunity to obtain repeated measurements without a prodecision to conduct additional laboratory testing would be vider present, thereby minimizing the potential for a white coat appropriate in the context of increased hypertension severity, effect. Change in blood pressure from seated to standing position should poor response to standard treatment approaches, a disproporbe measured to detect orthostatic hypotension (a decline 20 tionate severity of target organ damage for the level of blood pressure, or mm Hg in SBP or 10 mm Hg in DBP after 1 minute is abnorhistorical or clinical clues that support a secondary cause. mal). For adults ≤30 years of age with elevated brachial blood pressure, a thigh blood pressure measurement is indicated; if the thigh measurement 7. 2. Cardiovascular Target Organ Damage is lower than arm pressures, a diagnosis of coarctation of the Pulse-wave velocity, carotid intima-media thickness, and aorta should be considered. The physical examination should coronary artery calcium score provide noninvasive estimates Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e39 Table 17. Basic and Optional Laboratory Tests for Primary who are young (≤18 years of age) or have evidence of secHypertension ondary hypertension, chronic uncontrolled hypertension, or history of symptoms of heart failure. Electrocardiographic criteria Basic testing Fasting Blood glucose for LVH correlate weakly with echocardiographic or magnetic resonance imaging Complete Blood count definitions of LVH and are less strongly related to cardiovascular disease Lipid profile outcomes. S7. 2-12S7. 2-15 Imprecision in lead placement accounts, in part, for the poor correlation of electrocardiographic meaSerum Creatinine with estimated glomerular filtration rate surements with direct imaging results. However, electrocarSerum Sodium, Potassium, calcium diographic LVH has been valuable in predicting cardiovascular disease risk Thyroid-stimulating hormone in some reports. S7. 2-16, S7. 2-17 Electrocardiography may also be Urinalysis useful in the assessment of comorbidities, such as rhythm disturbances and prior myocardial infarction. Electrocardiogram LVH, as assessed by electrocardiography, echocarOptional testing Echocardiogram diography, or magnetic resonance imaging, is an independent predictor of cardiovascular disease Uric acid complications. S7. 2-18, S7. 2-19 Reduction in LVH can predict a reduction in cardiovascular disease risk, independent of change in blood pressure. S7.",
    "word_count": 589,
    "char_count": 4201,
    "sentence_count": 35,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 37,
      "total_chunks": 166,
      "position": "38/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "creatinine",
        "sodium",
        "potassium",
        "calcium",
        "uric acid",
        "serum creatinine",
        "cardiovascular disease",
        "heart failure"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 38,
    "text": "2-19 Reduction in LVH can predict a reduction in cardiovascular disease risk, independent of change in blood pressure. S7. 2-20 Urinary albumin to Creatinine ratio When used in cardiovascular disease risk predictor models, echocardiographic May be included in a comprehensive metabolic panel. LVH has a small but significant independent effect on cardiovascular disease estimated glomerular filtration rate indicates estimated glomerular estimated glomerular filtration rate. risk in younger patients. At older ages, LVH measured by electrocardiography or magnetic resonance imaging provides no independent conof vascular target organ injury and atherosclerosis. S7. 2-1 tribution to prediction of cardiovascular disease risk. S7. 2-21S7. 2-23 Patients can High blood pressure readings, especially when obtained several years be classified into 4 groups on the basis of the presence or before a noninvasive measurement, are associated with absence of LVH and a determination of whether the LVH has an increase in subclinical cardiovascular disease risk. S7. 2-2S7. 2-4 Although an eccentric (normal relative wall thickness) or concentric carotid intima-media thickness values and coronary artery geometry. S7. 2-6, S7. 2-22 calcium scores are associated with cardiovascular events, inadequate or absent information on the effect of improve8. Treatment of High blood pressure ment in these markers on cardiovascular events prevents Clinicians managing adults with High blood pressure should focus on overtheir routine use as surrogate markers in the treatment all patient health, with a particular emphasis on reducing the of hypertension. risk of future adverse cardiovascular disease outcomes. All patient risk factors LVH is a secondary manifestation of hypertension and need to be managed in an integrated fashion with a comprehenindependently predicts future cardiovascular disease events. LVH is comsive set of nonpharmacological (see Section 6) and pharmacomonly measured by electrocardiography, echocardiography, logical strategies. As patient blood pressure and risk of future cardiovascular disease events or magnetic resonance imaging. S7. 2-5, S7. 2-6 Left ventricular (LV) mass is associated increase, blood pressure management should be intensified. with body size (particularly lean body mass), tobacco use, Heart rate (inverse), and long-standing diabetes mellitus. S7. 2-7S7. 2-9 blood pressure Low8. 1. Pharmacological Treatment ering leads to a reduction in LV mass. In TOMHS (Treatment of Mild Hypertension Study), the long-acting diuretic 8. 1. 1. Initiation of Pharmacological blood pressure Treatment in the chlorthalidone was slightly more effective in reducing LVH Context of Overall cardiovascular disease Risk than were a calcium channel blocker (calcium channel blocker) (amlodipine), For any specific difference in blood pressure, the relative risk of cardiovascular disease ACE inhibitor (enalapril), alpha-receptor blocker (doxazois constant across groups that differ in absolute risk of athsin), or beta-receptor blocker (acebutolol). S7. 2-10 Beta blockerosclerotic cardiovascular disease, S8. 1. 1-1S8. 1. 1-4 albeit with some evidence ers are inferior to angiotensin receptor blockers (ARBs), of lesser relative risk but greater excess risk in older than angiotensin-converting enzyme (ACE) inhibitors, and CCBs in younger adults. S8. 1. 1-5S8. 1. 1-8 Thus, there are more potenin reducing LVH. S7. 2-11 tially preventable cardiovascular disease events attributable to elevated blood pressure Hypertension adversely impacts other echocardiographic in individuals with higher than with lower risk of cardiovascular disease and markers of cardiac structure and function, including left atrial in older than in younger adults. The relative risk reduction size (both diameter and area; left atrial size is also a precursor for cardiovascular disease prevention with use of blood pressure-lowering medications is of atrial fibrillation); diastolic function (many parameters; a precursor of fairly constant for groups that differ in cardiovascular disease risk across a heart failure with preserved ejection fraction HFpEF); cardiac strucwide range of estimated absolute riskS8. 1. 1-9, S8. 1.",
    "word_count": 594,
    "char_count": 4221,
    "sentence_count": 52,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 38,
      "total_chunks": 166,
      "position": "39/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "glomerular filtration rate",
        "creatinine",
        "calcium",
        "ARBs",
        "angiotensin receptor blockers",
        "cardiovascular disease",
        "heart failure"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 39,
    "text": "1. 1-9, S8. 1. 1-10 and across ture; and subclinical markers of LV systolic function, such groups defined by sex, age, body mass index, and the presas myocardial strain assessment with echocardiography and ence or absence of diabetes mellitus, atrial fibrillation, and chronic kidney disease. S8. 1. 1-5, S8. 1. 1-11S8. 1. 1-21 As magnetic resonance imaging. a consequence, the absolute cardiovascular disease risk reduction attributable Assessment of LVH by means of echocardiography or to blood pressure lowering is greater at greater absolute levels of cardiovascular disease magnetic resonance imaging is not universally recommended during evaluation risk. S8. 1. 1-9, S8. 1. 1-10, S8. 1. 1-12, S8. 1. 1-15S8. 1. 1-19, S8. 1. 1-22, S8. 1. 1-23 Put another and management of hypertension in adults because there way, for a given magnitude of blood pressure reduction due to antihyare limited data on the cost and value of these measures for pertensive medications, fewer individuals at High cardiovascular disease risk cardiovascular disease risk reclassification and changes in type or intensity would need to be treated to prevent a cardiovascular disease event (ie, lower of treatment. Assessment of LVH is most useful in adults number needed to treat) than those at Low cardiovascular disease risk. Downloaded from by on December 30, 2025 e40 Hypertension June 2018 8. 1. 2. blood pressure Treatment Threshold and the Use of cardiovascular disease Risk including the use of blood pressure-lowering medications. Although Estimation to Guide Drug Treatment of Hypertension several cardiovascular disease risk assessment tools are available, on the basis of current knowledge, we recommend use of the Recommendations for blood pressure Treatment Threshold and Use of ACC/AHA Pooled Cohort Equations ( Risk Estimation to Guide Drug Treatment of Hypertension ASCVD-Risk-Estimator/) to estimate 10-year risk of atheroReferences that support recommendations are summarized sclerotic cardiovascular disease (ASCVD) to establish the blood pressure threshold for in Online Data Supplement 23. treatment. S8. 1. 2-56, S8. 1. 2-57 It should be kept in mind that the ACC/AHA Pooled Cohort Equations are validated for ultrasound COR LOE Recommendations adults ages 40 to 79 years in the absence of concurrent statin 1. Use of blood pressure-lowering medications is therapy. S8. 1. 2-56 For those 79 years old, the 10-year ASCVD recommended for secondary prevention of risk is generally 10%, and thus the SBP threshold for antiSBP: A recurrent cardiovascular disease events in patients with clinical cardiovascular disease and an average SBP of 130 mm Hg or hypertensive drug treatment for patients 79 years old is 130 higher or an average DBP of 80 mm Hg or mm Hg. Two recent reviews have highlighted the importance I higher, and for primary prevention in adults of using predicted cardiovascular disease risk together with blood pressure to guide antihywith an estimated 10-year atherosclerotic pertensive drug therapy. S8. 1. 2-22, S8. 1. 2-23 cardiovascular disease (ASCVD) risk of 10% Figure 4 is an algorithm on blood pressure thresholds and recommenDBP: C-EO or higher and an average SBP 130 mm Hg dations for treatment and follow-up. or higher or an average DBP 80 mm Hg or higher. S8. 1. 2-1S8. 1. 2-9 Recommendation-Specific Supportive Text 2. Use of blood pressure-lowering medication is 1. For the purposes of secondary prevention, clinical cardiovascular disease is recommended for primary prevention defined as CHD, congestive heart failure, and stroke.",
    "word_count": 549,
    "char_count": 3559,
    "sentence_count": 55,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 39,
      "total_chunks": 166,
      "position": "40/166",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "cardiovascular disease",
        "heart failure"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 40,
    "text": "Several metaof cardiovascular disease in adults with no history of analyses of RCTs support the value of using blood pressure-lowering I C-LD cardiovascular disease and with an estimated 10-year medications, in addition to nonpharmacological treatASCVD risk 10% and an SBP of 140 mm Hg or higher or a DBP of ment, in patients with established cardiovascular disease in the absence 90 mm Hg or higher. S8. 1. 2-3, S8. 1. 2-10S8. 1. 2-13 of hypertension, defined previously by an SBP ≥140 mm Hg or a DBP ≥90 mm Hg. S8. 1. 2-1, S8. 1. 2-6, S8. 1. 2-7, S8. 1. 2-9 ACC/AHA Pooled Cohort Equations ( to estimate 10-year risk of atherosclerotic cardiovascular disease. ASCVD was Many RCTs of blood pressure lowering in adults without cardiovascular disease have defined as a first CHD death, non-fatal myocardial infarction or fatal or non-fatal stroke. used inclusion criteria designed to increase the level of cardiovascular disease risk in the study populations to increase trial efSynopsis ficiency by facilitating shorter duration and a smaller sample size. As a consequence, few relatively Low-risk Whereas treatment of High blood pressure with blood pressure-lowering mediadults with hypertension have been included in the trials. cations on the basis of blood pressure level alone is considered cost Trial results provide evidence of cardiovascular disease prevention from effective, S8. 1. 2-14 use of a combination of absolute cardiovascular disease risk use of blood pressure-lowering medications in adults with an averand blood pressure level to guide such treatment is more efficient and age SBP ≥130 mm Hg or an average DBP ≥80 mm Hg cost effective at reducing risk of cardiovascular disease than is use of blood pressure level and clinical cardiovascular disease; 5-year risk of cardiovascular disease (defined as stroke, alone. S8. 1. 2-15S8. 1. 2-24 Practical approaches have been developed CHD, heart failure, or other cardiovascular disease death) of approximately 6% to translate evidence from RCTs into individual patient treatto 7%; S8. 1. 2-3, S8. 1. 2-5 an estimated 10-year cardiovascular disease death rate ment recommendations that are based on absolute net benof approximately 4. 5%; S8. 1. 2-4 or an annual rate of major efit for cardiovascular disease risk, S8. 1. 2-25 and several national and international cardiovascular disease events of approximately 0. 9% per year. S8. 1. 2-7 In the guidelines recommend basing use of blood pressure-lowering medicaabsence of clinical cardiovascular disease, these risk estimates are roughly tions on a combination of absolute risk of cardiovascular disease and level of equivalent to a 10-year risk of ASCVD exceeding 10% blood pressure instead of relying solely on level of blood pressure. S8. 1. 2-26S8. 1. 2-31 as per the ACC/AHA Pooled Cohort Equations. S8. 1. 2-56 Attempts to use absolute risk to guide implementation SPRINT (Systolic Blood Hypertension Intervention Trial) of pharmacological treatment to prevent cardiovascular disease have had provides additional support for the use of blood pressure-lowering mixed results, with many reports of improvements in promedications in patients without cardiovascular disease at SBP levels ≥130 mm Hg; however, it is important to note that few SPRINT vider prescribing behaviors, patient adherence, and reducparticipants had untreated SBP between 130 mm Hg and tions in risk, S8. 1. 2-32S8. 1. 2-38 but with others showing no impact on 139 mm Hg at baseline. Furthermore, SPRINT used provider behaviors. S8. 1. 2-39, S8. 1. 2-40 Use of global cardiovascular disease risk assessa Framingham 10-year risk of general cardiovascular disease exceeding ment is infrequent in routine clinical practice, S8. 1. 2-41S8. 1. 2-46 which 15% to identify increased cardiovascular disease risk. S8. 1.",
    "word_count": 592,
    "char_count": 3803,
    "sentence_count": 65,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 40,
      "total_chunks": 166,
      "position": "41/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "cardiovascular disease",
        "heart failure",
        "adherence"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 41,
    "text": "1. 2-41S8. 1. 2-46 which 15% to identify increased cardiovascular disease risk. S8. 1. 2-8 Although this suggests that intensive efforts would be required to achieve level of risk is lower than the levels described previously, universal implementation. The choice of specific risk calculators being roughly equivalent to a 6% to 7% 10-year ASCVD for estimation of risk and risk threshold has been an important risk per the ACC/AHA Pooled Cohort Equations, most source of variability, ambiguity, and controversy. S8. 1. 2-47S8. 1. 2-54 of the participants in SPRINT had a much higher level In addition, implementation of a standard (worldwide) absoof cardiovascular disease risk. This recommendation differs from JNC 7 lute cardiovascular disease risk threshold for initiating use of blood pressure-lowering in its use of cardiovascular disease risk, rather than Diabetes or chronic kidney disease, to medications would result in large variations in medication recognize patients, including older adults, with a SBP/ use at a given level of blood pressure across countries. S8. 1. 2-48, S8. 1. 2-54, S8. 1. 2-55 DBP 140/90 mm Hg who are likely to benefit from Future research in this area should focus on issues related to blood pressure lowering drug therapy in addition to nonpharmaimplementation of a risk-based approach to cardiovascular disease prevention, cological antihypertensive treatment. In JNC 7, the blood pressure Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e41 Figure 4. Blood Hypertension (blood pressure) thresholds and recommendations for treatment and follow-up. Colors correspond to Class of Recommendation in Table 1. Using the ACC/AHA Pooled Cohort Equations. S8. 1. 2-56, S8. 1. 2-57 Note that patients with diabetes mellitus or chronic kidney disease are automatically placed in the High-risk category. For initiation of renal artery stenosis inhibitor or diuretic therapy, assess Blood tests for electrolytes and renal function 2 to 4 weeks after initiating therapy. Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of different classes. Patients with stage 2 hypertension and blood pressure ≥160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward medication dose adjustment as necessary to control blood pressure. Reassessment includes blood pressure measurement, detection of orthostatic hypotension in selected patients (eg, older or with postural symptoms), identification of white coat hypertension or a white coat effect, documentation of adherence, monitoring of the response to therapy, reinforcement of the importance of adherence, reinforcement of the importance of treatment, and assistance with treatment to achieve blood pressure target. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; blood pressure, Blood Hypertension; chronic kidney disease, chronic Kidney disease; diabetes mellitus, Diabetes mellitus; and renal artery stenosis, renin-angiotensin system. threshold for initiation of antihypertensive drug therapy 2. This recommendation is consistent with prior guidelines, was ≥ 140/90 mm Hg for the general adult population such as JNC 7. In addition, for those for whom nonpharand ≥ 130/80 mm Hg for adults with Diabetes or chronic kidney disease. macological therapy has been ineffective, antihypertenSince the publication of JNC 7 in 2003, we have gained sive drug treatment should be added in patients with an additional experience with risk assessment and new data SBP ≥140 mm Hg or a DBP ≥90 mm Hg, even in adults from randomized trials, observational studies and simuwho are at lower risk than those included in RCTs.",
    "word_count": 560,
    "char_count": 3787,
    "sentence_count": 39,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 41,
      "total_chunks": 166,
      "position": "42/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "antihypertensive",
        "cardiovascular disease",
        "adherence",
        "monitoring",
        "stage 2",
        "guideline",
        "risk category"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 42,
    "text": "The lation analyses have demonstrated that antihypertensive rationale for drug treatment in patients with an SBP ≥140 drug treatment based on overall ASCVD risk assessment mm Hg or a DBP ≥90 mm Hg and an estimated 10-year combined with blood pressure levels may prevent more cardiovascular disease events risk of cardiovascular disease 10% is based on several lines of evidence. than treatment based on blood pressure levels alone. S8. 1. 2-15S8. 1. 2-24 First, the relationship of SBP with risk of cardiovascular disease is known According to an analysis of NHANES 2011-2014, the to be continuous across levels of SBP and similar across new definition results in only a small increase in the pergroups that differ in level of absolute risk. S8. 1. 2-10 Second, centage of ultrasound adults for whom antihypertensive medicathe relative risk reduction attributable to blood pressure-lowering tion is recommended in conjunction with lifestyle modifimedication therapy is consistent across the range of abcation. The previously cited meta-analyses are consistent solute risk observed in trials, S8. 1. 2-3, S8. 1. 2-11, S8. 1. 2-58 supporting with the conclusion that lowering of blood pressure results in benefit the contention that the relative risk reduction may be simiin higher-risk individuals, regardless of their baseline lar at lower levels of absolute risk. This is the case even treated or untreated blood pressure ≥130/80 mm Hg and irrespective in a meta-analysis of trials in adults without clinical cardiovascular disease of the specific cause of their elevated risk. These analyand an average SBP/DBP of 146/84 mm Hg. S8. 1. 2-5 Finally, ses indicate that the benefit of treatment outweighs the modeling studies support the effectiveness and costpotential harm at threshold blood pressure ≥130/80 mm Hg. effectiveness of treatment of younger, lower-risk patients Downloaded from by on December 30, 2025 e42 Hypertension June 2018 over the course of their life spans. S8. 1. 2-12, S8. 1. 2-13 Although the are recommended depending on the stage of hypertension, the numbers needed to treat with blood pressure-lowering medications to presence or absence of target organ damage, treatment with prevent a cardiovascular disease event in the short term are greater in youngantihypertensive medications, and the level of blood pressure control. er, lower-risk individuals with hypertension than in older, Recommendations for follow-up are summarized in Figure 4. higher-risk adults with hypertension, the estimated gains in life expectancy attributable to long-term use of blood pressure-lowering Recommendation-Specific Supportive Text medications are correspondingly greater in younger, Low1. Nonpharmacological therapy (see Section 6. 2) is the er-risk individuals than in older adults with a higher risk of preferred therapy for adults with elevated blood pressure and an cardiovascular disease. S8. 1. 2-12, S8. 1. 2-13 Indirect support is also provided by eviappropriate first-line therapy for adults with stage 1 hydence from trials using blood pressure-lowering medications to reduce pertension who have an estimated 10-year ASCVD risk the risk of developing higher levels of BPS8. 1. 2-59S8. 1. 2-61 and, of 10%. Adherence to and impact of nonpharmacologiin one case, to achieve a reduction in LV mass. S8. 1. 2-62 In the cal therapy should be assessed within 3 to 6 months. HOPE-3 (Heart Outcomes Prevention Evaluation-3) blood pressure 2. Nonpharmacological therapy can help reduce blood pressure in paTrial, there was no evidence of short-term benefit during tients with stage 1 hypertension with an estimated 10treatment of adults (average age 66 years) with a relatively year ASCVD risk of ≥10% and should be used in addition Low risk of cardiovascular disease (3. 8% cardiovascular disease event rate during 5. 6 years of to pharmacological therapy as first-line therapy in such follow-up).",
    "word_count": 598,
    "char_count": 3912,
    "sentence_count": 48,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 42,
      "total_chunks": 166,
      "position": "43/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "blood pressure control",
        "adherence",
        "stage 1"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 43,
    "text": "8% cardiovascular disease event rate during 5. 6 years of to pharmacological therapy as first-line therapy in such follow-up). However, subgroup analysis suggested benefit patients (see Section 6. 2). in those with an average SBP approximately 140 mm Hg 3. Prompt evaluation and treatment of patients with stage (and a cardiovascular disease risk of 6. 5% during the 5. 6 years of follow2 hypertension with a combination of drug and nonup). S8. 1. 2-63 We acknowledge the importance of excluding pharmacological therapy are important because of the white coat hypertension before initiating pharmacological elevated risk of cardiovascular disease events in this subgroup, especially therapy in hypertensive patients with Low ASCVD risk. those with multiple ASCVD risk factors or target organ This may be accomplished (as described in Section 4) by damage. S8. 1. 3-1, S8. 1. 3-2 HBPM or ABPM as appropriate. 4. Prompt management of very High blood pressure is important to reduce the risk of target organ damage (see Section 11. 2). 8. 1. 3. Follow-Up After Initial blood pressure Evaluation The rapidity of the treatment needed is dependent on the Recommendations for Follow-Up After Initial blood pressure Evaluation patients clinical presentation (presence of new or worsening target organ damage) and presence or absence of References that support recommendations are summarized cardiovascular disease complications, but treatment should be initiated in Online Data Supplement 24. within at least 1 week. COR LOE Recommendations 5. Given that the lifetime risk of hypertension exceeds 80% in ultrasound adults, S8. 1. 3-3 it is likely that individuals with a normal 1. Adults with an elevated blood pressure or stage 1 hypertension who have an estimated 10blood pressure will develop elevated blood pressure in the future. blood pressure may change year ASCVD risk less than 10% should be over time because of changes in blood pressure-related lifestyle facI B-R managed with nonpharmacological therapy tors, such as degree of sedentary lifestyle, dietary Sodium and have a repeat blood pressure evaluation within 3 to intake, body weight, and alcohol intake. Less commonly, 6 months. S8. 1. 3-1, S8. 1. 3-2 secondary causes of hypertension can occur over time and 2. Adults with stage 1 hypertension who have lead to an increase in blood pressure. Periodic blood pressure screening can idenan estimated 10-year ASCVD risk of 10% tify individuals who develop elevated blood pressure over time. More or higher should be managed initially with frequent blood pressure screening may be particularly important for I B-R a combination of nonpharmacological and individuals with elevated ASCVD risk. antihypertensive drug therapy and have a repeat blood pressure evaluation in 1 month. S8. 1. 3-1, S8. 1. 3-2 8. 1. 4. General Principles of Drug Therapy 3. Adults with stage 2 hypertension should be evaluated by or referred to a primary Recommendation for General Principle of Drug Therapy care provider within 1 month of the References that support recommendations are summarized initial diagnosis, have a combination of I B-R in Online Data Supplement 25. nonpharmacological and antihypertensive drug therapy (with 2 agents of different COR LOE Recommendation classes) initiated, and have a repeat blood pressure 1. Simultaneous use of an ACE inhibitor, angiotensin receptor blocker, evaluation in 1 month. S8. 1. 3-1, S8. 1. 3-2 and/or renin inhibitor is potentially harmful III: Harm A 4. For adults with a very High average blood pressure and is not recommended to treat adults with (eg, SBP ≥180 mm Hg or DBP ≥110 mm Hg), hypertension. S8. 1. 4-1S8. 1. 4-3 I B-R evaluation followed by prompt antihypertensive drug treatment is recommended. S8. 1. 3-1, S8. 1. 3-2 Synopsis 5.",
    "word_count": 597,
    "char_count": 3779,
    "sentence_count": 66,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 43,
      "total_chunks": 166,
      "position": "44/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "sodium",
        "antihypertensive",
        "cardiovascular disease",
        "screening",
        "stage 1",
        "stage 2"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 44,
    "text": "4-3 I B-R evaluation followed by prompt antihypertensive drug treatment is recommended. S8. 1. 3-1, S8. 1. 3-2 Synopsis 5. For adults with a normal blood pressure, repeat Pharmacological agents, in addition to lifestyle modification IIa C-EO evaluation every year is reasonable. (see Section 6. 2), provide the primary basis for treatment of High blood pressure. A large number of clinical trials have demonstrated Synopsis that antihypertensive pharmacotherapy not only lowers blood pressure An important component of blood pressure management in hypertensive but reduces the risk of cardiovascular disease, cerebrovascular events, and patients is follow-up. Different periods of time for follow-up death. S8. 1. 4-4S8. 1. 4-7 Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e43 Numerous classes of antihypertensive agents are available to inhibitor aliskiren) increases cardiovascular and renal treat High blood pressure (Table 18). Agents that have been shown to reduce risk. S8. 1. 4-1S8. 1. 4-3 clinical events should be used preferentially. Therefore, the pri8. 1. 5. blood pressure Goal for Patients With Hypertension mary agents used in the treatment of hypertension include thiazide diuretics, ACE inhibitors, ARBs, and CCBsS8. 1. 4-8S8. 1. 4-11 (see Recommendations for blood pressure Goal for Patients With Section 8. 1. 6). Although many other drugs and drug classes are Hypertension available, either confirmation that these agents decrease clinical References that support recommendations are summarized outcomes to an extent similar to that of the primary agents is lackin Online Data Supplement 26 and Systematic Review Report. ing, or safety and tolerability may relegate their role to use as secondary agents. In particular, there is inadequate evidence to support COR LOE Recommendations the initial use of beta blockers for hypertension in the absence of 1. For adults with confirmed hypertension SBP: B-RSR specific cardiovascular comorbidities (see Section 9). and known cardiovascular disease or 10-year ASCVD event When the initial drug treatment of High blood pressure is being considI risk of 10% or higher (see Section 8. 1. 2), a blood pressure target of less than 130/80 mm Hg is ered, several different strategies may be contemplated. Many DBP: C-EO recommended. S8. 1. 5-1S8. 1. 5-5 patients can be started on a single agent, but consideration should be given to starting with 2 drugs of different classes SBP: B-NR 2. For adults with confirmed hypertension, without additional markers of increased cardiovascular disease for those with stage 2 hypertension (see Section 8. 1. 6. 1). In IIb risk, a blood pressure target of less than 130/80 mm Hg addition, other patient-specific factors, such as age, concurDBP: C-EO may be reasonable. S8. 1. 5-6S8. 1. 5-9 rent medications, drug adherence, drug interactions, the overSR indicates systematic review. all treatment regimen, out-of-pocket costs, and comorbidities, should be considered. From a societal perspective, total costs Synopsis must be taken into account. Shared decision making, with the Refer to the Systematic Review for the 2017 ACC/AHA/ patient influenced by clinician judgment, should drive the ultiAAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA mate choice of antihypertensive agent(s). Guideline for the Prevention, Detection, Evaluation, and Many patients started on a single agent will subsequently Management of Hypertension in Adults for the require ≥2 drugs from different pharmacological classes complete systematic evidence review for additional data to reach their blood pressure goals. S8. 1. 4-12, S8. 1. 4-13, S8. 1. 4-14 Knowledge of and analyses. S8. 1. 5-10 Several trials have tested whether more the pharmacological mechanisms of action of each agent intensive blood pressure control improves major cardiovascular disease outcomes. Metais important.",
    "word_count": 582,
    "char_count": 3908,
    "sentence_count": 69,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 44,
      "total_chunks": 166,
      "position": "45/166",
      "content_type": "treatment",
      "content_type_confidence": 9,
      "medical_entities": [
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "cardiovascular disease",
        "blood pressure control",
        "adherence",
        "stage 2",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 45,
    "text": "Metais important. Drug regimens with complementary activity, analyses and systematic reviews of these trials provide strong where a second antihypertensive agent is used to block comsupport for the more intensive approach, but the data are less pensatory responses to the initial agent or affect a different clear in identification of a specific optimal blood pressure target. S8. 1. 5-1 pressor mechanism, can result in additive lowering of blood pressure. For S8. 1. 5-5, S8. 1. 5-7, S8. 1. 5-11S8. 1. 5-13 Recent trials that address optimal blood pressure example, thiazide diuretics may stimulate the renin-angiotargets include SPRINT and ACCORD (Action to Control tensin-aldosterone system. By adding an ACE inhibitor or Cardiovascular Risk in Diabetes), with targets for more intenangiotensin receptor blocker to the thiazide, an additive blood pressure-lowering effect may be sive (SBP 120 mm Hg) and standard (SBP 140 mm Hg) obtained. S8. 1. 4-13 Use of combination therapy may also improve treatment, S8. 1. 5-14, S8. 1. 5-15 and SPS-3, with a more intensive target adherence. Several 2and 3-fixed-dose drug combinations of of 130/80 mm Hg. S8. 1. 5-16 These trials yielded mixed results in antihypertensive drug therapy are available, with complemenachieving their primary endpoints. SPRINT was stopped early, tary mechanisms of action among the components (Online after a median follow-up of 3. 26 years, when more intensive Data Supplement D). However, it should be noted that many treatment resulted in a significant reduction in the primary triple-dose combinations may contain a lower-than-optimal outcome (a cardiovascular disease composite) and in all-cause mortality rate. In dose of thiazide diuretic. ACCORD, more intensive blood pressure treatment failed to demonstrate Table 18 is a summary of oral antihypertensive drugs. a significant reduction in the primary outcome (a cardiovascular disease composite). However, the incidence of stroke, a component of the Recommendation-Specific Supportive Text primary outcome, was significantly reduced. The standard gly1. Drug combinations that have similar mechanisms of before mealscemia subgroup did show significant benefit in ACCORD, and tion or clinical effects should be avoided. For example, a meta-analysis of the only 2 trials (ACCORD and SPRINT) 2 drugs from the same class should not be administered testing an SBP goal of 120 mm Hg showed significant reductogether (eg, 2 different beta blockers, ACE inhibitors, tion in cardiovascular disease events. S8. 1. 5-17 SPS-3 failed to demonstrate benefit or nondihydropyridine CCBs). Likewise, 2 drugs from for the primary endpoint of recurrent stoke (P0. 08) but found classes that target the same blood pressure control system are less a significant reduction in a subgroup with hemorrhagic stroke. effective and potentially harmful when used together (eg, ACE inhibitors, ARBs). Exceptions to this rule inPooling of the experience from 19 trials (excluding SPRINT) clude concomitant use of a thiazide diuretic, potassium-sparing that randomly assigned participants to different blood pressure treatment diuretic, and/or loop diuretic in various combinations. targets identified a significant reduction in cardiovascular disease events, myocardial infarction, Also, dihydropyridine and nondihydropyridine CCBs can and stroke in those assigned to a lower (average achieved be combined. High-quality RCT data demonstrate that SBP/DBP was 133/76 mm Hg) versus a higher blood pressure treatment simultaneous administration of renal artery stenosis blockers (ie, ACE target. S8. 1. 5-2 Similar patterns of benefit were reported in 3 other inhibitor with angiotensin receptor blocker; ACE inhibitor or angiotensin receptor blocker with renin meta-analyses of trials in which participants were randomly Downloaded from by on December 30, 2025 e44 Hypertension June 2018 Table 18. Oral Antihypertensive Drugs Usual Dose, Range Daily Class Drug (magnesium/d) Frequency Comments Primary agents Thiazide or thiazideChlorthalidone 12.",
    "word_count": 591,
    "char_count": 4046,
    "sentence_count": 49,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 45,
      "total_chunks": 166,
      "position": "46/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "potassium",
        "magnesium",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "cardiovascular disease",
        "blood pressure control",
        "adherence"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 46,
    "text": "Oral Antihypertensive Drugs Usual Dose, Range Daily Class Drug (magnesium/d) Frequency Comments Primary agents Thiazide or thiazideChlorthalidone 12. 525 1 Chlorthalidone is preferred on the basis of prolonged half-life and proven trial type diuretics reduction of cardiovascular disease. Hydrochlorothiazide 2550 1 Monitor for hyponatremia and hypokalemia, uric acid and calcium levels. Indapamide 1. 252. 5 1 Use with caution in patients with history of acute gout unless patient is on uric Metolazone 2. 55 1 acidlowering therapy. ACE inhibitors Benazepril 1040 1 or 2 Do not use in combination with ARBs or direct renin inhibitor. Captopril 12. 5150 2 or 3 There is an increased risk of hyperkalemia, especially in patients with chronic kidney disease or in those on potassium supplements or potassium-sparing drugs. Enalapril 540 1 or 2 There is a risk of acute renal failure in patients with severe bilateral renal artery Fosinopril 1040 1 stenosis. Lisinopril 1040 1 Do not use if patient has history of angioedema with ACE inhibitors. Avoid in pregnancy. Moexipril 7. 530 1 or 2 Perindopril 416 1 Quinapril 1080 1 or 2 Ramipril 2. 520 1 or 2 Trandolapril 14 1 ARBs Azilsartan 4080 1 Do not use in combination with ACE inhibitors or direct renin inhibitor. Candesartan 832 1 There is an increased risk of hyperkalemia in chronic kidney disease or in those on potassium supplements or potassium-sparing drugs. Eprosartan 600800 1 or 2 There is a risk of acute renal failure in patients with severe bilateral renal artery Irbesartan 150300 1 stenosis. Losartan 50100 1 or 2 Do not use if patient has history of angioedema with ARBs. Patients with a history of angioedema with an ACE inhibitor can receive an angiotensin receptor blocker beginning 6 Olmesartan 2040 1 weeks after ACE inhibitor is discontinued. Telmisartan 2080 1 Avoid in pregnancy. Valsartan 80320 1 calcium channel blocker Amlodipine 2. 510 1 Avoid use in patients with HFrEF; amlodipine or felodipine may be used if dihydropyridines required. Felodipine 2. 510 1 They are associated with dose-related pedal Edema, which is more common in Isradipine 510 2 women than men. Nicardipine SR 60120 2 Nifedipine LA 3090 1 Nisoldipine 1734 1 calcium channel blocker Diltiazem ER 120360 1 Avoid routine use with beta blockers because of increased risk of bradycardia nondihydropyridines and Heart block. Verapamil IR 120360 3 Do not use in patients with HFrEF. Verapamil SR 120360 1 or 2 There are drug interactions with diltiazem and verapamil (CYP3A4 major Verapamil-delayed 100300 1 (in the substrate and moderate inhibitor). onset ER evening) Secondary agents Diureticsloop Bumetanide 0. 52 2 These are preferred diuretics in patients with symptomatic heart failure. They are preferred over thiazides in patients with moderate-to-severe chronic kidney disease (eg, glomerular filtration rate 30 Furosemide 2080 2 milliliters per minute). Torsemide 510 1 Diuretics Amiloride 510 1 or 2 These are monotherapy agents and minimally effective antihypertensive Potassium sparing agents. Triamterene 50100 1 or 2 Combination therapy of Potassium-sparing diuretic with a thiazide can be considered in patients with hypokalemia on thiazide monotherapy. Avoid in patients with significant chronic kidney disease (eg, glomerular filtration rate 45 milliliters per minute). (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e45 Table 18. Continued Usual Dose, Range Daily Class Drug (magnesium/d) Frequency Comments Diuretics Eplerenone 50100 1 or 2 These are preferred agents in primary aldosteronism and resistant hypertension. aldosterone Spironolactone 25100 1 Spironolactone is associated with greater risk of gynecomastia and impotence antagonists as compared with eplerenone. This is common add-on therapy in resistant hypertension.",
    "word_count": 593,
    "char_count": 3859,
    "sentence_count": 38,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 46,
      "total_chunks": 166,
      "position": "47/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal failure",
        "potassium",
        "calcium",
        "magnesium",
        "uric acid",
        "supplements",
        "ACE inhibitors",
        "ARBs"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 47,
    "text": "This is common add-on therapy in resistant hypertension. Avoid use with potassium supplements, other potassium-sparing diuretics, or significant renal dysfunction. Eplerenone often requires twice-daily dosing for adequate blood pressure lowering. Beta blockers Atenolol 25100 2 Beta blockers are not recommended as first-line agents unless the patient has cardioselective IHD or heart failure. Betaxolol 520 1 These are preferred in patients with bronchospastic airway disease requiring a Bisoprolol 2. 510 1 beta blocker. Metoprolol tartrate 100200 2 Bisoprolol and metoprolol succinate are preferred in patients with HFrEF. Metoprolol succinate 50200 1 Avoid abrupt cessation. Beta blockers Nebivolol 540 1 Nebivolol induces nitric oxideinduced vasodilation. cardioselective and Avoid abrupt cessation. vasodilatory Beta blockers Nadolol 40120 1 Avoid in patients with reactive airways disease. noncardioselective Propranolol IR 80160 2 Avoid abrupt cessation. Propranolol LA 80160 1 Beta blockers Acebutolol 200800 2 Generally avoid, especially in patients with IHD or heart failure. intrinsic Penbutolol 1040 1 Avoid abrupt cessation. sympathomimetic activity Pindolol 1060 2 Beta blockers Carvedilol 12. 550 2 Carvedilol is preferred in patients with HFrEF. Avoid abrupt cessation. combined alphaCarvedilol phosphate 2080 1 and beta-receptor Labetalol 200800 2 Direct renin inhibitor Aliskiren 150300 1 Do not use in combination with ACE inhibitors or ARBs. Aliskiren is very long acting. There is an increased risk of hyperkalemia in chronic kidney disease or in those on potassium supplements or potassium-sparing drugs. Aliskiren may cause acute renal failure in patients with severe bilateral renal artery stenosis. Avoid in pregnancy. Alpha-1 blockers Doxazosin 116 1 These are associated with orthostatic hypotension, especially in older adults. Prazosin 220 2 or 3 They may be considered as second-line agent in patients with concomitant BPH. Terazosin 120 1 or 2 Central alphaClonidine oral 0. 10. 8 2 These are generally reserved as last-line because of significant CNS adverse 2 agonist and other effects, especially in older adults. Clonidine patch 0. 10. 3 1 weekly centrally acting Avoid abrupt discontinuation of clonidine, which may induce hypertensive crisis; drugs Methyldopa 2501000 2 clonidine must be tapered to avoid rebound hypertension. Guanfacine 0. 52 1 Direct vasodilators Hydralazine 100200 2 or 3 These are associated with Sodium and Water retention and reflex tachycardia; use with a diuretic and beta blocker. Minoxidil 5100 1-3 Hydralazine is associated with drug-induced lupus-like syndrome at higher doses. Minoxidil is associated with hirsutism and requires a loop diuretic. Minoxidil can induce pericardial effusion. Dosages may vary from those listed in the FDA-approved labeling (available at From Chobanian et al JNC 7. S8. 1. 4-15 ACE indicates angiotensin-converting enzyme; angiotensin receptor blocker, angiotensin receptor blocker; blood pressure, Blood Hypertension; BPH, benign prostatic hyperplasia; calcium channel blocker, calcium channel blocker; chronic kidney disease, chronic Kidney disease; CNS, central nervous system; cardiovascular disease, cardiovascular disease; ER, extended release; glomerular filtration rate, glomerular estimated glomerular filtration rate; heart failure, Heart failure; HFrEF, Heart failure with reduced ejection fraction; IHD, ischemic Heart disease; IR, immediate release; LA, long-acting; and SR, sustained release. Downloaded from by on December 30, 2025 e46 Hypertension June 2018 assigned to different blood pressure targetsS8. 1. 5-3S8. 1. 5-5 and in larger metaSynopsis analyses that additionally included trials that compared difThe overwhelming majority of persons with blood pressure sufficiently ferent intensities of treatment. S8. 1. 5-12 Data from the most elevated to warrant pharmacological therapy may be best recent meta-analysis (42 trials and 144 220 patients)S8. 1. 5-5 treated initially with 2 agents (see Section 8. 1. 6. 1).",
    "word_count": 571,
    "char_count": 4034,
    "sentence_count": 52,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 47,
      "total_chunks": 166,
      "position": "48/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal failure",
        "sodium",
        "potassium",
        "calcium",
        "phosphate",
        "supplements",
        "ACE inhibitors",
        "ARBs"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 48,
    "text": "1. 5-5 treated initially with 2 agents (see Section 8. 1. 6. 1). When inidemonstrate a linear association between mean achieved tiation of pharmacological therapy with a single medication is SBP and risk of cardiovascular disease mortality with the lowest risk at 120 appropriate, primary consideration should be given to comorto 124 mm Hg. The totality of the available information protwice daily conditions (eg, heart failure, chronic kidney disease) for which specific classes of vides evidence that a lower blood pressure target is generally better than blood pressure-lowering medication are indicated (see Section 9). S8. 1. 6-1 In a higher blood pressure target and that some patients will benefit from an the largest head-to-head comparison of first-step drug therapy SBP treatment goal 120 mm Hg, especially those at High risk for hypertension, S8. 1. 6-3 the thiazide-type diuretic chlorthalidone of cardiovascular disease. S8. 1. 5-15 The specific inclusion and exclusion criteria of was superior to the calcium channel blocker amlodipine and the ACE inhibitor any RCT may limit extrapolation to a more general population lisinopril in preventing heart failure, a blood pressure-related outcome of increaswith hypertension. In addition, all of the relevant trials have ing importance in the growing population of older persons with been efficacy studies in which blood pressure measurements were more hypertension. S8. 1. 6-4S8. 1. 6-7 Additionally, ACE inhibitors were less consistent with guideline recommendations than is common effective than thiazide diuretics and CCBs in lowering blood pressure and in clinical practice, resulting in lower absolute values for SBP. in prevention of stroke. For black patients, ACE inhibitors were For both of these reasons, the SBP target recommended duralso notably less effective than CCBs in preventing HFS8. 1. 6-8 and ing blood pressure lowering (130 mm Hg) is higher than that which was in the prevention of strokeS8. 1. 6-9 (see Section 10. 1). ARBs may be used in SPRINT. better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but according to the limited available Recommendation-Specific Supportive Text experience they offer no proven advantage over ACE inhibitors 1. Meta-analysis and systematic review of trials that comin preventing stroke or cardiovascular disease in this population, making thiazide pare more intensive blood pressure reduction to standard blood pressure reducdiuretics (especially chlorthalidone) or CCBs the best initial tion report that more intense blood pressure lowering significantly choice for single-drug therapy. For stroke, in the general populareduces the risk of stroke, coronary events, major cardiotion, beta blockers were less effective than CCBs (36% lower vascular events, and cardiovascular mortality. S8. 1. 5-1 In a risk) and thiazide diuretics (30% lower risk). CCBs have been stratified analysis of these data, achieving an additional shown to be as effective as diuretics for reducing all cardiovascular disease events 10mm Hg reduction in SBP reduced cardiovascular disease risk when other than heart failure, and CCBs are a Good alternative choice for initial compared with an average SBP of 158/82 to 143/76 therapy when thiazide diuretics are not tolerated. Alpha blockmm Hg, 144/85 to 137/81 mm Hg, and 134/79 to 125/76 ers are not used as first-line therapy for hypertension because mm Hg. Patients with diabetes mellitus and chronic kidney disease were included in they are less effective for prevention of cardiovascular disease than other first-step the analysis. S8. 1. 5-1, S8. 1. 5-2, S8. 1. 5-11S8. 1. 5-13, S8. 1. 5-18 (Specific managents, such as thiazide diuretics. S8. 1. 6-3, S8. 1. 6-10 agement details are in Section 9. 3 for chronic kidney disease and Section 9. 6 for diabetes mellitus. ) Recommendation-Specific Supportive Text 2.",
    "word_count": 596,
    "char_count": 3894,
    "sentence_count": 57,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 48,
      "total_chunks": 166,
      "position": "49/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "calcium",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 49,
    "text": "3 for chronic kidney disease and Section 9. 6 for diabetes mellitus. ) Recommendation-Specific Supportive Text 2. The treatment of patients with hypertension without elevated risk has been systematically understudied because 1. The overall goal of treatment should be reduction in blood pressure, lower-risk groups would require prolonged follow-up in the context of underlying cardiovascular disease risk. Five drug classes to have a sufficient number of clinical events to provide have been shown, in High-quality RCTs, to prevent cardiovascular disease as useful information. Although there is clinical trial evicompared with placebo (diuretics, ACE inhibitors, ARBs, dence that both drug and nondrug therapy will interrupt CCBs, and beta blockers). S8. 1. 6-11, S8. 1. 6-12 In head-to-head comparisons of first-step therapy, different drug classes the progressive course of hypertension, S8. 1. 5-6 there is no have been reported to provide somewhat divergent capactrial evidence that this treatment decreases cardiovascular disease mority to prevent specific cardiovascular disease events. Interpretation of metabidity and mortality. The clinical trial evidence is stronanalyses comparing agents from different drug classes is gest for a target blood pressure of 140/90 mm Hg in this population. challenging because the relevant RCTs were conducted in However, observational studies suggest that these indidifferent time periods, during which concurrent antihyperviduals often have a High lifetime risk and would benefit tensive therapy was less or more common, and the efficacy from blood pressure control earlier in life. S8. 1. 5-19, S8. 1. 5-20 of agents from certain drug classes may have changed. In 8. 1. 6. Choice of Initial Medication recognition of this, someS8. 1. 6-2 but not allS8. 1. 6-11, S8. 1. 6-12 metaanalyses, as well as the largest individual RCT that comRecommendation for Choice of Initial Medication pared first-step agents, S8. 1. 6-3 have suggested that diuretics, especially the long-acting thiazide-type agent chlorthaReferences that support the recommendation are lidone, may provide an optimal choice for first-step drug summarized in Online Data Supplement 27 and Systematic therapy of hypertension. In contrast, some meta-analyses Review Report. have suggested that beta blockers may be less effective, COR LOE Recommendation especially for stroke prevention in older adults, but inter1. For initiation of antihypertensive drug pretation is hampered by inclusion of RCTs that used beta therapy, first-line agents include thiazide blockers that are now considered to be inferior for prevenI ASR diuretics, CCBs, and ACE inhibitors or tion of cardiovascular disease. S8. 1. 6-13, S8. 1. 6-14 In a systematic review and netARBs. S8. 1. 6-1, S8. 1. 6-2 work meta-analysis conducted for the present guideline, SR indicates systematic review. beta blockers were significantly less effective than diuretics Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e47 for prevention of stroke and cardiovascular events. S8. 1. 6-1 who have a history of hypotension or drug-associated Diuretics were also significantly better than CCBs for preside effects. However, caution is advised in initiating vention of heart failure. There were some other nonsignificant differantihypertensive pharmacotherapy with 2 drugs in older ences between diuretics, ACE inhibitors, ARBs, and CCBs, patients because hypotension or orthostatic hypotension but the general pattern was for similarity in effect. As inmay develop in some patients; blood pressure should be carefully dicated in Section 8. 1. 6. 1, most adults with hypertension monitored. require 1 drug to control their blood pressure. As recommended in 2. The stepped-care approach defined by the initiation of anSection 10.",
    "word_count": 566,
    "char_count": 3841,
    "sentence_count": 60,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 49,
      "total_chunks": 166,
      "position": "50/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 50,
    "text": "As recommended in 2. The stepped-care approach defined by the initiation of anSection 10. 1, for black adults with hypertension (without tihypertensive drug therapy with a single agent followed heart failure or chronic kidney disease), initial antihypertensive treatment should inby the sequential titration of the dose and addition of othclude a thiazide diuretic or calcium channel blocker. er agents has been the recommended treatment strategy since the first report of the National Hypertension 8. 1. 6. 1. Choice of Initial Monotherapy Versus Initial Education Program. S8. 1. 6. 1-7 This approach is also reasonCombination Drug Therapy able in older adults or those at risk or who have a history Recommendations for Choice of Initial Monotherapy Versus of hypotension or drug-associated side effects. This stratInitial Combination Drug Therapy egy has been used successfully in nearly all hypertension treatment trials but has not been formally tested against COR LOE Recommendations other antihypertensive drug treatment strategies for effec1. Initiation of antihypertensive drug therapy tiveness in achieving blood pressure control or in preventing adverse with 2 first-line agents of different classes, outcomes. either as separate agents or in a fixed-dose I C-EO combination, is recommended in adults 8. 2. Achieving blood pressure Control in Individual Patients with stage 2 hypertension and an average blood pressure more than 20/10 mm Hg above their blood pressure Recommendations for lifestyle modifications and drug selectarget. tion are specified in Sections 6. 2, 8. 1. 4, and 8. 1. 6. Initial drug selections should be based on trial evidence of treatment effi2. Initiation of antihypertensive drug therapy cacy, combined with recognition of compelling indications for with a single antihypertensive drug is reasonable in adults with stage 1 use of an agent from a specific drug class, as well as the indiIIa C-EO hypertension and blood pressure goal 130/80 mm Hg vidual patients lifestyle preferences and traits. For a subset of with dosage titration and sequential addition patients (25% to 50%), S8. 2-1 the initial drug therapy will be well of other agents to achieve the blood pressure target. tolerated and effective in achieving the desired level of blood pressure, Fixed-dose combination antihypertensive medications are listed in Online with only the need for subsequent monitoring (see Section 8. 3 Data Supplement D. for an appropriate follow-up schedule). For others, the initial drug will not be tolerated or will not be effective, requiring Synopsis either a change in medication or addition of another mediSystematic review of the evidence comparing the initiation of cation, followed by blood pressure monitoring. S8. 2-2 Approximately 25% antihypertensive treatment with monotherapy and sequential of patients will require additional treatment adjustments. (stepped-care) titration of additional agents versus initiation In a minority of this group, achievement of goal blood pressure can be of treatment with combination therapy (including fixedchallenging. dose combinations) did not identify any RCTs meeting the In patients who do not respond to or do not tolerate treatsystematic review questions posed in the PICOTS format ment with 2 to 3 medications or medication combinations, (Ppopulation, Iintervention, Ccomparator, Ooutcome, additional trials of treatment tend to be ineffective or poorly Ttiming, Ssetting). However, in both ACCORD and tolerated. Some patients may become disillusioned and lost to SPRINT, 2-drug therapy was recommended for most particifollow-up, whereas others will identify an alternative healthpants in the intensivebut not standard-therapy groups. care provider, including nontraditional healers, or will try popular home remedies. Working with this more demanding Recommendation-Specific Supportive Text subset requires provider expertise, patience, and a mecha1.",
    "word_count": 576,
    "char_count": 3935,
    "sentence_count": 38,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 50,
      "total_chunks": 166,
      "position": "51/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "calcium",
        "antihypertensive",
        "heart failure",
        "blood pressure control",
        "monitoring",
        "stage 1",
        "stage 2"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 51,
    "text": "Working with this more demanding Recommendation-Specific Supportive Text subset requires provider expertise, patience, and a mecha1. Because most patients with hypertension require multiple nism to respond efficiently and sensitively to concerns as they agents for control of their blood pressure and those with higher BPs arise. In this setting, team-based care (see Section 12) may be are at greater risk, more rapid titration of antihyperteneffective, encouraging coupling of nonpharmacological and sive medications began to be recommended in patients pharmacological treatments, while improving access to and with blood pressure 20/10 mm Hg above their target, beginning communication with care providers. with the JNC 7 report. S8. 1. 6. 1-1 In these patients, initiation In the setting of medication intolerance, consider allowing of antihypertensive therapy with 2 agents is recommenda defined period of time to evaluate the effects of lifestyle moded. Evidence favoring this approach comes mostly from studies using fixed-dose combination products showification in patients with a relatively Low cardiovascular disease risk (10-year ing greater blood pressure lowering with fixed-dose combination risk of ASCVD 10%, based on the ASCVD Risk Estimator agents than with single agents, as well as better adher- with schedence to therapy. S8. 1. 6. 1-2, S8. 1. 6. 1-3 The safety and efficacy of uled follow-up visits for assessment of blood pressure levels, including this strategy have been demonstrated in adults to reduce a review of HBPM data, and an appraisal of lifestyle change BPs to 140/90 mm Hg though not compared with other goal achievements. For patients with a higher level of cardiovascular disease strategies. S8. 1. 6. 1-4S8. 1. 6. 1-6 In general, this approach is rearisk or with significant elevations in blood pressure (SBP or DBP 20 or sonable in older adults, those at High cardiovascular disease risk, or those 10 mm Hg above target, respectively), medication is usually Downloaded from by on December 30, 2025 e48 Hypertension June 2018 started even while the patient is pursuing lifestyle change orthostatic hypotension, adverse effects from medication (see Section 8. 1. 2). therapy, adherence to medication and lifestyle therapy, Consideration of patient comorbidities, lifestyle, and prefneed for adjustment of medication dosage, laboratory erences may suggest better tolerance or greater effect from testing (including electrolyte and renal function status), one class of medication versus other classes. For example, if and other assessments of target organ damage. S8. 3. 1-1S8. 3. 1-3 hyponatremia is present, it would be important to avoid or stop 8. 3. 2. Monitoring Strategies to Improve Control of blood pressure thiazide diuretic therapy. In this case, a loop diuretic should in Patients on Drug Therapy for High blood pressure be used if a diuretic is required. If hypokalemia is present, primary or secondary aldosteronism should be excluded, after Recommendation for Monitoring Strategies to which one should consider a Potassium-sparing agent, such Improve Control of blood pressure in Patients on Drug Therapy for as spironolactone, eplerenone, triamterene, or amiloride. In High blood pressure addition, reducing dietary Sodium intake will diminish urinary References that support the recommendation are Potassium losses. If the patient has chronic cough or a history summarized in Online Data Supplement 29. of ACE inhibitorinduced cough or develops a cough or bronCOR LOE Recommendation chial responsiveness while on an ACE inhibitor, one should use an angiotensin receptor blocker in place of an ACE inhibitor. For patients with 1. Follow-up and monitoring after initiation bronchospastic lung disease, a beta-1-selective blocker (eg, of drug therapy for hypertension control should include systematic strategies bisoprolol, metoprolol) should be considered if beta-blocker I A to help improve blood pressure, including use of therapy is required.",
    "word_count": 597,
    "char_count": 3996,
    "sentence_count": 42,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 51,
      "total_chunks": 166,
      "position": "52/166",
      "content_type": "treatment",
      "content_type_confidence": 9,
      "medical_entities": [
        "renal function",
        "sodium",
        "potassium",
        "antihypertensive",
        "hypokalemia",
        "cardiovascular disease",
        "adherence",
        "monitoring"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 52,
    "text": "A patient who is already adherent to lifeHBPM, team-based care, and telehealth style change recommendations, including diligent reduction in strategies. S8. 3. 2-1S8. 3. 2-6 Sodium intake, may show a greater response to a renal artery stenosis blocker. Prior patient experience should be considered, as in the case of Recommendation-Specific Supportive Text cough associated with prior use of an ACE inhibitor, which is 1. Systematic approaches to follow-up have been shown likely to reoccur if an agent from the same class is prescribed. to improve hypertension control and can be adapted and incorporated into clinical practices according to local 8. 3. Follow-Up of blood pressure During Antihypertensive needs and resource availability (see Section 8. 3. 1 for Drug Therapy time intervals for treatment follow-up and monitoring Appropriate follow-up and monitoring enable assessment of and Sections 12. 2 and 12. 3. 2 on systematic strategies to adherence (see Section 12. 1) and response to therapy, help improve blood pressure control). identify adverse responses to therapy and target organ damage, and allow assessment of progress toward treatment goals. High9. Hypertension in Patients With quality RCTs have successfully and safely developed strategies Comorbidities for follow-up, monitoring, and reassessment from which recCertain comorbidities may affect clinical decision-making in ommendations can be made (Figure 4). S8. 2-1, S8. 2-2 A systematic hypertension. These include ischemic Heart disease, heart failure with approach to out-of-office blood pressure assessment is an essential part of reduced ejection fraction (HFrEF), HFpEF, chronic kidney disease (includfollow-up and monitoring of blood pressure, to assess response to therapy; ing renal transplantation), cerebrovascular disease, atrial fibrillation, peripheral arterial disease, check for evidence of white coat hypertension, white coat diabetes mellitus, and metabolic syndrome. S9-1 As noted in Section 8. 1. 2, effect, masked hypertension, or masked uncontrolled hypertenthis guideline generally recommends use of blood pressure-lowering sion; and help achieve blood pressure targets (see Sections 4 and 12). medications for secondary prevention of cardiovascular disease in patients 8. 3. 1. Follow-Up After Initiating Antihypertensive with clinical cardiovascular disease (CHD, heart failure, and stroke) and an average Drug Therapy blood pressure ≥130/80 mm Hg and for primary prevention of cardiovascular disease in adults with an estimated 10-year ASCVD risk of ≥10% and Recommendation for Follow-Up After Initiating an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg. Antihypertensive Drug Therapy Although we recommend use of the ACC/AHA Pooled Cohort References that support the recommendation are Equations ( to summarized in Online Data Supplement 28. estimate 10-year risk of ASCVD to establish the blood pressure threshold for treatment, the vast majority of adults with a co-morbidity COR LOE Recommendation are likely to have a 10-year risk of ASCVD that exceeds 10%. 1. Adults initiating a new or adjusted In some instances, clinical trial confirmation of treatment in drug regimen for hypertension should patients with comorbidities is limited to a target blood pressure of 140/90 have a follow-up evaluation of adherence I B-R mm Hg. In addition, the selection of medications for use in and response to treatment at monthly intervals until control is treating High blood pressure in patients with cardiovascular disease is guided by their use achieved. S8. 3. 1-1S8. 3. 1-3 for other compelling indications (eg, beta blockers after myocardial infarction, ACE inhibitors for HFrEF), as discussed in specific guidelines Recommendation-Specific Supportive Text for the clinical condition. S9-2S9-4 The present guideline does 1. Components of the follow-up evaluation should include not address the recommendations for treatment of hypertenassessment of blood pressure control, as well as evaluation for sion occurring with acute coronary syndromes.",
    "word_count": 591,
    "char_count": 4049,
    "sentence_count": 42,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 52,
      "total_chunks": 166,
      "position": "53/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "sodium",
        "ACE inhibitors",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 53,
    "text": "Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e49 9. 1. Stable Ischemic Heart Disease Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD) References that support recommendations are summarized in Online Data Supplements 30-32. COR LOE Recommendations SBP: B-R 1. In adults with SIHD and hypertension, a I blood pressure target of less than 130/80 mm Hg is DBP: C-EO recommended. S9. 1-1S9. 1-5 2. Adults with SIHD and hypertension (blood pressure ≥130/80 mm Hg) should be treated with SBP: B-R medications (eg, GDMTS9. 1-6 beta blockers, ACE inhibitors, or ARBs) for compelling indications (eg, previous myocardial infarction, stable angina) I as first-line therapy, with the addition of other drugs (eg, dihydropyridine CCBs, DBP: C-EO thiazide diuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension. S9. 1-7S9. 1-10 Figure 5. Management of hypertension in patients with SIHD. 3. In adults with SIHD with angina and persistent Colors correspond to Class of Recommendation in Table 1. uncontrolled hypertension, the addition of GDMT beta blockers for blood pressure control or relief of angina include I B-NR dihydropyridine CCBs to GDMTS9. 1-6 beta carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, blockers is recommended. S9. 1-8, S9. 1-11, S9. 1-12 bisoprolol, propranolol, and timolol. Avoid beta blockers with intrinsic sympathomimetic activity. The beta blocker atenolol 4. In adults who have had a myocardial infarction or acute coronary should not be used because it is less effective than placebo in syndrome, it is reasonable to continue GDMT reducing cardiovascular events. If needed for blood pressure control. ACE IIa B-NR (S9. 1-6) beta blockers beyond 3 years as longindicates angiotensin-converting enzyme; angiotensin receptor blocker, angiotensin term therapy for hypertension. S9. 1-13, S9. 1-14 receptor blocker; blood pressure, Blood Hypertension; calcium channel blocker, calcium channel blocker; GDMT, guideline-directed management and therapy; and 5. Beta blockers and/or CCBs might be SIHD, stable ischemic Heart disease. considered to control hypertension in patients IIb C-EO with coronary artery disease (without HFrEF) who had an myocardial infarction more than 3 years ago and have angina. until the onset of angina pectoris, reducing exercise-induced ischemic ST-segment depression, and preventing coronary events. S9. 1-8, S9. 1-17S9. 1-22 Because of their comSynopsis pelling indications for treatment of SIHD, these drugs Hypertension is a major risk factor for ischemic Heart disease. are recommended as a first-line therapy in the treatment Numerous RCTs have demonstrated the benefits of antihyof hypertension when it occurs in patients with SIHD. pertensive drug therapy in reducing the risk of ischemic Heart GDMT beta blockers for SIHD that are also effective disease. The following recommendations apply only to manin lowering blood pressure include carvedilol, metoprolol tartrate, agement of hypertension in patients with SIHD without heart failure. metoprolol succinate, nadolol, bisoprolol, propranolol, See Section 9. 2 for recommendations for the treatment of and timolol. Atenolol is not as effective as other antihypatients with SIHD and heart failure. pertensive drugs in the treatment of hypertension. S9. 1-23 Figure 5 is an algorithm on management of hypertension in 3. Dihydropyridine CCBs are effective antianginal drugs patients with SIHD. that can lower blood pressure and relieve angina pectoris when added to beta blockers in patients in whom hypertenRecommendation-Specific Supportive Text sion is present and angina pectoris persists despite beta1. In patients with increased cardiovascular risk, reduction blocker therapy. S9. 1-8, S9. 1-17, S9. 1-19S9. 1-22, S9. 1-24, S9.",
    "word_count": 566,
    "char_count": 3897,
    "sentence_count": 55,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 53,
      "total_chunks": 166,
      "position": "54/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "calcium",
        "supplements",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "heart failure",
        "exercise",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 54,
    "text": "In patients with increased cardiovascular risk, reduction blocker therapy. S9. 1-8, S9. 1-17, S9. 1-19S9. 1-22, S9. 1-24, S9. 1-25 GDMT of SBP to 130/80 mm Hg has been shown to reduce beta blockers for SIHD that are also effective in Lowcardiovascular disease complications by 25% and all-cause mortality by ering blood pressure include carvedilol, metoprolol tartrate, meto27%. S9. 1-1 prolol succinate, nadolol, bisoprolol, propranolol, 2. After 5 years of randomized therapy in High-cardiovascular disease-risk and timolol. patients, ramipril produced a 22% reduction in myocardial infarction, 4. In randomized long-term trials, use of beta blockers atrial fibrillationstroke, or cardiovascular disease compared with placebo. S9. 1-10 No added ter myocardial infarction reduced all-cause mortality by 23%. S9. 1-13 Given benefit on cardiovascular disease outcomes was seen when compared the established efficacy of beta blockers for treating hywith CCBs and diuretics. S9. 1-15, S9. 1-16 After 4. 2 years of pertension and SIHD, their use for treatment continuing randomized therapy in patients with SIHD, perindopril beyond 3 years after myocardial infarction is reasonable. S9. 1-6, S9. 1-25 reduced cardiovascular disease death, myocardial infarction, or cardiac arrest by 20% com5. GDMT beta blockers and CCBs are effective antihyperpared with placebo. S9. 1-7 Beta blockers are effective drugs tensive and antianginal agents. CCBs include dihydrofor preventing angina pectoris, improving exercise time pyridine and nondihydropyridine agents. CCBs can be Downloaded from by on December 30, 2025 e50 Hypertension June 2018 used separately or together with beta blockers beginning 9. 2. 1. Heart Failure With Reduced Ejection Fraction 3 years after myocardial infarction in patients with coronary artery disease who have both hypertension and angina. Recommendations for Treatment of Hypertension in Patients With HFrEF 9. 2. Heart Failure References that support recommendations are summarized in Online Data Supplement 34. Recommendation for Prevention of heart failure in Adults With Hypertension COR LOE Recommendations 1. Adults with HFrEF and hypertension References that support the recommendation are should be prescribed GDMTS9. 2. 1-2 summarized in Online Data Supplement 33. I C-EO titrated to attain a blood pressure of less than COR LOE Recommendation 130/80 mm Hg. SBP: B-R 1. In adults at increased risk of heart failure, the optimal 2. Nondihydropyridine CCBs are not III: No I blood pressure in those with hypertension should be less B-R recommended in the treatment of Benefit DBP: C-EO than 130/80 mm Hg. S9. 2-1S9. 2-3 hypertension in adults with HFrEF. S9. 2. 1-1 Synopsis Synopsis Antecedent hypertension is present in 75% of patients with Approximately 50% of patients with heart failure have HFrEF. S9. 2. 1-2S9. 2. 1-6 chronic heart failure. S9. 2-4 In the Cardiovascular Health StudyS9. 2-5 and Numerous RCTs have shown that treatment of HFrEF with the Health, Aging and Body Composition Study, S9. 2-6 11. 2% GDMT reduces mortality and heart failure hospitalizations. S9. 2. 1-7 of 4408 persons (53. 1% women, with a mean age of 72. 8 Large-scale RCTs have shown that antihypertensive drug years, living in the community, and not receiving antihypertherapy reduces the incidence of heart failure in patients with tensive drugs at baseline) developed heart failure over 10 years. S9. 2-7 hypertension. S9. 2. 1-8S9. 2. 1-11 In ALLHAT (Antihypertensive and Compared with those with an average SBP 120 mm Hg, Lipid-Lowering Treatment to Prevent Heart Attack Trial), the adjusted incidence of heart failure was increased 1. 6, 2. 2, and chlorthalidone reduced the risk of HFrEF more than amlo2. 6 times in those with average SBPs between 120 and 139 dipine and doxazosin but similarly to lisinopril. S9. 2. 1-12, S9. 2.",
    "word_count": 590,
    "char_count": 3847,
    "sentence_count": 78,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 54,
      "total_chunks": 166,
      "position": "55/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "diuretics",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "exercise"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 55,
    "text": "S9. 2. 1-12, S9. 2. 1-13 mm Hg, between 140 and 159 mm Hg, and ≥160 mm Hg, respectively. S9. 2-7 Recommendation-Specific Supportive Text No RCTs are available that compare one blood pressure-lowering 1. This recommendation is based on guidance in the 2017 agent to another for the management of patients with heart failure. ACC/AHA/HFSA guideline focused update on Heart The following recommendations for treatment of hypertenfailureS9. 2. 1-14 (see figure from the heart failure focused update that sion in heart failure are based on use of drugs that lower blood pressure and also is reproduced in Online Data Supplement A). Lifestyle have compelling indications for management of heart failure (with modification, such as weight loss and Sodium reduction, HFrEF or HFpEF) as recommended in current ACC/AHA may serve as adjunctive measures to help these agents guidelines. S9. 2-4, S9. 2-8 work better. No RCT evidence is available to support the superiority of one blood pressure-lowering medication with compelRecommendation-Specific Supportive Text ling indications for treatment of HFrEF over another. 1. In adults with hypertension (SBP ≥130 mm Hg or Medications with compelling indications for heart failure that DBP ≥80 mm Hg) and a High risk of cardiovascular disease, a strong body may be used as first-line therapy to treat High blood pressure include of evidence supports treatment with antihypertensive ACE inhibitors or ARBs, angiotensin receptorneprilysin medications (see Section 8. 1. 2) and more-intensive rathinhibitors, mineralocorticoid receptor antagonists, diureter than less-intensive intervention (see Section 8. 1. 5). ics, and GDMT beta blockers (carvedilol, metoprolol In SPRINT, a more intensive intervention that targeted succinate, or bisoprolol). an SBP 120 mm Hg significantly reduced the primary Clinical trials evaluating goal blood pressure reduction and optioutcome (cardiovascular disease composite) by about 25%. S9. 2-9 The inmal blood pressure-lowering agents in the setting of HFrEF and concidence of heart failure, a component of the primary outcome, comitant hypertension have not been performed. However, was also substantially decreased (hazard ratio: 0. 62; in patients at higher cardiovascular disease risk, blood pressure lowering is associated 95% confidence interval: 0. 450. 84). Meta-analyses of clinical trials have identified a similar beneficial efwith fewer adverse cardiovascular events. S9. 2. 1-7 GDMT for fect of more-intensive blood pressure reduction on the incidence of HFrEF with agents known to lower blood pressure should consider a heart failure, S9. 2-2, S9. 2-10 but the body of information from studgoal blood pressure reduction consistent with a threshold now associies confined to trials that randomly assigned particiated with improved clinical outcomes but not yet proven pants to different blood pressure targets is more limited and less by RCTs in an heart failure population. compelling. S9. 2-3 In addition, the available trials were effi2. Nondihydropyridine CCBs (verapamil, diltiazem) have cacy studies in which blood pressure measurements were more conmyocardial depressant activity. Several clinical trials sistent with guideline recommendations than is common have demonstrated either no clinical benefit or even in clinical practice, resulting in lower absolute values for worse outcomes in patients with heart failure treated with these SBP. For both of these reasons, the SBP target recomdrugs. S9. 2. 1-1 Therefore, nondihydropyridine CCBs are mended during blood pressure lowering (130 mm Hg) is higher not recommended in patients with hypertension and than that used in SPRINT. HFrEF. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e51 9. 2. 2. Heart Failure With Preserved Ejection Fraction 22% for candesartan and 24% for placebo (11% reduction), but fewer patients receiving candesartan were hosRecommendations for Treatment of Hypertension in pitalized for heart failure. S9. 2.",
    "word_count": 595,
    "char_count": 4027,
    "sentence_count": 52,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 55,
      "total_chunks": 166,
      "position": "56/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "sodium",
        "ACE inhibitors",
        "ARBs",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 56,
    "text": "S9. 2. 2-5 The use of nitrates in the setting of Patients With HFpEF HFpEF is associated with a signal of harm and in most References that support recommendations are summarized situations should be avoided. For many other common in Online Data Supplements 35 and 36. antihypertensive agents, including alpha blockers, beta blockers, and calcium channel blockers, limited data exCOR LOE Recommendations ist to guide the choice of antihypertensive therapy in the 1. In adults with HFpEF who present setting of HFpEF. S9. 2. 2-21 Renin-angiotensin-aldosterone with symptoms of volume overload, I C-EO system inhibition, however, with ACE inhibitor or angiotensin receptor blocker diuretics should be prescribed to control and especially MRA would represent the preferred hypertension. choice. A shared decision-making discussion, with the 2. Adults with HFpEF and persistent patient influenced by clinician judgment, should drive hypertension after management of the ultimate choice of antihypertensive agents. volume overload should be prescribed I C-LD ACE inhibitors or ARBs and beta blockers 9. 3. Chronic Kidney Disease titrated to attain SBP of less than 130 mm Hg. S9. 2. 2-1S9. 2. 2-6 Recommendations for Treatment of Hypertension in Patients With chronic kidney disease Synopsis References that support recommendations are summarized Approximately 50% of patients with heart failure have in Online Data Supplements 37 and 38 and Systematic HFpEF. S9. 2. 2-2, S9. 2. 2-7S9. 2. 2-11 The ejection fraction in these studies Review Report. has varied from 40% to ≥55%. S9. 2. 2-2 Patients with HFpEF are COR LOE Recommendations usually older women with a history of hypertension. Obesity, CHD, diabetes mellitus, atrial fibrillation, and hyperlipidemia are also highly prevaSBP: B-RSR 1. Adults with hypertension and chronic kidney disease I should be treated to a blood pressure goal of less than lent in patients with HFpEF. S9. 2. 2-2, S9. 2. 2-11, S9. 2. 2-12 Hypertension DBP: C-EO 130/80 mm Hg. S9. 3-1S9. 3-6 is the most important cause of HFpEF, with a prevalence of 60% to 89% in large RCTs, epidemiological studies, and heart failure 2. In adults with hypertension and chronic kidney disease (stage 3 or higher or stage 1 or 2 with registries. S9. 2. 2-2, S9. 2. 2-13 Patients with HFpEF also have an exagalbuminuria ≥300 magnesium/d, or ≥300 gerated hypertensive response to exercise. S9. 2. 2-14 Hypertensive magnesium/g albumin-to-Creatinine ratio or acute pulmonary Edema is an expression of HFpEF. S9. 2. 2-15 IIa B-R the equivalent in the first morning blood pressure control is important for prevention of HFpEF in void), treatment with an ACE inhibitor patients with hypertension. S9. 2. 2-2, S9. 2. 2-16S9. 2. 2-19 ALLHAT showed is reasonable to slow Kidney disease that treatment of hypertension with chlorthalidone reduced progression. S9. 3-3, S9. 3-7S9. 3-12 the risk of heart failure compared with amlodipine, doxazosin, and 3. In adults with hypertension and chronic kidney disease (stage lisinopril. S9. 2. 2-19, S9. 2. 2-20 Improved blood pressure control also reduces hospi3 or higher or stage 1 or 2 with albuminuria talization, cardiovascular disease events, and mortality. S9. 2. 2-2, S9. 2. 2-16S9. 2. 2-19 ≥300 magnesium/d, or ≥300 magnesium/g albumin-toIIb C-EO Creatinine ratio in the first morning void) Recommendation-Specific Supportive Text (S9. 3-7, S9. 3-8), treatment with an angiotensin receptor blocker may be reasonable if an ACE inhibitor is not 1. Diuretics are the only drugs used for the treatment of tolerated. hypertension and heart failure that can adequately control the SR indicates systematic review. fluid retention of heart failure. Appropriate use of diuretics is also crucial to the success of other drugs used for the treatment of hypertension in the presence of heart failure.",
    "word_count": 600,
    "char_count": 3839,
    "sentence_count": 84,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 56,
      "total_chunks": 166,
      "position": "57/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "albuminuria",
        "creatinine",
        "calcium",
        "magnesium",
        "supplements",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 57,
    "text": "Synopsis The use of inappropriately Low doses of diuretics can Refer to the Systematic Review for the 2017 ACC/AHA/ result in fluid retention. Conversely, the use of inapAAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA propriately High doses of diuretics can lead to volume Guideline for the Prevention, Detection, Evaluation, and contraction, which can increase the risk of hypotension Management of Hypertension in Adults for the and renal insufficiency. Diuretics should be prescribed complete systematic evidence review for additional data and to all patients with hypertension and HFpEF who have analyses. S9. 3-13 Hypertension is the most common comorbidity evidence of, and to most patients with a prior history of, affecting patients with chronic kidney disease. Hypertension has been reported fluid retention. in 67% to 92% of patients with chronic kidney disease, with increasing preva2. In a trial of patients with HFpEF and myocardial infarction, patients ranlence as Kidney function declines. S9. 3-14 Hypertension may domized to propranolol had at 32-month follow-up a occur as a result of Kidney disease, yet the presence of hyper35% reduction in mortality rate. S9. 2. 2-3 After 21 months of tension may also accelerate further Kidney injury; therefore, treatment in patients with HFrEF and HFpEF, compared with placebo, those randomized to nebivolol had a 14% treatment is an important means to prevent further Kidney reduction in mortality or cardiovascular disease hospitalization if they had functional decline. This tight interaction has led to extenHFrEF and a 19% reduction if they had HFpEF. S9. 2. 2-4 In sive debate about the optimal blood pressure target for patients with patients with HFpEF, the primary outcome (a composite chronic kidney disease. S9. 3-15S9. 3-18 Masked hypertension may occur in up to of cardiovascular disease death or heart failure hospitalization) was observed in 30% of patients with chronic kidney disease and portends higher risk of chronic kidney disease Downloaded from by on December 30, 2025 e52 Hypertension June 2018 progression. S9. 3-19S9. 3-23 chronic kidney disease is an important risk factor for cardiovascular disease, S9. 3-24 and the coexistence of hypertension and chronic kidney disease further increases the risk of adverse cardiovascular disease and cerebrovascular events, particularly when proteinuria is present. S9. 3-25 Even as the importance of hypertension treatment is widely accepted, data supporting blood pressure targets in chronic kidney disease are limited, as patients with chronic kidney disease were historically excluded from clinical trials. Furthermore, chronic kidney disease is not included in the cardiovascular disease risk calculations used to determine suitability for most clinical trials. S9. 3-26S9. 3-28 Until publication of the SPRINT results, most guidelines for blood pressure targets in patients with chronic kidney disease favored treatment to a blood pressure 140/90 mm Hg, S9. 3-15 with consideration of the lower target of 130/80 mm Hg for those with more severe proteinuria (≥300 magnesium albuminuria in 24 hours or the equivalent), if tolerated. S9. 3-16S9. 3-18 Patients with stage 3 to 4 chronic kidney disease (estimated glomerular filtration rate of 20 to 60 mL/minute/1. 73 m2) comprised 28% of the SPRINT study population, and in this group intensive blood pressure management seemed to provide the same benefits for reduction in the cardiovascular disease composite primary outcome and all-cause mortality as were seen in the full study cohort. Given that most patients with chronic kidney disease die from cardiovascular disease complications, this RCT evidence supports a lower target of 130/80 mm Hg for all patients with chronic kidney disease (Figure 6). It is appropriate to acknowledge that many patients with chronic kidney disease have additional comorbidities and evidence of frailty that caused them to be excluded from past clinical trials.",
    "word_count": 596,
    "char_count": 3966,
    "sentence_count": 37,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 57,
      "total_chunks": 166,
      "position": "58/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "albuminuria",
        "proteinuria",
        "magnesium",
        "diuretics",
        "cardiovascular disease",
        "heart failure",
        "stage 3"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 58,
    "text": "Observational studies of chronic kidney disease cohorts indicate a higher risk of mortality at lower systolic pressures and a flat relationship of SBP to Figure 6. Management of hypertension in patients with chronic kidney disease. event risk in elderly patients with chronic kidney disease, S9. 3-29, S9. 3-30 which supColors correspond to Class of Recommendation in Table 1. chronic kidney disease stage 3 or higher or stage 1 or 2 with albuminuria ≥300 ports concerns that these complex patients may be at greater magnesium/d or ≥300 magnesium/g Creatinine. ACE indicates angiotensinrisk of complications from intensive blood pressure treatment and may converting enzyme; angiotensin receptor blocker, angiotensin receptor blocker; blood pressure fail to achieve benefits from lower blood pressure targets. In contrast, in Blood Hypertension; and chronic kidney disease, chronic Kidney disease. the prespecified subgroup analysis of the elderly cohort in SPRINT, frail elderly patients did sustain benefit from the Figure 6 is an algorithm on management of hypertension in lower blood pressure target, which supports a lower goal for all patients, patients with chronic kidney disease. including those with chronic kidney disease. S9. 3-31 In this setting, incremental blood pressure reduction may be appropriate, with careful monitoring of Recommendation-Specific Supportive Text physical and Kidney function. 1. We recommend ASCVD risk assessment in all adults An ACE inhibitor (or an angiotensin receptor blocker, in case of ACE inhibitor with hypertension, including those with chronic kidney disease. As a intolerance) is a preferred drug for treatment of hypertenmatter of convenience, however, it can be assumed that sion if albuminuria (≥300 magnesium/day or ≥300 magnesium/g Creatinine the vast majority of patients with chronic kidney disease have a 10-year by first morning void) is present, although the evidence is ASCVD risk ≥10%, placing them in the High risk catmixedS9. 3-10, S9. 3-11 (Figure 6). In the course of reducing intraegory that requires initiation of antihypertensive drug therapy at blood pressure ≥130/80 mm Hg (see Section 8. 1. 2, glomerular Hypertension and thereby reducing albuminuria, Figure 4 and Table 23 for blood pressure thresholds for initiating serum Creatinine may increase up to 30% because of concurantihypertensive drug treatment). In SPRINT, the parrent reduction in glomerular filtration rate. S9. 3-32 Further glomerular filtration rate decline should be ticipants with chronic kidney disease who were randomized to intensive investigated and may be related to other factors, including antihypertensive therapy (SBP target 120 mm Hg) apvolume contraction, use of nephrotoxic agents, or renovaspeared to derive the same beneficial reduction in cardiovascular disease cular disease. S9. 3-33 The combination of an ACE inhibitor and events and all-cause mortality that was seen in their an angiotensin receptor blocker should be avoided because of reported harms demcounterparts without chronic kidney disease at baseline. Likewise, inonstrated in several large cardiology trialsS9. 3-34, S9. 3-35 and in 1 tensive therapy was beneficial even in those ≥75 years diabetic nephropathy trial. S9. 3-36 Because of the greater risk of age with frailty or the slowest gait speed. There was of hyperkalemia and hypotension and lack of demonstrated no difference in the principal Kidney outcome (≥50% benefit, the combination of an angiotensin receptor blocker (or ACE inhibitor) and a decline in estimated glomerular filtration rate or end-stage renal disease) between the intensive-and direct renin inhibitor is also contraindicated during managestandard-therapy (SBP target 140 mm Hg) groups. S9. 3-26 ment of patients with chronic kidney disease. S9. 3-37 Three other RCTsS9. 3-1S9.",
    "word_count": 566,
    "char_count": 3828,
    "sentence_count": 35,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 58,
      "total_chunks": 166,
      "position": "59/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "end-stage renal disease",
        "nephropathy",
        "albuminuria",
        "creatinine",
        "magnesium",
        "serum creatinine",
        "antihypertensive"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 59,
    "text": "S9. 3-26 ment of patients with chronic kidney disease. S9. 3-37 Three other RCTsS9. 3-1S9. 3-3 have evaluated the effect Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e53 of differing blood pressure goals of 140/90 mm Hg versus 125 less common when calcineurin inhibitors have been used 130/7580 mm Hg on chronic kidney disease progression in patients with without corticosteroids in Liver transplantation patients, S9. 3. 1-8 chronic kidney disease. None of these trials demonstrated a benefit for although prevalence rates have not differed in steroid minimore intensive blood pressure reduction, although post hoc followmization trials after Kidney transplantation. S9. 3. 1-9, S9. 3. 1-10 up analyses favored the lower targets in patients with Reports from long-term belatacept-based immunosuppresmore severe proteinuria, S9. 3-38, S9. 3-39 and these trials were sion studies indicate higher glomerular filtration rate and preservation of kidunderpowered to detect differences in cardiovascular disease event rates. ney function. However, hypertension was still present in the Recent meta-analyses and systematic reviews that inmajority of patients, although fewer agents were needed to cluded patients with chronic kidney disease from SPRINT support more achieve blood pressure goals. S9. 3. 1-11 Severity of hypertension and intenintensive blood pressure treatmentS9. 3-40S9. 3-42 to reduce cardiovassity of treatment may differ somewhat depending on the cular events but do not demonstrate a reduction in the type of organ transplanted; however, most concepts relevant rate of progression of Kidney disease (doubling of seto Kidney transplant recipients will apply to the other solid rum Creatinine or reaching end-stage renal disease). More intensive blood pressure organ recipients as well. treatment may result in a modest reduction in glomerular filtration rate, blood pressure targets change over time after transplantation. Initially, which is thought to be primarily due to a hemodynamic it is important to maintain ample organ perfusion with less effect and may be reversible. Electrolyte abnormalities are also more likely during intensive blood pressure treatment. stringent blood pressure targets (160/90 mm Hg) to avoid hypotenMore intensive blood pressure lowering in patients with chronic kidney disease is sion and risk of graft thrombosis. Beyond the first month, also supported by a blood pressure Lowering Treatment Trialists blood pressure should be controlled to prevent target organ damage as in Collaboration meta-analysis of RCTs in patients with the nontransplantation setting. S9. 3. 1-12, S9. 3. 1-13 Hypertension after chronic kidney disease. S9. 3-43 transplantation is often associated with altered circadian blood pressure 2. Evidence comes from AASK (The African American Study rhythm with loss of the normal nocturnal blood pressure fallS9. 3. 1-14, S9. 3. 1-15 of Kidney Disease and Hypertension), 2 small trials (1 and, in some, a nocturnal blood pressure rise. These changes may return to positive, 1 negative), and a meta-analysis. S9. 3-3, S9. 3-6, S9. 3-10, S9. 3-11 normal after a longer period of follow-up. S9. 3. 1-16 Albuminuria is quantified by 24-hour Urine collection. A 10% to 25% increase in serum Creatinine may occur Recommendation-Specific Supportive Text in some patients with chronic kidney disease as a result of ACE inhibitor 1. Although treatment targets for hypertension after transtherapy. plantation should probably be similar to those for other 3. ARBs were shown to be noninferior to ACE inhibitors patients with chronic kidney disease, there are no trials in post-transplanin clinical trials in the non-chronic kidney disease population. S9. 3-35 A 10% tation patients comparing different blood pressure targets.",
    "word_count": 569,
    "char_count": 3835,
    "sentence_count": 56,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 59,
      "total_chunks": 166,
      "position": "60/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "serum creatinine",
        "ACE inhibitors",
        "ARBs",
        "kidney transplant"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 60,
    "text": "S9. 3-35 A 10% tation patients comparing different blood pressure targets. As Kidney to 25% increase in serum Creatinine may occur in some transplant recipients generally have a single functioning patients with chronic kidney disease as a result of angiotensin receptor blocker therapy. Kidney and chronic kidney disease, blood pressure targets should be similar to those for the general chronic kidney disease population. 9. 3. 1. Hypertension After Renal Transplantation 2. Limited studies have compared drug choice for initial Recommendations for Treatment of Hypertension After antihypertensive therapy in patients after Kidney transRenal Transplantation plantation. On the basis of a Cochrane analysis, S9. 3. 1-2 most studies favor CCBs to reduce graft loss and mainReferences that support recommendations are summarized tain higher glomerular filtration rate, with some evidence suggesting potenin Online Data Supplements 39 and 40. tial harm from ACE inhibitors because of anemia, hyperCOR LOE Recommendations kalemia, and lower glomerular filtration rate. In recognition of this concern, SBP: B-NR 1. After Kidney transplantation, it is reasonable renal artery stenosis inhibitors may be reserved for the subset of patients IIa to treat patients with hypertension to a blood pressure with hypertension and additional comorbidities that supDBP: C-EO goal of less than 130/80 mm Hg. S9. 3. 1-1 port the need for ACE inhibitor therapy (ie, proteinuria or heart failure after transplantation). With appropriate Potassium 2. After Kidney transplantation, it is reasonable and Creatinine monitoring, this has been demonstrated to to treat patients with hypertension with a IIa B-R calcium antagonist on the basis of improved be safe. S9. 3. 1-17 glomerular filtration rate and Kidney survival. S9. 3. 1-2 9. 4. Cerebrovascular Disease Synopsis Stroke is a leading cause of death, disability, and dementia. S9. 4-1 After Kidney transplantation, hypertension is common because Because of its heterogeneous causes and hemodynamic conof preexisting Kidney disease, the effects of immunosuppressequences, the management of blood pressure in adults with stroke is sive medications, and the presence of allograft pathology. S9. 3. 1-3 complex and challenging. S9. 4-2 To accommodate the variety of Transplant recipients frequently harbor multiple cardiovascular disease risk facimportant issues pertaining to blood pressure management in the stroke tors and are at High risk of cardiovascular disease events. Hypertension may patient, treatment recommendations require recognition of accelerate target organ damage and Kidney function decline, stroke acuity, stroke type, and therapeutic objectives. Future particularly when proteinuria is present. S9. 3. 1-4S9. 3. 1-6 studies should target more narrowly defined questions, such Use of calcineurin inhibitorbased immunosuppression as optimal blood pressure-reduction timing and target, as well as ideal regimens after transplantation is associated with a High (70% antihypertensive agent therapeutic class by patient type and to 90%) prevalence of hypertension. S9. 3. 1-7 Hypertension is event type. Downloaded from by on December 30, 2025 e54 Hypertension June 2018 9. 4. 1. Acute Intracerebral Hemorrhage lowering of SBP in ICH patients with markedly High SBP levels (220 mm Hg) might be sensible. A secondRecommendations for Management of Hypertension in ary endpoint in 1 RCT and an overview of data from 4 Patients With Acute Intracerebral Hemorrhage (ICH) RCTs indicate that intensive blood pressure reduction, versus blood pressureReferences that support recommendations are summarized lowering guideline treatment, is associated with greater in Online Data Supplement 41. functional recovery at 3 months. S9. 4. 1-1, S9. 4. 1-7 2. RCT data have suggested that immediate blood pressure lowering COR LOE Recommendations (to 140/90 mm Hg) within 6 hours of an acute ICH 1. In adults with ICH who present with SBP was feasible and safe, S9. 4. 1-1, S9. 4. 1-8, S9. 4.",
    "word_count": 595,
    "char_count": 4019,
    "sentence_count": 61,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 60,
      "total_chunks": 166,
      "position": "61/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "creatinine",
        "potassium",
        "calcium",
        "serum creatinine",
        "supplements",
        "ACE inhibitors"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 61,
    "text": "In adults with ICH who present with SBP was feasible and safe, S9. 4. 1-1, S9. 4. 1-8, S9. 4. 1-9 may be linked to greater than 220 mm Hg, it is reasonable greater attenuation of absolute hematoma growth at 24 IIa C-EO to use continuous intravenous drug infusion hours, S9. 4. 1-7 and might be associated with modestly better (Table 19) and close blood pressure monitoring to lower functional recovery in survivors. S9. 4. 1-1, S9. 4. 1-7 However, a SBP. recent RCTS9. 4. 1-2 that examined immediate blood pressure lowering 2. Immediate lowering of SBP (Table 19) to less within 4. 5 hours of an acute ICH found that treatment to than 140 mm Hg in adults with spontaneous achieve a target SBP of 110 to 139 mm Hg did not lead to ICH who present within 6 hours of the a lower rate of death or disability than standard reduction III: Harm A acute event and have an SBP between 150 mm Hg and 220 mm Hg is not of benefit to to a target of 140 to 179 mm Hg. Moreover, there were reduce death or severe disability and can be significantly more renal adverse events within 7 days atrial fibrillationpotentially harmful. S9. 4. 1-1, S9. 4. 1-2 ter randomization in the intensive-treatment group than in the standard-treatment group. S9. 4. 1-2 Put together, neither of the 2 key trialsS9. 4. 1-1, S9. 4. 1-2 evaluating the effect of Synopsis lowering SBP in the acute period after spontaneous ICH Spontaneous, nontraumatic ICH is a significant global cause of met their primary outcomes of reducing death and severe morbidity and mortality. S9. 4. 1-3 Elevated blood pressure is highly prevalent disability at 3 months. in the setting of acute ICH and is linked to greater hematoma expansion, neurological worsening, and death and dependency 9. 4. 2. Acute Ischemic Stroke after ICH. Figure 7 is an algorithm on management of hypertension in Recommendations for Management of Hypertension in patients with acute ICH. Patients With Acute Ischemic Stroke References that support recommendations are summarized Recommendation-Specific Supportive Text in Online Data Supplement 42. 1. Information about the safety and effectiveness of early intensive blood pressure-lowering treatment is least well established COR LOE Recommendations for patients with markedly elevated blood pressure (sustained SBP 1. Adults with acute ischemic stroke and 220 mm Hg) on presentation, patients with large and elevated blood pressure who are eligible for treatment severe ICH, or patients requiring surgical decompreswith intravenous tissue plasminogen I B-NR sion. However, given the consistent nature of the data activator should have their blood pressure slowly linking High blood pressure with poor clinical outcomesS9. 4. 1-4S9. 4. 1-6 lowered to less than 185/110 mm Hg before thrombolytic therapy is initiated. S9. 4. 2-1, S9. 4. 2-2 and some suggestive data for treatment in patients with modestly High initial SBP levels, S9. 4. 1-1, S9. 4. 1-7 early 2. In adults with an acute ischemic stroke, blood pressure should be less than 185/110 mm Hg before administration of intravenous tissue I B-NR plasminogen activator and should be maintained below 180/105 mm Hg for at least the first 24 hours after initiating drug therapy. S9. 4. 2-3 3. Starting or restarting antihypertensive therapy during hospitalization in patients with blood pressure greater than 140/90 mm Hg who are IIa B-NR neurologically stable is safe and reasonable to improve long-term blood pressure control, unless contraindicated. S9. 4. 2-4, S9. 4. 2-5 4.",
    "word_count": 576,
    "char_count": 3505,
    "sentence_count": 68,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 61,
      "total_chunks": 166,
      "position": "62/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "antihypertensive",
        "blood pressure control",
        "monitoring"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 62,
    "text": "S9. 4. 2-4, S9. 4. 2-5 4. In patients with blood pressure of 220/120 mm Hg or higher who did not receive intravenous alteplase or endovascular treatment and have no comorbid conditions requiring acute antihypertensive treatment, the benefit IIb C-EO of initiating or reinitiating treatment of hypertension within the first 48 to 72 hours Figure 7. Management of hypertension in patients with acute is uncertain. It might be reasonable to lower ICH. Colors correspond to Class of Recommendation in Table 1. blood pressure by 15% during the first 24 hours after blood pressure indicates Blood Hypertension; ICH, intracerebral hemorrhage; IV, onset of stroke. intravenous; and SBP, systolic Blood Hypertension. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e55 stroke subtype and other patient-specific comorbidities. Recommendations for Management of Hypertension in Early initiation or resumption of antihypertensive treatment Patients With Acute Ischemic Stroke (Continued) after acute ischemic stroke is indicated only in specific COR LOE Recommendations situations: 1) patients treated with tissue-type plasminogen 5. In patients with blood pressure less than 220/120 activator, S9. 4. 2-1, S9. 4. 2-2 and 2) patients with SBP 220 mm Hg mm Hg who did not receive intravenous or DBP 120 mm Hg. For the latter group, it should be kept thrombolysis or endovascular treatment in mind that cerebral autoregulation in the ischemic penumbra and do not have a comorbid condition of the stroke is grossly abnormal and that systemic perfusion III: No requiring acute antihypertensive treatment, A Hypertension is needed for Blood flow and oxygen delivery. Rapid Benefit initiating or reinitiating treatment of hypertension within the first 48 to 72 reduction of blood pressure, even to lower levels within the hypertensive hours after an acute ischemic stroke range, can be detrimental. For all other acute ischemic stroke is not effective to prevent death or patients, the advantage of lowering blood pressure early to reduce death dependency. S9. 4. 2-4S9. 4. 2-9 and dependency is uncertain, S9. 4. 2-4S9. 4. 2-9 but restarting antihypertensive therapy to improve long-term blood pressure control is reasonSynopsis able after the first 24 hours for patients who have preexisting Elevated blood pressure is common during acute ischemic stroke hypertension and are neurologically stable. S9. 4. 2-4, S9. 4. 2-5, S9. 4. 2-14 (occurring in up to 80% of patients), especially among Figure 8 is an algorithm on management of hypertension in patients with a history of hypertension. S9. 4. 2-10 However, patients with acute ischemic stroke. blood pressure often decreases spontaneously during the acute phase of ischemic stroke, as soon as 90 minutes after the onset Recommendation-Specific Supportive Text of symptoms. Countervailing theoretical concerns about 1. These blood pressure cutoffs correspond to study inclusion criteria arterial hypertension during acute ischemic stroke include in pivotal clinical trials of intravenous thrombolysis for aiming to enhance cerebral perfusion of the ischemic tissue acute ischemic stroke. S9. 4. 2-1 while minimizing the exacerbation of brain Edema and hem2. In a large observational study of patients with acute orrhagic transformation of the ischemic tissue. S9. 4. 2-11, S9. 4. 2-12 ischemic stroke who received intravenous tissue-type Some studies have shown a U-shaped relationship between plasminogen activator, High blood pressure during the initial the admission blood pressure and favorable clinical outcomes, with an 24 hours was linked to greater risk of symptomatic optimal SBP and DBP ranging from 121 to 200 mm Hg and ICH. S9. 4. 2-3 81 to 110 mm Hg, respectively. S9. 4. 2-13 It is conceivable that 3. For the goal of antihypertensive therapy, see Section 8. 1.",
    "word_count": 593,
    "char_count": 3863,
    "sentence_count": 59,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 62,
      "total_chunks": 166,
      "position": "63/166",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "antihypertensive",
        "edema",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 63,
    "text": "S9. 4. 2-13 It is conceivable that 3. For the goal of antihypertensive therapy, see Section 8. 1. 5. an optimal arterial blood pressure range exists during acute ischemic 4. Extreme arterial hypertension is detrimental because it stroke on an individual basis, contingent on the ischemic can lead to encephalopathy, cardiac compromise, and Figure 8. Management of hypertension in patients with acute ischemic stroke. Colors correspond to Class of Recommendation in Table 1. blood pressure indicates Blood Hypertension; DBP, diastolic Blood Hypertension; IV, intravenous; and SBP, systolic Blood Hypertension. Downloaded from by on December 30, 2025 e56 Hypertension June 2018 renal damage. However, hypotension, especially when Synopsis too rapidly achieved, is potentially harmful because it Each year in the United States, 750 000 adult patients experiabruptly reduces perfusion to multiple organs, including ence a stroke, of which up to 25% are recurrent strokes. S9. 4. 3-10 the brain. For an individual who experiences an initial stroke or TIA, the 5. Data from 2 RCTs, S9. 4. 2-5, S9. 4. 2-9 as well as systematic reannual risk of a subsequent or secondary stroke is approxiviews and meta-analyses, S9. 4. 2-6S9. 4. 2-8 indicate that antihymately 4%, S9. 4. 3-11 and the case mortality rate is 41% after a pertensive agents reduce blood pressure during the acute phase of an recurrent stroke versus 22% after an initial stroke. S9. 4. 3-12 Among ischemic stroke but do not confer benefit with regard to patients with a recent stroke or TIA, the prevalence of premorshort- and long-term dependency and mortality rate. One twice daily hypertension is approximately 70%. S9. 4. 3-13 Risk of recurrent RCT did not demonstrate a benefit of continuing prestroke is heightened by presence of elevated blood pressure, and guidelinestroke antihypertensive drugs during the first few days recommended antihypertensive drug treatment to lower blood pressure has after an acute stroke, but it was substantially underpowbeen linked to a reduction in 1-year recurrent stroke risk. S9. 4. 3-14 ered to answer the question. S9. 4. 2-4 RCT meta-analyses show an approximately 30% decrease in recurrent stroke risk with blood pressure-lowering therapies. S9. 4. 3-1S9. 4. 3-3 An 9. 4. 3. Secondary Stroke Prevention issue frequently raised by clinicians is whether the presence of Recommendations for Treatment of Hypertension for clinically asymptomatic cerebral infarction incidentally noted on Secondary Stroke Prevention brain imaging (computed tomography or magnetic resonance imaging scan) in patients without a history of or symptoms of a stroke or TIA warrants References that support recommendations are summarized implementation of secondary stroke prevention measures. in Online Data Supplements 43 and 44. Clinically asymptomatic vascular brain injury is increasingly COR LOE Recommendations being considered as an entry point for secondary stroke preven1. Adults with previously treated hypertension tion therapies, because these apparently silent brain infarctions who experience a stroke or transient are associated with typical stroke risk factors, accumulatively ischemic attack (TIA) should be restarted lead to subtle neurological impairments, and bolster risk of I A on antihypertensive treatment after the first future symptomatic stroke events. S9. 4. 3-15 Although the evidence few days of the index event to reduce the for using antihypertensive treatment to prevent recurrent stroke risk of recurrent stroke and other vascular events. S9. 4. 3-1S9. 4. 3-3 in stroke patients with elevated blood pressure is compelling, S9. 4. 3-1S9. 4. 3-3 questions remain about when precisely after an index stroke to 2.",
    "word_count": 564,
    "char_count": 3719,
    "sentence_count": 62,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 63,
      "total_chunks": 166,
      "position": "64/166",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "supplements",
        "antihypertensive"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 64,
    "text": "4. 3-1S9. 4. 3-3 questions remain about when precisely after an index stroke to 2. For adults who experience a stroke initiate it, what specific agent(s) to use (if any), which therapeuor TIA, treatment with a thiazide diuretic, ACE inhibitor, or angiotensin receptor blocker, or tic targets to aim for, and whether the treatment approach should I A combination treatment consisting of a vary by index stroke mechanism and baseline level of blood pressure. S9. 4. 3-16 thiazide diuretic plus ACE inhibitor, is Figure 9 is an algorithm on management of hypertension useful. S9. 4. 3-1, S9. 4. 3-3S9. 4. 3-5 in patients with a previous history of stroke (secondary stroke 3. Adults not previously treated for prevention). hypertension who experience a stroke or TIA and have an established blood pressure of 140/90 Recommendation-Specific Supportive Text mm Hg or higher should be prescribed 1. Two overviews of RCTs published through 2009 showed I B-R antihypertensive treatment a few days that antihypertensive medications lowered the risk of after the index event to reduce the risk recurrent vascular events in patients with stroke or of recurrent stroke and other vascular TIA. S9. 4. 3-1S9. 4. 3-3 events. S9. 4. 3-1S9. 4. 3-3 2. Specific agents that have shown benefit in either dedi4. For adults who experience a stroke or cated RCTs or systematic reviews of RCT data include TIA, selection of specific drugs should diuretics, ACE inhibitors, and ARBs. I B-NR be individualized on the basis of patient 3. Support for this recommendation is based on data from comorbidities and agent pharmacological 2 dedicated RCTs, as well as a systematic review and class. S9. 4. 3-6 meta-analysis, among patients with a history of stroke or 5. For adults who experience a stroke or TIA, a TIA. S9. 4. 3-1S9. 4. 3-3 IIb B-R blood pressure goal of less than 130/80 mm Hg may be 4. Reduction in blood pressure appears to be more important than the reasonable. S9. 4. 3-6, S9. 4. 3-7 choice of specific agents used to achieve this goal. Thus, 6. For adults with a lacunar stroke, a target if diuretic and ACE inhibitor or angiotensin receptor blocker treatment do not IIb B-R SBP goal of less than 130 mm Hg may be achieve blood pressure target, other agents, such as calcium channel blocker and/or reasonable. S9. 4. 3-8 mineralocorticoid receptor antagonist, may be added. 7. In adults previously untreated for 5. An overview of RCTs showed that larger reductions in hypertension who experience an ischemic SBP tended to be associated with greater reduction in stroke or TIA and have a SBP less than 140 risk of recurrent stroke. However, a separate overview IIb C-LD mm Hg and a DBP less than 90 mm Hg, of RCTs in patients who experienced a stroke noted that the usefulness of initiating antihypertensive achieving an SBP level 130 mm Hg was not associtreatment is not well established. S9. 4. 3-9 ated with a lower stroke risk, and several observational Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e57 Figure 9. Management of hypertension in patients with a previous history of stroke (secondary stroke prevention). Colors correspond to Class of Recommendation in Table 1. DBP indicates diastolic Blood Hypertension; SBP, systolic Blood Hypertension; and TIA, transient ischemic attack. studies did not show benefit with achieved SBP levels are commonly enrolled in trials of antihypertensive drug 120 mm Hg. S9. 4. 3-5 therapy. However, patients with peripheral arterial disease typically comprise a 6.",
    "word_count": 586,
    "char_count": 3552,
    "sentence_count": 67,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 64,
      "total_chunks": 166,
      "position": "65/166",
      "content_type": "treatment",
      "content_type_confidence": 10,
      "medical_entities": [
        "calcium",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 65,
    "text": "S9. 4. 3-5 therapy. However, patients with peripheral arterial disease typically comprise a 6. Patients with a lacunar stroke treated to an SBP target small fraction of participants, so in the few trials that report of 130 mm Hg versus 130 to 140 mm Hg may be less results in patients with peripheral arterial disease, subgroup analyses are generally likely to experience a future ICH. underpowered. 7. No published RCTs have specifically addressed this question, but a post hoc analysis of an RCT suggests that Recommendation-Specific Supportive Text the effectiveness of antihypertensive treatment for sec1. There is no major difference in the relative risk reondary stroke prevention diminishes as initial baseline duction in cardiovascular disease from blood pressure-lowering therapy between blood pressure declines. S9. 4. 3-9 patients with hypertension and peripheral arterial disease and patients without peripheral arterial disease. S9. 5-1 There is also no evidence that any 9. 5. Peripheral Artery Disease one class of antihypertensive medication or strategy is superior. S9. 5-2S9. 5-4 In the INVEST (International Recommendation for Treatment of Hypertension in Patients Verapamil-Trandolapril) study, the beta blocker atWith peripheral arterial disease enolol (with or without hydrochlorothiazide) was References that support the recommendation are compared with the calcium channel blocker verapamil (with or withsummarized in Online Data Supplement 45. out perindopril). The study showed no significant COR LOE Recommendation difference in cardiovascular disease outcomes between the 2 drug 1. Adults with hypertension and peripheral arterial disease should regimens in patients with and without peripheral arterial disease. S9. 5-3 I B-NR be treated similarly to patients with No trials have reported the effects of a higher verhypertension without peripheral arterial disease. S9. 5-1S9. 5-4 sus a lower blood pressure goal in patients with peripheral arterial disease. In the 1 trial (ALLHAT) that reported the effects of different Synopsis classes of blood pressure medications on peripheral arterial disease as an outcome, Patients with peripheral arterial disease are at increased risk of cardiovascular disease and stroke. there was no significant difference by medication Hypertension is a major risk factor for peripheral arterial disease, so these patients class. S9. 5-5 Downloaded from by on December 30, 2025 e58 Hypertension June 2018 9. 6. Diabetes Mellitus matter of convenience, however, it can be assumed that the vast majority of adults with diabetes mellitus have a 10Recommendations for Treatment of Hypertension in year ASCVD risk ≥ 10%, placing them in the High risk Patients With diabetes mellitus category that requires initiation of antihypertensive drug therapy at blood pressure ≥ 130/80 mm Hg (see Section 8. 1. 2, References that support recommendations are summarized Figure 4 and Table 23 for blood pressure thresholds for initiating anin Online Data Supplements 46 and 47 and Systematic tihypertensive drug treatment). The ACCORD trial, S9. 6-5 Review Report. which compared cardiovascular disease outcomes in adults with diabetes mellitus and COR LOE Recommendations hypertension who were randomized to an SBP target 1. In adults with diabetes mellitus and hypertension, of 140 mm Hg (standard therapy) or 120 mm Hg SBP: B-RSR antihypertensive drug treatment should be (intensive therapy), did not document a significant reI initiated at a blood pressure of 130/80 mm Hg or higher duction in the primary outcome (cardiovascular disease composite) with with a treatment goal of less than 130/80 DBP: C-EO the lower blood pressure goal, but the trial was underpowered to mm Hg. S9. 6-1S9. 6-8 detect a statistically significant difference between the 2. In adults with diabetes mellitus and hypertension, all first2 treatment arms. The ACCORD trial demonstrated a line classes of antihypertensive agents (ie, small reduction in absolute risk (1.",
    "word_count": 597,
    "char_count": 3993,
    "sentence_count": 43,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 65,
      "total_chunks": 166,
      "position": "66/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "calcium",
        "supplements",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 66,
    "text": "The ACCORD trial demonstrated a line classes of antihypertensive agents (ie, small reduction in absolute risk (1. 1%) for stroke, but I ASR diuretics, ACE inhibitors, ARBs, and CCBs) there were few such events. More adverse events (2% are useful and effective. S9. 6-1, S9. 6-9, S9. 6-10 increase in absolute risk) were identified in the lower 3. In adults with diabetes mellitus and hypertension, ACE blood pressure group, especially self-reported hypotension and a IIb B-NR inhibitors or ARBs may be considered in the reduction in estimated glomerular filtration rate, but these did not result presence of albuminuria. S9. 6-11, S9. 6-12 in an excess of stroke or end-stage renal disease. The ACCORD trial SR indicates systematic review. was a factorial study; secondary analysis demonstrated a significant outcome benefit in the intensive blood pressure/ Synopsis standard glycemic group, S9. 6-3 but benefit in the intenRefer to the Systematic Review for the 2017 ACC/AHA/AAPA/ sive blood pressure/intensive glycemic control group was no betABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline ter than in the intensive blood pressure/standard glycemic control for the Prevention, Detection, Evaluation, and Management group, which suggests a floor benefit beyond which the of Hypertension in Adults for the complete systemcombined intensive interventions were ineffective. S9. 6-5 atic evidence review for additional data and analyses. S9. 6-13 The An ACCORD secondary analysis suggested that an prevalence of hypertension among adults with diabetes mellitus is approxiSBP 120 mm Hg is superior to standard blood pressure control in mately 80%, and hypertension is at least twice as common in reducing LVH. S9. 6-6 persons with type 2 diabetes mellitus than in age-matched individuals withA meta-analysis of 73 913 patients with diabetes mellitus reported out diabetes mellitus. S9. 6-14S9. 6-16 The coexistence of hypertension and diabetes mellitus that an SBP 130 mm Hg reduced stroke by 39%. However, markedly increases the risk of developing cardiovascular disease damage, resultthere was no significant risk reduction for myocardial infarction. S9. 6-23 Two ing in a higher incidence of CHD, heart failure, peripheral arterial disease, stroke, and cardiovascular disease meta-analyses addressing target blood pressure in adults with diabetes mellitus mortality, S9. 6-17 and may increase risk of microvascular disease, restricted the analysis to RCTs that randomized patients to such as nephropathy or retinopathy. S9. 6-16, S9. 6-18 different blood pressure levels. S9. 6-4, S9. 6-7 Target blood pressure of 133/76 mm Hg There is limited quality evidence to determine a precise blood pressure provided significant benefit compared with that of 140/81 target in adults with diabetes mellitus. No RCTs have explicitly 1) documm Hg for major cardiovascular events, myocardial infarction, stroke, albumented whether treatment to an SBP goal 140 mm Hg versus minuria, and retinopathy progression. S9. 6-4 Several metaa higher goal improves clinical outcomes in adults with hyperanalyses of RCTs included all trials with a difference in tension and diabetes mellitus or 2) directly evaluated clinical outcomes blood pressure, S9. 6-24, S9. 6-25 but 2 restricted their analyses to trials in associated with SBP 130 mm Hg. S9. 6-2 However, 2 High-qualwhich participants were randomized to different blood pressure target ity systematic reviews of RCTs support an SBP target of 140 levels. S9. 6-4, S9. 6-7 mm Hg. S9. 6-4, S9. 6-7 SPRINT demonstrated cardiovascular benefit from intenThere is little or no available RCT evidence supporting a sive treatment of blood pressure to a goal of 120 mm Hg as compared specific DBP threshold for initiation of pharmacological therwith 140 mm Hg but did not include patients with diabetes mellitus. apy.",
    "word_count": 580,
    "char_count": 3838,
    "sentence_count": 47,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 66,
      "total_chunks": 166,
      "position": "67/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "glomerular filtration rate",
        "end-stage renal disease",
        "nephropathy",
        "albuminuria",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 67,
    "text": "apy. Several RCTs, including the HOT (Hypertension Optimal However, the results of ACCORD and SPRINT were generally Treatment) trial, UKPDS (United Kingdom Prospective consistent. S9. 6-26 In addition, a SPRINT substudy demonstrated Diabetes Study), and ABCD (Appropriate Blood Hypertension that patients with prediabetes derived a benefit similar to that of Control in Diabetes) trial, S9. 6-19S9. 6-22 are often cited to support patients with normoglycemia. S9. 6-8 Previous trials have shown a lower DBP target (eg, ≤85 or 80 mm Hg) for adults with similar quantitative benefits from lowering blood pressure in persons with hypertension and diabetes mellitus. However, these trials were conducted and without diabetes mellitus. S9. 6-9 when the diagnostic criteria for diabetes mellitus were more conservative 2. blood pressure control is more difficult to achieve in patients with than they are currently (2 fasting glucose levels 140 milligrams per deciliter as diabetes mellitus than in those without diabetes mellitus, necessitating use of opposed to 126 mm/dL today). combination therapy in the majority of patients. S9. 6-27 All major antihypertensive drug classes (ie, ACE inhibitors, Recommendation-Specific Supportive Text ARBs, CCBs, and diuretics) are useful in the treatment 1. We recommend ASCVD risk assessment in all adults of hypertension in diabetes mellitus. S9. 6-1, S9. 6-9 However, in ALLHAT, with hypertension, including adults with diabetes mellitus. As a doxazosin was clearly inferior to chlorthalidone, which Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e59 also reduced some events more than amlodipine or 9. 8. Atrial Fibrillation lisinopril. S9. 6-28 3. ACE inhibitors and ARBs have the best efficacy among Recommendation for Treatment of Hypertension in Patients the drug classes on urinary albumin excretionS9. 6-12 (see With atrial fibrillation Section 9. 3). Therefore, an ACE inhibitor or angiotensin receptor blocker may References that support the recommendation are be considered as part of the combination. A metasummarized in Online Data Supplement 48. analysis of RCTs of primary prevention of albuminuria in patients with diabetes mellitus demonstrated a significant COR LOE Recommendation reduction in progression of moderately to severely in1. Treatment of hypertension with an angiotensin receptor blocker creased albuminuria with the use of ACE inhibitors or IIa B-R can be useful for prevention of recurrence ARBs. S9. 6-11 of atrial fibrillation. S9. 8-1, S9. 8-2 9. 7. Metabolic Syndrome Synopsis Metabolic syndrome is a state of metabolic dysregulation atrial fibrillation and hypertension are common and often coexistent concharacterized by visceral fat accumulation, insulin resisditions, both of which increase in frequency with age. atrial fibrillation tance, hyperinsulinemia, and hyperlipidemia, as well as preoccurs in 3% to 4% of the population 65 years of age. S9. 8-3 disposition to type 2 diabetes mellitus, hypertension, and atherosclerotic Hypertension is present in 80% of patients with atrial fibrillation and is cardiovascular disease. S9. 7-1S9. 7-3 According to data from the NHANES III and by far the most common comorbid condition, regardless of NHANES 19992006, S9. 7-1, S9. 7-4 the prevalence of metabolic age. S9. 8-4 atrial fibrillation is associated with systemic thromboembolism, syndrome in the United States was 34. 2% in 2006 and has as recognized in the CHADS2 and CHA2DS2-VASc scoring likely increased substantially since that time. The metabolic systems for stroke risk. S9. 8-5 It is also associated with gradual syndrome is linked to several other disorders, including nonworsening of ventricular function, the subsequent development alcoholic steatohepatitis, polycystic ovary syndrome, certain of heart failure, and increased mortality. cancers, chronic kidney disease, Alzheimers disease, Cushings syndrome, Hypertension has long been recognized as a risk factor lipodystrophy, and hyperalimentation. S9. 7-5, S9.",
    "word_count": 594,
    "char_count": 4057,
    "sentence_count": 53,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 67,
      "total_chunks": 166,
      "position": "68/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "albuminuria",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "insulin",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 68,
    "text": "S9. 7-5, S9. 7-6 for atrial fibrillation because it is associated with LVH, decreased diastolic Lifestyle modification, with an emphasis on improvfunction with impaired LV filling, rising left atrial pressures ing insulin sensitivity by means of dietary modification, with left atrial hypertrophy and enlargement, increased atrial weight reduction, and exercise, is the foundation of treatfibrosis, and slowing of intra-atrial and interatrial electrical ment of the metabolic syndrome. The optimal antihyperconduction velocities. Such a distortion of atrial anatomy and tensive drug therapy for patients with hypertension in the physiology increases the incidence of atrial fibrillation. S9. 8-6 Left atrial pressetting of the metabolic syndrome has not been clearly sure also increases with ischemic or valvular Heart disease and defined. S9. 7-1 Although caution exists with regard to the use myopathies that are often associated with systemic hypertenof thiazide diuretics in this population because of their abilsion, potentially leading to atrial fibrillation. ity to increase insulin resistance, dyslipidemia, and hyperAlthough management of atrial fibrillation will continue to revolve uricemia and to accelerate conversion to overt diabetes mellitus, no data around restoration of sinus rhythm when appropriate, rate conare currently available demonstrating deterioration in cartrol when it is not, and anticoagulation, control of hypertension diovascular or renal outcomes in patients treated with these is a key component of therapy. S9. 8-1, S9. 8-2 agents. S9. 7-1 Indeed, as shown in follow-up of ALLHAT, Treatment of hypertension may prevent new-onset atrial fibrillation, espechlorthalidone use was associated with only a small increase cially in patients with LVH or LV dysfunction. S9. 8-1 Five RCTs in fasting glucose levels (1. 54. 0 milligrams per deciliter), and this increase have compared the value of antihypertensive agents for reducdid not translate into increased cardiovascular disease risk at a later date. S9. 7-7 tion of new-onset atrial fibrillation. S9. 8-7S9. 8-11 One study suggested superiority S9. 7-10 In addition, in post hoc analysis of the nearly two thirds of renal artery stenosis blockade over a calcium channel blocker, S9. 8-8 and another reported supeof participants in ALLHAT that met criteria for the metariority of renal artery stenosis blockade over a beta blocker that is no longer bolic syndrome, chlorthalidone was unsurpassed in reducing recommended for treatment of hypertension. S9. 8-9 In the largest cardiovascular disease and renal outcomes compared with lisinopril, amlotrial, there was no difference in incident atrial fibrillation among adults with dipine, or doxazosin. S9. 7-9, S9. 7-11 Similarly, High-dose angiotensin receptor blocker hypertension assigned to first-step therapy with a diuretic, ACE therapy reduces arterial stiffness in patients with hyperteninhibitor, or calcium channel blocker. S9. 8-10 In ALLHAT, the incidence of atrial fibrillation was sion with the metabolic syndrome, but no outcomes data are 23% higher during first-step antihypertensive therapy with the available from patients in which this form of treatment was alpha-receptor blocker doxazosin than with chlorthalidone. used. S9. 7-12 Use of traditional beta blockers may lead to dysFurthermore, the occurrence of atrial fibrillation or atrial flutter during the lipidemia or deterioration of glucose tolerance, and ability study, either new onset or recurrent, was associated with an to lose weight. S9. 7-2 In several large clinical trials, the risk of increase in mortality of nearly 2. 5-fold. S9. 8-10 developing diabetes mellitus as a result of traditional beta-blocker therapy was 15% to 29%. S9. 7-2 However, the newer vasodilating beta Recommendation-Specific Supportive Text blockers (eg, labetalol, carvedilol, nebivolol) have shown 1.",
    "word_count": 565,
    "char_count": 3894,
    "sentence_count": 43,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 68,
      "total_chunks": 166,
      "position": "69/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "calcium",
        "diuretics",
        "insulin",
        "antihypertensive",
        "cardiovascular disease",
        "exercise"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 69,
    "text": "S9. 7-2 However, the newer vasodilating beta Recommendation-Specific Supportive Text blockers (eg, labetalol, carvedilol, nebivolol) have shown 1. Although renal artery stenosis blockade in theory is the treatment of choice neutral or favorable effects on metabolic profiles compared for hypertension in patients with prior atrial fibrillation, relative to other with the traditional beta blockers. S9. 7-13 Trials using vasodilaclasses of agents, all of the trials that have shown clinical tor beta blockers have not been performed to demonstrate superiority of ARBs over other agents were comparisons effects on cardiovascular disease outcomes. with CCBs or beta blockers that are no longer recommended Downloaded from by on December 30, 2025 e60 Hypertension June 2018 as first-line agents for treatment of hypertension. S9. 8-2 There (stage B progressive asymptomatic aortic regurgitaare no available trials comparing ACE inhibitors with tion and stage C asymptomatic severe AR). However, other drugs or any renal artery stenosis-blocking agents with diuretics. there are no outcomes data to support these theoretical concerns. 9. 9. Valvular Heart Disease 9. 10. Aortic Disease Recommendations for Treatment of Hypertension in Patients With Valvular Heart Disease Recommendation for Management of Hypertension in Patients With Aortic Disease References that support recommendations are summarized in Online Data Supplements 49 and 50. COR LOE Recommendation 1. Beta blockers are recommended as the COR LOE Recommendations preferred antihypertensive agents in patients I C-EO 1. In adults with asymptomatic aortic with hypertension and thoracic aortic stenosis, hypertension should be treated disease. S9. 10-1, S9. 10-2 I B-NR with pharmacotherapy, starting at a Low dose and gradually titrating upward as Synopsis needed. S9. 9-1S9. 9-4 Thoracic aortic aneurysms are generally asymptomatic until 2. In patients with chronic aortic insufficiency, a person presents with a sudden catastrophic event, such as treatment of systolic hypertension with IIa C-LD an aortic dissection or rupture, which is rapidly fatal in the agents that do not slow the Heart rate (ie, majority of patients. S9. 10-3, S9. 10-4 The rationale for antihypertenavoid beta blockers) is reasonable. S9. 9-5, S9. 9-6 sive therapy is based largely on animal and observational studRecommendation-Specific Supportive Text ies associating hypertension with aortic dissection. S9. 10-5, S9. 10-6 1. Hypertension is a risk factor for the development of RCTs specifically addressing hypertension and aortic disaortic stenosis (stage A eg, aortic sclerosis or bicuspid ease are not available, and trials in patients with primary aortic valve) and asymptomatic aortic stenosis (stage B hypertension do not provide insight on either the optimal blood pressure progressive asymptomatic aortic stenosis). The combitarget or choice of antihypertensive drug therapy in patients nation of hypertension and aortic stenosis, 2 resistors in with thoracic aortic aneurysm, aortic dissection, or aortic series, increases the rate of complications. In patients disease. S9. 10-7, S9. 10-8 A study in 20 humans with hypertension with asymptomatic mild-to-moderate aortic stenosis, suggested that hypertension is associated with significant hypertension has been associated with more abnormal changes in the mechanical properties of the aortic wall, with LV structure and increased cardiovascular morbidity and more strain-induced stiffening in hypertension than in normomortality. S9. 9-1 There is no evidence that antihypertensive tension, which may reflect destruction of elastin and predispomedications will produce an inordinate degree of hyposition to aortic dissection in the presence of hypertension. S9. 10-9 tension in patients with aortic stenosis. Nitroprusside In a retrospective observational study, High blood pressure variability infusion in hypertensive patients with severe aortic stewas an independent risk factor for the prognosis of aortic nosis lowers pulmonary and systemic resistance, with dissection. S9.",
    "word_count": 583,
    "char_count": 4081,
    "sentence_count": 46,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 69,
      "total_chunks": 166,
      "position": "70/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "supplements",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 70,
    "text": "S9. 10-10 Recommendations for treatment of acute aorimprovements in stroke volume and LV end-diastolic tic dissection are provided in Section 11. 2. Hypertension. S9. 9-2 Thus, careful use of antihypertensive agents to achieve blood pressure control in patients with hypertension and Recommendation-Specific Supportive Text aortic stenosis is beneficial. Although there are no spe1. In patients with chronic aortic dissection, observational cific trials comparing various classes of antihypertensive studies suggest lower risk for operative repair with betaagents, renal artery stenosis blockade may be advantageous because of blocker therapy. S9. 10-1 In a series of patients with type A the potentially beneficial effects on LV fibrosis, S9. 9-3 conand type B aortic dissections, beta blockers were assotrol of hypertension, reduction of dyspnea, and improved ciated with improved survival in both groups, whereas effort tolerance. S9. 9-4 Diuretics should be used sparingly ACE inhibitors did not improve survival. S9. 10-2 in patients with small LV chamber dimensions. Beta blockers may be appropriate for patients with aortic 10. Special Patient Groups stenosis who have reduced ejection fraction, prior myocardial infarction, Special attention is needed for specific patient subgroups. arrhythmias, or angina pectoris. In patients with moderate or severe aortic stenosis, consultation or co-man10. 1. Race and Ethnicity agement with a cardiologist is preferred for hypertension In the United States, at any decade of life, blacks have a higher management. prevalence of hypertension than that of Hispanic Americans, 2. Vasodilator therapy can reduce the LV volume and mass whites, Native Americans, and other subgroups defined by and improve LV performance in patients with aortic regurgitation, S9. 9-5 but improvement of long-term clinical race and ethnicity (see Section 3. 3). Hypertension control outcomes, such as time to valve replacement, have been rates are lower for blacks, Hispanic Americans, and Asian variable. S9. 9-5, S9. 9-6 Beta blockers may result in increased Americans than for whites. S10. 1-1 Among men with hypertendiastolic filling period because of bradycardia, potension, non-Hispanic white (53. 8%) adults had a higher prevatially causing increased aortic insufficiency. Marked lence of controlled Hypertension than did non-Hispanic reduction in DBP may lower coronary perfusion presblack (43. 8%), non-Hispanic Asian (39. 9%), and Hispanic sure in patients with chronic severe aortic regurgitation (43. 5%) adults. For women with hypertension, the percentage Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e61 of non-Hispanic white (59. 1%) adults with controlled High healthy foods, and financial considerations. The greater prevBlood Hypertension was higher than among non-Hispanic black alence of lower socioeconomic status may impede access to (52. 3%) and non-Hispanic Asian (46. 8%) adults. S10. 1-1 In basic living necessities, S10. 1. 1-8 including medical care and mediHispanic Americans, the lower control rates result primarcations. Consideration must also be given to learning styles and ily from lack of awareness and treatment, S10. 1-2, S10. 1-3 whereas preference, personal beliefs, values, and culture. S10. 1. 1-9, S10. 1. 1-10 in blacks, awareness and treatment are at least as High as in The principles of antihypertensive drug selection discussed whites, but hypertension is more severe and some agents are in Sections 8. 1. 4 through 8. 1. 6 apply to ethnic minorities with less effective at blood pressure control. S10. 1-4 Morbidity and mortality a few caveats. In blacks, thiazide-type diuretics and CCBs attributed to hypertension are also more common in blacks are more effective in lowering blood pressure when given as monotherand Hispanic Americans than in whites. Blacks have a 1. 3apy or as initial agents in multidrug regimens. S10. 1. 1-11S10. 1. 1-13 times greater risk of nonfatal stroke, 1.",
    "word_count": 598,
    "char_count": 4015,
    "sentence_count": 67,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 70,
      "total_chunks": 166,
      "position": "71/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "ACE inhibitors",
        "diuretics",
        "antihypertensive",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 71,
    "text": "3apy or as initial agents in multidrug regimens. S10. 1. 1-11S10. 1. 1-13 times greater risk of nonfatal stroke, 1. 8-times greater risk In addition, thiazide-type agents are superior to drugs that of fatal strokes, 1. 5-times greater risk of heart failure, and 4. 2-times inhibit the renal artery stenosis (ie, ACE inhibitors, ARBs, renin inhibitors, greater risk of end-stage renal disease. S10. 1-4 Hispanic Americans have lower and beta blockers) for prevention of selected clinical outrates of hypertension awareness and treatment than those of comes in blacks. S10. 1. 1-2, S10. 1. 1-14S10. 1. 1-16 For optimum endpoint whites and blacks, as well as a High prevalence of comorbid protection, the thiazide chlorthalidone should be administered cardiovascular disease risk factors (eg, obesity, diabetes mellitus). In 2014, age-adjusted at a dose of 12. 5 to 25 magnesium/day (or 2550 magnesium/d for hydrohypertension-attributable mortality rates per 1 000 persons chlorothiazide) because lower doses are either unproven or for non-Hispanic white, non-Hispanic black, and Hispanicless effective in clinical outcome trials. S10. 1. 1-2, S10. 1. 1-16 The calcium channel blocker American men and women were 19. 3 and 15. 8, 50. 1 and 35. 6, amlodipine is as effective as chlorthalidone and more effective and 19. 1 and 14. 6, respectively. S10. 1-5 However, Hispanics in than the ACE inhibitor lisinopril in reducing blood pressure, cardiovascular disease, and the United States are a heterogeneous subgroup, and rates stroke events but less effective in preventing heart failure. Blacks have of both hypertension and its consequences vary according to a greater risk of angioedema with ACE inhibitors, S10. 1. 1-2, S10. 1. 1-3 whether their ancestry is from the Caribbean, Mexico, Central and Asian Americans have a higher incidence of ACE inhibior South America, or Europe. S10. 1-6S10. 1-8 Hispanics from torinduced cough. S10. 1. 1-17 ACE inhibitors and ARBs are Mexico and Central America have lower cardiovascular disease rates than ultrasound recommended more generally as components of multidrug whites, whereas those of Caribbean origin have higher rates. antihypertensive regimens in blacks with chronic kidney disease (see Section Thus, pooling of data for Hispanics may not accurately reflect 9. 3), with the addition of beta blockers in those with heart failure (see risk in a given patient. Finally, the excess risk of chronic kidney disease outSection 9. 2). Beta blockers are recommended for treatment comes in at least some blacks with hypertension may be due to of patients with CHD who have had a myocardial infarction. Most patients with the presence of High-risk APOL1 (apolipoprotein L1) genetic hypertension, especially blacks, require ≥2 antihypertensive variants. S10. 1-9S10. 1-11 The rate of renal decline associated with medications to achieve adequate blood pressure control. A single-tablet this genotype appears to be largely unresponsive to either blood pressure combination that includes either a diuretic or a calcium channel blocker may be lowering or renal artery stenosis inhibition. S10. 1-9S10. 1-12 particularly effective in achieving blood pressure control in blacks. Racial and ethnic differences should not be the basis for excluding 10. 1. 1. Racial and Ethnic Differences in Treatment any class of antihypertensive agent in combination therapy. Recommendations for Race and Ethnicity Recommendation-Specific Supportive Text References that support recommendations are summarized 1. In blacks, thiazide diuretics or CCBs are more effective in Online Data Supplement 51. in lowering blood pressure than are renal artery stenosis inhibitors or beta blockers and more effective in reducing cardiovascular disease events than are COR LOE Recommendations renal artery stenosis inhibitors or alpha blockers. renal artery stenosis inhibitors are 1.",
    "word_count": 587,
    "char_count": 3888,
    "sentence_count": 64,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 71,
      "total_chunks": 166,
      "position": "72/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "end-stage renal disease",
        "calcium",
        "magnesium",
        "ACE inhibitors",
        "ARBs",
        "diuretics",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 72,
    "text": "renal artery stenosis inhibitors are 1. In black adults with hypertension but recommended in black patients with hypertension, diabetes mellitus, without heart failure or chronic kidney disease, including those with and nephropathy, but they offer no advantage over diuretI B-R diabetes mellitus, initial antihypertensive treatment ics or CCBs in hypertensive patients with diabetes mellitus without should include a thiazide-type diuretic or nephropathy or heart failure. calcium channel blocker. S10. 1. 1-1S10. 1. 1-4 2. Four drug classes (thiazide diuretic, calcium channel blocker, ACE inhibi2. Two or more antihypertensive medications tor, or angiotensin receptor blocker) lower blood pressure and reduce cardiovascular or reare recommended to achieve a blood pressure target of nal outcomes. S10. 1. 1-18S10. 1. 1-21 Thus, except for the combiI C-LD less than 130/80 mm Hg in most adults with nation of ACE inhibitors and ARBs, regimens containing hypertension, especially in black adults with a combination of these classes are reasonable to achieve hypertension. S10. 1. 1-5S10. 1. 1-7 the blood pressure target. S10. 1. 1-16, S10. 1. 1-21 Furthermore, the combination of an ACE inhibitor or angiotensin receptor blocker with a calcium channel blocker or thiaSynopsis zide diuretic produces similar blood pressure lowering in blacks as Lifestyle modification (ie, weight reduction, dietary modificain other racial or ethnic groups. For blacks who do not tion, and increased physical activity) is particularly important achieve control with 3 drugs, see resistant hypertension in blacks and Hispanic Americans for prevention and first-line (see Section 11. 1). or adjunctive therapy of hypertension (see Sections 12. 1. 2 and 12. 1. 3). However, the adoption of lifestyle recommendations is 10. 2. Sex-Related Issues often challenging in ethnic minority patients because of poor The prevalence of hypertension is lower in women than in men social support, limited access to exercise opportunities and until about the fifth decade but is higher later in life. S10. 2-1 Other Downloaded from by on December 30, 2025 e62 Hypertension June 2018 than special recommendations for management of hypertenSynopsis sion during pregnancy, there is no evidence that the blood pressure threshblood pressure usually declines during the first trimester of pregnancy old for initiating drug treatment, the treatment target, the and then slowly rises. Hypertension management during choice of initial antihypertensive medication, or the combinapregnancy includes 4 general areas: 1) the newly pregnant tion of medications for lowering blood pressure differs for women versus mother with existing hypertension; 2) incident hypertenmen. S10. 2-2, S10. 2-3 sion; 3) preeclampsia (a dangerous form of hypertension with proteinuria that has the potential to result in serious 10. 2. 1. Women adverse consequences for the mother stroke, heart failure and fetus A potential limitation of RCTs, including SPRINT, is that they small for gestational age, premature birth); and 4) severe are not specifically powered to determine the value of intenhypertension, often in the setting of preeclampsia, requirsive SBP reduction in subgroups, including women in the case ing urgent treatment to prevent heart failure, stroke, and adverse fetal of SPRINT. However, in prespecified analyses, there was no outcomes. Hypertension during pregnancy and preeclampevidence of an interaction between sex and treatment effect. sia are recognized as risk factors for future hypertension Furthermore, no significant differences in cardiovascular disease outcomes and cardiovascular disease. S10. 2. 2-7S10. 2. 2-9 blood pressure management during pregnancy is were observed between men and women in a large metacomplicated by the fact that many commonly used antihyanalysis that included 31 RCTs with about 100 000 men and pertensive agents, including ACE inhibitors and ARBs, are 90 000 women with hypertension. S10. 2.",
    "word_count": 590,
    "char_count": 3984,
    "sentence_count": 54,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 72,
      "total_chunks": 166,
      "position": "73/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "nephropathy",
        "proteinuria",
        "calcium",
        "ACE inhibitors",
        "ARBs",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "exercise"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 73,
    "text": "S10. 2. 1-1 Some have called for contraindicated during pregnancy because of potential harm a SPRINT-like trial with sufficient power to assess the effects to the fetus. S10. 2. 2-2, S10. 2. 2-3 The goal of antihypertensive treatof intensive SBP reduction in women. S10. 2. 1-2 In meta-analyses, ment during pregnancy includes prevention of severe hyperthere was no convincing evidence that different antihypertentension and the possibility of prolonging gestation to allow sive drug classes exerted sex-related differences in blood pressure Lowthe fetus more time to mature before delivery. ering or provided distinct cardiovascular disease protection. S10. 2. 1-1 Calcium There are 3 Cochrane database reviews of treatment for antagonists offered slightly greater benefits for stroke prevenmild-to-moderate hypertension during pregnancy. S10. 2. 2-10S10. 2. 2-12 tion than did ACE inhibitors for women than for men, whereas With regard to the treatment of mild-to-moderate hypertencalcium antagonists reduced all-cause deaths compared with sion (SBP of 140169 or DBP of 90109 mm Hg), antiplacebo in men but not in women. However, these sex-related hypertensive treatment reduces the risk of progression to differences might have been due to chance because of the large severe hypertension by 50% compared with placebo but number of statistical comparisons that were performed. The Heart Attack Trial and Hypertension Care Computing Project has not been shown to prevent preeclampsia, preterm birth, reported that beta blockers were associated with reduced morsmall for gestational age, or infant mortality. Beta blockers tality in men but not in women, but this finding was likely and CCBs appear superior to alpha-methyldopa in preventdue to the Low event rates in women. S10. 2. 1-3 Similarly, in the ing preeclampsia. S10. 2. 2-10 An earlier review of 2 small trials open-label Second Australian National blood pressure study, a significant did not show improved outcomes with more comprehenreduction in cardiovascular disease events was demonstrated in men but not in sive treatment of blood pressure to a target of 130/80 mm Hg. S10. 2. 2-11 women with ACE inhibitors versus diuretics. S10. 2. 1-4 Consistent with the results of the Cochrane reviews, a large Adverse effects of antihypertensive therapy were noted multinational RCT of treatment in pregnant women with twice as often in women as in men in the TOMHS study. S10. 2. 1-5 mild-to-moderate hypertension also reported that treatA higher incidence of ACE inhibitorinduced cough and of ment prevented progression to severe hypertension, but Edema with calcium antagonists was observed in women than other maternal and infant outcomes were unaffected by the in men. S10. 2. 1-6 Women were more likely to experience hypokaintensity of treatment. S10. 2. 2-13 An earlier review confined to lemia and hyponatremia and less likely to experience gout with assessing the effect of beta blockers found them generally diuretics. S10. 2. 1-7 Hypertension in pregnancy has special requiresafe and effective but of no benefit for newborn outcomes, ments (see Section 10. 2. 2). either in placebo-controlled studies or when compared with other antihypertensive agents. There was a suggestion that 10. 2. 2. Pregnancy beta-blocker therapy might be associated with small for gestational age and neonatal bradycardia. S10. 2. 2-12 The largRecommendations for Treatment of Hypertension in est experience for beta blockers is with labetalol; the largPregnancy est experience for CCBs is with nifedipine. Methyldopa and References that support recommendations are summarized hydralazine may also be used. A review of treatment for in Online Data Supplement 53. pregnancy-associated severe hypertension found insufficient COR LOE Recommendations evidence to recommend specific agents; rather, clinician experience was recommended in this setting. S10. 2. 2-14 1.",
    "word_count": 588,
    "char_count": 3907,
    "sentence_count": 62,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 73,
      "total_chunks": 166,
      "position": "74/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "calcium",
        "ACE inhibitors",
        "diuretics",
        "antihypertensive",
        "edema",
        "cardiovascular disease"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 74,
    "text": "S10. 2. 2-14 1. Women with hypertension who become pregnant, or are planning to become Preeclampsia is a potentially dangerous condition for the I C-LD pregnant, should be transitioned to pregnant woman and fetus, occurring in 3. 8% of pregnancies, methyldopa, nifedipine, and/or labetalolS10. 2. 2-1 and preeclampsia and eclampsia account for 9% of maternal during pregnancy. S10. 2. 2-2S10. 2. 2-6 deaths in the United States. S10. 2. 2-15 Preeclampsia is associ2. Women with hypertension who become ated with an increased risk of preterm delivery, intrauterine pregnant should not be treated with growth restriction, placental abruption, and perinatal mortality III: Harm C-LD ACE inhibitors, ARBs, or direct renin and is twice as likely to occur in the first pregnancy. The ultrasound inhibitors. S10. 2. 2-4S10. 2. 2-6 Preventive Services Task Force has recommended screening Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e63 all pregnant women for preeclampsia by measuring blood pressure at decreases while SBP continues to rise. S10. 3. 1-6 Thus, isolated every prenatal visit. S10. 2. 2-16 systolic hypertension is the predominant form of hypertenIt is beyond the scope of the present guideline to address sion in older persons. S10. 3. 1-7, S10. 3. 1-8 RCTs have clearly demthe management of hypertension during pregnancy in detail. onstrated that blood pressure lowering in isolated systolic hypertension Several international guidelines provide guidance on manage- (defined as SBP ≥160 mm Hg with variable DBP ≤90, ≤95, ment of hypertension during pregnancy. S10. 2. 2-2, S10. 2. 2-3, S10. 2. 2-17 or ≤110 mm Hg) is effective in reducing the risk of fatal and The American College of Obstetricians and Gynecologists nonfatal stroke (primary outcome), cardiovascular events, and has issued a task force report that includes recommendadeath. S10. 3. 1-9S10. 3. 1-12 tions for prevention (aspirin in selected cases) and treatment Cross-sectional and longitudinal epidemiologic studies (magnesium for severe hypertension) of hypertension in in older adults have raised questions about the benefits of pregnancy. S10. 2. 2-2 A report detailing treatment of hypertensive more intensive antihypertensive treatment and the relationemergencies during pregnancy and postpartum has also been ship between blood pressure lowering and risk of falls. S10. 3. 1-13 Treatment released. S10. 2. 2-2, S10. 2. 2-17, S10. 2. 2-18 of elevated blood pressure in older persons is challenging because of a High degree of heterogeneity in comorbidity, as well as Recommendation-Specific Supportive Text poly-pharmacy, frailty, cognitive impairment, and variable 1. ACE inhibitors and ARBs are not approved for use during life expectancy. However, over the past 3 decades, RCTs pregnancy; they are fetotoxic. Among the agents recomof antihypertensive therapy have included large numbers mended, no specific agent is first choice because there are of older persons, and in every instance, including when the no data supporting one over another. Therapeutic classes SBP treatment goal was 120 mm Hg, more intensive treatare not recommended because potential toxicity differs ment has safely reduced the risk of cardiovascular disease for persons over among agents within classes. the ages of 65, 75, and 80 years. S10. 3. 1-1, S10. 3. 1-14 Both HYVET 2. ACE inhibitors and ARBs are fetotoxic in the second and (Hypertension in the Very Elderly Trial) and SPRINT third trimesters of pregnancy. Adverse effects in the first included those who were frail but still living independently trimester of pregnancy may be secondary to hypertension in the community, S10. 3. 1-1, S10. 3. 1-14 and both were stopped early or the medication. S10. 2. 2-4, S10. 2. 2-5 Adverse events in the later for benefit (HYVET after 1.",
    "word_count": 595,
    "char_count": 3848,
    "sentence_count": 80,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 74,
      "total_chunks": 166,
      "position": "75/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "magnesium",
        "ACE inhibitors",
        "ARBs",
        "antihypertensive",
        "cardiovascular disease",
        "screening",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 75,
    "text": "S10. 2. 2-4, S10. 2. 2-5 Adverse events in the later for benefit (HYVET after 1. 8 years and SPRINT after 3. 26 trimesters have been suggested by observational data and years). In fact, blood pressure-lowering therapy is one of the few intermeta-analyses. S10. 2. 2-6 For ARBs, case reports with effects ventions shown to reduce mortality risk in frail older indisimilar to ACE inhibitors have been published. S10. 2. 2-19 viduals. RCTs in noninstitutionalized community-dwelling older persons have also demonstrated that improved blood pressure con10. 3. Age-Related Issues trol does not exacerbate orthostatic hypotension and has no adverse impact on risk of injurious falls. S10. 3. 1-1, S10. 3. 1-15, S10. 3. 1-16 It 10. 3. 1. Older Persons should be noted, however, that SPRINT excluded those with Recommendations for Treatment of Hypertension Low (110 mm Hg) standing blood pressure on study entry. Older persons in Older Persons need to be carefully monitored for orthostatic hypotension during treatment. Intensive blood pressure control increases the risk of References that support recommendations are summarized acute Kidney injury, but this is no different from the risk seen in Online Data Supplement 54. in younger adults. S10. 3. 1-1 In summary, despite the complexity COR LOE Recommendations of management in caring for older persons with hypertension, 1. Treatment of hypertension with a SBP RCTs have demonstrated that in many community-dwelling treatment goal of less than 130 mm Hg older adults, even adults 80 years of age, blood pressure-lowering goals I A is recommended for noninstitutionalized during antihypertensive treatment need not differ from those ambulatory community-dwelling adults (≥65 selected for persons 65 years of age. S10. 3. 1-17 Importantly, no years of age) with an average SBP of 130 randomized trial of blood pressure lowering in persons 65 years of age mm Hg or higher. S10. 3. 1-1 has ever shown harm or less benefit for older versus younger 2. For older adults (≥65 years of age) adults. However, clinicians should implement careful titrawith hypertension and a High burden of tion of blood pressure lowering and monitoring in persons with High comorbidity and limited life expectancy, comorbidity burden; large RCTs have excluded older persons clinical judgment, patient preference, and IIa C-EO a team-based approach to assess risk/ at any age who live in nursing homes, as well as those with benefit is reasonable for decisions regarding prevalent dementia and advanced heart failure. intensity of blood pressure lowering and choice of antihypertensive drugs. Recommendation-Specific Supportive Text 1. We recommend ASCVD risk assessment in all adults Synopsis with hypertension, including older persons. As a matBecause of its extremely High prevalence in older adults, hyperter of convenience, however, it can be assumed that the tension is not only a leading cause of preventable morbidity and vast majority of older adults have a 10-year ASCVD mortality but, perhaps more importantly, is under-recognized risk ≥ 10%, placing them in the High risk category that as a major contributor to premature disability and institution requires initiation of antihypertensive drug therapy at alization. S10. 3. 1-2S10. 3. 1-5 Both SBP and DBP increase linearly up blood pressure ≥ 130/80 mm Hg (see Section 8. 1. 2, Figure 4 and to the fifth or sixth decade of life, after which DBP gradually Table 23 for blood pressure thresholds for initiating antihypertensive Downloaded from by on December 30, 2025 e64 Hypertension June 2018 drug treatment). Large RCTs using medications to re11. Other Considerations duce hypertension-related cardiovascular disease risk with a mean fol11. 1. Resistant Hypertension Low-up of ≥2 years have now included a large number of adults ≥65 years of age.",
    "word_count": 598,
    "char_count": 3830,
    "sentence_count": 56,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 75,
      "total_chunks": 166,
      "position": "76/166",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "acute kidney injury",
        "ACE inhibitors",
        "ARBs",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control",
        "monitoring",
        "risk category"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 76,
    "text": "1. Resistant Hypertension Low-up of ≥2 years have now included a large number of adults ≥65 years of age. These trials have enrolled a The diagnosis of resistant hypertension is made when a patient broad range of ages ≥65 years, including persons in their takes 3 antihypertensive medications with complementary 90s and even 100s, as well as those with mild-to-modmechanisms of action (a diuretic should be 1 component) but erate frailty but who were ambulatory and able to travel does not achieve control or when blood pressure control is achieved but to a treatment clinic. In these patients, RCTs have shown requires ≥4 medications. S11. 1-1 On the basis of the previous that blood pressure lowering decreased cardiovascular disease morbidity and mortalicutoff of 140/90 mm Hg, the prevalence of resistant hypertenty but did not increase the risk of orthostatic hypotension sion is approximately 13% in the adult population. S11. 1-2, S11. 1-3 or falls. S10. 3. 1-1, S10. 3. 1-15, S10. 3. 1-16 Analysis of the NHANES Multiple single-cohort studies have indicated that common risk (20112014) data set indicates that 88% of ultrasound adults factors for resistant hypertension include older age, obesity, (98% men and 80% women) ≥65 years old have a 10chronic kidney disease, black race, and diabetes mellitus. Estimates suggest the prevalence year predicted ASCVD risk ≥10% or have a history of would be about 4% higher with the newly recommended concardiovascular disease (CHD, stroke, or heart failure). For persons ≥75 years of trol target of 130/80 mm Hg (subject to validation in future age, 100% have an ASCVD risk score ≥10% or a history study). The prognosis of resistant hypertension (by the previof cardiovascular disease. Therefore, the blood pressure target of ≤130/80 mm Hg ous definition), S11. 1-1 compared with the prognosis of those who would be appropriate (see Section 8. 1. 2). Initiation of more readily achieve control, has not been fully ascertained; antihypertensive therapy with 2 agents should be unhowever, risk of myocardial infarction, stroke, end-stage renal disease, and death in adults with dertaken cautiously in older persons, and they need resistant hypertension and CHD may be 2to 6-fold higher than to be monitored carefully for orthostatic hypotension and history of falls. In SPRINT, the benefit was for an in hypertensive adults without resistant hypertension. S11. 1-4S11. 1-6 SBP goal of 120 mm Hg. Older persons may presThe evaluation of resistant hypertension involves consideration ent with neurogenic orthostatic hypotension associated of many patient characteristics, pseudoresistance (blood pressure technique, with supine hypertension. This is particularly common white coat hypertension, and medication compliance), and screenin Parkinsons disease and other neurodegenerative dising for secondary causes of hypertension (Figure 10; Section 5. 4; orders. For management of this problem, the reader is Table 13). The term refractory hypertension has been used to referred to the recommendations of a 2017 consensus refer to an extreme phenotype of antihypertensive treatment failpanel. S10. 3. 1-18 ure, defined as failure to control blood pressure despite use of at least 5 anti2. Patients with prevalent and frequent falls, advanced coghypertensive agents of different classes, including a long-acting nitive impairment, and multiple comorbidities may be thiazide-type diuretic, such as chlorthalidone, and a mineralocorat risk of adverse outcomes with intensive blood pressure lowering, ticoid receptor antagonist, such as spironolactone. S11. 1-7 The especially when they require multiple blood pressure-lowering mediprevalence of refractory hypertension is Low; patients with cations. Older persons in this category typically reside in refractory hypertension experience High rates of cardiovascular disease complinursing homes and assisting living facilities, are unable to cations, including LVH, heart failure, and stroke.",
    "word_count": 594,
    "char_count": 3980,
    "sentence_count": 40,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 76,
      "total_chunks": 166,
      "position": "77/166",
      "section": "1. Resistant Hypertension Low",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "end-stage renal disease",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 77,
    "text": "live independently in the community, and have not been Treatment of resistant hypertension involves improvrepresented in RCTs. ing medication adherence, improving detection and correc10. 3. 2. Children and Adolescents tion of secondary hypertension, and addressing other patient Pediatric guidelines are available from other characteristics. S11. 1-8S11. 1-10 Pharmacological therapy with comorganizations. S10. 3. 2-1, S10. 3. 2-2 The 2011 report updates the 2004 binations of medications with complementary mechanisms of report for publications through 2008 (antihypertensive mediaction provides an empirical approach that enhances blood pressure control cation trials, normative data on pediatric blood pressure) but is otherwise while mitigating untoward effects of potent vasodilators (eg, unchanged. In the 2011 guideline, S10. 3. 2-3 blood pressure was stratified into fluid retention and reflex tachycardia). CCBs, inhibitors of renal artery stenosis, normal, prehypertension (90th percentile to 95th percentile), and chlorthalidone comprise a common 3-drug regimen. S11. 1-11 stage 1 hypertension (95th percentile to 99th percentile), and Considerable evidence indicates that the addition of spironolacstage 2 hypertension (above stage 1) by using age-, sex-, and tone to multidrug regimens provides substantial blood pressure reductionS11. 1-12 height-based tables beginning at 1 year of age, which were when compared with placebo. Substantial data also demonstrate based on the distribution of blood pressure in 60 000 healthy children in the advantage of spironolactone as compared with other active various population-based studies. S10. 3. 2-1 These definitions were drugs. S11. 1-8, S11. 1-13S11. 1-15 In particular, the recent PATHWAY-2 designed to be analogous to definitions in the extant JNC 7 (Optimum Treatment for Drug-Resistant Hypertension) RCT report; for older adolescents (≥14 years), the JNC 7 threshdemonstrated the superiority of spironolactone over alpha and beta olds generally apply. S10. 3. 2-4 Treatment recommendations are blockers. S11. 1-13 There is also clinical trial evidence that the addition based on hypertension severity, published short-term clinical of hydralazine or minoxidil is effective in achieving blood pressure control trials of antihypertensive treatment, age, coexisting cardiovascular disease risk in patients resistant to usual combination therapy. S11. 1-8, S11. 1-12S11. 1-16 factors, and risk stratification by presence of LVH on echoThe dosing of multidrug regimens, occasionally including nightcardiogram. The treatment goal is to achieve blood pressure 90th pertime dosing, may be best optimized by hypertension specialists. centile. New tables for ambulatory blood pressure distribution in children Several studies have investigated devices that interrupt have been developed. A classification of blood pressure that is based on sympathetic nerve activity (carotid baroreceptor pacing these ambulatory blood pressure results has been proposed. S10. 3. 2-5, S10. 3. 2-6 A and catheter ablation of renal sympathetic nerves); hownew pediatric blood pressure guideline was published in late 2017. S10. 3. 2-7 ever, these studies have not provided sufficient evidence to Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e65 Figure 10. Resistant hypertension: diagnosis, evaluation, and treatment. See additional details in Section 6, Nonpharmacological Intervention. See Section 5. 4. 1 and Table 14 for complete list of drugs that elevate blood pressure. See Section 5. 4 and Table 13 for secondary hypertension. blood pressure indicates Blood Hypertension; chronic kidney disease, chronic Kidney disease; DBP, diastolic Blood Hypertension; estimated glomerular filtration rate, estimated glomerular estimated glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs; and SBP, systolic Blood Hypertension. Adapted with permission from Calhoun et alS11. 1-1 (American Heart Association, Inc. ). recommend the use of these device in managing resistant Recommendations for Hypertensive Crises and hypertension. S11. 1-8S11. 1-10 In particular, 2 RCTS of renal sympaEmergencies (Continued) thetic nerve ablation have been negative. S11. 1-8, S11. 1-9 COR LOE Recommendations 11. 2.",
    "word_count": 598,
    "char_count": 4306,
    "sentence_count": 67,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 77,
      "total_chunks": 166,
      "position": "78/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "antihypertensive",
        "catheter",
        "cardiovascular disease",
        "blood pressure control",
        "adherence",
        "stage 1",
        "guideline",
        "classification"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 78,
    "text": "S11. 1-8, S11. 1-9 COR LOE Recommendations 11. 2. Hypertensive CrisesEmergencies and Urgencies 2. For adults with a compelling condition (ie, aortic dissection, severe preeclampsia Recommendations for Hypertensive Crises and or eclampsia, or pheochromocytoma Emergencies I C-EO crisis), SBP should be reduced to less than 140 mm Hg during the first hour References that support recommendations are summarized and to less than 120 mm Hg in aortic in Online Data Supplement 55. dissection. COR LOE Recommendations 3. For adults without a compelling condition, 1. In adults with a hypertensive emergency, SBP should be reduced by no more than admission to an intensive care unit is I C-EO 25% within the first hour; then, if stable, recommended for continuous monitoring to 160/100 mm Hg within the next 2 to 6 I B-NR of blood pressure and target organ damage and for hours; and then cautiously to normal during parenteral administration of an appropriate the following 24 to 48 hours. agent (Tables 19 and 20). S11. 2-1, S11. 2-2 Downloaded from by on December 30, 2025 e66 Hypertension June 2018 Synopsis hypertensive emergency and instead are treated by reinstituHypertensive emergencies are defined as severe elevations in tion or intensification of antihypertensive drug therapy and blood pressure (180/120 mm Hg) associated with evidence of new or treatment of anxiety as applicable. There is no indication for worsening target organ damage. S11. 2-3S11. 2-6 The 1-year death referral to the emergency department, immediate reduction rate associated with hypertensive emergencies is 79%, and in blood pressure in the emergency department, or hospitalization for the median survival is 10. 4 months if the emergency is left such patients. untreated. S11. 2-7 The actual blood pressure level may not be as important Figure 11 is an algorithm on diagnosis and management as the rate of blood pressure rise; patients with chronic hypertension can of a hypertensive crisis. Tables 19 and 20 summarize intraoften tolerate higher blood pressure levels than previously normotensive venous antihypertensive drugs for treatment of hypertensive individuals. Hypertensive emergencies demand immediate emergencies. reduction of blood pressure (not necessarily to normal) to prevent or limit Recommendation-Specific Supportive Text further target organ damage. Examples of target organ damage 1. There is no RCT evidence that antihypertensive drugs include hypertensive encephalopathy, ICH, acute ischemic reduce morbidity or mortality in patients with hyperstroke, acute myocardial infarction, acute LV failure with pulmonary Edema, tensive emergencies. S11. 2-8 However, from clinical expeunstable angina pectoris, dissecting aortic aneurysm, acute rience, it is highly likely that antihypertensive therapy renal failure, and eclampsia. In general, use of oral therapy is an overall benefit in a hypertensive emergency. S11. 2-9 is discouraged for hypertensive emergencies. Hypertensive There is also no High-quality RCT evidence to inform emergencies in patients with acute ICH and acute ischemic clinicians as to which first-line antihypertensive drug stroke are discussed in Section 9. 4. class provides more benefit than harm in hypertensive In contrast, hypertensive urgencies are situations associemergencies. S11. 2-8 This lack of evidence is related to the ated with severe blood pressure elevation in otherwise stable patients small size of trials, the lack of long-term follow-up, and without acute or impending change in target organ damage failure to report outcomes. However, 2 trials have demor dysfunction. Many of these patients have withdrawn from onstrated that nicardipine may be better than labetalol or are noncompliant with antihypertensive therapy and do in achieving the short-term blood pressure target. S11. 2-1, S11. 2-10S11. 2-12 not have clinical or laboratory evidence of acute target organ Several antihypertensive agents in various pharmacologidamage.",
    "word_count": 588,
    "char_count": 3974,
    "sentence_count": 41,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 78,
      "total_chunks": 166,
      "position": "79/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "renal failure",
        "antihypertensive",
        "edema",
        "monitoring"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 79,
    "text": "2-1, S11. 2-10S11. 2-12 not have clinical or laboratory evidence of acute target organ Several antihypertensive agents in various pharmacologidamage. These patients should not be considered as having a cal classes are available for the treatment of hypertensive Figure 11. Diagnosis and management of a hypertensive crisis. Colors correspond to Class of Recommendation in Table 1. Use drug(s) specified in Table 19. If other comorbidities are present, select a drug specified in Table 20. blood pressure indicates Blood Hypertension; DBP, diastolic Blood Hypertension; ICU, intensive care unit; and SBP, systolic Blood Hypertension. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e67 Table 19. Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies Class Drug(s) Usual Dose Range Comments calcium channel blocker Nicardipine Initial 5 magnesium/h, increasing every 5 min by 2. 5 magnesium/h to Contraindicated in advanced aortic stenosis; no dose dihydropyridines maximum 15 magnesium/h. adjustment needed for elderly. Clevidipine Initial 12 magnesium/h, doubling every 90 s until blood pressure Contraindicated in patients with soybean, soy product, approaches target, then increasing by less than double egg, and egg product allergy and in patients with defective every 510 min; maximum dose 32 magnesium/h; maximum lipid metabolism (eg, pathological hyperlipidemia, lipoid duration 72 h. nephrosis or acute pancreatitis). Use Low-end dose range for elderly patients. VasodilatorsNitricSodium Initial 0. 30. 5 microgram/kg/min; increase in increments Intra-arterial blood pressure monitoring recommended to prevent oxide dependent nitroprusside of 0. 5 microgram/kg/min to achieve blood pressure target; maximum overshoot. Lower dosing adjustment required for elderly. dose 10 microgram/kg/min; duration of treatment as short Tachyphylaxis common with extended use. as possible. For infusion rates ≥410 microgram/kg/min or Cyanide toxicity with prolonged use can result in duration 30 min, thiosulfate can be coadministered irreversible neurological changes and cardiac arrest. to prevent cyanide toxicity. Nitroglycerin Initial 5 microgram/min; increase in increments of 5 microgram/min Use only in patients with acute coronary syndrome and/or every 35 min to a maximum of 20 microgram/min. acute pulmonary Edema. Do not use in volume-depleted patients. Vasodilatorsdirect Hydralazine Initial 10 magnesium via slow IV infusion (maximum initial dose blood pressure begins to decrease within 1030 min, and the fall 20 magnesium); repeat every 46 h as needed. lasts 24 h. Unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in most patients. Adrenergic Esmolol Loading dose 5001000 microgram/kg/min over 1 min Contraindicated in patients with concurrent beta-blocker blockersbeta followed by a 50-microgram/kg/min infusion. For additional therapy, bradycardia, or decompensated heart failure. 1 receptor selective dosing, the bolus dose is repeated and the infusion Monitor for bradycardia. antagonist increased in 50-microgram/kg/min increments as needed to a May worsen heart failure. maximum of 200 microgram/kg/min. Higher doses may block beta receptors and impact lung 2 function in reactive airway disease. Adrenergic Labetalol Initial 0. 31. 0-magnesium/kg dose (maximum 20 magnesium) slow IV Contraindicated in reactive airways disease or chronic blockerscombined injection every 10 min or 0. 41. 0-magnesium/kg/h IV infusion up obstructive pulmonary disease. Especially useful in alpha and to 3 magnesium/kg/h. Adjust rate up to total cumulative dose of hyperadrenergic syndromes. May worsen heart failure and should 1 nonselective beta 300 magnesium. This dose can be repeated every 46 h. not be given in patients with secondor third-degree receptor antagonist Heart block or bradycardia. Adrenergic Phentolamine IV bolus dose 5 magnesium. Additional bolus doses every 10 min Used in hypertensive emergencies induced by blockers as needed to lower blood pressure to target.",
    "word_count": 583,
    "char_count": 4141,
    "sentence_count": 45,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 79,
      "total_chunks": 166,
      "position": "80/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "calcium",
        "magnesium",
        "antihypertensive",
        "edema",
        "heart failure",
        "monitoring",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 80,
    "text": "catecholamine excess (pheochromocytoma, interactions nonselective alpha between monamine oxidase inhibitors and other drugs receptor antagonist or food, cocaine toxicity, amphetamine overdose, or clonidine withdrawal). Dopamine-receptor Fenoldopam Initial 0. 10. 3 microgram/kg/min; may be increased in Contraindicated in patients at risk of increased intraocular 1 selective agonist increments of 0. 050. 1 microgram/kg/min every 15 min until Hypertension (glaucoma) or intracranial Hypertension and those target blood pressure is reached. Maximum infusion rate 1. 6 microgram/ with sulfite allergy. kg/min. ACE inhibitor Enalaprilat Initial 1. 25 magnesium over a 5-min period. Doses can be Contraindicated in pregnancy and should not be used in increased up to 5 magnesium every 6 h as needed to achieve acute myocardial infarction or bilateral renal artery stenosis. blood pressure target. Mainly useful in hypertensive emergencies associated with High plasma renin activity. Dose not easily adjusted. Relatively slow onset of action (15 min) and unpredictability of blood pressure response. blood pressure indicates Blood Hypertension; calcium channel blocker, calcium channel blocker; heart failure, Heart failure; IV, intravenous; and myocardial infarction, myocardial infarction. emergencies (Table 19). Because autoregulation of tisdegree of progression of target organ damage, the desue perfusion is disturbed in hypertensive emergencies, sirable rate of blood pressure decline, and the presence of comorcontinuous infusion of short-acting titratable antihyperbidities (Table 20). The therapeutic goal is to minimize tensive agents is often preferable to prevent further target target organ damage safely by rapid recognition of the organ damage. S11. 2-5, S11. 2-6 The selection of an antihyperproblem and early initiation of appropriate antihypertentensive agent should be based on the drugs pharmacolsive treatment. ogy, pathophysiological factors underlying the patients 2. Compelling conditions requiring rapid lowering of SBP, hypertension (as well as they can be rapidly determined), usually to 140 mm Hg, in the first hour of treatment Downloaded from by on December 30, 2025 e68 Hypertension June 2018 Table 20. Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies in Patients With Selected Comorbidities Comorbidity Preferred Drug(s) Comments Acute aortic dissection Esmolol, labetalol Requires rapid lowering of SBP to ≤120 mm Hg. Beta blockade should precede vasodilator (eg, nicardipine or nitroprusside) administration, if needed for blood pressure control or to prevent reflex tachycardia or inotropic effect; SBP ≤120 mm Hg should be achieved within 20 min. Acute pulmonary Edema Clevidipine, nitroglycerin, Beta blockers contraindicated. nitroprusside Acute coronary syndromes Esmolol, labetalol, nicardipine, Nitrates given in the presence of PDE-5 inhibitors may induce profound nitroglycerin hypotension. Contraindications to beta blockers include moderate-to-severe LV failure with pulmonary Edema, bradycardia (60 bpm), hypotension (SBP 100 mm Hg), poor peripheral perfusion, secondor third-degree Heart block, and reactive airways disease. Acute renal failure Clevidipine, fenoldopam, N/A nicardipine Eclampsia or preeclampsia Hydralazine, labetalol, nicardipine Requires rapid blood pressure lowering. ACE inhibitors, ARBs, renin inhibitors, and nitroprusside contraindicated. Perioperative hypertension (blood pressure ≥160/90 Clevidipine, esmolol, nicardipine, Intraoperative hypertension is most frequently seen during anesthesia mm Hg or SBP elevation ≥20% of nitroglycerin induction and airway manipulation. the preoperative value that persists for 15 min) Acute sympathetic discharge or Clevidipine, nicardipine, Requires rapid lowering of blood pressure. catecholamine excess states (eg, phentolamine pheochromocytoma, post-carotid endarterectomy status) Acute ICH Section 9. 4. 1 Section 9. 4. 1 Acute ischemic stroke Section 9. 4. 2 Section 9. 4. 2 Agents are listed in alphabetical order, not in order of preference. Agent of choice for acute coronary syndromes. ACE indicates angiotensin-converting enzyme; angiotensin receptor blocker, angiotensin receptor blocker; blood pressure, Blood Hypertension; bpm, beats per minute; ICH, intracerebral hemorrhage; LV, left ventricular; PDE-5, phosphodiesterase type-5; and SBP, systolic Blood Hypertension. include aortic dissection, severe preeclampsia or eclampSynopsis sia, and pheochromocytoma with hypertensive crisis.",
    "word_count": 600,
    "char_count": 4535,
    "sentence_count": 46,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 80,
      "total_chunks": 166,
      "position": "81/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "renal failure",
        "calcium",
        "magnesium",
        "ACE inhibitors",
        "ARBs",
        "antihypertensive",
        "edema",
        "heart failure",
        "blood pressure control"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 81,
    "text": "include aortic dissection, severe preeclampsia or eclampSynopsis sia, and pheochromocytoma with hypertensive crisis. Dementia is a leading cause of mortality and placement into 3. There is no RCT evidence comparing different strategies to nursing homes and assisted living facilities, affecting 46 milreduce blood pressure, except in patients with ICH. S11. 2-9, S11. 2-13 Neither lion individuals globally and 5 million persons in the United is there RCT evidence to suggest how rapidly or how much States, a number that is expected to double by 2050. S11. 3-7 A blood pressure should be lowered in a hypertensive emergency. S11. 2-9 5-year delay in onset of dementia would likely decrease the However, clinical experience indicates that excessive renumber of cases of incident dementia by about 50% after duction of blood pressure may cause or contribute to renal, cerebral, several decades. S11. 3-8 Vascular disease and its risk factors or coronary ischemia and should be avoided. Thus, comare implicated in a large proportion of patients with demenprehensive dosing of intravenous or even oral antihypertia, including those with Alzheimers dementia. S11. 3-9S11. 3-11 tensive agents to rapidly lower blood pressure is not without risk. Oral Hypertension is also the primary risk factor for small-vessel loading doses of antihypertensive agents can engender cumulative effects, causing hypotension after discharge ischemic disease and cortical white matter abnormalities. S11. 3-12 from the emergency department or clinic. S11. 3-15 Most observational studies have suggested that better control of SBP may reduce Alzheimers disease and other dementias, and the evidence is stronger for blood pressure lowering in 11. 3. Cognitive Decline and Dementia middle age than in older adults. S11. 3-9, S11. 3-16 Clinical trials with Recommendation for Prevention of Cognitive Decline and dementia assessment have evaluated all-cause dementia but Dementia not Alzheimers disease specifically. However, all of these trials have methodological issues, such as Low power, insufReferences that support the recommendation are ficient follow-up length, and inadequately designed dementia summarized in Online Data Supplement 56. assessment batteries. COR LOE Recommendation 1. In adults with hypertension, blood pressure lowering is Recommendation-Specific Supportive Text IIa B-R reasonable to prevent cognitive decline and 1. Five clinical trials of blood pressure lowering have included asdementia. S11. 3-1S11. 3-6 sessment for incident dementia. Of these 5 trials, 4 Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e69 demonstrated a reduction in dementia incidence, disease. S11. 4-7 These drugs have additive effects on lowering with 2 of these 4 demonstrating statistical significance blood pressure and are recommended as a primary therapy for pulmonary (746-751). SYST-EUR (Systolic Hypertension in hypertension. S11. 4-8 Although data are available to suggest that Europe)S11. 3-17 and PROGRESS (Perindopril Protection some antihypertensive medications affect erectile dysfuncAgainst Recurrent Stroke)S11. 3-18 both showed statistion more than others, the use of phosphodiesterase-5 inhibitically significant reductions in incident dementia. tors make drug class distinctions for erectile dysfunction less SYST-EUR achieved an SBP of 152 mm Hg in the relevant. S11. 4-9 The long-term safety and efficacy of chronic treatment arm (8. 3 mm Hg lower than placebo arm) administration of phosphodiesterase-5 inhibitors for the mitduring its blinded phase and an SBP of 149 mm Hg igation of cardiovascular disease has yet to be determined and represents an (7. 0 mm Hg lower than comparison group) during its open-label follow-up phase. S11. 3-2, S11. 3-3 PROGRESS important knowledge gap. achieved an SBP of 138 mm Hg in the treatment group (9 mm Hg lower than the placebo group) and demon11. 5. Patients Undergoing Surgical Procedures strated dementia prevention in patients with a recent stroke. S11.",
    "word_count": 596,
    "char_count": 4049,
    "sentence_count": 53,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 81,
      "total_chunks": 166,
      "position": "82/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 82,
    "text": "5. Patients Undergoing Surgical Procedures strated dementia prevention in patients with a recent stroke. S11. 3-5 The trial showing no benefit in the direcRecommendations for Treatment of Hypertension in tion of dementia reduction achieved an SBP reduction Patients Undergoing Surgical Procedures of only 3. 2 mm Hg, whereas the other 4 trials achieved References that support recommendations are summarized SBP reductions of 7 to 15 mm Hg (746-751). When in Online Data Supplements 57 and 58. the rate of cognitive decline (not dementia) has been a trial outcome, 7 clinical trials of blood pressure-lowering therCOR LOE Recommendations apy have been completed, and 2 of these have shown Preoperative benefit. S11. 3-4S11. 3-6, S11. 3-19S11. 3-22 No randomized trial of 1. In patients with hypertension undergoing blood pressure lowering has demonstrated an adverse impact on major surgery who have been on beta dementia incidence or cognitive function. However, I B-NR blockers chronically, beta blockers should be the anticipated results from SPRINT, the first adcontinued. S11. 5-1S11. 5-7 equately powered RCT to test whether intensive blood pressure 2. In patients with hypertension undergoing control reduces dementia, may help clarify this issue planned elective major surgery, it is in the near future. IIa C-EO reasonable to continue medical therapy for hypertension until surgery. 11. 4. Sexual Dysfunction and Hypertension 3. In patients with hypertension undergoing An association among sexual dysfunction, atherosclerosis, major surgery, discontinuation of ACE IIb B-NR and hypertension can be constructed from several epidemiinhibitors or ARBs perioperatively may be considered. S11. 5-8S11. 5-10 ology surveys, clinical trials, and cohort studies. Although these data converge to suggest that endothelial dysfunc4. In patients with planned elective major tion is a common denominator, the story is incomplete. surgery and SBP of 180 mm Hg or higher IIb C-LD or DBP of 110 mm Hg or higher, deferring Sexual dysfunction represents several domains in desire surgery may be considered. S11. 5-11, S11. 5-12 or interest, as well as physical limitations such as erectile dysfunction. In addition, beta blockers, mineralocorticoid 5. For patients undergoing surgery, abrupt preoperative discontinuation of beta receptor antagonists, and other antihypertensive drugs can III: Harm B-NR blockers or clonidine is potentially have negative effects on libido and erectile function. There harmful. S11. 5-2, S11. 5-13 are emerging data on the association between erectile dysfunction and cardiovascular disease compared with other domains of sexual 6. Beta blockers should not be started on III: Harm B-NR the day of surgery in beta blockernaïve dysfunction. Experimental and clinical studies describe a patients. S11. 5-14 role for angiotensin II, endothelin, and hydrogen sulfide on cavernous tissue function. S11. 4-1 Many of the signaling pathIntraoperative ways for the increased production of oxidative stress and 7. Patients with intraoperative the subsequent deleterious effects of oxidative stress on hypertension should be managed with vascular tissue have been described. Accordingly, it is reaI C-EO intravenous medications (Table 19) until such time as oral medications can be sonable to suggest that hypertension might lead to vascuresumed. lar changes that cause erectile dysfunction but, conversely, erectile dysfunction may be part of the causal pathway to Synopsis cardiovascular disease. S11. 4-1 Although there is insufficient evidence to recommend screening for cardiovascular disease risk factors in all men with Hypertension in the perioperative period increases the risk erectile dysfunction, it has been reported as a sole precurof cardiovascular disease, cerebrovascular events, and bleeding. S11. 5-15, S11. 5-16 sor for cardiovascular disease in men. S11. 4-2S11. 4-6 As many as 25% of patients who undergo major noncarWith the introduction of the phosphodiesterase-5 inhibidiac surgeryS11.",
    "word_count": 589,
    "char_count": 4021,
    "sentence_count": 54,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 82,
      "total_chunks": 166,
      "position": "83/166",
      "section": "5. Patients Undergoing Surgical Procedures strated dementia prevention in patients with a recent stroke",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "supplements",
        "ARBs",
        "antihypertensive",
        "cardiovascular disease",
        "screening"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 83,
    "text": "S11. 4-2S11. 4-6 As many as 25% of patients who undergo major noncarWith the introduction of the phosphodiesterase-5 inhibidiac surgeryS11. 5-17 and 80% of patients who have cardiac tors, which can be coadministered with antihypertensive surgery experience perioperative hypertension. S11. 5-16, S11. 5-18 medications, there is now effective therapy for erectile In general, the level of risk is related to the severity of the dysfunction that has implications for systemic vascular hypertension. Downloaded from by on December 30, 2025 e70 Hypertension June 2018 No High-quality RCTs were identified relating to the evidence from a large cohort study demonstrates that treatment of hypertension in patients undergoing major patients who stopped their ACE inhibitors or ARBs 24 surgical procedures. One analysis evaluated data from 3 hours before noncardiac surgery were less likely to sufprospective, randomized, open-label, parallel-comparison fer the primary composite outcome (all-cause death, studies in patients undergoing cardiac surgery and concluded stroke, or myocardial injury) and intraoperative hypothat clevidipine is a safe and effective treatment for acute tension than were those continuing these medications until surgery. S11. 5-10 hypertension in patients undergoing cardiac surgery. S11. 5-19 4. JNC 6S11. 5-23 noted conflicting evidence for patients with Another systematic review and meta-analysis, including 4 DBP 110 mm Hg and recommended delay of surgery studies, concluded that clevidipine is more effective than for gradual reduction in DBP before proceeding with other antihypertensive drugs in the management of periopsurgery. In a systematic review and meta-analysis of erative hypertension without adverse events. S11. 5-20 Several 30 observational studies, preoperative hypertension general strategies and principles based on experience and was associated with a 35% increase in cardiovascular observation are recommended for this section. In the mancomplications. S11. 5-12 An increase in complications, inagement of patients with perioperative hypertension, it is cluding dysrhythmias, myocardial ischemia or infarcimportant to assess other potential contributing factors, such tion, neurological complications, and renal failure, as volume status, Pain control, oxygenation, and bladder has been reported in patients with DBP ≥110 mm Hg distention, when the use of pharmacological therapy to conimmediately before surgery. S11. 5-24 In contrast, patients trol blood pressure is under consideration. Uncontrolled hypertension with DBP 110 mm Hg do not appear to be at signifiis associated with increased perioperative and postoperacantly increased risk. S11. 5-25 The relationship of systolic tive complications. Certain medications (eg, beta blockers, hypertension to surgical risk is less certain. Among clonidine) may be associated with rebound hypertension if patients undergoing carotid endarterectomy, increased discontinued abruptly. S11. 5-13 Therefore, several general stratrisk of postoperative hypertension and neurologiegies and principles based on experience and observation are cal defects were observed, S11. 5-26 and an increased risk recommended for this section. of cardiovascular disease morbidity after coronary artery bypass graft These recommendations for beta blockers, ACE inhibisurgery has been observed in patients with isolated systolic hypertension. S11. 5-27 During induction of antors, and ARBs are generally consistent with the 2014 esthesia for surgery, sympathetic action can result in ACC/AHA Guideline on Perioperative Cardiovascular a 20 to 30mm Hg increase in blood pressure and a 15to 20Evaluation and Management of Patients Undergoing bpm increase in Heart rate among patients with normal Noncardiac Surgery and are provided to assist in the manblood pressure. S11. 5-24 Exaggerated responses may occur in patients agement of patients undergoing major noncardiac surgical with poorly treated or untreated hypertension by as procedures. S11. 5-21 much as 90 mm Hg and 40 bpm. S11. 5-24 With further anesthesia, the accompanying inhibition of the sympaRecommendation-Specific Supportive Text thetic nervous system and loss of baroreceptor control 1.",
    "word_count": 590,
    "char_count": 4221,
    "sentence_count": 40,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 83,
      "total_chunks": 166,
      "position": "84/166",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "renal failure",
        "ACE inhibitors",
        "ARBs",
        "antihypertensive",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 84,
    "text": "If well tolerated, beta blockers should be continued in may result in intraoperative hypotension. Lability in blood pressure patients who are currently receiving them for longituappears more likely in patients with poorly controlled dinal reasons, particularly when longitudinal treatment hypertension, S11. 5-25 whereas studies have observed that is provided according to GDMT, such as for myocardial infarction. S11. 5-22 patients with controlled hypertension respond similarly Multiple observational studies support the benefits of to those who are normotensive. S11. 5-28 Early work indicated continuing beta blockers in patients who are undergothat patients with severe hypertension (SBP 210 mm Hg ing surgery and who are on these agents for longitudinal and DBP 105 mm Hg) had exaggerated responses in indications. S11. 5-1S11. 5-7 blood pressure during the induction of anesthesia. S11. 5-28 2. In the absence of conclusive RCTs, the expert opinion 5. Although few studies describe risks of withdrawing of this writing committee is that control of blood pressure to levbeta blockers in the perioperative time period, S11. 5-2, S11. 5-5 els recommended by the present guideline (blood pressure 130/80 longstanding evidence from other settings suggests mm Hg) or other target levels specified for a particular that abrupt withdrawal of long-term beta blockers is individual is reasonable before undertaking major elecharmful. S11. 5-29S11. 5-31 There are fewer data to describe tive procedures in either the inpatient or outpatient setwhether short-term (1 to 2 days) perioperative use of ting. If the patient is unable to take oral medications, it is beta blockers, followed by rapid discontinuation, is reasonable to use intravenous medications (Table 19) as harmful. S11. 5-5, S11. 5-14, S11. 5-21, S11. 5-30 necessary to control blood pressure. Special consideration of paren6. The 2014 ACC/AHA perioperative guideline specifically teral therapy usually occurs for patients taking clonidine recommends against starting beta blockers on the day of or beta blockers because of the risk of stopping these surgery in beta-blockernaive patients, S11. 5-5, S11. 5-21, S11. 5-30 medications acutely. Withdrawal syndromes, accompaparticularly at High initial doses, in long-acting nied by sympathetic discharge and acute hypertension, form, and if there are no plans for dose titration or can occur on cessation of these agents. S11. 5-13 monitoring for adverse events. Data from the POISE 3. Data on the potential risk and benefit of ACE inhibi- (Perioperative Ischemic Evaluation) study demonstrate tors in the perioperative setting are limited to observathe risk of initiating long-acting beta blockers on the day tional analyses, and this area is controversial. Recent of surgery. S11. 5-14 Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e71 7. Several antihypertensive agents in a variety of pharmacoSupplement F for barriers to medication adherence and the logical classes are available for the treatment of hypertenmost successful interventions. sive emergencies (Table 19). The creation of an encouraging, blame-free environment in which patients are recognized for achieving treatment goals 12. Strategies to Improve Hypertension and given permission to answer questions related to their Treatment and Control treatment honestly is essential to identify and address nonadIn addition to promoting pharmacological and nonpharmacoherence. Patient medication adherence assessment toolsS12. 1. 1-17 logical treatment adherence in individual patients with hyperare presented in Online Data Supplement A. Members of tension, several population-based systems approaches can the hypertension care team may use these self-report tools play an important role in treatment goals. in a nonthreatening fashion to identify barriers and facilitate behaviors associated with improved adherence to antihypertensive medications. Use of more objective methods (eg, pill 12. 1.",
    "word_count": 583,
    "char_count": 4019,
    "sentence_count": 49,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 84,
      "total_chunks": 166,
      "position": "85/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "antihypertensive",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 85,
    "text": "Use of more objective methods (eg, pill 12. 1. Adherence Strategies for Treatment counts, data on medication refills) to assess adherence along of Hypertension with self-report methods is optimal. Therapeutic nonadherence (not following recommended medical or health advice, including failure to persist with Recommendation-Specific Supportive Text medications and recommended lifestyle modifications) is 1. Remembering to take medication is often challenging, a major contributor to poor control of hypertension and a particularly for regimens that must be dosed several key barrier to reducing cardiovascular disease deaths. Adherence rates vary times daily. Taking medications several times throughsubstantially in different populations and, in general, are out the day requires greater attention to scheduling, as lower for lifestyle change and more behaviorally demanding well as additional issues such as transportation or storregimens. age, which can be challenging for some patients. The impact of once-daily dosing of antihypertensive drugs 12. 1. 1. Antihypertensive Medication Adherence Strategies versus dosing multiple times daily has been evaluated in several meta-analyses. S12. 1. 1-1S12. 1. 1-3 Medication adRecommendations for Antihypertensive Medication herence was greatest with once-daily dosing (range Adherence Strategies 71% to 94%) and declined as dosing frequency References that support recommendations are summarized increased. S12. 1. 1-1, S12. 1. 1-2 in Online Data Supplements 59 and 60. 2. Assessment and possible modification of drug therapy regimens can improve suboptimal adherence. Simplifying COR LOE Recommendations medication regimens, either by less frequent dosing (ie, 1. In adults with hypertension, dosing of once daily versus multiple times daily) or use of comI B-R antihypertensive medication once daily bination drug therapy, improves adherence. Available rather than multiple times daily is beneficial fixed-dose combination drug therapy is listed in Online to improve adherence. S12. 1. 1-1S12. 1. 1-3 Data Supplement D. 2. Use of combination pills rather than free individual components can be useful to 12. 1. 2. Strategies to Promote Lifestyle Modification IIa B-NR improve adherence to antihypertensive therapy. S12. 1. 1-4S12. 1. 1-7 Recommendation for Strategies to Promote Lifestyle Modification Synopsis References that support the recommendation are Up to 25% of patients do not fill their initial prescription for summarized in Online Data Supplement 61. antihypertensive therapy. S12. 1. 1-8S12. 1. 1-10 During the first year of COR LOE Recommendation treatment, the average patient has possession of antihyperten1. Effective behavioral and motivational sive medications only 50% of the time, and only 1 in 5 patients strategies to achieve a healthy lifestyle has sufficiently High adherence to achieve the benefits observed (ie, tobacco cessation, weight loss, in clinical trials. S12. 1. 1-11, S12. 1. 1-12 moderation in alcohol intake, increased I C-EO Factors contributing to poor adherence are myriad, comphysical activity, reduced Sodium plex, and multilevel. S12. 1. 1-11, S12. 1. 1-13, S12. 1. 1-14 Therefore, soluintake, and consumption of a healthy tions to improve adherence may be introduced at patient, diet) are recommended for adults with hypertension. S12. 1. 2-1, S12. 1. 2-2 provider, and healthcare system levels. S12. 1. 1-13, S12. 1. 1-15, S12. 1. 1-16 Several systematic reviews and meta-analyses have assessed the impact of interventions on adherence to antihypertenSynopsis sive medications, including modification of antihypertensive The primary lifestyle modification interventions that can therapy. S12. 1. 1-1S12. 1. 1-7, S12. 1. 1-11, S12. 1. 1-15, S12. 1. 1-16 No single interhelp reduce High blood pressure are outlined in Section 6 (healthy diet, vention is uniquely effective, and a sustained, coordinated weight loss, exercise and moderate alcohol intake). In addieffort that targets all barriers to adherence in an individual tion, tobacco cessation is crucial for cardiovascular disease risk reduction. is likely to be the most effective approach.",
    "word_count": 597,
    "char_count": 4144,
    "sentence_count": 84,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 85,
      "total_chunks": 166,
      "position": "86/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "diet",
        "supplements",
        "antihypertensive",
        "cardiovascular disease",
        "exercise",
        "adherence"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 86,
    "text": "is likely to be the most effective approach. See Online Data These modifications are central to Good health and require Downloaded from by on December 30, 2025 e72 Hypertension June 2018 specific motivational and cognitive intervention strategies Table 21. Clinicians Sequential Flow Chart for the designed to promote adherence to these healthy behaviors. Management of Hypertension High-quality evidence supporting some of these strategies Clinicians Sequential Flow Chart for the Management of Hypertension is provided in Online Data Supplement G. Additionally, interventions such as goal setting, provision of feedback, Measure office blood pressure accurately Section 4 self-monitoring, follow-up, motivational interviewing, and Detect white coat hypertension or masked Section 4 promotion of self-sufficiency are most effective when comhypertension by using ABPM and HBPM bined. Most individuals have clear expectations about what a Evaluate for secondary hypertension Section 5 new lifestyle will provide; if their experiences do not match Identify target organ damage Sections 5 and 7 these expectations, they will be dissatisfied and less motivated to maintain a lifestyle change, particularly in enviIntroduce lifestyle interventions Section 6 ronments that do not support healthy choices. Other factors Identify and discuss treatment goals Sections 7 and 8 that may influence adoption and maintenance of new physiUse ASCVD risk estimation to guide blood pressure Section 8. 1. 2 cal activity or dietary behaviors include age, sex, baseline threshold for drug therapy health status, and body mass index, as well as the presence of Align treatment options with comorbidities Section 9 comorbid conditions and depression, which negatively affect adherence to most lifestyle change regimens. S12. 1. 2-1 Primary Account for age, race, ethnicity, sex, and Sections 10 and 11 strategies include cognitive-behavioral strategies for prospecial circumstances in antihypertensive treatment moting behavior change, intervention processes and delivery strategies, and addressing cultural and social context variInitiate antihypertensive pharmacological Section 8 ables that influence behavioral change. therapy Insure appropriate follow-up Section 8 Recommendation-Specific Supportive Text Use team-based care Section 12 1. It is crucial to translate and implement into practice Connect patient to clinician via telehealth Section 12 the most effective evidence-based strategies for adherence to nonpharmacological treatment for hyperDetect and reverse nonadherence Section 12 tension. Both adoption and maintenance of new cardiovascular disease Detect white coat effect or masked Section 4 risk-reducing behaviors pose challenges for many inuncontrolled hypertension dividuals. Success requires consideration of race, ethUse health information technology for remote Section 12 nicity, and socioeconomic status, as well as individual, monitoring and self-monitoring of blood pressure provider, and environmental factors that may influence ABPM indicates ambulatory Blood Hypertension monitoring; ASCVD, the design of such interventions. S12. 1. 2-1 High-quality eviatherosclerotic cardiovascular disease; blood pressure, Blood Hypertension; and HBPM, home dence has shown that even modest sustained lifestyle Blood Hypertension monitoring. changes can substantially reduce cardiovascular disease morbidity and mortality. S12. 1. 2-1 Because many beneficial effects of minorities (see Section 10. 1), residents located in rural areas, lifestyle changes accrue over time, long-term adherence maximizes individual and population benefits. and older adults. The more comprehensive blood pressure targets proInterventions targeting Sodium restriction, other dietary posed in the present guideline will present added challenges patterns, weight reduction, and new physical activity in these populations. habits often result in impressive rates of initial behavior It is crucial to invest in measures to enhance health litchanges but frequently are not translated into long-term eracy and reinforce the importance of adhering to treatment behavioral maintenance. strategies, while paying attention to cultural sensitivities. These measures may include identification of and partner12. 1. 3.",
    "word_count": 581,
    "char_count": 4281,
    "sentence_count": 30,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 86,
      "total_chunks": 166,
      "position": "87/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "sodium restriction",
        "antihypertensive",
        "cardiovascular disease",
        "physical activity",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 87,
    "text": "strategies, while paying attention to cultural sensitivities. These measures may include identification of and partner12. 1. 3. Improving Quality of Care for Resource-Constrained ing with community resources and organizations devoted to Populations hypertension control and cardiovascular health. Although The availability of financial, informational, and instrumental comparative-effectiveness data documenting efficacy of support resources can be important though not sole determivarious interventions are limited, multidisciplinary team nants of hypertension control. S12. 1. 3-1, S12. 1. 3-2 The management of hypertension in resource-constrained populations poses a based approaches and the use of community health workchallenge that will require the implementation of all recomers (see Sections 12. 1. 1 and 12. 2) have shown some utility, mendations discussed in Section 13 (Table 21), with specific as has the use of out-of-office blood pressure monitoring (or no-cost sensitivity to challenges posed by limited financial resources, blood pressure control visits), particularly among resource-constrained including those related to health literacy, alignment of and populations. S12. 1. 3-3S12. 1. 3-5 Long-acting once-daily medicapotential need to realign healthcare priorities by patients, the tions (eg, chlorthalidone, amlodipine) that are now availconvenience and complexity of the management strategy, able generically and often on discount formularies can often accessibility to health care, and health-related costs (includbe used to reduce complexity of the regimen and promote ing medications). Resource-constrained populations are also adherence by decreasing the effect of missed medication populations with High representation of groups most likely dosages. When possible, prescriptions requiring longer to manifest health disparities, including racial and ethnic than 30-day refills should be considered, especially once a Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e73 stable regimen is achieved. Where appropriate, using scored performance, are likely to augment and intensify team-based tablets and pill cutters can decrease the cost of medication care efforts to reduce High blood pressure. for patients. Recommendation-Specific Supportive Text 12. 2. Structured, Team-Based Care Interventions 1. RCTs and meta-analyses of RCTs of team-based hyperfor Hypertension Control tension care involving nurse or pharmacist intervention demonstrated reductions in SBP and DBP and/or greater Recommendation for Structured, Team-Based Care achievement of blood pressure goals when compared with usual Interventions for Hypertension Control care. S12. 2-1, S12. 2-2, S12. 2-4, S12. 2-5 Similarly, systematic reviews of team-based care, including a review of studies that inReferences that support the recommendation are summarized in Online Data Supplement 62. cluded community health workers, for patients with primary hypertension showed reductions in SBP and DBP COR LOE Recommendation and improvements in blood pressure control, appointment keeping, 1. A team-based care approach is and hypertension medication adherence as compared I A recommended for adults with with usual care. S12. 2-3, S12. 2-12 hypertension. S12. 2-1S12. 2-7 12. 3. Health Information TechnologyBased Synopsis Strategies to Promote Hypertension Control Team-based care to improve blood pressure control is a health sys12. 3. 1. EHR and Patient Registries temslevel, organizational intervention that incorporates a multidisciplinary team to improve the quality of hypertenRecommendations for EHR and Patient Registries sion care for patients. S12. 2-8S12. 2-10 Various team-based hyperReferences that support recommendations are summarized tension care models have been demonstrated to increase the in Online Data Supplement 63. proportion of individuals with controlled blood pressure and to reduce both SBP and DBP. S12. 2-1S12. 2-7, S12. 2-11, S12. 2-12 A team-based care COR LOE Recommendations approach is patient centered and is frequently implemented 1. Use of the EHR and patient registries is as part of a multifaceted approach, with systems support for beneficial for identification of patients I B-NR clinical decision making (ie, treatment algorithms), collabowith undiagnosed or undertreated hypertension. S12. 3.",
    "word_count": 600,
    "char_count": 4374,
    "sentence_count": 55,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 87,
      "total_chunks": 166,
      "position": "88/166",
      "content_type": "reference",
      "content_type_confidence": 4,
      "medical_entities": [
        "blood pressure control",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 88,
    "text": "S12. 3. 1-1S12. 3. 1-3 ration, adherence to prescribed regimen, blood pressure monitoring, and patient self-management. Team-based care for hypertension 2. Use of the EHR and patient registries is beneficial includes the patient, the patients primary care provider, and I B-NR for guiding quality improvement efforts designed other professionals, such as cardiologists, nurses, pharmato improve hypertension control. S12. 3. 1-1S12. 3. 1-3 cists, physician assistants, dietitians, social workers, and community health workers. These professionals complement Synopsis the activities of the primary care provider by providing proA growing number of health systems are developing or using cess support and sharing the responsibilities of hypertension registries and EHR that permit large-scale queries to supcare. Section 13 contains a comprehensive, patient-centered port population health management strategies to identify plan of care that should be the basis of all team-based care undiagnosed or undertreated hypertension. Such innovations for hypertension. are implemented as ongoing quality improvement initiaTeam-based care aims to achieve effective control of tives in clinical practice. To reduce undiagnosed hypertenhypertension by application of the strategies outlined in sion and improve hypertension management, a multipronged Online Data Supplement H. S12. 2-3 Delineation of individual approach may include 1) application of hypertension screenteam member roles on the basis of knowledge, skill set, and ing algorithms to EHR databases to identify at-risk patients, availability, as well as the patients needs, allows the pri2) contacting at-risk patients to schedule blood pressure measurements, 3) mary care provider to delegate routine matters to the team, monthly written feedback to clinicians about at-risk patients thereby permitting more time to manage complex and critiwho have yet to complete a blood pressure measurement, and 4) electronic cal patient-care issues. Important implementation aspects, prompts for blood pressure measurements whenever at-risk patients visit such as type of team member added, role of team members the clinic. S12. 3. 1-1, S12. 3. 1-2 related to medication management, and number of team members, influence blood pressure outcomes. S12. 2-3, S12. 2-13 Team member Recommendation-Specific Supportive Text roles should be clear to all team members and to patients 1. A growing number of health systems have implemented and families. secure EHR and are developing databases that permit Team-based care often requires organizational change large-scale queries to support population health manageand reallocation of resources. S12. 2-14, S12. 2-15 Systems-level supment strategies for more effective and accurate identificaport, such as use of electronic health records (EHR) (see tion of patients with hypertension. S12. 3. 1-1S12. 3. 1-3 Section 12. 3. 1), clinical decision support (ie, treatment algo2. A growing number of health systems have implemented rithms), technology-based remote monitoring (see Section secure EHR and are developing databases that permit 12. 3. 2), self-management support tools, and monitoring of large-scale quality improvement initiativedesigned Downloaded from by on December 30, 2025 e74 Hypertension June 2018 queries to support population health management 12. 4. Improving Quality of Care for Patients With strategies for more effective management and control Hypertension of hypertension. S12. 3. 1-1S12. 3. 1-3 12. 4. 1. Performance Measures 12. 3. 2. Telehealth Interventions to Improve Hypertension Recommendation for Performance Measures Control References that support the recommendation are Recommendation for Telehealth Interventions to Improve summarized in Online Data Supplement 65. Hypertension Control COR LOE Recommendation References that support the recommendation are 1. Use of performance measures in summarized in Online Data Supplement 64. combination with other quality improvement COR LOE Recommendation IIa B-NR strategies at patient-, provider-, and systembased levels is reasonable to facilitate 1. Telehealth strategies can be useful optimal hypertension control. S12. 4. 1-1S12. 4.",
    "word_count": 587,
    "char_count": 4195,
    "sentence_count": 62,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 88,
      "total_chunks": 166,
      "position": "89/166",
      "content_type": "dietary",
      "content_type_confidence": 3,
      "medical_entities": [
        "adherence",
        "monitoring"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 89,
    "text": "Telehealth strategies can be useful optimal hypertension control. S12. 4. 1-1S12. 4. 1-3 adjuncts to interventions shown to IIa A reduce blood pressure for adults with hypertension. S12. 3. 2-1S12. 3. 2-5 Synopsis Efforts to improve suboptimal medical care include the use of Synopsis performance measures, which are defined as standardized, valiTelehealth strategies, such as telemedicine, digital health dated approaches to assess whether correct healthcare processes (eHealth), and use of mobile computing and communicaare being performed and that desired patient outcomes are being tion technologies (mHealth), are new and innovative tools to achieved. S12. 4. 1-4 Performance measures are often combined with facilitate improvements in managing patients with hypertenother quality improvement strategies, such as certification or sion. mHealth interventions show promise in reducing SBP in financial incentives tied to higher-quality care. S12. 4. 1-5 Guidelines patients with hypertension but with large variability in behavhelp define clinical care standards that can be used to develop perioral targets, intervention components, delivery modalities, formance measures. As guidelines evolve over time to incorporate and patient engagement. S12. 3. 2-5 In addition, there are important new evidence, related performance measures may also evolve. implications for the role of social networks, social media, and Because identification, treatment, and control of hypertenelectronic technology as viable components of weight mansion are suboptimal, performance measures for hypertension agement and other lifestyle modification and disease managecontrol have been developed and recommended for use in qualment programs. S12. 3. 2-6 ity improvement projects aimed at improving hypertension Commonly used telehealth interventions for hypertencontrol and related outcomes in clinical practice. S12. 4. 1-6S12. 4. 1-8 sion management are listed in Online Data Supplement I. Because the specific methods used in performance measures Wireless technologies (Online Data Supplement I) allow linkcan have an impact on their accuracy and ultimate impact (eg, ing blood pressure devices and other measurement devices to telephoneor the method of blood pressure measurement used in the assessment), they Internet-based transmission systems or to Wi-Fi access points should be developed, tested, and implemented according to available in users homes and in communities. Some systems published standards. S12. 4. 1-9 See Online Data Supplement J for require patients to manually enter data, which is then forwarded publicly available performance measures to assess the quality to a remote computer or the mobile device of the telehealth of hypertension care (generally using JNC 7 criteria). provider through a telephone line or the Internet. S12. 3. 2-7 When data are received, they are stored and analyzed, and reports are Recommendation-Specific Supportive Text generated, including variations and averages in blood pressure and other 1. RCTs on the impact of performance measures on hyperparameters over the recording period. tension control are lacking; RCTs of quality improvement protocols have shown improvements in hypertension Recommendation-Specific Supportive Text control. S12. 4. 1-1, S12. 4. 1-2 Furthermore, a large observational 1. Meta-analyses of RCTs of different telehealth interstudy showed that a systematic approach to hypertension ventions have demonstrated greater SBP and DBP control, including the use of performance measures, was reductionsS12. 3. 2-1, S12. 3. 2-2, S12. 3. 2-4 and a larger proportion of associated with significant improvement in hypertension patients achieving blood pressure controlS12. 3. 2-2 than those achieved control compared with historical control groups. S12. 4. 1-3 with usual care without telehealth. The effect of various telehealth interventions on blood pressure lowering was signifi12. 4. 2. Quality Improvement Strategies cantly greater than that of blood pressure self-monitoring without transmission of blood pressure data, which suggests a possible addRecommendation for Quality Improvement Strategies ed value of the teletransmission approach. S12. 3. 2-1, S12. 3.",
    "word_count": 595,
    "char_count": 4220,
    "sentence_count": 67,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 89,
      "total_chunks": 166,
      "position": "90/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "monitoring"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 90,
    "text": "S12. 3. 2-1, S12. 3. 2-3 References that support the recommendation are Although mHealth interventions in general showed summarized in Online Data Supplements 66 and 67. promise in reducing SBP in patients with hypertenCOR LOE Recommendation sion, results were inconsistent. S12. 3. 2-5 It is unclear which combination of telehealth intervention features is most 1. Use of quality improvement strategies at effective, and telehealth has not been demonstrated to the health system, provider, and patient IIa B-R be effective as a standalone strategy for improving levels to improve identification and control of hypertension can be effective. S12. 4. 2-1S12. 4. 2-8 hypertension control. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e75 Synopsis Recommendations for Financial Incentives (Continued) High-quality blood pressure management is multifactorial and requires COR LOE Recommendations the engagement of patients, families, providers, and healthcare delivery systems. S12. 4. 2-9 The difference between patient out2. Health system financing strategies (eg, insurance coverage and copayment benefit comes achieved with current hypertension treatment methods IIa B-NR design) can be useful in facilitating improved and patient outcomes thought to be possible with best-practice medication adherence and blood pressure control in treatment methods is known as a quality gap, and such gaps patients with hypertension. S12. 5-4 are at least partly responsible for the loss of thousands of lives each year. S12. 4. 2-10 This includes expanding patient and healthcare Synopsis provider awareness, appropriate lifestyle modifications, access With the evolution of the ultrasound health system to reward value to care, evidence-based treatment, a High level of medication over volume, payment systems have focused on financial adherence, and adequate follow-up. S12. 4. 2-9 Quality improvement incentives to improve quality of care. Use of performance strategies or interventions aimed at reducing the quality gap measures promulgated by national organizations, governfor a group of patients who are representative of those encounmental payers, and commercial payers have fostered greater tered in routine practice have been effective in improving the attention to control of High blood pressure among healthcare providers hypertension care and outcomes across a wide variety of clinic and their patients. These performance measures have formed and community settings. S12. 4. 2-1S12. 4. 2-4, S12. 4. 2-6, S12. 4. 2-8, S12. 4. 2-10 the basis for determining financial incentives for pay for Hypertension quality improvement strategies, with examperformance initiatives, commercial insurer pay-for-value ples of substrategies that have been demonstrated to reduce contracts, and the Medicare Shared Savings Programs develblood pressure and improve blood pressure, are provided in Online Data Supplement oped by the Centers for Medicare Medicaid Services E. Because the effects of the different quality improvement Innovation for Accountable Care Organizations. In addistrategies varied across trials, and most trials included 1 qualtion, the Centers for Medicare and Medicaid Services has ity improvement strategy, it is not possible to discern which developed The Million Hearts: Cardiovascular Disease specific quality improvement strategies have the greatest Risk Reduction Model, which is an RCT designed to ideneffects. Team-based care (see Section 12. 4) and an organized tify and test scalable models of care delivery that reduce system of regular review, with antihypertensive drug therapy cardiovascular disease risk. S12. 5-5 implemented via a stepped-care protocol, had a clinically sigGreater attention is being paid to the influence of health nificant effect on reducing SBP and DBP and improving blood pressure insurance coverage and benefit designs focused on reducing control. The assessed strategies in Online Data Supplement E patient copayments for antihypertensive medications. may be beneficial under some circumstances and in varying combinations. S12. 4. 2-1S12. 4.",
    "word_count": 593,
    "char_count": 4139,
    "sentence_count": 51,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 90,
      "total_chunks": 166,
      "position": "91/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "supplements",
        "antihypertensive",
        "cardiovascular disease",
        "blood pressure control",
        "adherence",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 91,
    "text": "may be beneficial under some circumstances and in varying combinations. S12. 4. 2-1S12. 4. 2-5 National initiatives such as Million Recommendation-Specific Supportive Text Hearts Make Control Your Goal Blood Hypertension Toolkit and 1. Moderate-quality evidence with mixed results sugTeam Up Hypertension Down provide quality improvement tools gests that population-based payment incentive proto support hypertension care in communities and clinical grams can play an important role in achieving better blood pressure settings. S12. 4. 2-11 For other national and regional initiatives to control. S12. 5-1S12. 5-3 improve hypertension, see Online Data Supplement G. 2. Reduced copayments for health care, including for medications, and improved outcomes of hypertension care Recommendation-Specific Supportive Text have been identified in several ultrasound studies and in single 1. Systematic review and meta-analyses of trials of quality studies in Finland, Israel, and Brazil. S12. 5-4 This is conimprovement interventions at health system, provider, and sistent with other evidence on how copayments reduce patient levels have demonstrated greater SBP and DBP reuptake of care and has implications for policy makers, ductions and a larger proportion of patients achieving blood pressure particularly because the balance of evidence does not control than those observed with no intervention or usual suggest that reducing medication copayments leads to an care. Multicomponent and multilevel strategies at the loincrease in overall healthcare expenditure. cal community and healthcare delivery system levels have been shown to improve blood pressure control. S12. 4. 2-6, S12. 4. 2-7 13. The Plan of Care for Hypertension 12. 5. Financial Incentives Recommendation for the Plan of Care for Hypertension Recommendations for Financial Incentives COR LOE Recommendation References that support recommendations are summarized 1. Every adult with hypertension should have a in Online Data Supplement 68. clear, detailed, and current evidence-based plan of care that ensures the achievement COR LOE Recommendations of treatment and self-management goals, I C-EO 1. Financial incentives paid to providers can encourages effective management of be useful in achieving improvements in comorbid conditions, prompts timely followIIa B-R treatment and management of patient up with the healthcare team, and adheres to populations with hypertension. S12. 5-1S12. 5-3 cardiovascular disease GDMT (Table 22). Downloaded from by on December 30, 2025 e76 Hypertension June 2018 Synopsis Table 22. Evidence-Based Elements of the Plan of Care for Patients With Hypertension A specific plan of care for hypertension is essential and should reflect understanding of the modifiable and nonmodifiable Associated Section(s) determinants of health behaviors, including the social deterof Guideline and Other minants of risk and outcomes. A clinicians sequential flow Plan of Care Reference(s) chart for management of hypertension is presented in Table 21. Pharmacological and nonpharmacological treatments Detailed evidence-based elements of the plan of care are listed Medication selection (initial and Section 8. 1 in Table 22. The determinants will vary among demographic ongoing) subgroups (see Section 10 for additional information). Monitoring for adverse effects and Sections 8. 3. 1, Recommendation-Specific Supportive Text adherence 8. 3. 2, 12. 1. 1 1. Studies demonstrate that implementation of a plan of care Nonpharmacological interventions Sections 6, for hypertension can lead to sustained reduction of blood pressure Diet 12. 1. 2S13. 1-2 and attainment of blood pressure targets over several years. S13-1S13-6 Exercise Meta-analysis of RCTs shows reductions in blood pressure of paWeight loss if overweight tients with hypertension and achievement of blood pressure goals Moderate alcohol consumption at 6 months and 1 year when compared with usual care. Management of common comorbidities and conditions 13. 1. Health Literacy Ischemic Heart disease Section 9. 1S13. 1-3, S13. 1-4 Communicating alternative behaviors that support selfHeart failure Section 9. 2S13.",
    "word_count": 594,
    "char_count": 4160,
    "sentence_count": 57,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 91,
      "total_chunks": 166,
      "position": "92/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "diet",
        "cardiovascular disease",
        "exercise",
        "blood pressure control",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 92,
    "text": "1S13. 1-3, S13. 1-4 Communicating alternative behaviors that support selfHeart failure Section 9. 2S13. 1-5 management of healthy blood pressure in addition to medication adherReduced ejection fraction ence is important. This should be done both verbally and in Preserved ejection fraction writing. Today, mobile phones have a recording option. For patients with mobile phones, the phone can be used to inform Diabetes mellitus Section 9. 6S13. 1-6 patients and family members of medical instructions after Chronic Kidney disease Section 9. 3 the doctors visit as an additional level of communication. Cerebrovascular disease Section 9. 4 Inclusion of a family member or friend that can help interpret Peripheral artery disease Section 9. 5 and encourage self-management treatment goals is suggested when appropriate. Examples of needed communication for Atrial fibrillation Section 9. 8 alternative behaviors include a specific regimen relating to Valvular Heart disease Section 9. 9 physical activity; a specific Sodium-reduced meal plan indiLeft ventricular hypertrophy Section 7. 3 cating selections for breakfast, lunch, and dinner; lifestyle recommendations relating to sleep, rest, and relaxation; and Thoracic aortic disease Section 9. 10 finally, suggestions and alternatives to environmental barriPatient and family education ers, such as barriers that prevent healthy food shopping or Achieving blood pressure control and self-monitoring Sections 4. 2, 8. 2 limit reliable transportation to and from appointments with health providers and pharmacy visits. Risk assessment and prognosis Section 8. 1. 2 Sexual activity and dysfunction Section 11. 4 13. 2. Access to Health Insurance and Medication Special patient groups Assistance Plans Pregnancy Section 10. 2. 2 Health insurance and medication plan assistance for patients is especially important to improving access to and affordability Older persons Section 10. 3. 1 of medical care and blood pressure medications. Learning how the patient Children and adolescents Section 10. 3. 2 financially supports and budgets for his or her medical care and Metabolic syndrome Section 9. 7 medications offers the opportunity to share additional insight relating to cost reductions, including restructured payment Possible secondary causes of Section 5. 4 hypertension plans. Ideally, this would improve the patients compliance with medication adherence and treatment goals. Resistant hypertension Section 11. 1 Patients with hypertension undergoing Section 11. 5 13. 3. Social and Community Services surgery Health care can be strengthened through local partnerRenal transplantation Section 9. 3. 1 ships. Hypertensive patients, particularly patients with lower incomes, have more opportunity to achieve treatment goals Psychosocial factors with the assistance of strong local partnerships. In patients with Sex-specific issues Section 10. 2 Low socioeconomic status or patients who are challenged by Culturally sensitive issues (race and Section 10. 1 social situations, integration of social and community services ethnicity) offers complementary reinforcement of clinically identified Resource constraints Section 12. 5 treatment goals. Social and community services are helpful when explicitly related to medical care. However, additional (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e77 Table 22. Continued Table 23. blood pressure Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Associated Section(s) Conditions of Guideline and Other Plan of Care Reference(s) blood pressure Threshold, Clinical Condition(s) mm Hg blood pressure Goal, mm Hg Clinician follow-up, monitoring, and care coordination General Follow-up visits Sections 8. 1. 3, 8. 3. 1, 8. 3. 2 Clinical cardiovascular disease or 10-year ASCVD ≥130/80 130/80 risk ≥10% Team-based care Section 12. 2 No clinical cardiovascular disease and 10-year ≥140/90 130/80 Electronic health record Section 12. 3. 1 ASCVD risk 10% Health information technology tools for Section 12. 3.",
    "word_count": 590,
    "char_count": 4118,
    "sentence_count": 62,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 92,
      "total_chunks": 166,
      "position": "93/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "sodium",
        "cardiovascular disease",
        "physical activity",
        "blood pressure control",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 93,
    "text": "3. 1 ASCVD risk 10% Health information technology tools for Section 12. 3. 2 Older persons (≥65 years of age; ≥130 (SBP) 130 (SBP) remote and self-monitoring noninstitutionalized, ambulatory, Socioeconomic and cultural factors community-living adults) Health literacy Section 13. 1. 3 Specific comorbidities Access to health insurance and Section 13. 1. 3 Diabetes mellitus ≥130/80 130/80 medication assistance plans Chronic Kidney disease ≥130/80 130/80 Social services Section 13. 1. 3 Chronic Kidney disease after renal ≥130/80 130/80 Community services Section 13. 1. 3 transplantation blood pressure indicates Blood Hypertension. Heart failure ≥130/80 130/80 Stable ischemic Heart disease ≥130/80 130/80 financial support and financial services are incredibly beneficial to patients, some of whom may choose to skip a doctors Secondary stroke prevention ≥140/90 130/80 appointment to pay a residential utility bill. Peripheral artery disease ≥130/80 130/80 ASCVD indicates atherosclerotic cardiovascular disease; blood pressure, Blood Hypertension; 14. Summary of blood pressure Thresholds and Goals cardiovascular disease, cardiovascular disease; and SBP, systolic Blood Hypertension. for Pharmacological Therapy Several different blood pressure thresholds and goals for the long-term of cardiovascular disease. diabetes mellitus may provide a population in whom to test this treatment of hypertension with pharmacological therapy are hypothesis. Composite outcomes that include both prevention recommended in this guideline. To provide a quick reference of events and surrogates, such as prevention of decline in renal function or amelioration of measures of subclinical atherosclefor practicing clinicians, these are summarized for hypertenrosis, vascular stiffness, or LV structure and function, should sive patients in general and for those with specific comorbidibe considered. Otherwise, these younger individuals may be ties in Table 23. undertreated and experience mortality or cardiovascular disease events before being old enough to enter hard outcomedriven trials such 15. Evidence Gaps and Future Directions as SPRINT. Replication of SPRINT, especially in younger In the present guideline, the writing committee was able to call patients with diabetes mellitus and in countries where nonischemic stroke is on the large body of literature on blood pressure and hypertension to make the predominant cause of cardiovascular disease, is highly desirable. Likewise, strong recommendations across a broad range of medical conimplementation studies that demonstrate the practicality of ditions. Nonetheless, significant gaps in knowledge exist. SPRINT-like interventions in resource-constrained practice Importantly, there are areas where epidemiological and settings are needed. natural history studies suggest that hypertension prevention or More information is urgently needed relating hypertensive earlier treatment of hypertension might substantially improve target organ damage to cardiovascular disease risk and outcomes. Should the outcomes, but clinical trials are lacking to provide guidance. identification of target organ damage and hypertensive Heart The combination of epidemiological data showing a graded disease prompt more aggressive blood pressure management (ie, increase relationship between blood pressure and outcomes, particularly above the rationale for instituting pharmacological therapy earlier a blood pressure of 120/80 mm Hg, and the results of the SPRINT trial or more intensively? Should all patients with hypertension be showing benefit of more comprehensive treatment to a target screened with echocardiogram for LVH? Should echocardiogblood pressure of 120/80 mm Hg, suggests that a lifelong blood pressure below that raphy be repeated once LVH is noted? Is it important to doculevel will substantially lower cardiovascular disease and chronic kidney disease incidence. This ment LVH regression? At present, there are no RCT data to is especially the case for younger individuals, those with diabetes mellitus, inform guideline recommendations. and those with High lifetime cardiovascular disease risk based on the presence of ABPM and HBPM provide enhanced ability to both diagmultiple risk factors, including High blood pressure. If hard, cardiovascular nose hypertension and monitor treatment.",
    "word_count": 598,
    "char_count": 4343,
    "sentence_count": 35,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 93,
      "total_chunks": 166,
      "position": "94/166",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "cardiovascular disease",
        "heart failure",
        "monitoring",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 94,
    "text": "If hard, cardiovascular nose hypertension and monitor treatment. Although evidence outcome clinical trials remain the sole driver of evidence-based is sufficient to recommend incorporating these tools into cliniguidelines, then determining the full benefit of earlier intervencal practice, more knowledge about them is required. Areas tion may not be possible because of the cost and length of time of inquiry include closer mapping of the relationship of outneeded for intervention. Outcomes may be different if antihycomes to ambulatory and home blood pressure measurements, so that pertensive treatment is initiated earlier in the natural history definitions of hypertension and hypertension severity based on Downloaded from by on December 30, 2025 e78 Hypertension June 2018 these measures can be developed, including the importance of is a need for further research in this area, considering both masked hypertension, white coat hypertension, and nocturnal proximate (during the pregnancy and postpartum period) and hypertension. Reproducibility of ambulatory and home BPs distant (cardiovascular disease prevention) outcomes. S15-1 must be studied, and cohorts should include a broader range In the very old, frailty and higher risk of medication side of ethnicities. Trials with entry criteria and treatment goals effects complicate treatment. Additional knowledge of the based on ambulatory or home blood pressure measures should be coneffects of antihypertensive treatment for patients with demenducted, including studies of masked and white coat hypertentia and patients who reside in long-term-care facility settings sion. The practicality and cost of incorporating ABPM into is needed. The best approach to older persons who have supine EHR and routine care should be assessed. The existence of hypertension but postural hypotension needs to be clarified. these techniques should not hamper efforts to investigate ways Further research related to shared decision-making with to improve accuracy in the measurement of clinic blood pressure. Further patients and their families is needed. Examples include areas research on improving accuracy of office blood pressure measurements, where evidence does not clearly identify one treatment or goal including number of measurements, training of personnel meaas substantially better than another, where improved patient suring blood pressure, and device comparisons, will help standardize care knowledge (or improved provider knowledge of the patients and thus improve outcomes. Technology for measurement of circumstances) might improve compliance, where reliance on blood pressure continues to evolve with the emergence of cuffless devices patient collaboration improves achievement of outcomes (eg, and other strategies that provide the opportunity for continuous HBPM, use of social media), and where there are competing noninvasive assessment of blood pressure. The accuracy, cost, and usefulhealth concerns (eg, older individuals with frailty). ness of these new technologies will need to be assessed. Finally, clinical guidelines are increasingly required to manThe contemporary healthcare environment is dramatically age the large body of accumulated knowledge related to diagdifferent from the European Renal Association in which awareness of hypertension as nosis and management of High blood pressure. However, guidelines often a risk factor and benefits of treatment were discovered. With cause controversy and confusion when competing recommenthe advent of the EHR, complex calculations of cardiovascular disease risk and dations are made by different expert groups or when changes renal function can be incorporated into routine reports, and in definitions, treatments, or treatment goals are introduced. many new avenues to support intervention strategies are availNow may be the time to begin the investigation of the impact able to clinicians. Optimizing these approaches will require of guidelines on clinical practice, costs, and patient outcomes, continued focused research.",
    "word_count": 574,
    "char_count": 4050,
    "sentence_count": 22,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 94,
      "total_chunks": 166,
      "position": "95/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "renal function",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 95,
    "text": "Optimizing these approaches will require of guidelines on clinical practice, costs, and patient outcomes, continued focused research. Recognition that simply applying as well as ways to facilitate communication and collaboration what we know about blood pressure control would have a large impact between different guideline-developing organizations. This on population health, observations on inefficiencies and document is, as its name implies, a guide. In managing patients, excessive cost in the ultrasound healthcare system, and the growth the responsible clinicians judgment remains paramount. of information technology have led to promising studies of ways to improve and monitor hypertension care. Results of Presidents and Staff this research are reflected in this guideline, but further work is American College of Cardiology required. Examples for study include the effectiveness of multidisciplinary healthcare teams to achieve blood pressure treatment goals Mary Norine Walsh, MD, MACC, President at lower cost, social media to maintain contact with patients, Shalom Jacobovitz, Chief Executive Officer information technology to monitor outcomes and decrease William J. Oetgen, MD, MBA, FACC, Executive Vice practice variability, and incentives to providers to achieve betPresident, Science, Education, Quality, and Publishing ter outcomes for patients. A key goal of these efforts should MaryAnne Elma, MPH, Senior Director, Science, Education, be to demonstrate reduction in healthcare disparities across Quality, and Publishing ethnicity, sex, social and economic class, and age barriers. Amelia Scholtz, PhD, Publications Manager, Science, More research on the prevention of the development of Education, Quality, and Publishing hypertension and the benefit of lifetime Low blood pressure should be conducted. In this regard, elucidation of genetic expression, American College of Cardiology/American Heart epigenetic effects, transcriptomics, and proteomics that link Association genotypes with longitudinal databases may add considerKatherine A. Sheehan, PhD, Director, Guideline Strategy and able knowledge about beneficial outcomes of lifelong lower Operations blood pressure, determinants of rise in blood pressure over time, and identification Abdul R. Abdullah, MD, Science and Medicine Advisor of new treatment targets through understanding the underNaira Tahir, MPH, Associate Guideline Advisor lying pathophysiological mechanisms. Research should be directed toward the development of therapies that directly American Heart Association counteract the mechanisms accounting for the development John J. Warner, MD, President of hypertension and disease progression. Additional research Nancy Brown, Chief Executive Officer aimed at development of practical approaches to implemenRose Marie Robertson, MD, FAHA, Chief Science and tation of clinical and population-based strategies to prevent Medicine Officer obesity, increase physical fitness, and control excess salt and Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice Glucose intake could have significant public health impact. In President, Office of Science Operations addition, there are minimal, if any, data on whether treatment Jody Hundley, Manager, Production and Operations, Scientific of hypertension during pregnancy mitigates risk; thus, there Publications, Office of Science Operations Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e79 References Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Hypertension. Hypertension. 2003; 42: 120652. Preamble S1. 5-8. Reboussin diabetes mellitus, Allen NB, Griswold ME, et al. Systematic review for P-1. Gibbons GH, Harold JG, Jessup M, et al. The next steps in develthe 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ oping clinical practice guidelines for prevention. Circulation. NMA/PCNA guideline for the prevention, detection, evaluation, and 2013; 128: 17167. management of Hypertension in adults: a report of the American P-2. Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the College of Cardiology/American Heart Association Task Force on agenda on cardiovascular guidelines: an announcement from the Clinical Practice Guidelines. Hypertension. 2018; 71: e116e135. National Heart, Lung, and Blood Institute. Circulation. 2013; 128: S1. 5-9.",
    "word_count": 596,
    "char_count": 4387,
    "sentence_count": 31,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 95,
      "total_chunks": 166,
      "position": "96/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 96,
    "text": "Hypertension. 2018; 71: e116e135. National Heart, Lung, and Blood Institute. Circulation. 2013; 128: S1. 5-9. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ 17135. PCNA/SCAI/STS guideline for the diagnosis and management of P-3. Committee on Standards for Developing Trustworthy Clinical patients with stable ischemic Heart disease: a report of the American Practice Guidelines, Institute of Medicine (U. S. ). Clinical Practice College of Cardiology Foundation/American Heart Association Guidelines We Can Trust. Washington, DC: The National Academies Task Force on Practice Guidelines, and the American College of Press; 2011. Physicians, American Association for Thoracic Surgery, Preventive P-4. Committee on Standards for Systematic Reviews of Comparative Cardiovascular Nurses Association, Society for Cardiovascular Effectiveness Research, Institute of Medicine (U. S. ). Finding Angiography and Interventions, and Society of Thoracic Surgeons. What Works in Health Care: Standards for Systematic Reviews. Circulation. 2012; 126: e354471. Washington, DC: The National Academies Press; 2011. S1. 5-10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideP-5. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA stateline for the management of Heart failure: a report of the American ment on cost/value methodology in clinical practice guidelines College of Cardiology Foundation/American Heart Association Task and performance measures: a report of the American College Force on Practice Guidelines. Circulation. 2013; 128: e240327. of Cardiology/American Heart Association Task Force on S1. 5-11. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ Performance Measures and Task Force on Practice Guidelines. ACC guideline on the management of patients with lower extremCirculation. 2014; 129: 232945. ity peripheral artery disease: a report of the American College of P-6. ACCF/AHA Task Force on Practice Guidelines. Methodology Cardiology/American Heart Association Task Force on Clinical Manual and Policies From the ACCF/AHA Task Force on Practice Practice Guidelines. Circulation. 2017; 135: e72679. Guidelines. American College of Cardiology and American Heart S1. 5-12. Funder JW, Carey RM, Mantero F, et al. The management of priAssociation, 2010. Available at: mary aldosteronism: case detection, diagnosis, and treatment: an Methodology_Manual_for_ACC_AHA_Writing_Committees. Endocrine Society clinical practice guideline. J Clin Endocrinol pdf and Metab. 2016; 101: 18891916. wcm/sop/documents/downloadable/ucm_319826. pdf. Accessed S1. 5-13. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ September 15, 2017. AATS/PCNA/SCAI/STS focused update of the guideline for P-7. Halperin JL, Levine glomerulonephritis, Al-Khatib SM, et al. Further evolution the diagnosis and management of patients with stable ischemic of the ACC/AHA clinical practice guideline recommendation clasHeart disease: a report of the American College of Cardiology/ sification system: a report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines, Foundation/American Heart Association Task Force on Clinical and the American Association for Thoracic Surgery, Preventive Practice Guidelines. Circulation. 2016; 133: 142628. Cardiovascular Nurses Association, Society for Cardiovascular P-8. Jacobs AK, Kushner FG, Ettinger SM. ACCF/AHA clinical Angiography and Interventions, and Society of Thoracic Surgeons. practice guideline methodology summit report: a report of the Circulation. 2014; 130: 174967. American College of Cardiology Foundation/American Heart S1. 5-14. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma Association Task Force on Practice Guidelines. Circulation. and paraganglioma: an Endocrine Society clinical practice guide2013; 127: 268310. line. J Clin Endocrinol Metab. 2014; 99: 191542. P-9. Jacobs AK, Anderson JL, Halperin JL. The evolution and future S1. 5-15. January computed tomography, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideof ACC/AHA clinical practice guidelines: a 30-year journey: a line for the management of patients with atrial fibrillation: a report report of the American College of Cardiology/American Heart of the American College of Cardiology/American Heart Association Association Task Force on Practice Guidelines. Circulation.",
    "word_count": 591,
    "char_count": 4370,
    "sentence_count": 76,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 96,
      "total_chunks": 166,
      "position": "97/166",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "heart failure",
        "guideline"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 97,
    "text": "Circulation. Task Force on Practice Guidelines and the Heart Rhythm Society. 2014; 130: 120817. Circulation. 2014; 130: e199267. P-10. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS S1. 5-16. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused strategies to enhance application of clinical practice guidelines in update of the 2014 AHA/ACC Guideline for the Management of patients with cardiovascular disease and comorbid conditions: from Patients With Valvular Heart Disease: a report of the American the American Heart Association, American College of Cardiology, College of Cardiology/American Heart Association Task Force on and U. S. Department of Health and Human Services. Circulation. Clinical Practice Guidelines. Circulation. 2017; 135: e115995. 2014; 130: 166267. S1. 5-17. Goff DC Jr, Lloyd-Jones diabetes mellitus, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association 1. Introduction Task Force on Practice Guidelines. Circulation. 2014; 129(suppl S1. 5-1. Society of Actuaries. Build and Blood Hypertension Study, Vol 1. Ann 2): S4973. Arbor, myocardial infarction: The University of Michigan; 1959. S1. 5-18. American College of Obstetricians and Gynecologists, Task Force on S1. 5-2. Dawber TR. The Framingham Study: The Epidemiology of Hypertension in Pregnancy. Hypertension in pregnancy. Report of the Atherosclerotic Disease. Cambridge, MA: Harvard University Press; American College of Obstetricians and Gynecologists Task Force on 1980. Hypertension in Pregnancy. Obstet Gynecol. 2013; 122: 112231. S1. 5-3. Effects of treatment on morbidity in hypertension. I. Results in S1. 5-19. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA patients with diastolic Blood pressures averaging 115 through 129 focused update of the 2013 ACCF/AHA guideline for the manmm Hg. JAMA. 1967; 202: 102834. agement of Heart failure: a report of the American College of S1. 5-4. Effects of treatment on morbidity in hypertension. II. Results in Cardiology/American Heart Association Task Force on Clinical patients with diastolic Blood Hypertension averaging 90 through 114 Practice Guidelines and the Heart Failure Society of America. mm Hg. JAMA. 1970; 213: 114352. Circulation. 2017; 136: e13761. S1. 5-5. Report of the Joint National Committee on Detection, Evaluation, S1. 5-20. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline and Treatment of Hypertension. A cooperative study. JAMA. on lifestyle management to reduce cardiovascular risk: a report of 1977; 237: 25561. the American College of Cardiology/American Heart Association S1. 5-6. Moser M, Roccella EJ. The treatment of hypertension: a remarkable Task Force on Practice Guidelines. Circulation. 2014; 129(suppl success story. J Clin Hypertens (Greenwich). 2013; 15: 8891. 2): S7699. S1. 5-7. Chobanian AV, Bakris GL, Black heart rate, et al; the National High Blood S1. 5-21. Mancia G, Fagard R, Narkiewicz potassium, et al. 2013 ESH/ESC guidelines Hypertension Education Program Coordinating Committee. Seventh for the management of arterial hypertension: the Task Force for the Downloaded from by on December 30, 2025 e80 Hypertension June 2018 Management of Arterial Hypertension of the European Society of S1. 5-36. OBrien E, Parati G, Stergiou G, et al. European Society of Hypertension (ESH) and of the European Society of Cardiology Hypertension position paper on ambulatory Blood Hypertension monitor- (ESC). Eur Heart J. 2013; 34: 2159219. ing. J Hypertens. 2013; 31: 173168. S1. 5-22. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS S1. 5-37. Drozda J Jr, Messer JV, Spertus J, et al.",
    "word_count": 553,
    "char_count": 3708,
    "sentence_count": 96,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 97,
      "total_chunks": 166,
      "position": "98/166",
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "medical_entities": [
        "potassium",
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 98,
    "text": "2013 AHA/ACC/TOS S1. 5-37. Drozda J Jr, Messer JV, Spertus J, et al. ACCF/AHA/AMAguideline for the management of overweight and obesity in adults: PCPI 2011 performance measures for adults with coronary artery a report of the American College of Cardiology/American Heart disease and hypertension: a report of the American College of Association Task Force on Practice Guidelines and The Obesity Cardiology Foundation/American Heart Association Task Force Society. Circulation. 2014; 129(suppl 2): S10238. on Performance Measures and the American Medical AssociationS1. 5-23. OGara patient, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Physician Consortium for Performance Improvement. Circulation. guideline for the management of ST-elevation myocardial infarc2011; 124: 24870. tion: a report of the American College of Cardiology Foundation/ S1. 5-38. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to American Heart Association Task Force on Practice Guidelines. promote physical activity and dietary lifestyle changes for carCirculation. 2013; 127: e362425. diovascular risk factor reduction in adults: a scientific statement S1. 5-24. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA from the American Heart Association. Circulation. 2010; 122: guideline on the treatment of Blood cholesterol to reduce atheroscle40641. rotic cardiovascular risk in adults: a report of the American College S1. 5-39. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: of Cardiology/American Heart Association Task Force on Practice diagnosis, evaluation, and treatment: a scientific statement from the Guidelines. Circulation. 2014; 129(suppl 2): S145. American Heart Association Professional Education Committee S1. 5-25. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC of the Council for Hypertension Research. Hypertension. guidelines on the management of cardiovascular diseases during 2008; 51: 140319. pregnancy: the Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 314797. 2. blood pressure and cardiovascular disease Risk S1. 5-26. Mosca L, Benjamin EJ, Berra potassium, et al. Effectiveness-based guide2. 1. Observational Relationship lines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. S2. 1-1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of Circulation. 2011; 123: 124362. usual Blood Hypertension to vascular mortality: a meta-analysis of indiS1. 5-27. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondvidual data for one million adults in 61 prospective studies. Lancet. ary prevention and risk reduction therapy for patients with coronary 2002; 360: 190313. and other atherosclerotic vascular disease: 2011 update: a guideS2. 1-2. Rapsomaniki E, Timmis A, George J, et al. Blood Hypertension and line from the American Heart Association and American College incidence of twelve cardiovascular diseases: lifetime risks, healthy of Cardiology Foundation endorsed by the World Heart Federation life-years lost, and age-specific associations in 1. 25 million people. and the Preventive Cardiovascular Nurses Association. Circulation. Lancet. 2014; 383: 1899911. 2011; 124: 245873. S1. 5-28. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guide2. 2. blood pressure Components line for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American S2. 2-1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of Heart Association Task Force on Practice Guidelines. Circulation. usual Blood Hypertension to vascular mortality: a meta-analysis of indi2010; 122: e584636. vidual data for one million adults in 61 prospective studies. Lancet. S1. 5-29. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/ 2002; 360: 190313. AATS/albumin-creatinine ratio/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the S2. 2-2. Rapsomaniki E, Timmis A, George J, et al.",
    "word_count": 577,
    "char_count": 4077,
    "sentence_count": 81,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 98,
      "total_chunks": 166,
      "position": "99/166",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "creatinine",
        "potassium",
        "cardiovascular disease",
        "physical activity",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 99,
    "text": "2010 ACCF/AHA/ 2002; 360: 190313. AATS/albumin-creatinine ratio/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the S2. 2-2. Rapsomaniki E, Timmis A, George J, et al. Blood Hypertension and diagnosis and management of patients with thoracic aortic disincidence of twelve cardiovascular diseases: lifetime risks, healthy ease: a report of the American College of Cardiology Foundation/ life-years lost, and age-specific associations in 1. 25 million people. American Heart Association Task Force on Practice Guidelines, Lancet. 2014; 383: 1899911. American Association for Thoracic Surgery, American College of S2. 2-3. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with Radiology, American Stroke Association, Society of Cardiovascular diastolic hypertension and isolated systolic hypertension among Anesthesiologists, Society for Cardiovascular Angiography and men screened for the Multiple Risk Factor Intervention Trial. Interventions, Society of Interventional Radiology, Society of Circulation. 1988; 77: 50414. Thoracic Surgeons, and Society for Vascular Medicine. Circulation. S2. 2-4. Sesso hemodialysis, Stampfer MJ, Rosner B, et al. Systolic and diastolic 2010; 121: e266369. Blood Hypertension, pulse Hypertension, and mean arterial Hypertension as S1. 5-30. National Hypertension Education Program Working predictors of cardiovascular disease risk in men. Hypertension. Group on Hypertension in Children and Adolescents. The 2000; 36: 8017. fourth report on the diagnosis, evaluation, and treatment of High S2. 2-5. Stamler J, Stamler R, Neaton JD. Blood Hypertension, systolic and diaBlood Hypertension in children and adolescents. Pediatrics. 2004; 114: stolic, and cardiovascular risks. ultrasound population data. Arch Intern 55576. Med. 1993; 153: 598615. S1. 5-31. Elijovich F, Weinberger MH, Anderson CAM, et al. Salt sensitivity S2. 2-6. Benetos A, Thomas F, Bean potassium, et al. Prognostic value of systolic of Blood Hypertension: a scientific statement from the American Heart and diastolic Blood Hypertension in treated hypertensive men. Arch Association. Hypertension. 2016; 68: e746. Intern Med. 2002; 162: 57781. S1. 5-32. Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health CoconutS2. 2-7. Lindenstrom E, Boysen G, Nyboe J. Influence of systolic and diaicy statement on cardiovascular team-based care and the role of stolic Blood Hypertension on stroke risk: a prospective observational advanced practice providers. J Am Coll Cardiol. 2015; 65: 211836. study. Am J. Epidemiol. 1995; 142: 127990. S1. 5-33. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hyperS2. 2-8. Zhao L, Song Y, Dong P, et al. Brachial pulse Hypertension and cardiotension in patients with coronary artery disease: a scientific statevascular or all-cause mortality in the general population: a metament from the American Heart Association, American College of analysis of prospective observational studies. J Clin Hypertens Cardiology, and American Society of Hypertension. Circulation. (Greenwich). 2014; 16: 67885. 2015; 131: e43570. S2. 2-9. Mosley WJ, Greenland P, Garside DB, et al. Predictive utility of S1. 5-34. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory pulse Hypertension and other Blood Hypertension measures for cardiovascular Blood Hypertension monitoring in children and adolescents: a scientific outcomes. Hypertension. 2007; 49: 125664. statement from the American Heart Association. Hypertension. S2. 2-10. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined 2014; 63: 111635. Blood Hypertension components and risk for cardiovascular disease: the S1. 5-35. Go AS, Bauman MA, Coleman King SM, et al. An effective Framingham Heart Study. Circulation. 2009; 119: 24350. approach to Hypertension control: a science advisory from the S2. 2-11. Kodama S, Horikawa C, Fujihara potassium, et al. Meta-analysis of the American Heart Association, the American College of Cardiology, quantitative relation between pulse Hypertension and mean arterial presand the Centers for Disease Control and Prevention. Hypertension. sure and cardiovascular risk in patients with Diabetes mellitus. Am J 2014; 63: 87885. Cardiol. 2014; 113: 105865.",
    "word_count": 593,
    "char_count": 4190,
    "sentence_count": 98,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 99,
      "total_chunks": 166,
      "position": "100/166",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "creatinine",
        "potassium",
        "hemodialysis",
        "cardiovascular disease",
        "monitoring",
        "albumin-creatinine ratio"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 100,
    "text": "Hypertension. sure and cardiovascular risk in patients with Diabetes mellitus. Am J 2014; 63: 87885. Cardiol. 2014; 113: 105865. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e81 2. 3. Population Risk life-years lost, and age-specific associations in 125 million people. Lancet. 2014; 383: 1899911. S2. 3-1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessS3. 1-3. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for ment of burden of disease and injury attributable to 67 risk factors prevention of cardiovascular disease and death: a systematic review and risk factor clusters in 21 regions, 19902010: a systematic and meta-analysis. Lancet. 2016; 387: 95767. analysis for the Global Burden of Disease Study 2010. Lancet. S3. 1-4. Guo X, Zhang X, Guo L, et al. Association between pre-hyperten2012; 380: 222460. sion and cardiovascular outcomes: a systematic review and metaS2. 3-2. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hyperanalysis of prospective studies. Curr Hypertens Rep. 2013; 15: tension and systolic Blood Hypertension of at Least 110 to 115 mm Hg, 70316. 19902015. JAMA. 2017; 317: 16582. S3. 1-5. Guo X, Zhang X, Zheng L, et al. Prehypertension is not associated S2. 3-3. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of with all-cause mortality: a systematic review and meta-analysis of death in the United States: comparative risk assessment of dietary, prospective studies. PLoS ONE. 2013; 8: e61796. lifestyle, and metabolic risk factors. PLoS Med. 2009; 6: e1000058. S3. 1-6. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a S2. 3-4. Ford ES. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United meta-analysis. Neurology. 2014; 82: 115361. States. Circulation. 2011; 123: 173744. S3. 1-7. Huang Y, Cai X, Liu C, et al. Prehypertension and the risk of coroS2. 3-5. Cheng S, Claggett B, Correia AW, et al. Temporal trends in the popunary Heart disease in Asian and Western populations: a meta-analysis. lation attributable risk for cardiovascular disease: the Atherosclerosis J Am Heart Assoc. 2015; 4: e001519. Risk in Communities Study. Circulation. 2014; 130: 8208. S3. 1-8. Huang Y, Cai X, Zhang J, et al. Prehypertension and incidence of S2. 3-6. Willey JZ, Moon YP, Kahn E, et al. Population attributable risks of end-stage renal disease: a systematic review and meta-analysis. Am J Kidney Dis. hypertension and Diabetes for cardiovascular disease and stroke in 2014; 63: 7683. the northern Manhattan study. J Am Heart Assoc. 2014; 3: e001106. S3. 1-9. Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovasS2. 3-7. Saran R, Li Y, Robinson B, et al. ultrasound Renal Data System 2014 cular mortality with prehypertension: a meta-analysis. Am Heart J. annual data report: epidemiology of Kidney disease in the United 2014; 167: 1608. e1. States. Am J Kidney Dis. 2015; 66 Svii: S1305. S3. 1-10. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med. 2013; 11: 177. 2. 4. Coexistence of Hypertension and Related S3. 1-11. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowering drugs Chronic Conditions in the prevention of cardiovascular disease: meta-analysis of 147 S2. 4-1. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of randomised trials in the context of expectations from prospective metabolic factors and coronary Heart disease. Arch Intern Med. epidemiological studies. BMJ. 2009; 338: b1665. 1999; 159: 11049. S3. 1-12. Lee M, Saver JL, Chang B, et al. Presence of baseline prehyperS2. 4-2.",
    "word_count": 597,
    "char_count": 3726,
    "sentence_count": 114,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 100,
      "total_chunks": 166,
      "position": "101/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "end-stage renal disease",
        "calcium",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 101,
    "text": "1999; 159: 11049. S3. 1-12. Lee M, Saver JL, Chang B, et al. Presence of baseline prehyperS2. 4-2. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular distension and risk of incident stroke: a meta-analysis. Neurology. ease. N Engl J Med. 2012; 366: 3219. 2011; 77: 13307. S2. 4-3. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United S3. 1-13. Shen L, Ma H, Xiang M-X, et al. Meta-analysis of cohort studies of States, 1999 to 2012: progress toward Healthy People 2020 goals. baseline prehypertension and risk of coronary Heart disease. Am J Circulation. 2014; 130: 16929. Cardiol. 2013; 112: 26671. S2. 4-4. Centers for Disease Control and Prevention. National Diabetes S3. 1-14. Sundstrom J, Arima H, Jackson R, et al. Effects of Blood Hypertension Statistics Report: Estimates of Diabetes and Its Burden in the reduction in mild hypertension: a systematic review and meta-analyUnited States. Atlanta, GA: U. S. Department of Health and Human sis. Ann Intern Med. 2015; 162: 18491. Services; 2014. S3. 1-15. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension S2. 4-5. Muntner P, Anderson A, Charleston J, et al. Hypertension awarelowering on outcome incidence in hypertension: 2. Effects at differness, treatment, and control in adults with chronic kidney disease: results from the ent baseline and achieved Blood Hypertension levelsoverview and metaChronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney analyses of randomized trials. J Hypertens. 2014; 32: 2296304. Dis. 2010; 55: 44151. S3. 1-16. Wang S, Wu H, Zhang Q, et al. Impact of baseline prehypertension S2. 4-6. Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent on cardiovascular events and all-cause mortality in the general poputreatment-resistant hypertension among individuals with chronic kidney disease. Clin lation: a meta-analysis of prospective cohort studies. Int J Cardiol. J Am Soc Nephrol. 2013; 8: 158390. 2013; 168: 485760. S2. 4-7. Saydah S, Bullard KM, Cheng Y, et al. Trends in cardiovascular S3. 1-17. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension disease risk factors by obesity level in adults in the United States, lowering on cardiovascular and renal outcomes: updated systematic NHANES 19992010. Obesity (Silver Spring). 2014; 22: 188895. review and meta-analysis. Lancet. 2016; 387: 43543. S2. 4-8. Castelli WP. Epidemiology of coronary Heart disease: the S3. 1-18. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors Framingham study. Am J Med. 1984; 76: 412. of Blood Hypertension control in diverse North American settings: S2. 4-9. Sarzani R, Salvi F, Dessi-Fulgheri P, et al. Renin-angiotensin system, the antihypertensive and lipid-lowering treatment to prevent natriuretic peptides, obesity, metabolic syndrome, and hypertenHeart attack trial (ALLHAT). J Clin Hypertens (Greenwich). sion: an integrated view in humans. J Hypertens. 2008; 26: 83143. 2002; 4: 393404. S2. 4-10. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in S3. 1-19. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidobese normotensive subjects. Hypertension. 1995; 25: 5603. ity and mortality in the Losartan Intervention For Endpoint reduction S2. 4-11. Kim J, Montagnani M, Koh KK, et al. Reciprocal relationships in hypertension study (LIFE): a randomised trial against atenolol. between insulin resistance and endothelial dysfunction: molecuLancet. 2002; 359: 9951003. lar and pathophysiological mechanisms. Circulation. 2006; 113: S3. 1-20. Wald DS, Law M, Morris JK, et al. Combination therapy versus 1888904. monotherapy in reducing Blood Hypertension: meta-analysis on 11 000 S2. 4-12. McEvoy RD, Antic sodium, Heeley E, et al. CPAP for prevention of participants from 42 trials. Am J Med. 2009; 122: 290300. cardiovascular events in obstructive sleep apnea. N Engl J Med. S3. 1-21.",
    "word_count": 597,
    "char_count": 3882,
    "sentence_count": 116,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 101,
      "total_chunks": 166,
      "position": "102/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "sodium",
        "insulin",
        "antihypertensive"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 102,
    "text": "Am J Med. 2009; 122: 290300. cardiovascular events in obstructive sleep apnea. N Engl J Med. S3. 1-21. Chobanian AV, Bakris GL, Black heart rate, et al; the National High Blood 2016; 375: 91931. Hypertension Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, 3. Classification of blood pressure Evaluation, and Treatment of Hypertension. Hypertension. 2003; 42: 120652. 3. 1. Definition of High blood pressure S3. 1-22. Yoon SS, Gu Q, Nwankwo T, et al. Trends in Blood Hypertension among adults with hypertension: United States, 2003 to 2012. Hypertension. S3. 1-1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of 2015; 65: 5461. usual Blood Hypertension to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 3. 2. Lifetime Risk of Hypertension 2002; 360: 190313. S3. 1-2. Rapsomaniki E, Timmis A, George J, et al. Blood Hypertension and S3. 2-1. Muntner P, Woodward M, Mann diabetes mellitus, et al. Comparison of the incidence of twelve cardiovascular diseases: lifetime risks, healthy Framingham Heart Study hypertension model with Blood Hypertension Downloaded from by on December 30, 2025 e82 Hypertension June 2018 alone in the prediction of risk of hypertension: the Multi-Ethnic S3. 4-10. Fletcher RD, Amdur RL, Kolodner R, et al. Blood Hypertension control Study of Atherosclerosis. Hypertension. 2010; 55: 133945. among ultrasound veterans: a large multiyear analysis of Blood Hypertension data S3. 2-2. Parikh NI, Pencina MJ, Wang TJ, et al. A risk score for predicting from the Veterans Administration health data repository. Circulation. near-term incidence of hypertension: the Framingham Heart Study. 2012; 125: 24628. Ann Intern Med. 2008; 148: 10210. S3. 4-11. Jaffe magnesium, Lee GA, Young JD, et al. Improved Blood Hypertension conS3. 2-3. Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertrol associated with a large-scale hypertension program. JAMA. tension incidence among middle-aged and older adults: the multi2013; 310: 699705. ethnic study of atherosclerosis. Hypertension. 2011; 57: 110107. S3. 4-12. Jaffe magnesium, Young JD. The Kaiser Permanente Northern California S3. 2-4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for story: improving hypertension control from 44% to 90% in 13 years developing hypertension in middle-aged women and men: the (2000 to 2013). J Clin Hypertens (Greenwich). 2016; 18: 2601. Framingham Heart Study. JAMA. 2002; 287: 100310. S3. 2-5. Shihab HM, Meoni LA, Chu AY, et al. Body mass index and risk 4. Measurement of blood pressure of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012; 126: 29839. 4. 1. Accurate Measurement of blood pressure in the Office S4. 1-1. Leung AA, Daskalopoulou SS, Dasgupta potassium, et al. Hypertension 3. 3. Prevalence of High blood pressure Canadas 2017 guidelines for diagnosis, risk assessment, preS3. 3-1. Whelton PK. The elusiveness of population-wide High Blood presvention, and treatment of hypertension in adults. Can J Cardiol. sure control. Annu Rev Public Health. 2015; 36: 10930. 2017; 33: 55776. S3. 3-2. Crim MT, Yoon SSS, Ortiz E, et al. National surveillance definiS4. 1-2. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for Blood tions for hypertension prevalence and control among adults. Circ Hypertension measurement in humans and experimental animals: part 1: Cardiovasc Qual Outcomes. 2012; 5: 34351. Blood Hypertension measurement in humans: a statement for professionS3. 3-3. Chobanian AV, Bakris GL, Black heart rate, et al; the National High Blood als from the Subcommittee of Professional and Public Education of Hypertension Education Program Coordinating Committee. Seventh the American Heart Association Council on Hypertension Report of the Joint National Committee on Prevention, Detection, Research. Circulation. 2005; 111: 697716.",
    "word_count": 600,
    "char_count": 3995,
    "sentence_count": 107,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 102,
      "total_chunks": 166,
      "position": "103/166",
      "content_type": "monitoring",
      "content_type_confidence": 4,
      "medical_entities": [
        "potassium",
        "magnesium",
        "classification"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 103,
    "text": "Circulation. 2005; 111: 697716. Evaluation, and Treatment of Hypertension. Hypertension. S4. 1-3. Mancia G, Fagard R, Narkiewicz potassium, et al. 2013 ESH/ESC guide2003; 42: 120652. lines for the management of arterial hypertension: the Task Force for S3. 3-4. Report of the Joint National Committee on Detection, Evaluation, the Management of Arterial Hypertension of the European Society and Treatment of Hypertension. A cooperative study. JAMA. of Hypertension (ESH) and of the European Society of Cardiology 1977; 237: 25561. (ESC). Eur Heart J. 2013; 34: 2159219. S3. 3-5. The fifth report of the Joint National Committee on Detection, S4. 1-4. Weir MR. In the clinic: hypertension. Ann Intern Med. 2014; 161: Evaluation, and Treatment of Hypertension (JNC V). Arch ITC115. Intern Med. 1993; 153: 15483. S4. 1-5. Liu C, Griffiths C, Murray A, et al. Comparison of stethoscope bell S3. 3-6. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension and diaphragm, and of stethoscope tube length, for clinical Blood in the ultrasound adult population. Results from the Third National Health Hypertension measurement. Blood Press Monit. 2016; 21: 17883. and Nutrition Examination Survey, 19881991. Hypertension. S4. 1-6. Kantola I, Vesalainen R, Kangassalo potassium, et al. Bell or dia1995; 25: 30513. phragm in the measurement of Blood Hypertension? J Hypertens. S3. 3-7. Gee ME, Campbell N, Sarrafzadegan N, et al. Standards for the 2005; 23: 499503. uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League Expert 4. 2. Out-of-Office and Self-Monitoring of blood pressure Committee. J Clin Hypertens (Greenwich). 2014; 16: 77381. S4. 2-1. Uhlig potassium, Balk EM, Patel potassium, et al. Self-Measured Blood Hypertension Monitoring: Comparative Effectiveness. Rockville, MD: Agency 3. 4. Awareness, Treatment, and Control for Healthcare Research and Quality (U. S. ); 2012. S3. 4-1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, S4. 2-2. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home awareness, treatment, and control of hypertension in the adult ultrasound Blood Hypertension telemonitoring and pharmacist management on population. Data from the Health Examination Surveys, 1960 to Blood Hypertension control: a cluster randomized clinical trial. JAMA. 1991. Hypertension. 1995; 26: 609. 2013; 310: 4656. S3. 4-2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, S4. 2-3. McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and control of hypertension in the United States, 19882000. JAMA. and medication self-titration on systolic Blood Hypertension in hyperten2003; 290: 199206. sive patients at High risk of cardiovascular disease: the TASMIN-SR S3. 4-3. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United randomized clinical trial. JAMA. 2014; 312: 799808. States, 1999 to 2012: progress toward Healthy People 2020 goals. S4. 2-4. Siu AL. Screening for Hypertension in adults: U. S. Preventive Circulation. 2014; 130: 16929. Services Task Force recommendation statement. Ann Intern Med. S3. 4-4. Nwankwo T, Yoon SS, Burt V, et al. Hypertension among adults 2015; 163: 77886. in the United States: National Health and Nutrition Examination S4. 2-5. Yi SS, Tabaei blood pressure, Angell SY, et al. Self-Blood Hypertension monitorSurvey, 20112012. NCHS Data Brief. 2013: 18. ing in an urban, ethnically diverse population: a randomized cliniS3. 4-5. National Center for Health Statistics (U. S. ). Health, United States, cal trial utilizing the electronic health record. Circ Cardiovasc Qual 2013: With Special Feature on Prescription Drugs. Hyattsville, MD: Outcomes. 2015; 8: 13845. National Center for Health Statistics (U. S. ); 2014. S4. 2-6. Agarwal R, Bills JE, Hecht TJW, et al. Role of home Blood presS3. 4-6. Bromfield SG, Bowling CB, Tanner RM, et al.",
    "word_count": 595,
    "char_count": 3919,
    "sentence_count": 115,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 103,
      "total_chunks": 166,
      "position": "104/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "nutrition",
        "cardiovascular disease",
        "screening",
        "monitoring"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 104,
    "text": "Role of home Blood presS3. 4-6. Bromfield SG, Bowling CB, Tanner RM, et al. Trends in hypertensure monitoring in overcoming therapeutic inertia and improvsion prevalence, awareness, treatment, and control among ultrasound adults ing hypertension control: a systematic review and meta-analysis. 80 years and older, 19882010. J Clin Hypertens (Greenwich). Hypertension. 2011; 57: 2938. 2014; 16: 2706. S4. 2-7. OBrien E, Stergiou GS. The pursuit of accurate Blood Hypertension S3. 4-7. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive measurement: a 35-year travail. J Clin Hypertens (Greenwich). Blood-Hypertension control in type 2 Diabetes mellitus. N Engl J Med. 2017; 19: 74652. 2010; 362: 157585. S4. 2-8. Mancia G, Fagard R, Narkiewicz potassium, et al. 2013 ESH/ESC guidelines S3. 4-8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative for the management of arterial hypertension: the Task Force for the Research Group. Major outcomes in High-risk hypertensive patients ranManagement of Arterial Hypertension of the European Society of domized to angiotensin-converting enzyme inhibitor or calcium channel Hypertension (ESH) and of the European Society of Cardiology blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment (ESC). Eur Heart J. 2013; 34: 2159219. to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 298197. S4. 2-9. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use S3. 4-9. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs and reimbursement for home Blood Hypertension monitoring: a joint scistandard Blood Hypertension control and cardiovascular disease outentific statement from the American Heart Association, American comes in adults aged ≥75 years: a randomized clinical trial. JAMA. Society of Hypertension, and Preventive Cardiovascular Nurses 2016; 315: 267382. Association. Hypertension. 2008; 52: 1029. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e83 S4. 2-10. National Clinical Guideline Centre (UK). Hypertension: The S4. 3-21. Trudel X, Milot A, Brisson C. Persistence and progression of Clinical Management of Primary Hypertension in Adults: Update masked hypertension: a 5-year prospective study. Int J Hypertens. of Clinical Guidelines 18 and 34. London, UK: Royal College of 2013; 2013: 836387. Physicians (UK); 2011. S4. 3-22. Ugajin T, Hozawa A, Ohkubo T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med. 2005; 165: 15416. 4. 3. Ambulatory blood pressure Monitoring S4. 3-1. Pickering TG, Shimbo D, Haas D. Ambulatory Blood-Hypertension mon4. 4. Masked and White Coat Hypertension itoring. N Engl J Med. 2006; 354: 236874. S4. 4-1. Pickering TG, James GD, Boddie C, et al. How common is white S4. 3-2. Tunis SR. Decision Memo for Ambulatory Blood Hypertension coat hypertension? JAMA. 1988; 259: 2258. Monitoring (CAG-00067N). Centers for Medicare and Medicaid S4. 4-2. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive Services; October 17, 2001. accuracy of Blood Hypertension screening methods with consideration S4. 3-3. Shimbo D, Kent ST, Diaz KM, et al. The use of ambulatory Blood of rescreening intervals: a systematic review for the U. S. Preventive Hypertension monitoring among Medicare beneficiaries in 20072010. J Services Task Force. Ann Intern Med. 2015; 162: 192204. Am Soc Hypertens. 2014; 8: 8917. S4. 4-3. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of masked S4. 3-4. Kent ST, Shimbo D, Huang L, et al. Rates, amounts, and deterhypertension and white-coat hypertension detected by 24-h minants of ambulatory Blood Hypertension monitoring claim reimambulatory Blood Hypertension monitoring 10-year follow-up from the bursements among Medicare beneficiaries. J Am Soc Hypertens. Ohasama study. J Am Coll Cardiol. 2005; 46: 50815. 2014; 8: 898908. S4. 4-4. Fagard RH, Cornelissen VA.",
    "word_count": 595,
    "char_count": 3968,
    "sentence_count": 105,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 104,
      "total_chunks": 166,
      "position": "105/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "calcium",
        "antihypertensive",
        "cardiovascular disease",
        "screening",
        "monitoring",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 105,
    "text": "Ohasama study. J Am Coll Cardiol. 2005; 46: 50815. 2014; 8: 898908. S4. 4-4. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in S4. 3-5. Dabl Educational Trust. Information on validated Blood Hypertension white-coat, masked and sustained hypertension versus true normodevices and monitors. Available at: tension: a meta-analysis. J Hypertens. 2007; 25: 21938. Accessed September 17, 2017. S4. 4-5. National Clinical Guideline Centre (UK). Hypertension: The S4. 3-6. British Hypertension Society. blood pressure Monitors. Available at: http: // Clinical Management of Primary Hypertension in Adults: Update www. bhsoc. org/blood pressure-monitors/blood pressure-monitors. Accessed September 17, of Clinical Guidelines 18 and 34. London, UK: Royal College of 2017. Physicians (UK); 2011. S4. 3-7. Pickering TG, White WB; American Society of Hypertension S4. 4-6. Asayama potassium, Thijs L, Li Y, et al. Setting thresholds to varying Blood Writing Group. ASH position paper: home and ambulatory Blood Hypertension monitoring intervals differentially affects risk estimates Hypertension monitoring. When and how to use self (home) and ambuassociated with white-coat and masked hypertension in the populalatory Blood Hypertension monitoring. J Clin Hypertens (Greenwich). tion. Hypertension. 2014; 64: 93542. 2008; 10: 8505. S4. 4-7. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognosS4. 3-8. OBrien E, Parati G, Stergiou G, et al. European Society of tic value of white coat hypertension: an insight from diagnostic Hypertension position paper on ambulatory Blood Hypertension moniuse of both ambulatory and home Blood Hypertension measurements. toring. J Hypertens. 2013; 31: 173168. Hypertension. 2013; 62: 16874. S4. 3-9. Kikuya M, Hansen TW, Thijs L, et al. Diagnostic thresholds for S4. 4-8. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and ambulatory Blood Hypertension monitoring based on 10-year cardiovasmasked hypertension diagnosed by ambulatory monitoring in inicular risk. Circulation. 2007; 115: 214552. tially untreated subjects: an updated meta analysis. Am J Hypertens. S4. 3-10. Niiranen TJ, Asayama potassium, Thijs L, et al. Outcome-driven thresh2011; 24: 528. olds for home Blood Hypertension measurement: international database S4. 4-9. Viera AJ, Hinderliter AL, Kshirsagar AV, et al. Reproducibility of home Blood Hypertension in relation to cardiovascular outcome. of masked hypertension in adults with untreated borderline office Hypertension. 2013; 61: 2734. Blood Hypertension: comparison of ambulatory and home monitoring. S4. 3-11. Head GA, Mihailidou AS, Duggan ketoanalogue, et al. Definition of ambulaAm J Hypertens. 2010; 23: 11907. tory Blood Hypertension targets for diagnosis and treatment of hypertenS4. 4-10. Viera AJ, Lin F-C, Tuttle LA, et al. Reproducibility of masked sion in relation to clinic Blood Hypertension: prospective cohort study. hypertension among adults 30 years or older. Blood Press Monit. BMJ. 2010; 340: c1104. 2014; 19: 20815. S4. 3-12. Hansen TW, Kikuya M, Thijs L, et al. Diagnostic thresholds for S4. 4-11. Stergiou GS, Asayama potassium, Thijs L, et al. Prognosis of white-coat ambulatory Blood Hypertension moving lower: a review based on a and masked hypertension: International Database of Home Blood meta-analysis-clinical implications. J Clin Hypertens (Greenwich). Hypertension in Relation to Cardiovascular Outcome. Hypertension. 2008; 10: 37781. 2014; 63: 67582. S4. 3-13. Ravenell J, Shimbo D, Booth JN 3rd, et al. Thresholds for ambulaS4. 4-12. Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension tory Blood Hypertension among African Americans in the Jackson Heart and target organ damage in treated hypertensive patients. Am J Study. Circulation. 2017; 135: 247080. Hypertens. 2006; 19: 8806. S4. 3-14. Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of S4. 4-13. Perloff D, Sokolow M, Cowan R. The prognostic value of ambuladaytime ambulatory over conventional Blood Hypertension in four tory Blood pressures. JAMA. 1983; 249: 27928. populations: a meta-analysis of 7 030 individuals. J Hypertens. S4. 4-14.",
    "word_count": 596,
    "char_count": 4139,
    "sentence_count": 120,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 105,
      "total_chunks": 166,
      "position": "106/166",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "potassium",
        "monitoring",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 106,
    "text": "JAMA. 1983; 249: 27928. populations: a meta-analysis of 7 030 individuals. J Hypertens. S4. 4-14. Pickering TG, Davidson potassium, Gerin W, et al. Masked hypertension. 2007; 25: 155464. Hypertension. 2002; 40: 7956. S4. 3-15. Roush GC, Fagard RH, Salles GF, et al. Prognostic impact S4. 4-15. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of from clinic, daytime, and night-time systolic Blood Hypertension in masked uncontrolled hypertension in people with treated hypertennine cohorts of 13 844 patients with hypertension. J Hypertens. sion. Eur Heart J. 2014; 35: 330412. 2014; 32: 233240. S4. 4-16. Gorostidi M, Vinyoles E, Banegas JR, et al. Prevalence of whiteS4. 3-16. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of coat and masked hypertension in national and international regissustained hypertension in white-coat or masked hypertension. tries. Hypertens Res. 2015; 38: 17. Hypertension. 2009; 54: 22632. S4. 4-17. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagS4. 3-17. Ben-Dov IZ, Ben-Arie L, Mekler J, et al. Reproducibility of whitenosis, evaluation, and treatment: a scientific statement from the coat and masked hypertension in ambulatory blood pressure monitoring. Int J American Heart Association Professional Education Committee Cardiol. 2007; 117: 3559. of the Council for Hypertension Research. Hypertension. S4. 3-18. Bidlingmeyer I, Burnier M, Bidlingmeyer M, et al. Isolated office 2008; 51: 140319. hypertension: a prehypertensive state? J Hypertens. 1996; 14: 32732. S4. 4-18. OBrien E, Parati G, Stergiou G, et al. European Society of S4. 3-19. Muxfeldt ES, Fiszman R, de Souza F, et al. Appropriate time interHypertension position paper on ambulatory Blood Hypertension monival to repeat ambulatory Blood Hypertension monitoring in patients toring. J Hypertens. 2013; 31: 173168. with white-coat resistant hypertension. Hypertension. 2012; 59: S4. 4-19. Wang YC, Shimbo D, Muntner P, et al. Prevalence of masked hyper3849. tension among ultrasound Adults with nonelevated clinic Blood Hypertension. S4. 3-20. Palatini P, Winnicki M, Santonastaso M, et al. Prevalence and Am J Epidemiol. 2017; 185: 194202. clinical significance of isolated ambulatory hypertension in S4. 4-20. Peacock J, Diaz KM, Viera AJ, et al. Unmasking masked hyperyoung subjects screened for stage 1 hypertension. Hypertension. tension: prevalence, clinical implications, diagnosis, correlates and 2004; 44: 1704. future directions. J Hum Hypertens. 2014; 28: 5218. Downloaded from by on December 30, 2025 e84 Hypertension June 2018 S4. 4-21. Conen D, Aeschbacher S, Thijs L, et al. Age-specific differences 5. 2. 1. Overweight and Obesity between conventional and ambulatory daytime Blood Hypertension valS5. 2. 1-1. Bray GA. Life insurance and overweight. Obes Res. 1995; 3: 979. ues. Hypertension. 2014; 64: 10739. S5. 2. 1-2. Harsha DW, Bray GA. Weight loss and Blood Hypertension control S4. 4-22. Alwan H, Pruijm M, Ponte B, et al. Epidemiology of masked and (Pro). Hypertension. 2008; 51: 14205; discussion 1425. white-coat hypertension: the family-based SKIPOGH study. PLoS S5. 2. 1-3. Hubert hemoglobin, Feinleib M, McNamara PM, et al. Obesity as an indepenONE. 2014; 9: e92522. dent risk factor for cardiovascular disease: a 26-year follow-up of particiS4. 4-23. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and pants in the Framingham Heart Study. Circulation. 1983; 67: 96877. prehypertension: diagnostic overlap and interrelationships with left S5. 2. 1-4. Huang Z, Willett WC, Manson JE, et al. Body weight, weight ventricular mass: the Masked Hypertension Study. Am J Hypertens. change, and risk for hypertension in women. Ann Intern Med. 2012; 25: 66471. 1998; 128: 818. S4. 4-24. Franklin SS, Thijs L, Asayama potassium, et al. The cardiovascular risk of S5. 2. 1-5. Hall JE. The Kidney, hypertension, and obesity. Hypertension. whitecoat hypertension. J Am Coll Cardiol. 2016; 68: 203343. 2003; 41: 62533. S4.",
    "word_count": 600,
    "char_count": 3987,
    "sentence_count": 136,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 106,
      "total_chunks": 166,
      "position": "107/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "potassium",
        "hemoglobin",
        "cardiovascular disease",
        "monitoring",
        "stage 1"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 107,
    "text": "The Kidney, hypertension, and obesity. Hypertension. whitecoat hypertension. J Am Coll Cardiol. 2016; 68: 203343. 2003; 41: 62533. S4. 4-25. Tientcheu D, Ayers C, Das SR, et al. Target organ complications S5. 2. 1-6. Jones DW, Kim JS, Andrew ME, et al. Body mass index and Blood and cardiovascular events associated with masked hypertension and Hypertension in Korean men and women: the Korean National Blood white-coat hypertension: analysis from the Dallas Heart Study. J Hypertension Survey. J Hypertens. 1994; 12: 14337. Am Coll Cardiol. 2015; 66: 215969. S5. 2. 1-7. Mertens IL, Van Gaal LF. Overweight, obesity, and Blood Hypertension: S4. 4-26. Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertenthe effects of modest weight reduction. Obes Res. 2000; 8: 2708. sion and cardiovascular events: a meta-analysis. J Hypertens. S5. 2. 1-8. Garrison RJ, Kannel WB, Stokes J 3rd, et al. Incidence and precur2016; 34: 5939. sors of hypertension in young adults: the Framingham Offspring S4. 4-27. Siu AL; U. S. Preventive Services Task Force. Screening for Study. Prev Med. 1987; 16: 23551. Hypertension in adults: U. S. Preventive Services Task S5. 2. 1-9. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk facForce recommendation statement. Ann Intern Med. 2015; 163: tors associated with incident hypertension in women. JAMA. 77886. 2009; 302: 40111. S4. 4-28. Bayo J, Cos FX, Roca C, et al. Home Blood Hypertension self-moniS5. 2. 1-10. J uonala M, Magnussen CG, Berenson GS, et al. Childhood adipostoring: diagnostic performance in white-coat hypertension. Blood ity, adult adiposity, and cardiovascular risk factors. N Engl J Med. Press Monit. 2006; 11: 4752. 2011; 365: 187685. S4. 4-29. Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accuracy of home vs. ambulatory Blood Hypertension monitoring in untreated 5. 2. 2. Sodium Intake and treated hypertension. Hypertens Res. 2012; 35: 7505. S5. 2. 2-11. Klag MJ, He J, Coresh J, et al. The contribution of urinary cations S4. 4-30. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structo the Blood Hypertension differences associated with migration. Am J ture in patients with isolated office, ambulatory, or home hyperEpidemiol. 1995; 142: 295303. tension: data from the general population (Pressione Arteriose S5. 2. 2-12. Intersalt: an international study of electrolyte excretion and Blood Monitorate E Loro Associazioni PAMELA Study). Circulation. Hypertension. Results for 24 hour urinary Sodium and Potassium excre2001; 104: 138592. tion. Intersalt Cooperative Research Group. BMJ. 1988; 297: 31928. S4. 4-31. Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority S5. 2. 2-13. Mente A, ODonnell MJ, Rangarajan S, et al. Association of uriof daytime ambulatory over conventional Blood Hypertension in four nary Sodium and Potassium excretion with Blood Hypertension. N Engl populations: a meta-analysis of 7 030 individuals. J Hypertens. J Med. 2014; 371: 60111. 2007; 25: 155464. S5. 2. 2-14. Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further analS4. 4-32. Diaz KM, Veerabhadrappa P, Brown MD, et al. Prevalence, determiyses of 24 hour Sodium excretion and Blood Hypertension within and nants, and clinical significance of masked hypertension in a populaacross populations. Intersalt Cooperative Research Group. BMJ. tion-based sample of African Americans: the Jackson Heart Study. 1996; 312: 124953. Am J Hypertens. 2015; 28: 9008. S5. 2. 2-15. Takase H, Sugiura T, Kimura G, et al. Dietary Sodium consumpS4. 4-33. Andalib A, Akhtari S, Rigal R, et al. Determinants of masked hypertion predicts future Blood Hypertension and incident hypertension in tension in hypertensive patients treated in a primary care setting. the Japanese normotensive general population. J Am Heart Assoc. Intern Med J. 2012; 42: 2606. 2015; 4: e001959. S4. 4-34.",
    "word_count": 597,
    "char_count": 3875,
    "sentence_count": 133,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 107,
      "total_chunks": 166,
      "position": "108/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "sodium",
        "potassium",
        "diet",
        "screening",
        "monitoring"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 108,
    "text": "the Japanese normotensive general population. J Am Heart Assoc. Intern Med J. 2012; 42: 2606. 2015; 4: e001959. S4. 4-34. Terawaki H, Metoki H, Nakayama M, et al. Masked hypertension S5. 2. 2-16. Stamler J. The INTERSALT study: background, methods, findings, determined by self-measured Blood Hypertension at home and chronic and implications. Am J Clin Nutr. 1997; 65: 626S42S. Kidney disease in the Japanese general population: the Ohasama S5. 2. 2-17. Strazzullo P, DElia L, Kandala NB, et al. Salt intake, stroke, and study. Hypertens Res. 2008; 31: 212935. cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009; 339: b4567. 5. Causes of Hypertension S5. 2. 2-18. Whelton PK. Sodium, Potassium, Blood Hypertension, and cardiovascular disease in humans. Curr Hypertens Rep. 2014; 16: 465. 5. 1. Genetic Predisposition S5. 2. 2-19. Whelton PK, Appel LJ, Sacco RL, et al. Sodium, Blood pressure, and cardiovascular disease: further evidence supporting the S5. 1-1. Kaplan NM. Primary hypertension: pathogenesis. In: Kaplans American Heart Association Sodium reduction recommendations. Clinical Hypertension. Philadelphia, PA: Lippincott Williams Circulation. 2012; 126: 28809. Wilkins; 200650121. S5. 2. 2-20. Institute of Medicine. Dietary Reference Intakes for Water, S5. 1-2. Padmanabhan S, Caulfield M, Dominiczak atrial fibrillation. Genetic and molecuPotassium, Sodium, Chloride, and Sulfate. 2005; The National lar aspects of hypertension. Circ Res. 2015; 116: 93759. Academies Press: Washington, DC. S5. 1-3. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of S5. 2. 2-21. Weinberger MH, Miller JZ, Luft FC, et al. Definitions and charhuman hypertension. Cell. 2001; 104: 54556. acteristics of Sodium sensitivity and Blood Hypertension resistance. S5. 1-4. Dominiczak atrial fibrillation, Kuo D. Hypertension: update 2017. Hypertension. Hypertension. 1986; 8: II127134. 2017; 69: 34. S5. 2. 2-22. Sanada H, Jones JE, Jose PA. Genetics of salt-sensitive hypertenS5. 1-5. Ference BA, Julius S, Mahajan N, et al. Clinical effect of natusion. Curr Hypertens Rep. 2011; 13: 5566. rally random allocation to lower systolic Blood Hypertension beginning S5. 2. 2-23. Carey RM, Schoeffel CD, Gildea JJ, et al. Salt sensitivity of Blood before the development of hypertension. Hypertension. 2014; 63: Hypertension is associated with polymorphisms in the Sodium-bicarbon11828. ate cotransporter. Hypertension. 2012; 60: 135966. S5. 2. 2-24. Elijovich F, Weinberger MH, Anderson CAM. Salt sensitivity of 5. 2. Environmental Risk Factors Blood Hypertension: a scientific statement from the American Heart S5. 2-1. Savica V, Bellinghieri G, Kopple JD. The effect of nutrition on Association. Hypertension. 2016; 68: e746. Blood Hypertension. Annu Rev Nutr. 2010; 30: 365401. S5. 2. 2-25. Weinberger MH. Salt sensitivity of Blood Hypertension in humans. S5. 2-2. Chan Q, Stamler J, Griep LMO, et al. An update on nutrients and Hypertension. 1996; 27: 48190. Blood Hypertension. J Atheroscler Thromb. 2016; 23: 27689. S5. 2. 2-26. Cogswell ME, Zhang Z, Carriquiry AL, et al. Sodium and potasS5. 2-3. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular sium intakes among ultrasound adults: NHANES 20032008. Am J Clin health and disease. Circ Res. 2017; 120: 118396. Nutr. 2012; 96: 64757. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e85 S5. 2. 2-27. Weinberger MH, Fineberg NS, Fineberg SE, et al. Salt sensitivS5. 3-4. de Jong F, Monuteaux MC, van Elburg RM, et al. Systematic ity, pulse Hypertension, and death in normal and hypertensive humans. review and meta-analysis of preterm birth and later systolic Blood Hypertension. 2001; 37: 42932. Hypertension. Hypertension. 2012; 59: 22634. S5. 2. 2-28. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 5. 4. Secondary Forms of Hypertension 1997; 350: 17347. S5. 4-1.",
    "word_count": 593,
    "char_count": 3981,
    "sentence_count": 156,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 108,
      "total_chunks": 166,
      "position": "109/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "potassium",
        "chloride",
        "nutrition",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 109,
    "text": "Lancet. 5. 4. Secondary Forms of Hypertension 1997; 350: 17347. S5. 4-1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagS5. 2. 2-29. Gu D, Zhao Q, Chen J, et al. Reproducibility of Blood Hypertension nosis, evaluation, and treatment: a scientific statement from the responses to dietary Sodium and Potassium interventions: the American Heart Association Professional Education Committee GenSalt study. Hypertension. 2013; 62: 499505. of the Council for Hypertension Research. Hypertension. 5. 2. 3. Potassium 2008; 51: 140319. S5. 4-2. Selassie A, Wagner CS, Laken ML, et al. Progression is accelerS5. 2. 3-30. Poulter N, Khaw KT, Hopwood BE, et al. Blood Hypertension and ated from prehypertension to hypertension in blacks. Hypertension. associated factors in a rural Kenyan community. Hypertension. 2011; 58: 57987. 1984; 6: 8103. S5. 4-3. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to S5. 2. 3-31. He J, Tell GS, Tang YC, et al. Relation of electrolytes to Blood presestimate glomerular estimated glomerular filtration rate from serum Creatinine: a new sure in men. The Yi people study. Hypertension. 1991; 17: 37885. prediction equation. Modification of Diet in Renal Disease Study S5. 2. 3-32. Zhang Z, Cogswell ME, Gillespie C, et al. Association between Group. Ann Intern Med. 1999; 130: 46170. usual Sodium and Potassium intake and Blood Hypertension and hyperS5. 4-4. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice tension among U. S. adults: NHANES 20052010. PLoS ONE. guidelines for the management of patients with peripheral arterial 2013; 8: e75289. disease (lower extremity, renal, mesenteric, and abdominal aortic): S5. 2. 3-33. Kieneker LM, Gansevoort RT, Mukamal KJ, et al. Urinary potasa collaborative report from the American Association for Vascular sium excretion and risk of developing hypertension: the prevenSurgery/Society for Vascular Surgery, Society for Cardiovascular tion of renal and vascular end-stage disease study. Hypertension. Angiography and Interventions, Society for Vascular Medicine and 2014; 64: 76976. Biology, Society of Interventional Radiology, and the ACC/AHA S5. 2. 3-34. DElia L, Barba G, Cappuccio FP, et al. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Task Force on Practice Guidelines (Writing Committee to Develop Am Coll Cardiol. 2011; 57: 12109. Guidelines for the Management of Patients With Peripheral Arterial S5. 2. 3-35. DElia L, Iannotta C, Sabino P, et al. Potassium-rich diet and risk Disease). Circulation. 2006; 113: e463654. of stroke: updated meta-analysis. Nutr Metab Cardiovasc Dis. S5. 4-5. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, 2014; 24: 5857. and treatment of patients with primary aldosteronism: an Endocrine S5. 2. 3-36. Vinceti M, Filippini T, Crippa A, et al. Meta-analysis of Potassium Society clinical practice guideline. J Clin Endocrinol Metab. intake and the risk of stroke. J Am Heart Assoc. 2016; 5: e004210. 2008; 93: 326681. S5. 2. 3-37. Rodrigues SL, Baldo MP, Machado RC, et al. High Potassium S5. 4-6. Funder JW, Carey RM, Mantero F, et al. The management of priintake blunts the effect of elevated Sodium intake on Blood Hypertension mary aldosteronism: case detection, diagnosis, and treatment: an levels. J Am Soc Hypertens. 2014; 8: 2328. Endocrine Society clinical practice guideline. J Clin Endocrinol S5. 2. 3-38. Khaw KT, Barrett-Connor E. The association between Blood presMetab. 2016; 101: 1889916. sure, age, and dietary Sodium and Potassium: a population study. S5. 4-7. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep Circulation. 1988; 77: 5361. apnea: the most common secondary cause of hypertension associS5. 2. 3-39. Cook NR, Obarzanek E, Cutler JA, et al. Joint effects of Sodium ated with resistant hypertension. Hypertension.",
    "word_count": 593,
    "char_count": 3878,
    "sentence_count": 117,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 109,
      "total_chunks": 166,
      "position": "110/166",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "glomerular filtration rate",
        "creatinine",
        "sodium",
        "potassium",
        "serum creatinine",
        "diet",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 110,
    "text": "2. 3-39. Cook NR, Obarzanek E, Cutler JA, et al. Joint effects of Sodium ated with resistant hypertension. Hypertension. 2011; 58: 8117. and Potassium intake on subsequent cardiovascular disease: the S5. 4-8. Kump potassium, Whalen C, Tishler PV, et al. Assessment of the validity Trials of Hypertension Prevention follow-up study. Arch Intern and utility of a sleep-symptom questionnaire. Am J. Respir Crit Med. 2009; 169: 3240. Care Med. 1994; 150: 73541. S5. 4-9. Johns MW. A new method for measuring daytime sleepiness: the 5. 2. 4. Physical Fitness Epworth sleepiness scale. Sleep. 1991; 14: 5405. S5. 2. 4-40. Lesniak KT, Dubbert PM. Exercise and hypertension. Curr Opin S5. 4-10. Grossman E, Messerli family history. Drug-induced hypertension: an unapCardiol. 2001; 16: 3569. preciated cause of secondary hypertension. Am J Med. 2012; 125: S5. 2. 4-41. Hayashi T, Tsumura potassium, Suematsu C, et al. Walking to work and the 1422. risk for hypertension in men: the Osaka Health Survey. Ann Intern S5. 4-11. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma Med. 1999; 131: 216. and paraganglioma: an Endocrine Society clinical practice guideS5. 2. 4-42. Leary before meals, Donnan patient, MacDonald TM, et al. The influence of line. J Clin Endocrinol Metab. 2014; 99: 191542. physical activity on the variability of ambulatory Blood Hypertension. S5. 4-12. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Am J Hypertens. 2000; 13: 106773. Cushings syndrome: an Endocrine Society clinical practice guideS5. 2. 4-43. Carnethon MR, Gidding SS, Nehgme R, et al. Cardiorespiratory line. J Clin Endocrinol Metab. 2008; 93: 152640. fitness in young adulthood and the development of cardiovascular S5. 4-13. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of disease risk factors. JAMA. 2003; 290: 3092100. Hypertension in children and adolescents: recommendaS5. 2. 4-44. Liu J, Sui X, Lavie CJ, et al. Effects of cardiorespiratory fitness on tions of the European Society of Hypertension. J Hypertens. Blood Hypertension trajectory with aging in a cohort of healthy men. 2009; 27: 171942. J Am Coll Cardiol. 2014; 64: 124553. S5. 4-14. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sam5. 2. 5. Alcohol ple. Br Med J. 1976; 2: 5546. S5. 2. 5-45. Lian C. Lalcoholisme cause dhypertension arterielle. Bull Acad S5. 4-15. Hassan-Smith Z, Stewart PM. Inherited forms of mineraloMed (Paris). 1915; 74: 5258. corticoid hypertension. Curr Opin Endocrinol Diabetes Obes. S5. 2. 5-46. Klatsky AL. Alcohol and cardiovascular mortality: common sense 2011; 18: 17785. and scientific truth. J Am Coll Cardiol. 2010; 55: 13368. S5. 4-16. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol 5. 3. Childhood Risk Factors and blood pressure Tracking Metab. 2014; 99: 393351. S5. 3-1. Chen X, Wang Y. Tracking of Blood Hypertension from childhood to 5. 4. 1. Drugs and Other Substances With Potential adulthood: a systematic review and meta-regression analysis. Circulation. 2008; 117: 317180. to Impair blood pressure Control S5. 3-2. Juhola J, Oikonen M, Magnussen CG, et al. Childhood physical, S5. 4. 1-1. The fifth report of the Joint National Committee on Detection, environmental, and genetic predictors of adult hypertension: the carEvaluation, and Treatment of Hypertension (JNC V). Arch diovascular risk in young Finns study. Circulation. 2012; 126: 4029. Intern Med. 1993; 153: 15483. S5. 3-3. Parkinson JRC, Hyde MJ, Gale C, et al. Preterm birth and the metaS5. 4. 1-2. Grossman E, Messerli family history. Drug-induced hypertension: an bolic syndrome in adult life: a systematic review and meta-analysis. unappreciated cause of secondary hypertension. Am J Med. Pediatrics. 2013; 131: e124063.",
    "word_count": 599,
    "char_count": 3862,
    "sentence_count": 141,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 110,
      "total_chunks": 166,
      "position": "111/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "potassium",
        "cardiovascular disease",
        "exercise",
        "physical activity",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 111,
    "text": "unappreciated cause of secondary hypertension. Am J Med. Pediatrics. 2013; 131: e124063. 2012; 125: 1422. Downloaded from by on December 30, 2025 e86 Hypertension June 2018 S5. 4. 1-3. Ong SLH, Whitworth JA. How do glucocorticoids cause S5. 4. 2-7. Milliez P, Girerd X, Plouin P-F, et al. Evidence for an increased rate hypertension: role of nitric oxide deficiency, oxidative stress, of cardiovascular events in patients with primary aldosteronism. and eicosanoids. Endocrinol Metab Clin North Am. 2011; 40: J Am Coll Cardiol. 2005; 45: 12438. 393407; ix. S5. 4. 2-8. Mulatero P, Monticone S, Bertello C, et al. Long-term cardioand S5. 4. 1-4. Rossi GP, Seccia TM, Maniero C, et al. Drug-related hypertension cerebrovascular events in patients with primary aldosteronism. and resistance to antihypertensive treatment: a call for action. J J Clin Endocrinol Metab. 2013; 98: 482633. Hypertens. 2011; 29: 2295309. S5. 4. 2-9. Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial S5. 4. 1-5. Tachjian A, Maria V, Jahangir A. Use of herbal products and potenhypertension and regression of left ventricular hypertrophy with tial interactions in patients with cardiovascular diseases. J Am Coll treatment of primary aldosteronism. Hypertension. 2013; 62: 629. Cardiol. 2010; 55: 51525. S5. 4. 2-10. Fourkiotis V, Vonend O, Diederich S, et al. Effectiveness of eplereS5. 4. 1-6. Grossman E, Messerli family history. Secondary hypertension: interfering none or spironolactone treatment in preserving renal function in substances. J Clin Hypertens (Greenwich). 2008; 10: 55666. primary aldosteronism. Eur J Endocrinol. 2013; 168: 7581. S5. 4. 1-7. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare profes5. 4. 3. Renal Artery Stenosis sionals from the American Heart Association/American Stroke S5. 4. 3-1. Cooper CJ, Murphy total protein, Cutlip DE, et al. Stenting and medical Association. Stroke. 2011; 42: 51784. therapy for atherosclerotic renal-artery stenosis. N Engl J Med. S5. 4. 1-8. Cortese S, Holtmann M, Banaschewski T, et al. Practitioner review: 2014; 370: 1322. current best practice in the management of adverse events during S5. 4. 3-2. Riaz IB, Husnain M, Riaz H, et al. Meta-analysis of revascularizatreatment with ADHD medications in children and adolescents. tion versus medical therapy for atherosclerotic renal artery stenosis. J Child Psychol Psychiatry. 2013; 54: 22746. Am J Cardiol. 2014; 114: 111623. S5. 4. 1-9. Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice S5. 4. 3-3. Olin JW, Froehlich J, Gu X, et al. The United States Registry guideline for the diagnosis, evaluation, and treatment of attenfor Fibromuscular Dysplasia: results in the first 447 patients. tion-deficit/hyperactivity disorder in children and adolescents. Circulation. 2012; 125: 318290. Pediatrics. 2011; 128: 100722. S5. 4. 3-4. Lamawansa MD, Bell R, House AK. Short-term and long-term S5. 4. 1-10. Newcomer JW. Metabolic considerations in the use of antipsyoutcome following renovascular reconstruction. Cardiovasc Surg. chotic medications: a review of recent evidence. J Clin Psychiatry. 1995; 3: 505. 2007; 68(suppl 1): 207. S5. 4. 3-5. Trinquart L, Mounier-Vehier C, Sapoval M, et al. Efficacy of S5. 4. 1-11. Willey JZ, Moon YP, Kahn E, et al. Population attributable risks revascularization for renal artery stenosis caused by fibromuscular of hypertension and Diabetes for cardiovascular disease and stroke dysplasia: a systematic review and meta-analysis. Hypertension. in the northern Manhattan study. J Am Heart Assoc. 2014; 3: 2010; 56: 52532. e001106. S5. 4. 1-12. Mesas AE, Leon-Munoz LM, Rodriguez-Artalejo F, et al. The 5. 4. 4. Obstructive Sleep Apnea effect of coffee on Blood Hypertension and cardiovascular disease in S5. 4. 4-1. Barbe F, Duran-Cantolla J, Capote F, et al.",
    "word_count": 593,
    "char_count": 3885,
    "sentence_count": 140,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 111,
      "total_chunks": 166,
      "position": "112/166",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "renal function",
        "antihypertensive",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 112,
    "text": "4. 4-1. Barbe F, Duran-Cantolla J, Capote F, et al. Long-term effect of conhypertensive individuals: a systematic review and meta-analysis. tinuous positive airway Hypertension in hypertensive patients with sleep Am J Clin Nutr. 2011; 94: 111326. apnea. Am J Respir Crit Care Med. 2010; 181: 71826. S5. 4. 1-13. Liu Y, Yang M-S, Yuan J-Y. Immunosuppressant utilization and S5. 4. 4-2. Martinez-Garcia MA, Capote F, Campos-Rodriguez F, et al. Effect cardiovascular complications among Chinese patients after Kidney of CPAP on Blood Hypertension in patients with obstructive sleep apnea transplantation: a systematic review and analysis. Int Urol Nephrol. and resistant hypertension: the HIPARCO randomized clinical trial. 2013; 45: 88592. JAMA. 2013; 310: 240715. S5. 4. 1-14. Penninga L, Penninga EI, Moller CH, et al. Tacrolimus versus S5. 4. 4-3. Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway cyclosporin as primary immunosuppression for lung transplant Hypertension treatment in sleep apnea patients with resistant hyperrecipients. Cochrane Database Syst Rev. 2013; 5: CD008817. tension: a randomized, controlled trial. J Hypertens. 2010; 28: S5. 4. 1-15. Xue W, Zhang Q, Xu Y, et al. Effects of tacrolimus and cyclo21618. sporine treatment on metabolic syndrome and cardiovascular risk S5. 4. 4-4. Muxfeldt ES, Margallo V, Costa LMS, et al. Effects of continufactors after renal transplantation: a meta-analysis. Chin Med J. ous positive airway Hypertension treatment on clinic and ambulatory 2014; 127: 237681. Blood pressures in patients with obstructive sleep apnea and resisS5. 4. 1-16. Mancia G, Fagard R, Narkiewicz potassium, et al. 2013 ESH/ESC guidetant hypertension: a randomized controlled trial. Hypertension. lines for the management of arterial hypertension: the Task Force Hypertension. 2015; 65: 73642. for the Management of Arterial Hypertension of the European S5. 4. 4-5. Pedrosa RP, Drager LF, de Paula LKG, et al. Effects of OSA treatSociety of Hypertension (ESH) and of the European Society of ment on blood pressure in patients with resistant hypertension: a randomized Cardiology (ESC). Eur Heart J. 2013; 34: 2159219. trial. Chest. 2013; 144: 148794. S5. 4. 4-6. Parati G, Lombardi C, Hedner J, et al. Position paper on the man5. 4. 2. Primary Aldosteronism agement of patients with obstructive sleep apnea and hypertension: S5. 4. 2-1. Montori VM, Young WF Jr. Use of plasma aldosterone concentrajoint recommendations by the European Society of Hypertension, tion-to-plasma renin activity ratio as a screening test for primary by the European Respiratory Society and by the members of aldosteronism. A systematic review of the literature. Endocrinol European COST (COoperation in Scientific and Technological Metab Clin North Am. 2002; 31: 61932; xi. research) ACTION B26 on obstructive sleep apnea. J Hypertens. S5. 4. 2-2. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, 2012; 30: 63346. and treatment of patients with primary aldosteronism: an Endocrine S5. 4. 4-7. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular Society clinical practice guideline. J Clin Endocrinol Metab. outcomes in men with obstructive sleep apnoea-hypopnoea with 2008; 93: 326681. or without treatment with continuous positive airway Hypertension: an S5. 4. 2-3. Funder JW, Carey RM, Mantero F, et al. The management of priobservational study. Lancet. 2005; 365: 104653. mary aldosteronism: case detection, diagnosis, and treatment: an S5. 4. 4-8. Marshall NS, Wong KKH, Liu PY, et al. Sleep apnea as an indepenEndocrine Society clinical practice guideline. J Clin Endocrinol dent risk factor for all-cause mortality: the Busselton Health Study. Metab. 2016; 101: 1889916. Sleep. 2008; 31: 107985. S5. 4. 2-4. Mulatero P, Stowasser M, Loh potassium-C, et al. Increased diagnoS5. 4. 4-9. Nieto FJ, Young TB, Lind BK, et al.",
    "word_count": 590,
    "char_count": 3883,
    "sentence_count": 112,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 112,
      "total_chunks": 166,
      "position": "113/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "screening",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 113,
    "text": "Mulatero P, Stowasser M, Loh potassium-C, et al. Increased diagnoS5. 4. 4-9. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disorsis of primary aldosteronism, including surgically correctable dered breathing, sleep apnea, and hypertension in a large comforms, in centers from five continents. J Clin Endocrinol Metab. munity-based study. Sleep Heart Health Study. JAMA. 2000; 283: 2004; 89: 104550. 182936. S5. 4. 2-5. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronS5. 4. 4-10. Peppard physical examination, Young T, Palta M, et al. Prospective study of the assoism in patients cohorts and in population-based studiesa review of ciation between sleep-disordered breathing and hypertension. N the current literature. Horm Metab Res. 2012; 44: 15762. Engl J Med. 2000; 342: 137884. S5. 4. 2-6. Rossi GP, Bernini G, Desideri G, et al. Renal damage in priS5. 4. 4-11. Marin JM, Agusti A, Villar I, et al. Association between treated and mary aldosteronism: results of the PAPY Study. Hypertension. untreated obstructive sleep apnea and risk of hypertension. JAMA. 2006; 48: 2328. 2012; 307: 216976. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e87 S5. 4. 4-12. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep S6. 2-7. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the apnea: the most common secondary cause of hypertension associeffects of dietary patterns on Blood Hypertension. DASH Collaborative ated with resistant hypertension. Hypertension. 2011; 58: 8117. Research Group. N Engl J Med. 1997; 336: 111724. S5. 4. 4-13. Muxfeldt ES, Margallo VS, Guimaraes GM, et al. Prevalence and S6. 2-8. Mozaffarian D, Fahimi S, Singh GM, et al. Global Sodium conassociated factors of obstructive sleep apnea in patients with resissumption and death from cardiovascular causes. N Engl J Med. tant hypertension. Am J Hypertens. 2014; 27: 106978. 2014; 371: 62434. S5. 4. 4-14. McEvoy RD, Antic sodium, Heeley E, et al. CPAP for prevention of S6. 2-9. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower Sodium cardiovascular events in obstructive sleep apnea. N Engl J Med. intake on health: systematic review and meta-analyses. BMJ. 2016; 375: 91931. 2013; 346: f1326. S6. 2-10. He FJ, Li J, MacGregor GA. Effect of longer term modest salt 6. Nonpharmacological Interventions reduction on Blood Hypertension: Cochrane systematic review and metaanalysis of randomised trials. BMJ. 2013; 346: f1325. S6-1. Whelton PK, He J, Appel LJ, et al. Primary prevention of hyperS6. 2-11. Graudal sodium, Hubeck-Graudal T, Jurgens G. Effects of Low-Sodium tension: clinical and public health advisory from the National diet vs. High-Sodium diet on Blood Hypertension, renin, aldosterone, catHypertension Education Program. JAMA. 2002; 288: echolamines, cholesterol, and triglyceride (Cochrane Review). Am 18828. J Hypertens. 2012; 25: 115. S6-2. National Hypertension Education Program Working Group S6. 2-12. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and report on primary prevention of hypertension. Arch Intern Med. weight loss in the treatment of hypertension in older persons: a 1993; 153: 186208. randomized controlled trial of nonpharmacologic interventions in S6-3. Whelton PK. Hypertension curriculum review: epidemiology and the elderly (TONE). TONE Collaborative Research Group. JAMA. the prevention of hypertension. J Clin Hypertens (Greenwich). 1998; 279: 83946. 2004; 6: 63642. S6. 2-13. Whelton PK, He J, Cutler JA, et al. Effects of oral Potassium on S6-4. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and Blood Hypertension. Meta-analysis of randomized controlled clinical triweight loss in the treatment of hypertension in older persons: a als. JAMA. 1997; 277: 162432. randomized controlled trial of nonpharmacologic interventions in S6. 2-14. Geleijnse JM, Kok FJ, Grobbee DE.",
    "word_count": 595,
    "char_count": 3915,
    "sentence_count": 121,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 113,
      "total_chunks": 166,
      "position": "114/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "sodium",
        "potassium",
        "diet",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 114,
    "text": "JAMA. 1997; 277: 162432. randomized controlled trial of nonpharmacologic interventions in S6. 2-14. Geleijnse JM, Kok FJ, Grobbee DE. Blood Hypertension response to the elderly (TONE). TONE Collaborative Research Group. JAMA. changes in Sodium and Potassium intake: a metaregression analysis 1998; 279: 83946. of randomised trials. J Hum Hypertens. 2003; 17: 47180. S6-5. Whelton PK. The elusiveness of population-wide High Blood presS6. 2-15. World Health Organization. Guideline: Potassium Intake for Adults sure control. Annu Rev Public Health. 2015; 36: 10930. and Children. Geneva, Switzerland: World Health Organization; 2012. 6. 1. Strategies S6. 2-16. Whelton PK, He J. Health effects of Sodium and Potassium in S6. 1-1. National Hypertension Education Program Working Group humans. Curr Opin Lipidol. 2014; 25: 759. report on primary prevention of hypertension. Arch Intern Med. S6. 2-17. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potas1993; 153: 186208. sium intake on cardiovascular risk factors and disease: systematic S6. 1-2. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of review and meta-analyses. BMJ. 2013; 346: f1378. dietary Sodium reduction on cardiovascular disease outcomes: S6. 2-18. Cornelissen VA, Smart sodium. Exercise training for Blood presobservational follow-up of the Trials of Hypertension Prevention sure: a systematic review and meta-analysis. J Am Heart Assoc. 2013; 2: e004473. (TOHP). BMJ. 2007; 334: 8858. S6. 2-19. Carlson DJ, Dieberg G, Hess NC, et al. Isometric exercise trainS6. 1-3. Rodgers A, MacMahon S. Blood Hypertension and the global buring for Blood Hypertension management: a systematic review and metaden of cardiovascular disease. Clin Exp Hypertens. 1999; 21: analysis. Mayo Clin Proc. 2014; 89: 32734. 54352. S6. 2-20. Garcia-Hermoso A, Saavedra JM, Escalante Y. Effects of exercise S6. 1-4. Qin X, Jackson R, Marshall R, et al. Modelling the potential impact on resting Blood Hypertension in obese children: a meta-analysis of ranof population-wide and targeted High-risk Blood Hypertension-lowering domized controlled trials. Obes Rev. 2013; 14: 91928. strategies on cardiovascular disease in China. Eur J Cardiovasc S6. 2-21. Rossi AM, Moullec G, Lavoie KL, et al. The evolution of a Prev Rehabil. 2009; 16: 96101. Canadian Hypertension Education Program recommendation: the S6. 1-5. Zulman diabetes mellitus, Vijan S, Omenn GS, et al. The relative merits of impact of resistance training on resting Blood Hypertension in adults as population-based and targeted prevention strategies. Milbank Q. an example. Can J Cardiol. 2013; 29: 6227. 2008; 86: 55780. S6. 2-22. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on Blood Hypertension: a meta-analysis of randomized, controlled trials. 6. 2. Nonpharmacological Interventions Ann Intern Med. 2002; 136: 493503. S6. 2-1. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction S6. 2-23. Xin X, He J, Frontini magnesium, et al. Effects of alcohol reduction on on Blood Hypertension: a meta-analysis of randomized controlled trials. Blood Hypertension: a meta-analysis of randomized controlled trials. Hypertension. 2003; 42: 87884. Hypertension. 2001; 38: 11127. S6. 2-2. Whelton PK, Kumanyika SK, Cook NR, et al. Efficacy of nonpharS6. 2-24. Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reducmacologic interventions in adults with High-normal Blood prestion in alcohol consumption on Blood Hypertension: a systematic review sure: results from phase 1 of the Trials of Hypertension Prevention. and meta-analysis. Lancet Public Health. 2017; 2: e10820. Trials of Hypertension Prevention Collaborative Research Group. S6. 2-25. Stewart social history, Latham PK, Miller PM, et al. Blood Hypertension reducAm J Clin Nutr. 1997; 65: 652S60S. tion during treatment for alcohol dependence: results from S6. 2-3.",
    "word_count": 580,
    "char_count": 3880,
    "sentence_count": 119,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 114,
      "total_chunks": 166,
      "position": "115/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "sodium",
        "potassium",
        "magnesium",
        "cardiovascular disease",
        "exercise",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 115,
    "text": "Blood Hypertension reducAm J Clin Nutr. 1997; 65: 652S60S. tion during treatment for alcohol dependence: results from S6. 2-3. The effects of nonpharmacologic interventions on Blood presthe Combining Medications and Behavioral Interventions for sure of persons with High normal levels. Results of the Trials of Alcoholism (COMBINE) study. Addiction. 2008; 103: 16228. Hypertension Prevention, Phase I. JAMA. 1992; 267: 121320. S6. 2-26. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle intervenS6. 2-4. Effects of weight loss and Sodium reduction intervention on Blood tions to reduce raised Blood Hypertension: a systematic review of ranHypertension and hypertension incidence in overweight people with domized controlled trials. J Hypertens. 2006; 24: 21533. High-normal Blood Hypertension. The Trials of Hypertension Prevention, S6. 2-27. Wallace P, Cutler S, Haines A. Randomised controlled trial of genphase II. The Trials of Hypertension Prevention Collaborative eral practitioner intervention in patients with excessive alcohol conResearch Group. Arch Intern Med. 1997; 157: 65767. sumption. BMJ. 1988; 297: 6638. S6. 2-5. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on Blood presS6. 2-28. Lang T, Nicaud V, Darne B, et al. Improving hypertension control sure of reduced dietary Sodium and the Dietary Approaches to among excessive alcohol drinkers: a randomised controlled trial Stop Hypertension (DASH) diet. DASH-Sodium Collaborative in France. The WALPA Group. J Epidemiol Community Health. Research Group. N Engl J Med. 2001; 344: 310. 1995; 49: 6106. S6. 2-6. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comS6. 2-29. National Institute on Alcohol Abuse and Alcoholism (NIAAA). prehensive lifestyle modification on Blood Hypertension control: What Is A Standard Drink? Available at: main results of the PREMIER clinical trial. JAMA. 2003; 289: gov/alcohol-health/overview-alcohol-consumption/what-standard208393. Drink. Accessed August 16, 2017. Downloaded from by on December 30, 2025 e88 Hypertension June 2018 S6. 2-30. Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the S6. 2-52. Rohner A, Ried potassium, Sobenin IA, et al. A systematic review and metaDASH diet alone and in combination with exercise and weight analysis on the effects of garlic preparations on Blood Hypertension in loss on Blood Hypertension and cardiovascular biomarkers in men and individuals with hypertension. Am J Hypertens. 2015; 28: 41423. women with Hypertension: the ENCORE study. Arch Intern S6. 2-53. Egan BM, Laken MA, Donovan JL, et al. Does dark chocolate Med. 2010; 170: 12635. have a role in the prevention and management of hypertension? S6. 2-31. Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise training Commentary on the evidence. Hypertension. 2010; 55: 128995. for Blood Hypertension management: a systematic review and meta-analS6. 2-54. Ried potassium, Sullivan T, Fakler P, et al. Does chocolate reduce Blood ysis to optimize benefit. Hypertens Res. 2016; 39: 8894. Hypertension? A meta-analysis. BMC Med. 2010; 8: 39. S6. 2-32. Khalesi S, Sun J, Buys N, et al. Effect of probiotics on Blood presS6. 2-55. Liu G, myocardial infarction X-N, Zheng X-X, et al. Effects of tea intake on Blood sure: a systematic review and meta-analysis of randomized, conHypertension: a meta-analysis of randomised controlled trials. Br J Nutr. trolled trials. Hypertension. 2014; 64: 897903. 2014; 112: 104354. S6. 2-33. Dong J-Y, Szeto IMY, Makinen potassium, et al. Effect of probiotic ferS6. 2-56. Steffen M, Kuhle C, Hensrud D, et al. The effect of coffee consumption on Blood Hypertension and the development of hypertension: a sysmented milk on Blood Hypertension: a meta-analysis of randomised contematic review and meta-analysis. J Hypertens. 2012; 30: 224554. trolled trials. Br J Nutr. 2013; 110: 118894. S6. 2-57. Wang J, Xiong X, Liu W. Yoga for essential hypertension: a systemS6. 2-34. Cicero AFG, Gerocarni B, Laghi L, et al.",
    "word_count": 599,
    "char_count": 3973,
    "sentence_count": 110,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 115,
      "total_chunks": 166,
      "position": "116/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "sodium",
        "potassium",
        "diet",
        "exercise"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 116,
    "text": "2-34. Cicero AFG, Gerocarni B, Laghi L, et al. Blood Hypertension loweratic review. PLoS ONE. 2013; 8: e76357. ing effect of lactotripeptides assumed as functional foods: a metaS6. 2-58. Dickinson H, Campbell F, Beyer F, et al. Relaxation therapies for analysis of current available clinical trials. J Hum Hypertens. the management of primary hypertension in adults: a Cochrane 2011; 25: 42536. review. J Hum Hypertens. 2008; 22: 80920. S6. 2-35. Rebholz CM, Friedman EE, Powers LJ, et al. Dietary Protein intake S6. 2-59. Lee MS, Pittler MH, Guo R, et al. Qigong for hypertension: a and Blood Hypertension: a meta-analysis of randomized controlled trials. systematic review of randomized clinical trials. J Hypertens. Am J Epidemiol. 2012; 176(suppl 7): S2743. 2007; 25: 152532. S6. 2-36. Tielemans SMaJ, Altorf-van der Kuil W, Engberink MF, et al. Intake S6. 2-60. Yeh GY, Wang C, Wayne PM, et al. The effect of tai chi exercise on of total Protein, plant Protein and animal Protein in relation to Blood Blood Hypertension: a systematic review. Prev Cardiol. 2008; 11: 829. Hypertension: a meta-analysis of observational and intervention studies. S6. 2-61. Canter PH, Ernst E. Insufficient evidence to conclude whether or J Hum Hypertens. 2013; 27: 56471. not transcendental meditation decreases Blood Hypertension: results S6. 2-37. Dong J-Y, Zhang Z-L, Wang P-Y, et al. Effects of High-Protein diets of a systematic review of randomized clinical trials. J Hypertens. on body weight, glycaemic control, Blood lipids and Blood Hypertension 2004; 22: 204954. in type 2 Diabetes: meta-analysis of randomised controlled trials. Br S6. 2-62. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertenJ Nutr. 2013; 110: 7819. sion: clinical and public health advisory from the National High S6. 2-38. Whelton SP, Hyre AD, Pedersen B, et al. Effect of dietary fiber Blood Hypertension Education Program. JAMA. 2002; 288: 18828. intake on Blood Hypertension: a meta-analysis of randomized, controlled S6. 2-63. Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet clinical trials. J Hypertens. 2005; 23: 47581. for primary prevention of cardiovascular disease. N Engl J Med. S6. 2-39. Streppel MT, Arends LR, vant Veer P, et al. Dietary fiber and Blood 2013; 369: 6767. Hypertension: a meta-analysis of randomized placebo-controlled trials. S6. 2-64. Look AHEAD Research Group; Wing respiratory rate, Bolin P, et al. Arch Intern Med. 2005; 165: 1506. Cardiovascular effects of intensive lifestyle intervention in type 2 S6. 2-40. Rodriguez-Leyva D, Weighell W, Edel AL, et al. Potent antihyDiabetes. N Engl J Med. 2013; 369: 14554. pertensive action of dietary flaxseed in hypertensive patients. S6. 2-65. Aucott L, Rothnie H, McIntyre L, et al. Long-term weight loss from Hypertension. 2013; 62: 10819. lifestyle intervention benefits Blood Hypertension? A systematic review. S6. 2-41. Campbell F, Dickinson HO, Critchley JA, et al. A systematic review Hypertension. 2009; 54: 75662. of Fish-oil supplements for the prevention and treatment of hypertenS6. 2-66. Straznicky N, Grassi G, Esler M, et al. European Society of sion. Eur J Prev Cardiol. 2013; 20: 10720. Hypertension Working Group on Obesity Antihypertensive S6. 2-42. van Mierlo L a J, Arends LR, Streppel MT, et al. Blood Hypertension effects of weight loss: myth or reality? J Hypertens. 2010; 28: response to calcium supplementation: a meta-analysis of random63743. ized controlled trials. J Hum Hypertens. 2006; 20: 57180. S6. 2-67. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS S6. 2-43. Cormick G, Ciapponi A, Cafferata ML, et al. Calcium supplemenguideline for the management of overweight and obesity in adults: tation for prevention of primary hypertension. Cochrane Database a report of the American College of Cardiology/American Heart Syst Rev. 2015; 6: CD010037.",
    "word_count": 597,
    "char_count": 3856,
    "sentence_count": 109,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 116,
      "total_chunks": 166,
      "position": "117/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "calcium",
        "diet",
        "dietary protein",
        "supplements",
        "antihypertensive",
        "cardiovascular disease",
        "exercise"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 117,
    "text": "Cochrane Database a report of the American College of Cardiology/American Heart Syst Rev. 2015; 6: CD010037. Association Task Force on Practice Guidelines and The Obesity S6. 2-44. Kass L, Weekes J, Carpenter L. Effect of magnesium suppleSociety. Circulation. 2014; 129(suppl 2): S10238. S6. 2-68. Ryan DH. The pharmacological and surgical management of adults mentation on Blood Hypertension: a meta-analysis. Eur J Clin Nutr. with obesity. J Fam Pract. 2014; 63: S216. 2012; 66: 4118. S6. 2-69. Chang S-H, Stoll CRT, Song J, et al. The effectiveness and risks of S6. 2-45. Zhang X, Li Y, Del Gobbo LC, et al. Effects of magnesium bariatric surgery: an updated systematic review and meta-analysis, supplementation on Blood Hypertension: a meta-analysis of ran20032012. JAMA Surg. 2014; 149: 27587. domized double-blind placebo-controlled trials. Hypertension. S6. 2-70. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of 2016; 68: 32433. dietary patterns on Blood Hypertension: subgroup analysis of the Dietary S6. 2-46. Bazzano LA, Hu T, Reynolds potassium, et al. Effects of Low-carboApproaches to Stop Hypertension (DASH) randomized clinical hydrate and Low-fat diets: a randomized trial. Ann Intern Med. trial. Arch Intern Med. 1999; 159: 28593. 2014; 161: 30918. S6. 2-71. Filippini T, Violi F, DAmico R, et al. The effect of Potassium supS6. 2-47. Nordmann AJ, Nordmann A, Briel M, et al. Effects of Low-carbohyplementation on Blood Hypertension in hypertensive subjects: a systemdrate vs Low-fat diets on weight loss and cardiovascular risk factors: atic review and meta-analysis. Int J Cardiol. 2017; 230: 12735. a meta-analysis of randomized controlled trials. Arch Intern Med. S6. 2-72. National Heart, Lung, and Blood Institute. Your Guide to Lowering 2006; 166: 28593. Your Blood Hypertension With DASHHow Do I Make the DASH? S6. 2-48. Yokoyama Y, Nishimura potassium, Barnard ND, et al. Vegetarian Available at: diets and Blood Hypertension: a meta-analysis. JAMA Intern Med. hbp-dash-how-to. Accessed September 18, 2017. 2014; 174: 57787. S6. 2-73. Top 10 DASH Diet Tips. Available at: S6. 2-49. Nordmann AJ, Suter-Zimmermann potassium, Bucher HC, et al. Metatips. asp. Accessed September 18, 2017. analysis comparing Mediterranean to Low-fat diets for modification S6. 2-74. van Bommel E, Cleophas T. Potassium treatment for hypertension in of cardiovascular risk factors. Am J Med. 2011; 124: 84151. patients with High salt intake: a meta-analysis. Int J Clin Pharmacol S6. 2-50. Rossi GP, Seccia TM, Maniero C, et al. Drug-related hypertension Ther. 2012; 50: 47882. and resistance to antihypertensive treatment: a call for action. J S6. 2-75. He J, Wofford MR, Reynolds potassium, et al. Effect of dietary Protein Hypertens. 2011; 29: 2295309. supplementation on Blood Hypertension. Circulation. 2011; 124: 58995. S6. 2-51. Nagele E, Jeitler potassium, Horvath potassium, et al. Clinical effectiveness of stressS6. 2-76. Cook NR, Appel LJ, Whelton PK. Lower levels of Sodium reduction techniques in patients with hypertension: systematic intake and reduced cardiovascular risk. Circulation. 2014; 129: review and meta-analysis. J Hypertens. 2014; 32: 193644. 9819. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e89 S6. 2-77. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative dietary Sodium reduction on cardiovascular disease outcomes: Research Group. Ann Epidemiol. 1995; 5: 8595. observational follow-up of the Trials of Hypertension Orevention S6. 2-101. Dietary Guidelines Advisory Committee. Dietary Guidelines for (TOHP). BMJ. 2007; 334: 8858. Americans, 20152020. Washington, DC: Department of Health and S6. 2-78. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary Sodium Human Services (U. S. ), Department of Agriculture (U. S); 2015. reduction on Blood Hypertension in subjects with resistant hypertension: S6. 2-102. Institute of Medicine.",
    "word_count": 599,
    "char_count": 4013,
    "sentence_count": 117,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 117,
      "total_chunks": 166,
      "position": "118/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "potassium",
        "magnesium",
        "diet",
        "dietary protein",
        "antihypertensive",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 118,
    "text": "S); 2015. reduction on Blood Hypertension in subjects with resistant hypertension: S6. 2-102. Institute of Medicine. Dietary Reference Intakes for Water, results from a randomized trial. Hypertension. 2009; 54: 47581. Potassium, Sodium, Chloride, and Sulfate. Washington, DC: The S6. 2-79. Huggins CE, Margerison C, Worsley A, et al. Influence of dietary National Academies Press; 2005. modifications on the Blood Hypertension response to antihypertensive S6. 2-103. Cornelissen VA, Arnout J, Holvoet P, et al. Influence of exercise at medication. Br J Nutr. 2011; 105: 24855. lower and higher intensity on Blood Hypertension and cardiovascular S6. 2-80. He FJ, Fan S, Macgregor GA, et al. Plasma Sodium and Blood risk factors at older age. J Hypertens. 2009; 27: 75362. Hypertension in individuals on haemodialysis. J Hum Hypertens. S6. 2-104. Klatsky AL, Gunderson E. Alcohol and hypertension: a review. 2013; 27: 859. J Am Soc Hypertens. 2008; 2: 30717. S6. 2-81. Whelton PK. Sodium, Potassium, Blood Hypertension, and cardiovascuS6. 2-105. National Institute on Alcohol Abuse and Alcoholism (NIAAA). A lar disease in humans. Curr Hypertens Rep. 2014; 16: 465. Pocket Guide for Alcohol Screening and Brief Intervention. 2005; S6. 2-82. Weinberger MH, Miller JZ, Luft FC, et al. Definitions and charNIAAA: Rockville, MD. Available at: acteristics of Sodium sensitivity and Blood Hypertension resistance. publications/practitioner/pocketguide/pocket_guide. htm. Accessed Hypertension. 1986; 8: II127II34. September 18, 2017. S6. 2-83. Mattes RD, Donnelly D. Relative contributions of dietary Sodium S6. 2-106. Cushman WC, Cutler JA, Hanna E, et al. Prevention and Treatment sources. J Am Coll Nutr. 1991; 10: 38393. of Hypertension Study (PATHS): effects of an alcohol treatment S6. 2-84. Anderson CAM, Appel LJ, Okuda N, et al. Dietary sources of program on Blood Hypertension. Arch Intern Med. 1998; 158: 1197207. Sodium in China, Japan, the United Kingdom, and the United States, S6. 2-107. Rimm EB, Williams P, Fosher potassium, et al. Moderate alcohol intake and women and men aged 40 to 59 years: the INTERMAP study. J Am lower risk of coronary Heart disease: meta-analysis of effects on Diet Assoc. 2010; 110: 73645. lipids and haemostatic factors. BMJ. 1999; 319: 15238. S6. 2-85. Whelton PK, Appel LJ, Sacco RL, et al. Sodium, Blood presS6. 2-108. Mukamal KJ. Understanding the mechanisms that link alcohol and sure, and cardiovascular disease: further evidence supporting the lower risk of coronary Heart disease. Clin Chem. 2012; 58: 6646. American Heart Association Sodium reduction recommendations. S6. 2-109. Klatsky AL. Alcohol and cardiovascular mortality: common sense Circulation. 2012; 126: 28809. and scientific truth. J Am Coll Cardiol. 2010; 55: 13368. S6. 2-86. Cobb LK, Appel LJ, Anderson CAM. Strategies to reduce dietary S6. 2-110. Mukamal KJ, Chen CM, Rao SR, et al. Alcohol consumption and Sodium intake. Curr Treat Options Cardiovasc Med. 2012; 14: 42534. cardiovascular mortality among U. S. adults, 1987 to 2002. J Am S6. 2-87. McGuire S; Institute of Medicine. 2010. Strategies to Reduce Coll Cardiol. 2010; 55: 13285. Sodium Intake in the United States. Washington, DC: The National Academies Press. Adv Nutr; 2010. 4950. 7. Patient Evaluation S6. 2-88. He J, Tell GS, Tang YC, et al. Effect of migration on Blood Hypertension: the Yi People Study. Epidemiology. 1991; 2: 8897. 7. 1. Laboratory Tests and Other Diagnostic Procedures S6. 2-89. Stamler J. The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr. 1997; 65: 626S42S. S7. 1-1. Chang AR, Sang Y, Leddy J, et al. Antihypertensive medications S6. 2-90. Zhang Z, Cogswell ME, Gillespie C, et al. Association between and the prevalence of hyperkalemia in a large health system. usual Sodium and Potassium intake and Blood Hypertension and hyperHypertension.",
    "word_count": 593,
    "char_count": 3877,
    "sentence_count": 128,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 118,
      "total_chunks": 166,
      "position": "119/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "sodium",
        "potassium",
        "chloride",
        "diet",
        "antihypertensive",
        "hyperkalemia",
        "cardiovascular disease",
        "exercise",
        "screening"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 119,
    "text": "usual Sodium and Potassium intake and Blood Hypertension and hyperHypertension. 2016; 67: 11818. tension among U. S. adults: NHANES 20052010. PLoS ONE. 2013; 8: e75289. 7. 2. Cardiovascular Target Organ Damage S6. 2-91. Mente A, ODonnell MJ, Rangarajan S, et al. Association of uriS7. 2-1. Persu A, De Plaen J-F. Recent insights in the development of organ nary Sodium and Potassium excretion with Blood Hypertension. N Engl damage caused by hypertension. Acta Cardiol. 2004; 59: 36981. J Med. 2014; 371: 60111. S7. 2-2. Allen NB, Siddique J, Wilkins JT, et al. Blood Hypertension trajectories S6. 2-92. Kieneker LM, Gansevoort RT, Mukamal KJ, et al. Urinary potasin early adulthood and subclinical atherosclerosis in middle age. sium excretion and risk of developing hypertension: the prevenJAMA. 2014; 311: 4907. tion of renal and vascular end-stage disease study. Hypertension. S7. 2-3. Pletcher MJ, Bibbins-Domingo potassium, Lewis CE, et al. Prehypertension 2014; 64: 76976. during young adulthood and coronary calcium later in life. Ann S6. 2-93. Bazzano LA, He J, Ogden LG, et al. Dietary Potassium intake and Intern Med. 2008; 149: 919. risk of stroke in ultrasound men and women: National Health and Nutrition S7. 2-4. Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of Examination Survey I epidemiologic follow-up study. Stroke. child and adult elevated Blood Hypertension on subclinical atherosclero2001; 32: 147380. sis: the International Childhood Cardiovascular Cohort Consortium. S6. 2-94. Ascherio A, Rimm EB, Hernan MA, et al. Intake of Potassium, Circulation. 2013; 128: 21724. magnesium, calcium, and fiber and risk of stroke among ultrasound men. S7. 2-5. Santos M, Shah AM. Alterations in cardiac structure and function in Circulation. 1998; 98: 1198204. hypertension. Curr Hypertens Rep. 2014; 16: 428. S6. 2-95. Seth A, Mossavar-Rahmani Y, Kamensky V, et al. Potassium intake S7. 2-6. Devereux RB, Roman MJ. Left ventricular hypertrophy in hyperand risk of stroke in women with hypertension and nonhypertentension: stimuli, patterns, and consequences. Hypertens Res. sion in the Womens Health Initiative. Stroke. 2014; 45: 287480. 1999; 22: 19. S6. 2-96. DElia L, Barba G, Cappuccio FP, et al. Potassium intake, stroke, S7. 2-7. Gidding SS, Liu potassium, Colangelo LA, et al. Longitudinal determinants and cardiovascular disease a meta-analysis of prospective studies. J of left ventricular mass and geometry: the Coronary Artery Risk Am Coll Cardiol. 2011; 57: 12109. Development in Young Adults (CARDIA) Study. Circ Cardiovasc S6. 2-97. Bazzano LA, He J, Ogden LG, et al. Fruit and vegetable intake and Imaging. 2013; 6: 76975. risk of cardiovascular disease in ultrasound adults: the first National Health S7. 2-8. Fox ER, Musani SK, Samdarshi TE, et al. Clinical correlates and and Nutrition Examination Survey Epidemiologic Follow-up prognostic significance of change in standardized left ventricular Study. Am J Clin Nutr. 2002; 76: 939. mass in a community-based cohort of African Americans. J Am S6. 2-98. Gu D, Zhao Q, Chen J, et al. Reproducibility of Blood Hypertension Heart Assoc. 2015; 4: e001224. responses to dietary Sodium and Potassium interventions: the S7. 2-9. Lieb W, Xanthakis V, Sullivan LM, et al. Longitudinal tracking of GenSalt study. Hypertension. 2013; 62: 499505. left ventricular mass over the adult life course: clinical correlates S6. 2-99. Cook NR, Obarzanek E, Cutler JA, et al. Joint effects of Sodium of shortand long-term change in the framingham offspring study. and Potassium intake on subsequent cardiovascular disease: the Circulation. 2009; 119: 308592. Trials of Hypertension Prevention follow-up study. Arch Intern S7. 2-10. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five Med. 2009; 169: 3240. antihypertensive monotherapies and placebo for change in left venS6. 2-100. Whelton PK, Buring J, Borhani NO, et al.",
    "word_count": 598,
    "char_count": 3910,
    "sentence_count": 109,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 119,
      "total_chunks": 166,
      "position": "120/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "sodium",
        "potassium",
        "calcium",
        "magnesium",
        "nutrition",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 120,
    "text": "2-100. Whelton PK, Buring J, Borhani NO, et al. The effect of potastricular mass in patients receiving nutritional-hygienic therapy in sium supplementation in persons with a High-normal Blood presthe Treatment of Mild Hypertension Study (TOMHS). Circulation. sure. Results from phase I of the Trials of Hypertension Prevention 1995; 91: 698706. Downloaded from by on December 30, 2025 e90 Hypertension June 2018 S7. 2-11. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular individual data for one million adults in 61 prospective studies. mass by antihypertensive treatment: a meta-analysis of randomized Lancet. 2002; 360: 190313. comparative studies. Hypertension. 2009; 54: 108491. S8. 1. 1-7. Takashima N, Ohkubo T, Miura potassium, et al. Long-term risk of blood pressure values S7. 2-12. Norman JE Jr, Levy D. Improved electrocardiographic detecabove normal for cardiovascular mortality: a 24-year observation of tion of echocardiographic left ventricular hypertrophy: results of Japanese aged 30 to 92 years. J Hypertens. 2012; 30: 2299306. a correlated data base approach. J Am Coll Cardiol. 1995; 26: S8. 1. 1-8. Murakami Y. Meta-analyses using individual participant data from 10229. cardiovascular cohort studies in Japan: current status and future S7. 2-13. da Costa W, Riera ARP, Costa F de A, et al. Correlation of elecdirections. J Epidemiol. 2014; 24: 96101. trocardiographic left ventricular hypertrophy criteria with left S8. 1. 1-9. van Dieren S, Kengne AP, Chalmers J, et al. Effects of Blood presventricular mass by echocardiogram in obese hypertensive patients. sure lowering on cardiovascular outcomes in different cardiovascuJ Electrocardiol. 2008; 41: 7249. lar risk groups among participants with type 2 Diabetes. Diabetes S7. 2-14. Bacharova L, Schocken D, Estes EH, et al. The role of ECG in Res Clin Pract. 2012; 98: 8390. the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev. S8. 1. 1-10. Sundstrom J, Arima H, Woodward M, et al. Blood Hypertension 2014; 10: 25761. Lowering Treatment Trialists Collaboration. Blood Hypertension-LowS7. 2-15. Bang CN, Devereux RB, Okin PM. Regression of electrocardioering treatment based on cardiovascular risk: a meta-analysis of graphic left ventricular hypertrophy or strain is associated with individual patient data. Lancet. 2014; 384: 5918. lower incidence of cardiovascular morbidity and mortality in hyperS8. 1. 1-11. Turnbull F, Neal B, Algert C, et al. Effects of different Blood tensive patients independent of Blood Hypertension reductiona LIFE Hypertension-lowering regimens on major cardiovascular events in review. J Electrocardiol. 2014; 47: 6305. individuals with and without Diabetes mellitus: results of prospecS7. 2-16. Pewsner D, Juni P, Egger M, et al. Accuracy of electrocardiography tively designed overviews of randomized trials. Arch Intern Med. in diagnosis of left ventricular hypertrophy in arterial hypertension: 2005; 165: 14109. systematic review. BMJ. 2007; 335: 711. S8. 1. 1-12. Wang J-G, Staessen JA, Franklin SS, et al. Systolic and diastolic S7. 2-17. Rautaharju PM, Soliman EZ. Electrocardiographic left ventricular Blood Hypertension lowering as determinants of cardiovascular outhypertrophy and the risk of adverse cardiovascular events: a critical come. Hypertension. 2005; 45: 90713. appraisal. J Electrocardiol. 2014; 47: 64954. S8. 1. 1-13. Turnbull F, Woodward M, Neal B, et al. Do men and women S7. 2-18. Armstrong before meals, Gidding S, Gjesdal O, et al. LV mass assessed by respond differently to Blood Hypertension-lowering treatment? Results echocardiography and CMR, cardiovascular outcomes, and medical of prospectively designed overviews of randomized trials. Eur practice. J Am Coll Cardiol Img. 2012; 5: 83748. Heart J. 2008; 29: 266980. S7. 2-19. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideS8. 1. 1-14. Turnbull F, Neal B, Ninomiya T, et al.",
    "word_count": 580,
    "char_count": 3909,
    "sentence_count": 101,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 120,
      "total_chunks": 166,
      "position": "121/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "potassium",
        "antihypertensive"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 121,
    "text": "2010 ACCF/AHA guideS8. 1. 1-14. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regiline for assessment of cardiovascular risk in asymptomatic adults: a mens to lower Blood Hypertension on major cardiovascular events in report of the American College of Cardiology Foundation/American older and younger adults: meta-analysis of randomised trials. BMJ. Heart Association Task Force on Practice Guidelines. Circulation. 2008; 336: 11213. 2010; 122: e584636. S8. 1. 1-15. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events S7. 2-20. Devereux RB, Wachtell potassium, Gerdts E, et al. Prognostic significance and effects of routine Blood Hypertension lowering among patients with of left ventricular mass change during treatment of hypertension. type 2 Diabetes and atrial fibrillation: results of the ADVANCE JAMA. 2004; 292: 23506. study. Eur Heart J. 2009; 30: 112835. S7. 2-21. Armstrong before meals, Jacobs DR Jr, Gidding SS, et al. Framingham score S8. 1. 1-16. Czernichow S, Ninomiya T, Huxley R, et al. Impact of Blood presand LV mass predict events in young adults: CARDIA study. Int J sure lowering on cardiovascular outcomes in normal weight, overCardiol. 2014; 172: 3505. weight, and obese individuals: the Perindopril Protection Against S7. 2-22. Okwuosa TM, Soliman EZ, Lopez F, et al. Left ventricular hypertroRecurrent Stroke Study trial. Hypertension. 2010; 55: 11938. phy and cardiovascular disease risk prediction and reclassification in S8. 1. 1-17. Heerspink HJL, Ninomiya T, Perkovic V, et al. Effects of a fixed blacks and whites: the Atherosclerosis Risk in Communities Study. combination of perindopril and indapamide in patients with type 2 Am Heart J. 2015; 169: 15561. Diabetes and chronic Kidney disease. Eur Heart J. 2010; 31: 288896. S7. 2-23. Zalawadiya SK, Gunasekaran after meals, Bavishi CP, et al. Left ventricular S8. 1. 1-18. Ninomiya T, Zoungas S, Neal B, et al. Efficacy and safety of rouhypertrophy and risk reclassification for coronary events in multitine Blood Hypertension lowering in older patients with Diabetes: results ethnic adults. Eur J Prev Cardiol. 2015; 22: 6739. from the ADVANCE trial. J Hypertens. 2010; 28: 11419. S8. 1. 1-19. Collier DJ, Poulter NR, Dahlof B, et al. Impact of amlodipine8. Treatment of High blood pressure based therapy among older and younger patients in the AngloScandinavian Cardiac Outcomes Trial-Blood Hypertension Lowering 8. 1. Pharmacological Treatment Arm (ASCOT-BPLA). J Hypertens. 2011; 29: 58391. S8. 1. 1-20. Ninomiya T, Perkovic V, Turnbull F, et al. Blood Hypertension lowering and 8. 1. 1. Initiation of Pharmacological blood pressure Treatment in the major cardiovascular events in people with and without chronic Kidney Context of Overall cardiovascular disease Risk disease: meta-analysis of randomised controlled trials. Blood Hypertension Lowering Treatment Trialists Collaboration. BMJ. 2013; 347: f5680. S8. 1. 1-1. Lloyd-Jones diabetes mellitus, Evans JC, Levy D. Hypertension in adults across S8. 1. 1-21. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of Low the age spectrum: current outcomes and control in the community. Blood pressures among patients with Diabetes: subgroup analyses JAMA. 2005; 294: 46672. from the ONTARGET (ONgoing Telmisartan Alone and in comS8. 1. 1-2. Ozyilmaz A, Bakker SJL, de Zeeuw D, et al. Screening for albubination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. minuria with subsequent screening for hypertension and hypercho2012; 59: 7483. lesterolaemia identifies subjects in whom treatment is warranted to S8. 1. 1-22. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of prevent cardiovascular events. Nephrol Dial Transplant. 2013; 28: lowering Blood Hypertension in hypertensive patients according to the 280515. JNC VI risk stratification. Hypertension. 2000; 35: 53943. S8. 1. 1-3. Peters SAE, Huxley respiratory rate, Woodward M. Comparison of the sexS8.",
    "word_count": 600,
    "char_count": 3955,
    "sentence_count": 108,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 121,
      "total_chunks": 166,
      "position": "122/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "cardiovascular disease",
        "screening"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 122,
    "text": "Hypertension. 2000; 35: 53943. S8. 1. 1-3. Peters SAE, Huxley respiratory rate, Woodward M. Comparison of the sexS8. 1. 1-23. van der Leeuw J, Visseren FLJ, Woodward M, et al. Predicting the specific associations between systolic Blood Hypertension and the risk effects of Blood Hypertension-lowering treatment on major cardiovascular of cardiovascular disease: a systematic review and meta-analysis events for individual patients with type 2 Diabetes mellitus: results of 124 cohort studies, including 1. 2 million individuals. Stroke. from Action in Diabetes and Vascular Disease: Preterax and Diamicron 2013; 44: 2394401. MR Controlled Evaluation. Hypertension. 2015; 65: 11521. S8. 1. 1-4. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with 8. 1. 2. blood pressure Treatment Threshold and the Use SLE: a systematic review. Semin Arthritis Rheum. 2013; 43: of cardiovascular disease Risk Estimation to Guide Drug Treatment 7795. S8. 1. 1-5. Lawes CMM, Bennett DA, Lewington S, et al. Blood Hypertension and of Hypertension coronary Heart disease: a review of the evidence. Semin Vasc Med. S8. 1. 2-1. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowering 2002; 2: 35568. drugs in the prevention of cardiovascular disease: meta-analysis of S8. 1. 1-6. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance 147 randomised trials in the context of expectations from prospecof usual Blood Hypertension to vascular mortality: a meta-analysis of tive epidemiological studies. BMJ. 2009; 338: b1665. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e91 S8. 1. 2-2. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for S8. 1. 2-23. Muntner P, Whelton PK. Using predicted cardiovascular disease prevention of cardiovascular disease and death: a systematic review risk in conjunction with Blood Hypertension to guide antihypertensive and meta-analysis. Lancet. 2016; 387: 95767. medication treatment. J Am Coll Cardiol. 2017; 69: 244656. S8. 1. 2-3. Sundstrom J, Arima H, Woodward M, et al. Blood Hypertension S8. 1. 2-24. Sussman J, Vijan S, Hayward R. Using benefit-based tailored Lowering Treatment Trialists Collaboration. Blood Hypertension-Lowtreatment to improve the use of antihypertensive medications. ering treatment based on cardiovascular risk: a meta-analysis of Circulation. 2013; 128: 230917. individual patient data. Lancet. 2014; 384: 5918. S8. 1. 2-25. van der Leeuw J, Ridker PM, van der Graaf Y, et al. Personalized S8. 1. 2-4. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension cardiovascular disease prevention by applying individualized prelowering on outcome incidence in hypertension: 2. Effects at differdiction of treatment effects. Eur Heart J. 2014; 35: 83743. ent baseline and achieved Blood Hypertension levelsoverview and metaS8. 1. 2-26. Mendis S, Lindholm LH, Mancia G, et al. World Health analyses of randomized trials. J Hypertens. 2014; 32: 2296304. Organization (WHO) and International Society of Hypertension S8. 1. 2-5. Sundstrom J, Arima H, Jackson R, et al. Effects of Blood Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for reduction in mild hypertension: a systematic review and meta-analprevention and control of cardiovascular disease in Low and middleysis. Ann Intern Med. 2015; 162: 18491. income countries. J Hypertens. 2007; 25: 157882. S8. 1. 2-6. Thompson AM, Hu T, Eshelbrenner chloride, et al. Antihypertensive S8. 1. 2-27. van Dis I, Geleijnse JM, Verschuren WMM, et al. Cardiovascular treatment and secondary prevention of cardiovascular disease risk management of hypertension and hypercholesterolaemia in events among persons without hypertension: a meta-analysis. the Netherlands: from unifactorial to multifactorial approach. Neth JAMA. 2011; 305: 91322. Heart J. 2012; 20: 3205. S8. 1. 2-7. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension S8. 1. 2-28.",
    "word_count": 597,
    "char_count": 4038,
    "sentence_count": 113,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 122,
      "total_chunks": 166,
      "position": "123/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "calcium",
        "chloride",
        "antihypertensive",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 123,
    "text": "S8. 1. 2-7. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension S8. 1. 2-28. Nelson MR, Doust JA. Primary prevention of cardiovascular dislowering on cardiovascular and renal outcomes: updated systematic ease: new guidelines, technologies and therapies. Med J Aust. review and meta-analysis. Lancet. 2016; 387: 43543. 2013; 198: 60610. S8. 1. 2-8. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized S8. 1. 2-29. JBS3 Board. Joint British Societies consensus recommendatrial of intensive versus standard Blood-Hypertension control. SPRINT tions for the prevention of cardiovascular disease (JBS3). Heart. Research Group. N Engl J Med. 2015; 373: 210316. 2014; 100(suppl 2): ii167. S8. 1. 2-9. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of Blood S8. 1. 2-30. World Health Organization. Prevention of Cardiovascular Disease. Hypertension reduction and of different Blood Hypertension-lowering Guidelines for Assessment and Management of Cardiovascular regimens on major cardiovascular events according to baseline Risk. Geneva, Switzerland: World Health Organization; 2007. Blood Hypertension: meta-analysis of randomized trials. J Hypertens. S8. 1. 2-31. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement 2011; 29: 416. on cost/value methodology in clinical practice guidelines and perforS8. 1. 2-10. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance mance measures: a report of the American College of Cardiology/ of usual Blood Hypertension to vascular mortality: a meta-analysis of American Heart Association Task Force on Performance Measures and individual data for one million adults in 61 prospective studies. Task Force on Practice Guidelines. Circulation. 2014; 129: 232945. Lancet. 2002; 360: 190313. S8. 1. 2-32. Sheridan SL, Crespo E. Does the routine use of global coronary S8. 1. 2-11. van Dieren S, Kengne AP, Chalmers J, et al. Effects of Blood presHeart disease risk scores translate into clinical benefits or harms? sure lowering on cardiovascular outcomes in different cardiovascuA systematic review of the literature. BMC Health Serv Res. lar risk groups among participants with type 2 Diabetes. Diabetes 2008; 8: 60. Res Clin Pract. 2012; 98: 8390. S8. 1. 2-33. Sheridan SL, Viera AJ, Krantz MJ, et al. The effect of giving global S8. 1. 2-12. Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of coronary risk information to adults: a systematic review. Arch absolute cardiovascular risk, patient utilities, and costs on the deciIntern Med. 2010; 170: 2309. sion to treat hypertension: a Markov decision analysis. J Hypertens. S8. 1. 2-34. Viera AJ, Sheridan SL. Global risk of coronary Heart disease: 2003; 21: 17539. assessment and application. Am Fam Physician. 2010; 82: 26574. S8. 1. 2-13. Kassai B, Boissel J-P, Cucherat M, et al. Treatment of High Blood S8. 1. 2-35. Sheridan SL, Draeger LB, Pignone MP, et al. A randomized trial Hypertension and gain in event-free life expectancy. Vasc Health Risk of an intervention to improve use and adherence to effective coroManag. 2005; 1: 1639. nary Heart disease prevention strategies. BMC Health Serv Res. S8. 1. 2-13a. ACC/AHA Pooled Cohort Equations. Available at: ( 2011; 11: 331. org/ASCVD-Risk-Estimator/. Accessed November 3, 2017. S8. 1. 2-36. Brett T, Arnold-Reed D, Phan C, et al. The Fremantle Primary S8. 1. 2-14. Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the Prevention Study: a multicentre randomised trial of absolute carburden of cardiovascular disease attributable to modifiable risk facdiovascular risk reduction. Br J Gen Pract. 2012; 62: e228. tors and cost-effectiveness analysis of preventative interventions to S8. 1. 2-37. Sekaran NK, Sussman JB, Xu A, et al. Providing clinicians with a reduce this burden in Argentina. BMC Public Health. 2010; 10: 627. patients 10-year cardiovascular risk improves their statin prescribS8. 1. 2-15.",
    "word_count": 599,
    "char_count": 3930,
    "sentence_count": 126,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 123,
      "total_chunks": 166,
      "position": "124/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "cardiovascular disease",
        "adherence"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 124,
    "text": "BMC Public Health. 2010; 10: 627. patients 10-year cardiovascular risk improves their statin prescribS8. 1. 2-15. Baker S, Priest P, Jackson R. Using thresholds based on risk of caring: a true experiment using clinical vignettes. BMC Cardiovasc diovascular disease to target treatment for hypertension: modelling Disord. 2013; 13: 90. events averted and number treated. BMJ. 2000; 320: 6805. S8. 1. 2-38. Sheridan SL, Draeger LB, Pignone MP, et al. The effect of a deciS8. 1. 2-16. Gaziano TA, Steyn potassium, Cohen DJ, et al. Cost-effectiveness analysis sion aid intervention on decision making about coronary Heart disof hypertension guidelines in South Africa: absolute risk versus ease risk reduction: secondary analyses of a randomized trial. BMC Blood Hypertension level. Circulation. 2005; 112: 356976. Med Inform Decis Mak. 2014; 14: 14. S8. 1. 2-17. Eddy diabetes mellitus, Adler J, Patterson B, et al. Individualized guidelines: S8. 1. 2-39. Jansen J, Bonner C, McKinn S, et al. General practitioners use of the potential for increasing quality and reducing costs. Ann Intern absolute risk versus individual risk factors in cardiovascular disease Med. 2011; 154: 62734. prevention: an experimental study. BMJ Open. 2014; 4: e004812. S8. 1. 2-18. Marchant I, Nony P, Cucherat M, et al. The global risk approach S8. 1. 2-40. Vagholkar S, Zwar N, Jayasinghe UW, et al. Influence of cardiovasshould be better applied in French hypertensive patients: a comcular absolute risk assessment on prescribing of antihypertensive parison between simulation and observation studies. PLoS ONE. and lipid-lowering medications: a cluster randomized controlled 2011; 6: e17508. trial. Am Heart J. 2014; 167: 2835. S8. 1. 2-19. Cadilhac DA, Carter R, Thrift AG, et al. Organized Blood Hypertension S8. 1. 2-41. Rafter N, Connor J, Hall J, et al. Cardiovascular medications in control programs to prevent stroke in Australia: would they be costprimary care: treatment gaps and targeting by absolute risk. N Z effective? Stroke. 2012; 43: 13705. Med J. 2005; 118: U1676. S8. 1. 2-20. Cobiac LJ, Magnus A, Barendregt JJ, et al. Improving the costS8. 1. 2-42. Yong TY, Phillipov G, Phillips PJ. Management outcomes of effectiveness of cardiovascular disease prevention in Australia: a patients with type 2 Diabetes: targeting the 10-year absolute risk of modelling study. BMC Public Health. 2012; 12: 398. coronary Heart disease. Med J Aust. 2007; 186: 6224. S8. 1. 2-21. Cobiac LJ, Magnus A, Lim S, et al. Which interventions offer best S8. 1. 2-43. Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular disvalue for money in primary prevention of cardiovascular disease? ease risk management in Australian general practice. Med J Aust. PLoS ONE. 2012; 7: e41842. 2009; 191: 3249. S8. 1. 2-22. Karmali KN, Lloyd-Jones diabetes mellitus. Global risk assessment to guide S8. 1. 2-44. Frikke-Schmidt R, Tybjærg-Hansen A, Schnohr P, et al. Common Blood Hypertension management in cardiovascular disease prevention. clinical practice versus new PRIM score in predicting coronary Hypertension. 2017; 69: e29. Heart disease risk. Atherosclerosis. 2010; 213: 5328. Downloaded from by on December 30, 2025 e92 Hypertension June 2018 S8. 1. 2-45. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk percepS8. 1. 3-3. Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertion and evidencepractice gaps in Australian general practice (the tension incidence among middle-aged and older adults: the MultiAusHEART study). Med J Aust. 2010; 192: 2549. Ethnic study of Atherosclerosis. Hypertension. 2011; 57: 11017. S8. 1. 2-46. Shillinglaw B, Viera AJ, Edwards T, et al. Use of global coronary Heart disease risk assessment in practice: a cross-sectional survey 8. 1. 4. General Principles of Drug Therapy of a sample of U. S. physicians.",
    "word_count": 597,
    "char_count": 3841,
    "sentence_count": 127,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 124,
      "total_chunks": 166,
      "position": "125/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 125,
    "text": "1. 4. General Principles of Drug Therapy of a sample of U. S. physicians. BMC Health Serv Res. 2012; 12: 20. S8. 1. 4-1. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in S8. 1. 2-47. Game FL, Bartlett WA, Bayly GR, et al. Comparative accuracy of patients at High risk for vascular events. ONTARGET Investigators. cardiovascular risk prediction methods in patients with Diabetes N Engl J Med. 2008; 358: 154759. mellitus. Diabetes Obes Metab. 2001; 3: 27986. S8. 1. 4-2. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end S8. 1. 2-48. Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prepoints in a trial of aliskiren for type 2 Diabetes. N Engl J Med. diction rule is not valid in a European population of treated hyper2012; 367: 220413. tensive patients. J Hypertens. 2002; 20: 197380. S8. 1. 4-3. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin S8. 1. 2-49. Menotti A, Puddu physical examination, Lanti M. The estimate of cardiovascular risk. inhibition for the treatment of diabetic nephropathy. N Engl J Med. Theory, tools and problems. Ann Ital Med Int. 2002; 17: 8194. 2013; 369: 1892903. S8. 1. 2-50. de Visser chloride, Bilo HJG, Thomsen TF, et al. Prediction of coronary S8. 1. 4-4. Effects of treatment on morbidity in hypertension. Results in Heart disease: a comparison between the Copenhagen risk score patients with diastolic Blood pressures averaging 115 through 129 and the Framingham risk score applied to a Dutch population. J mm Hg. JAMA. 1967; 202: 102834. Intern Med. 2003; 253: 55362. S8. 1. 4-5. Five-year findings of the hypertension detection and follow-up proS8. 1. 2-51. Persson M, Carlberg B, Weinehall L, et al. Risk stratification by gram. I. Reduction in mortality of persons with High Blood presguidelines compared with risk assessment by risk equations applied sure, including mild hypertension. Hypertension Detection and to a MONICA sample. J Hypertens. 2003; 21: 108995. Follow-up Program Cooperative Group. JAMA. 1979; 242: 256271. S8. 1. 2-52. Doust J, Sanders S, Shaw J, et al. Prioritising cardiovascular disease prevention S8. 1. 4-6. Prevention of stroke by antihypertensive drug treatment in older therapyabsolute risk versus individual risk factors. Aust Fam persons with isolated systolic hypertension. Final results of the Physician. 2012; 41: 8059. Systolic Hypertension in the Elderly Program (SHEP). SHEP S8. 1. 2-53. Allan GM, Nouri F, Korownyk C, et al. Agreement among cardioCooperative Research Group. JAMA. 1991; 265: 325564. vascular disease risk calculators. Circulation. 2013; 127: 194856. S8. 1. 4-7. Kostis JB, Cabrera J, Cheng JQ, et al. Association between S8. 1. 2-54. Diverse Populations Collaborative Group. Prediction of mortality chlorthalidone treatment of systolic hypertension and long-term from coronary Heart disease among diverse populations: is there a survival. JAMA. 2011; 306: 258893. common predictive function? Heart. 2002; 88: 2228. S8. 1. 4-8. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowering S8. 1. 2-55. van den Hoogen after meals, Feskens EJ, Nagelkerke NJ, et al. The relation drugs in the prevention of cardiovascular disease: meta-analysis of between Blood Hypertension and mortality due to coronary Heart disease 147 randomised trials in the context of expectations from prospecamong men in different parts of the world. Seven Countries Study tive epidemiological studies. BMJ. 2009; 338: b1665. Research Group. N Engl J Med. 2000; 342: 18. S8. 1. 4-9. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension S8. 1. 2-56. Goff DC Jr, Lloyd-Jones diabetes mellitus, Bennett G, et al. 2013 ACC/AHA lowering on outcome incidence in hypertension: 2.",
    "word_count": 587,
    "char_count": 3709,
    "sentence_count": 132,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 125,
      "total_chunks": 166,
      "position": "126/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "nephropathy",
        "chloride",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 126,
    "text": "2-56. Goff DC Jr, Lloyd-Jones diabetes mellitus, Bennett G, et al. 2013 ACC/AHA lowering on outcome incidence in hypertension: 2. Effects at differguideline on the assessment of cardiovascular risk: a report of the ent baseline and achieved Blood Hypertension levelsoverview and metaAmerican College of Cardiology/American Heart Association Task analyses of randomized trials. J Hypertens. 2014; 32: 2296304. Force on Practice Guidelines. Circulation. 2014; 129(suppl 2): S4973. S8. 1. 4-10. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of Blood S8. 1. 2-57. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Hypertension reduction and of different Blood Hypertension-lowering regimens guideline on the treatment of Blood cholesterol to reduce atheroon major cardiovascular events according to baseline Blood Hypertension: sclerotic cardiovascular risk in adults: a report of the American meta-analysis of randomized trials. J Hypertens. 2011; 29: 416. College of Cardiology/American Heart Association Task Force on S8. 1. 4-11. Fretheim A, Odgaard-Jensen J, Brors O, et al. Comparative effecPractice Guidelines. Circulation. 2014; 129(suppl 2): S145. tiveness of antihypertensive medication for primary prevention of S8. 1. 2-58. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood prescardiovascular disease: systematic review and multiple treatments sure lowering on outcome incidence in hypertension: 3. Effects meta-analysis. BMC Med. 2012; 10: 33. in patients at different levels of cardiovascular riskoverview and S8. 1. 4-12. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors meta-analyses of randomized trials. J Hypertens. 2014; 32: 230514. of Blood Hypertension control in diverse North American settings: S8. 1. 2-59. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prethe Antihypertensive and Lipid-Lowering Treatment to Prevent hypertension with an angiotensin-receptor blocker. N Engl J Med. Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2006; 354: 168597. 2002; 4: 393404. S8. 1. 2-60. Julius S, Kaciroti N, Egan BM, et al. TROPHY study: outcomes S8. 1. 4-13. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in based on the Seventh Report of the Joint National Committee on hypertension. J Clin Hypertens (Greenwich). 2011; 13: 14654. Hypertension definition of hypertension. J Am Soc Hypertens. S8. 1. 4-14. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive 2008; 2: 3943. Blood-Hypertension control in type 2 Diabetes mellitus. ACCORD Study S8. 1. 2-61. Luders S, Schrader J, Berger J, et al. The PHARAO study: preGroup. N Engl J Med. 2010; 362: 157585. vention of hypertension with the angiotensin-converting enzyme S8. 1. 4-15. Chobanian AV, Bakris GL, Black heart rate, et al; the National High inhibitor ramipril in patients with High-normal Blood Hypertension: a Blood Hypertension Education Program Coordinating Committee. prospective, randomized, controlled prevention trial of the German Seventh Report of the Joint National Committee on Prevention, Hypertension League. J Hypertens. 2008; 26: 148796. Detection, Evaluation, and Treatment of Hypertension. S8. 1. 2-62. Fuchs SC, Poli-de-Figueiredo CE, Figueiredo Neto JA, et al. Hypertension. 2003; 42: 120652. Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER Prevention Randomized Clinical Trial. 8. 1. 5. blood pressure Goal for Patients With Hypertension J Am Heart Assoc. 2016; 5: e004248. S8. 1. 5-1. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension S8. 1. 2-63. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-Hypertension lowerlowering on outcome incidence in hypertension: 7. Effects of more ing in intermediate-risk persons without cardiovascular disease. N vs. less intensive Blood Hypertension lowering and different achieved Engl J Med. 2016; 374: 200920. Blood Hypertension levelsupdated overview and meta-analyses of randomized trials. J Hypertens. 2016; 34: 61322. 8. 1. 3. Follow-Up After Initial blood pressure Evaluation S8. 1. 5-2.",
    "word_count": 596,
    "char_count": 4083,
    "sentence_count": 115,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 126,
      "total_chunks": 166,
      "position": "127/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "antihypertensive",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 127,
    "text": "J Hypertens. 2016; 34: 61322. 8. 1. 3. Follow-Up After Initial blood pressure Evaluation S8. 1. 5-2. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension S8. 1. 3-1. Ambrosius weight, Sink KM, Foy CG, et al. The design and rationale lowering on cardiovascular and renal outcomes: updated systematic of a multicenter clinical trial comparing two strategies for control review and meta-analysis. Lancet. 2016; 387: 43543. of systolic Blood Hypertension: the Systolic Blood Hypertension Intervention S8. 1. 5-3. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive Trial (SPRINT). Clin Trials. 2014; 11: 53246. Blood Hypertension-lowering strategy: cumulative evidence and trial S8. 1. 3-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and sequential analysis. Hypertension. 2016; 68: 64253. design for the Blood Hypertension intervention of the Action to Control S8. 1. 5-4. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic Blood presCardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. sure target after SPRINT: insights from a network meta-analysis of 2007; 99: 44i55i. randomized trials. Am J Med. 2017; 30: 70719. e8. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e93 S8. 1. 5-5. Bundy JD, Li C, Stuchlik P, et al. Systolic Blood Hypertension reducS8. 1. 6-7. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure tion and risk of cardiovascular disease and mortality: a systematic prevalence, incidence, and mortality in the elderly with Diabetes. review and network meta-analysis. JAMA Cardiol. 2017; 2: 77581. Diabetes Care. 2004; 27: 699703. S8. 1. 5-6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating preS8. 1. 6-8. Ogedegbe G, Shah NR, Phillips C, et al. Comparative effectivehypertension with an angiotensin-receptor blocker. N Engl J Med. ness of angiotensin-converting enzyme inhibitor-based treatment 2006; 354: 168597. on cardiovascular outcomes in hypertensive blacks versus whites. S8. 1. 5-7. Lawes CMM, Bennett DA, Lewington S, et al. Blood Hypertension and J Am Coll Cardiol. 2015; 66: 122433. coronary Heart disease: a review of the evidence. Semin Vasc Med. S8. 1. 6-9. Leenen FHH, Nwachuku CE, Black heart rate, et al. Clinical events 2002; 2: 35568. in High-risk hypertensive patients randomly assigned to calcium S8. 1. 5-8. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-Hypertension lowerchannel blocker versus angiotensin-converting enzyme inhibitor ing in intermediate-risk persons without cardiovascular disease. in the Antihypertensive and Lipid-Lowering Treatment to Prevent N Engl J Med. 2016; 374: 200920. Heart Attack Trial. Hypertension. 2006; 48: 37484. S8. 1. 5-9. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild S8. 1. 6-10. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Hypertension Study. Final results. Treatment of Mild Hypertension Attack Trial Collaborative Research Group. Diuretic versus alphaStudy Research Group. JAMA. 1993; 270: 71324. blocker as first-step antihypertensive therapy: final results from S8. 1. 5-10. Reboussin diabetes mellitus, Allen NB, Griswold ME, et al. Systematic review for the Antihypertensive and Lipid-Lowering Treatment to Prevent the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ Heart Attack Trial (ALLHAT). Hypertension. 2003; 42: 23946. NMA/PCNA guideline for the prevention, detection, evaluation, and S8. 1. 6-11. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowering management of Hypertension in adults: a report of the American drugs in the prevention of cardiovascular disease: meta-analysis of College of Cardiology/American Heart Association Task Force on 147 randomised trials in the context of expectations from prospecClinical Practice Guidelines. Hypertension. 2018; 71: e116e135. tive epidemiological studies. BMJ. 2009; 338: b1665. S8. 1. 5-11. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at S8. 1. 6-12. Thomopoulos C, Parati G, Zanchetti A.",
    "word_count": 597,
    "char_count": 4023,
    "sentence_count": 121,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 127,
      "total_chunks": 166,
      "position": "128/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "calcium",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 128,
    "text": "1. 5-11. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at S8. 1. 6-12. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertensiondifferent Blood Hypertension levels in patients with Diabetes mellitus: lowering on outcome incidence in hypertension: 5. Head-to-head systematic review and meta-analyses. BMJ. 2016; 352: i717. comparisons of various classes of antihypertensive drugs-overS8. 1. 5-12. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for view and meta-analyses. J Hypertens. 2015; 33: 132141. prevention of cardiovascular disease and death: a systematic review S8. 1. 6-13. Zhang Y, Sun N, Jiang X, et al. Comparative efficacy of β-blockers and meta-analysis. Lancet. 2016; 387: 95767. on mortality and cardiovascular outcomes in patients with hyperS8. 1. 5-13. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive Blood prestension: a systematic review and network meta-analysis. J Am sure lowering on the progression of chronic Kidney disease: a sysSoc. Hypertens. 2017; 11: 394401. tematic review and meta-analysis. CMAJ. 2013; 185: 94957. S8. 1. 6-14. Larochelle P, Tobe SW, Lacourciere Y. β-Blockers in hypertenS8. 1. 5-14. Cushman WC, Evans GW, Byington RP, et al. Effects of intension: studies and meta-analyses over the years. Can J Cardiol. sive Blood-Hypertension control in type 2 Diabetes mellitus. ACCORD 2014; 30: S1622. Study. N Engl J Med. 2010; 362: 157585. S8. 1. 5-15. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized 8. 1. 6. 1. Choice of Initial Monotherapy Versus Initial trial of intensive versus standard Blood-Hypertension control. SPRINT Combination Drug Therapy Research Group. N Engl J Med. 2015; 373: 210316. S8. 1. 6. 1-1. Chobanian AV, Bakris GL, Black heart rate, et al; the National High S8. 1. 5-16. SPS3 Study Group. Blood-Hypertension targets in patients with recent Blood Hypertension Education Program Coordinating Committee. lacunar stroke: the SPS3 randomised trial. Lancet. 2013; 382: 50715. Seventh Report of the Joint National Committee on Prevention, S8. 1. 5-17. Perkovic V, Rodgers A. Redefining Blood-Hypertension targetsSPRINT Detection, Evaluation, and Treatment of Hypertension. starts the marathon. N Engl J Med. 2015; 373: 21758. Hypertension. 2003; 42: 120652. S8. 1. 5-18. Lawes CMM, Rodgers A, Bennett DA, et al. Blood Hypertension and S8. 1. 6. 1-2. Law MR, Wald NJ, Morris JK, et al. Value of Low dose combinacardiovascular disease in the Asia Pacific region. J Hypertens. tion treatment with Blood Hypertension lowering drugs: analysis of 354 2003; 21: 70716. randomised trials. BMJ. 2003; 326: 1427. S8. 1. 5-19. Allen NB, Siddique J, Wilkins JT, et al. Blood Hypertension trajectories S8. 1. 6. 1-3. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose comin early adulthood and subclinical atherosclerosis in middle age. binations improve medication compliance: a meta-analysis. Am J JAMA. 2014; 311: 4907. Med. 2007; 120: 7139. S8. 1. 5-20. Ference BA, Julius S, Mahajan N, et al. Clinical effect of naturally S8. 1. 6. 1-4. Jamerson potassium, Weber MA, Bakris GL, et al. Benazepril plus random allocation to lower systolic Blood Hypertension beginning before amlodipine or hydrochlorothiazide for hypertension in High-risk the development of hypertension. Hypertension. 2014; 63: 11828. patients. N Engl J Med. 2008; 359: 241728. S8. 1. 6. 1-5. Sundstrom J, Arima H, Jackson R, et al. Effects of Blood Hypertension 8. 1. 6. Choice of Initial Medication reduction in mild hypertension: a systematic review and metaS8. 1. 6-1. Reboussin diabetes mellitus, Allen NB, Griswold ME, et al. Systematic review for analysis. Ann Intern Med. 2015; 162: 18491. the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ S8. 1. 6. 1-6. Luders S, Schrader J, Berger J, et al.",
    "word_count": 582,
    "char_count": 3797,
    "sentence_count": 142,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 128,
      "total_chunks": 166,
      "position": "129/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "calcium",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 129,
    "text": "2015; 162: 18491. the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ S8. 1. 6. 1-6. Luders S, Schrader J, Berger J, et al. The PHARAO study: preNMA/PCNA guideline for the prevention, detection, evaluation, and vention of hypertension with the angiotensin-converting enzyme management of Hypertension in adults: a report of the American inhibitor ramipril in patients with High-normal Blood Hypertension: College of Cardiology/American Heart Association Task Force on a prospective, randomized, controlled prevention trial of the Clinical Practice Guidelines. Hypertension. 2018; 71: e116e135. German Hypertension League. J Hypertens. 2008; 26: 148796. S8. 1. 6-2. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes assoS8. 1. 6. 1-7. Report of the Joint National Committee on Detection, Evaluation, ciated with various antihypertensive therapies used as first-line and Treatment of Hypertension. A cooperative study. agents: a network meta-analysis. JAMA. 2003; 289: 253444. JAMA. 1977; 237: 25561. S8. 1. 6-3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in High-risk hypertensive patients 8. 2. Achieving blood pressure Control in Individual Patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and LipidS8. 2-1. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension Study. Final results. Treatment of Mild Hypertension JAMA. 2002; 288: 298197. Study Research Group. JAMA. 1993; 270: 71324. S8. 1. 6-4. Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, S8. 2-2. Senn S. Individual response to treatment: is it a valid assumption? Medicare charges, and nursing home admissions in the year when BMJ. 2004; 329: 9668. older persons become severely disabled. JAMA. 1997; 277: 72834. S8. 1. 6-5. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and preva8. 3. Follow-Up of blood pressure During Antihypertensive lence of Heart failure in elderly persons, 19942003. Arch Intern Drug Therapy Med. 2008; 168: 41824. S8. 1. 6-6. Bleumink GS, Knetsch AM, Sturkenboom MCJM, et al. S8. 3-1. Ambrosius weight, Sink KM, Foy CG, et al. The design and ratioQuantifying the Heart failure epidemic: prevalence, incidence rate, nale of a multicenter clinical trial comparing two strategies for lifetime risk and prognosis of Heart failure The Rotterdam Study. control of systolic Blood Hypertension: the Systolic Blood Hypertension Eur Heart J. 2004; 25: 16149. Intervention Trial (SPRINT). Clin Trials. 2014; 11: 53246. Downloaded from by on December 30, 2025 e94 Hypertension June 2018 S8. 3-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and 9. 1. Stable Ischemic Heart Disease design for the Blood Hypertension intervention of the Action to Control S9. 1-1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. trial of intensive versus standard Blood-Hypertension control. SPRINT 2007; 99: 44i55i. Research Group. N Engl J Med. 2015; 373: 210316. S9. 1-2. Bundy JD, Li C, Stuchlik P, et al. Systolic Blood Hypertension reduc8. 3. 1. Follow-Up After Initiating Antihypertensive tion and risk of cardiovascular disease and mortality: a systematic Drug Therapy review and network meta-analysis. JAMA Cardiol. 2017; 2: 77581. S8. 3. 1-1. Ambrosius weight, Sink KM, Foy CG, et al. The design and rationale S9. 1-3. Leenen FHH, Nwachuku CE, Black heart rate, et al. Clinical events in of a multicenter clinical trial comparing two strategies for control High-risk hypertensive patients randomly assigned to calcium of systolic Blood Hypertension: the Systolic Blood Hypertension Intervention channel blocker versus angiotensin-converting enzyme inhibitor in Trial (SPRINT). Clin Trials. 2014; 11: 53246. the antihypertensive and lipid-lowering treatment to prevent Heart S8. 3. 1-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and attack trial. Hypertension.",
    "word_count": 600,
    "char_count": 4043,
    "sentence_count": 115,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 129,
      "total_chunks": 166,
      "position": "130/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "calcium",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "blood pressure control",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 130,
    "text": "3. 1-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and attack trial. Hypertension. 2006; 48: 37484. design for the Blood Hypertension intervention of the Action to Control S9. 1-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. of hypertensive patients treated with regimens based on valsartan 2007; 99: 44i55i. and amlodipine: an analysis of findings from the VALUE trial. J S8. 3. 1-3. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic Blood presHypertens. 2006; 24: 21638. sure target, time to intensification, and time to follow-up in treatS9. 1-5. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ment of hypertension: population based retrospective cohort study. Attack Trial Collaborative Research Group. Diuretic versus alphaBMJ. 2015; 350: h158. blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 8. 3. 2. Monitoring Strategies to Improve Control of blood pressure in Attack Trial (ALLHAT). Hypertension. 2003; 42: 23946. Patients on Drug Therapy for High blood pressure S9. 1-6. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ S8. 3. 2-1. Brennan T, Spettell C, Villagra V, et al. Disease management to AATS/PCNA/SCAI/STS focused update of the Guideline for promote Blood Hypertension control among African Americans. Popul the diagnosis and management of patients with stable ischemic Health Manag. 2010; 13: 6572. Heart disease: a report of the American College of Cardiology/ S8. 3. 2-2. Bosworth hemoglobin, Olsen MK, Grubber JM, et al. Two self-management American Heart Association Task Force on Practice Guidelines, interventions to improve hypertension control: a randomized trial. and the American Association for Thoracic Surgery, Preventive Ann Intern Med. 2009; 151: 68795. Cardiovascular Nurses Association, Society for Cardiovascular S8. 3. 2-3. Bosworth hemoglobin, Powers BJ, Olsen MK, et al. Home Blood presAngiography and Interventions, and Society of Thoracic Surgeons. sure management and improved Blood Hypertension control: results Circulation. 2014; 130: 174967. from a randomized controlled trial. Arch Intern Med. 2011; 171: S9. 1-7. Fox KM. EURopean trial On reduction of cardiac events with 117380. Perindopril in stable coronary Artery disease Investigators. Efficacy S8. 3. 2-4. Green beta blocker, Cook AJ, Ralston JD, et al. Effectiveness of home Blood of perindopril in reduction of cardiovascular events among patients Hypertension monitoring, Web communication, and pharmacist care with stable coronary artery disease: randomised, double-blind, on hypertension control: a randomized controlled trial. JAMA. placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2008; 299: 285767. 2003; 362: 7828. S8. 3. 2-5. Heisler M, Hofer total protein, Schmittdiel JA, et al. Improving Blood presS9. 1-8. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowering sure control through a clinical pharmacist outreach program in drugs in the prevention of cardiovascular disease: meta-analysis of patients with Diabetes mellitus in 2 High-performing health systems: 147 randomised trials in the context of expectations from prospecthe adherence and intensification of medications cluster randomtive epidemiological studies. BMJ. 2009; 338: b1665. ized, controlled pragmatic trial. Circulation. 2012; 125: 286372. S9. 1-9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on S8. 3. 2-6. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home Blood presmortality and morbidity in patients with left ventricular dysfuncsure telemonitoring and pharmacist management on Blood Hypertension tion after myocardial infarction. Results of the survival and vencontrol: a cluster randomized clinical trial. JAMA. 2013; 310: 4656. tricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 66977. S9. 1-10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con9.",
    "word_count": 588,
    "char_count": 4042,
    "sentence_count": 100,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 130,
      "total_chunks": 166,
      "position": "131/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "hemoglobin",
        "antihypertensive",
        "cardiovascular disease",
        "adherence",
        "monitoring",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 131,
    "text": "1992; 327: 66977. S9. 1-10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con9. Hypertension in Patients With Comorbidities verting-enzyme inhibitor, ramipril, on cardiovascular events in HighS9-1. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert risk patients. The Heart Outcomes Prevention Evaluation Study consensus document on hypertension in the elderly: a report of the Investigators. N Engl J Med. 2000; 342: 14553. American College of Cardiology Foundation Task Force on Clinical S9. 1-11. Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of veraExpert Consensus Documents. Developed in collaboration with the pamil alone and combined with propranolol in treating patients with American Academy of Neurology, American Geriatrics Society, chronic stable angina pectoris. Am J Cardiol. 1981; 48: 1319. American Society for Preventive Cardiology, American Society S9. 1-12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind of Hypertension, American Society of Nephrology, Association comparison of placebo and active treatment for older patients with of Black Cardiologists, and European Society of Hypertension. isolated systolic hypertension. The Systolic Hypertension in Europe Circulation. 2011; 123: 2434506. (Syst-Eur) Trial Investigators. Lancet. 1997; 350: 75764. S9-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideS9. 1-13. Freemantle N, Cleland J, Young P, et al. Beta Blockade after myoline for the management of Heart failure: a report of the American cardial infarction: systematic review and meta regression analysis. College of Cardiology Foundation/American Heart Association BMJ. 1999; 318: 17307. Task Force on Practice Guidelines. Circulation. 2013; 128: S9. 1-14. de Peuter OR, Lussana F, Peters RJG, et al. A systematic review of e240327. selective and non-selective beta blockers for prevention of vascular S9-3. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ events in patients with acute coronary syndrome or Heart failure. AATS/PCNA/SCAI/STS focused update of the guideline for Neth J Med. 2009; 67: 28494. the diagnosis and management of patients with stable ischemic S9. 1-15. Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertenHeart disease: a report of the American College of Cardiology/ sive patients with concomitant peripheral and coronary artery disAmerican Heart Association Task Force on Practice Guidelines, ease: findings from the INternational VErapamil-SR/Trandolapril and the American Association for Thoracic Surgery, Preventive STudy. Hypertension. 2010; 55: 4853. Cardiovascular Nurses Association, Society for Cardiovascular S9. 1-16. Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and longAngiography and Interventions, and Society of Thoracic Surgeons. term follow-up of participants with peripheral arterial disease durCirculation. 2014; 130: 174967. ing ALLHAT. J Gen Intern Med. 2014; 29: 147583. S9-4. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ S9. 1-17. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hyperACC guideline on the management of patients with lower extremtension in patients with coronary artery disease: a scientific stateity peripheral artery disease: a report of the American College of ment from the American Heart Association, American College of Cardiology/American Heart Association Task Force on Clinical Cardiology, and American Society of Hypertension. Circulation. Practice Guidelines. Circulation. 2017; 135: e72679. 2015; 131: e43570. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e95 S9. 1-18. Ekelund LG, Olsson AG, Oro L, et al. Effects of the cardioseS9. 2-9. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized lective beta-adrenergic receptor blocking agent metoprolol in trial of intensive versus standard Blood-Hypertension control. SPRINT angina pectoris. Subacute study with exercise tests. Br Heart J. Research Group. N Engl J Med. 2015; 373: 210316. 1976; 38: 15561. S9. 2-10. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for S9.",
    "word_count": 600,
    "char_count": 4129,
    "sentence_count": 88,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 131,
      "total_chunks": 166,
      "position": "132/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "calcium",
        "heart failure",
        "exercise",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 132,
    "text": "1976; 38: 15561. S9. 2-10. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for S9. 1-19. Aronow WS, Turbow M, Van Camp S, et al. The effect of timolol vs prevention of cardiovascular disease and death: a systematic review placebo on angina pectoris. Circulation. 1980; 61: 669. and meta-analysis. Lancet. 2016; 387: 95767. S9. 1-20. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the 9. 2. 1. Heart Failure With Reduced Ejection Fraction American College of Cardiology Foundation Task Force on Clinical S9. 2. 1-1. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases Expert Consensus Documents. Developed in collaboration with the late-onset congestive Heart failure in postinfarction patients with American Academy of Neurology, American Geriatrics Society, early reduction in ejection fraction. The Adverse Experience American Society for Preventive Cardiology, American Society Committee; and the Multicenter Diltiazem Postinfarction Research of Hypertension, American Society of Nephrology, Association Group. Circulation. 1991; 83: 5260. of Black Cardiologists, and European Society of Hypertension. S9. 2. 1-2. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection Circulation. 2011; 123: 2434506. fraction in older persons with congestive Heart failure. Chest. S9. 1-21. Aronow WS, Frishman WH. Angina pectoris in the elderly. Aronow 1998; 113: 8679. WS, Fleg JL, Rich MW. Tresch and Aronows Cardiovascular S9. 2. 1-3. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of conDisease in the Elderly. 2013; CRC Press, Taylor Francis Group: gestive Heart failure in older African-Americans, Hispanics, and Boca Raton, FL: 21537. whites. Am J Cardiol. 1999; 84: 6112; A9. S9. 1-22. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondS9. 2. 1-4. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of conary prevention and risk reduction therapy for patients with coronary gestive Heart failure in elderly persons: influence of left ventricular and other atherosclerotic vascular disease: 2011 update: a guideline systolic function. The Cardiovascular Health Study. Ann Intern from the American Heart Association and American College of Med. 2002; 137: 6319. Cardiology Foundation. Circulation. 2011; 124: 245873. S9. 2. 1-5. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and S9. 1-23. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: outcome of Heart failure with preserved ejection fraction. N Engl J is it a wise choice? Lancet. 2004; 364: 16849. Med. 2006; 355: 2519. S9. 1-24. Mancia G, Fagard R, Narkiewicz potassium, et al. 2013 ESH/ESC guideS9. 2. 1-6. Vasan RS, Larson magnesium, Benjamin EJ, et al. Congestive Heart faillines for the management of arterial hypertension: the Task Force for ure in subjects with normal versus reduced left ventricular ejection the Management of Arterial Hypertension of the European Society fraction: prevalence and mortality in a population-based cohort. J of Hypertension (ESH) and of the European Society of Cardiology Am Coll Cardiol. 1999; 33: 194855. (ESC). Eur Heart J. 2013; 34: 2159219. S9. 2. 1-7. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA S9. 1-25. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ focused update on new pharmacological therapy for Heart failure: PCNA/SCAI/STS guideline for the diagnosis and management of an update of the 2013 ACCF/AHA guideline for the management patients with stable ischemic Heart disease: a report of the American of Heart failure: a report of the American College of Cardiology/ College of Cardiology Foundation/American Heart Association American Heart Association Task Force on Clinical Practice Task Force on Practice Guidelines, and the American College of Guidelines and the Heart Failure Society of America. Circulation.",
    "word_count": 594,
    "char_count": 3908,
    "sentence_count": 97,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 132,
      "total_chunks": 166,
      "position": "133/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "calcium",
        "magnesium",
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 133,
    "text": "Circulation. Physicians, American Association for Thoracic Surgery, Preventive 2016; 134: e28293. Cardiovascular Nurses Association, Society for Cardiovascular S9. 2. 1-8. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity Angiography and Interventions, and Society of Thoracic Surgeons. results from the European Working Party on Hypertension Circulation. 2012; 126: e354471. in the Elderly trial. Lancet. 1985; 1: 134954. S9. 2. 1-9. Kostis JB, Davis BR, Cutler J, et al. Prevention of Heart failure 9. 2. Heart Failure by antihypertensive drug treatment in older persons with isolated S9. 2-1. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive Blood pressystolic hypertension. SHEP Cooperative Research Group. JAMA. sure lowering on the progression of chronic Kidney disease: a sys1997; 278: 2126. tematic review and meta-analysis. CMAJ. 2013; 185: 94957. S9. 2. 1-10. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyperS9. 2-2. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension tension in patients 80 years of age or older. N Engl J Med. lowering on outcome incidence in hypertension: 7. Effects of more 2008; 358: 188798. vs. less intensive Blood Hypertension lowering and different achieved S9. 2. 1-11. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowering Blood Hypertension levelsupdated overview and meta-analyses of randrugs in the prevention of cardiovascular disease: meta-analysis of domized trials. J Hypertens. 2016; 34: 61322. 147 randomised trials in the context of expectations from prospecS9. 2-3. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension tive epidemiological studies. BMJ. 2009; 338: b1665. lowering on cardiovascular and renal outcomes: updated systematic S9. 2. 1-12. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with prereview and meta-analysis. Lancet. 2016; 387: 43543. served and reduced left ventricular ejection fraction in the antihyS9. 2-4. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA pertensive and lipid-lowering treatment to prevent Heart attack trial. focused update on new pharmacological therapy for Heart failure: Circulation. 2008; 118: 225967. an update of the 2013 ACCF/AHA guideline for the management S9. 2. 1-13. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of of Heart failure: a report of the American College of Cardiology/ participants with Heart failure in the Antihypertensive and LipidAmerican Heart Association Task Force on Clinical Practice Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Guidelines and the Heart Failure Society of America. Circulation. Circulation. 2011; 124: 18118. 2016; 134: e28293. S9. 2. 1-14. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA S9. 2-5. Visser M, Langlois J, Guralnik JM, et al. High body fatness, but not focused update of the 2013 ACCF/AHA Guideline for the Low fat-free mass, predicts disability in older men and women: the Management of Heart Failure: a report of the American College Cardiovascular Health Study. Am J Clin Nutr. 1998; 68: 58490. of Cardiology/American Heart Association Task Force on Clinical S9. 2-6. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal Practice Guidelines and the Heart Failure Society of America. muscle strength, mass, and quality in older adults: the health, Circulation. 2017; 136: e13761. aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006; 61: 105964. 9. 2. 2. Heart Failure With Preserved Ejection Fraction S9. 2-7. Butler J, Kalogeropoulos AP, Georgiopoulou VV, et al. Systolic S9. 2. 2-1. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation Blood Hypertension and incident Heart failure in the elderly.",
    "word_count": 574,
    "char_count": 3727,
    "sentence_count": 100,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 133,
      "total_chunks": 166,
      "position": "134/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 134,
    "text": "2-1. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation Blood Hypertension and incident Heart failure in the elderly. The in patients and outcomes in the Treatment of Preserved Cardiac Cardiovascular Health Study and the Health, Ageing and Body Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Composition Study. Heart. 2011; 97: 130411. trial. Circulation. 2015; 131: 3442. S9. 2-8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline S9. 2. 2-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of Heart failure: a report of the American College for the management of Heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128: e240327. on Practice Guidelines. Circulation. 2013; 128: e240327. Downloaded from by on December 30, 2025 e96 Hypertension June 2018 S9. 2. 2-3. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no 9. 3. Chronic Kidney Disease propranolol on total mortality plus nonfatal myocardial infarction S9. 3-1. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary Protein in older patients with prior myocardial infarction, congestive Heart restriction and Blood-Hypertension control on the progression of chronic failure, and left ventricular ejection fraction or 40% treated renal disease. Modification of Diet in Renal Disease Study Group. with diuretics plus angiotensin-converting enzyme inhibitors. Am J N Engl J Med. 1994; 330: 87784. Cardiol. 1997; 80: 2079. S9. 3-2. Ruggenenti P, Perna A, Loriga G, et al. Blood-Hypertension control S9. 2. 2-4. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with for renoprotection in patients with non-diabetic chronic renal disnebivolol in elderly Heart failure patients with impaired and preserved ease (REIN-2): multicentre, randomised controlled trial. Lancet. left ventricular ejection fraction: Data From SENIORS (Study of 2005; 365: 93946. Effects of Nebivolol Intervention on Outcomes and Rehospitalization S9. 3-3. Wright JT Jr, Bakris G, Greene T, et al. Effect of Blood presin Seniors With Heart Failure). J Am Coll Cardiol. 2009; 53: 21508. sure lowering and antihypertensive drug class on progression of S9. 2. 2-5. Yusuf S, Pfeffer MA, Swedberg potassium, et al. Effects of candesartan in hypertensive Kidney disease: results from the AASK trial. JAMA. patients with chronic Heart failure and preserved left-ventricular ejec2002; 288: 242131. tion fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 77781. S9. 3-4. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: S9. 2. 2-6. Massie BM, Carson physical examination, McMurray JJ, et al. Irbesartan in patients Blood Hypertension target in chronic Kidney disease and proteinuria as with Heart failure and preserved ejection fraction. N Engl J Med. an effect modifier. Ann Intern Med. 2011; 154: 5418. 2008; 359: 245667. S9. 3-5. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive Blood presS9. 2. 2-7. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection sure lowering on the progression of chronic Kidney disease: a sysfraction in older persons with congestive Heart failure. Chest. tematic review and meta-analysis. CMAJ. 2013; 185: 94957. 1998; 113: 8679. S9. 3-6. Jafar TH, Stark after meals, Schmid CH, et al. Progression of chronic kidS9. 2. 2-8. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of conney disease: the role of Blood Hypertension control, proteinuria, and gestive Heart failure in older African-Americans, Hispanics, and angiotensin-converting enzyme inhibition: a patient-level metawhites. Am J Cardiol. 1999; 84: 6112; A9. analysis. Ann Intern Med. 2003; 139: 24452. S9. 2. 2-9. Vasan RS, Larson magnesium, Benjamin EJ, et al. Congestive Heart failS9. 3-7.",
    "word_count": 594,
    "char_count": 3903,
    "sentence_count": 105,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 134,
      "total_chunks": 166,
      "position": "135/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "proteinuria",
        "potassium",
        "magnesium",
        "diet",
        "dietary protein",
        "diuretics",
        "antihypertensive",
        "heart failure",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 135,
    "text": "2003; 139: 24452. S9. 2. 2-9. Vasan RS, Larson magnesium, Benjamin EJ, et al. Congestive Heart failS9. 3-7. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, et al. ure in subjects with normal versus reduced left ventricular ejection Albuminuria assessed from first-morning-void Urine samples verfraction: prevalence and mortality in a population-based cohort. J sus 24-hour Urine collections as a predictor of cardiovascular morAm Coll Cardiol. 1999; 33: 194855. bidity and mortality. Am J Epidemiol. 2008; 168: 897905. S9. 2. 2-10. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of conS9. 3-8. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. gestive Heart failure in elderly persons: influence of left ventricular Comparison of different measures of urinary Protein excretion for systolic function. The Cardiovascular Health Study. Ann Intern prediction of renal events. J Am Soc Nephrol. 2010; 21: 135560. Med. 2002; 137: 6319. S9. 3-9. Contreras G, Greene T, Agodoa LY, et al. Blood Hypertension conS9. 2. 2-11. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and trol, drug therapy, and Kidney disease. Hypertension. 2005; 46: outcome of Heart failure with preserved ejection fraction. N Engl J 4450. Med. 2006; 355: 2519. S9. 3-10. Esnault VLM, Brown EA, Apetrei E, et al. The effects of amlodipS9. 2. 2-12. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis ine and enalapril on renal function in adults with hypertension and and risk factors to Heart failure with preserved or reduced ejection nondiabetic nephropathies: a 3-year, randomized, multicenter, doufraction: insights from the Framingham Heart Study of the National ble-blind, placebo-controlled study. Clin Ther. 2008; 30: 48298. Heart, Lung, and Blood Institute. Circulation. 2009; 119: 30707. S9. 3-11. Marin R, Ruilope LM, Aljama P, et al. A random comparison of S9. 2. 2-13. Bhuiyan T, Maurer MS. Heart failure with preserved ejection fracfosinopril and nifedipine GITS in patients with primary renal distion: persistent diagnosis, therapeutic enigma. Curr Cardiovasc ease. J Hypertens. 2001; 19: 18716. Risk Rep. 2011; 5: 4409. S9. 3-12. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting S9. 2. 2-14. Kato S, Onishi potassium, Yamanaka T, et al. Exaggerated hypertenenzyme inhibitors on the progression of nondiabetic renal disease: sive response to exercise in patients with diastolic Heart failure. a meta-analysis of randomized trials. Angiotensin-ConvertingHypertens Res. 2008; 31: 67984. Enzyme Inhibition and Progressive Renal Disease Study Group. S9. 2. 2-15. St Gyalai-Korpos I, Tomescu M, Pogorevici A. Hypertensive acute Ann Intern Med. 1997; 127: 33745. pulmonary oedema as expression of diastolic Heart failure. Rom J S9. 3-13. Reboussin diabetes mellitus, Allen NB, Griswold ME, et al. Systematic review Intern Med. 2008; 46: 1537. for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ S9. 2. 2-16. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert ASPC/NMA/PCNA guideline for the prevention, detection, evaluconsensus document on hypertension in the elderly: a report of the ation, and management of Hypertension in adults: a report of American College of Cardiology Foundation Task Force on Clinical the American College of Cardiology/American Heart Association Expert Consensus Documents. Developed in collaboration with the Task Force on Clinical Practice Guidelines. Hypertension. American Academy of Neurology, American Geriatrics Society, 2018; 71: e116e135. American Society for Preventive Cardiology, American Society S9. 3-14. Muntner P, Anderson A, Charleston J, et al. Hypertension awareof Hypertension, American Society of Nephrology, Association ness, treatment, and control in adults with chronic kidney disease: results from the of Black Cardiologists, and European Society of Hypertension. Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Circulation. 2011; 123: 2434506. Dis. 2010; 55: 44151. S9. 2. 2-17. Kostis JB, Davis BR, Cutler J, et al.",
    "word_count": 597,
    "char_count": 4015,
    "sentence_count": 106,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 135,
      "total_chunks": 166,
      "position": "136/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "albuminuria",
        "potassium",
        "magnesium",
        "heart failure",
        "exercise",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 136,
    "text": "2011; 123: 2434506. Dis. 2010; 55: 44151. S9. 2. 2-17. Kostis JB, Davis BR, Cutler J, et al. Prevention of Heart failure S9. 3-15. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideby antihypertensive drug treatment in older persons with isolated line for the management of Hypertension in adults: report systolic hypertension. SHEP Cooperative Research Group. JAMA. from the panel members appointed to the Eighth Joint National 1997; 278: 2126. Committee (JNC 8). JAMA. 2014; 311: 50720. S9. 2. 2-18. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyperS9. 3-16. National Clinical Guideline Centre (UK). Chronic Kidney tension in patients 80 years of age or older. N Engl J Med. Disease (Partial Update): Early Identification and Management 2008; 358: 188798. of Chronic Kidney Disease in Adults in Primary and Secondary S9. 2. 2-19. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of Care. London, UK: National Institute for Health and Care participants with Heart failure in the antihypertensive and lipid-LowExcellence (UK); 2014. ering treatment to prevent Heart attack trial (ALLHAT). Circulation. S9. 3-17. Mancia G, Fagard R, Narkiewicz potassium, et al. 2013 ESH/ESC guide2011; 124: 18118. lines for the management of arterial hypertension: the Task Force S9. 2. 2-20. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with prefor the Management of Arterial Hypertension of the European served and reduced left ventricular ejection fraction in the antihySociety of Hypertension (ESH) and of the European Society of pertensive and lipid-lowering treatment to prevent Heart attack trial. Cardiology (ESC). Eur Heart J. 2013; 34: 2159219. Circulation. 2008; 118: 225967. S9. 3-18. Kidney Disease: Improving Global Outcomes clinical practice guideline for the management of Blood S9. 2. 2-21. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesHypertension in chronic Kidney disease. Kidney Int Suppl (2011). terase-5 inhibition on exercise capacity and clinical status in Heart 2012; 2(5): 337414. failure with preserved ejection fraction: a randomized clinical trial. S9. 3-19. Kanno A, Metoki H, Kikuya M, et al. Usefulness of assessing JAMA. 2013; 309: 126877. masked and white-coat hypertension by ambulatory Blood Hypertension Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e97 monitoring for determining prevalent risk of chronic Kidney disS9. 3-40. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for ease: the Ohasama study. Hypertens Res. 2010; 33: 11928. prevention of cardiovascular disease and death: a systematic review S9. 3-20. Terawaki H, Metoki H, Nakayama M, et al. Masked hypertension and meta-analysis. Lancet. 2016; 387: 95767. determined by self-measured Blood Hypertension at home and chronic S9. 3-41. Thomopoulos C, Parati G, Zanchetti A. Effects of Blood Hypertension Kidney disease in the Japanese general population: the Ohasama lowering on outcome incidence in hypertension: 7. Effects of more study. Hypertens Res. 2008; 31: 212935. vs. less intensive Blood Hypertension lowering and different achieved S9. 3-21. Minutolo R, Gabbai FB, Agarwal R, et al. Assessment of achieved Blood Hypertension levelsupdated overview and meta-analyses of ranclinic and ambulatory Blood Hypertension recordings and outcomes domized trials. J Hypertens. 2016; 34: 61322. during treatment in hypertensive patients with chronic kidney disease: a multicenter S9. 3-42. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension prospective cohort study. Am J Kidney Dis. 2014; 64: 74452. lowering on cardiovascular and renal outcomes: updated systematic S9. 3-22. Drawz physical examination, Alper AB, Anderson AH, et al. Masked hypertension review and meta-analysis. Lancet. 2016; 387: 43543. and elevated nighttime Blood Hypertension in chronic kidney disease: prevalence and S9. 3-43. Ninomiya T, Perkovic V, Turnbull F, et al.",
    "word_count": 598,
    "char_count": 3982,
    "sentence_count": 93,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 136,
      "total_chunks": 166,
      "position": "137/166",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "calcium",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "exercise",
        "monitoring",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 137,
    "text": "3-43. Ninomiya T, Perkovic V, Turnbull F, et al. Blood Hypertension lowerassociation with target organ damage. Clin J Am Soc Nephrol. ing and major cardiovascular events in people with and without 2016; 11: 64252. chronic Kidney disease: meta-analysis of randomised controlled triS9. 3-23. Agarwal R, Andersen MJ. Prognostic importance of ambulatory als. BMJ. 2013; 347: f5680. Blood Hypertension recordings in patients with chronic Kidney disease. Kidney Int. 2006; 69: 117580. 9. 3. 1. Hypertension After Renal Transplantation S9. 3-24. Navaneethan SD, Schold JD, Arrigain S, et al. Cause-specific S9. 3. 1-1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized deaths in non-Dialysis-dependent chronic kidney disease. J Am Soc Nephrol. trial of intensive versus standard Blood-Hypertension control. SPRINT 2015; 26: 251220. Research Group. N Engl J Med. 2015; 373: 210316. S9. 3-25. Matsushita potassium, van der Velde M, Astor BC, et al. Association of estiS9. 3. 1-2. Cross NB, Webster before meals, Masson P, et al. Antihypertensive treatmated glomerular estimated glomerular filtration rate and albuminuria with all-cause and ment for Kidney transplant recipients. Cochrane Database Syst Rev. cardiovascular mortality in general population cohorts: a collabora2009: CD003598. tive meta-analysis. Chronic Kidney Disease Prognosis Consortium. S9. 3. 1-3. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated Blood presLancet. 2010; 375: 207381. sure predicts the risk of acute rejection in renal allograft recipients. S9. 3-26. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized Kidney Int. 2001; 59: 115864. trial of intensive versus standard Blood-Hypertension control. SPRINT S9. 3. 1-4. Peschke B, Scheuermann EH, Geiger H, et al. Hypertension Research Group. N Engl J Med. 2015; 373: 210316. is associated with hyperlipidemia, coronary Heart disease and S9. 3-27. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive chronic graft failure in Kidney transplant recipients. Clin Nephrol. Blood-Hypertension control in type 2 Diabetes mellitus. ACCORD Study 1999; 51: 2905. Group. N Engl J Med. 2010; 362: 157585. S9. 3. 1-5. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and S9. 3-28. Goff DC Jr, Lloyd-Jones diabetes mellitus, Bennett G, et al. 2013 ACC/AHA renal allograft survival. JAMA. 2000; 283: 6338. guideline on the assessment of cardiovascular risk: a report of S9. 3. 1-6. Mange KC, Feldman HI, Joffe MM, et al. Blood Hypertension and the the American College of Cardiology/American Heart Association survival of renal allografts from living donors. J Am Soc Nephrol. Task Force on Practice Guidelines. Circulation. 2014; 129(suppl 2004; 15: 18793. 2): S4973. S9. 3. 1-7. Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced S9. 3-29. Kovesdy CP, Alrifai A, Gosmanova EO, et al. Age and outcomes hypertension: incidence, pathogenesis and management. Drug Saf. associated with blood pressure in patients with incident chronic kidney disease. Clin J Am Soc 1999; 20: 43749. Nephrol. 2016; 11: 82131. S9. 3. 1-8. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose S9. 3-30. Weiss JW, Peters D, Yang X, et al. Systolic blood pressure and mortality in hypertension early after Liver transplantation with tacrolimus in older adults with chronic kidney disease. Clin J Am Soc Nephrol. 2015; 10: (FK506) and cyclosporine. Transplantation. 1996; 62: 158892. 15539. S9. 3. 1-9. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, S9. 3-31. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs double-blind, placebo-controlled multicenter trial comparing early standard Blood Hypertension control and cardiovascular disease out- (7 day) corticosteroid cessation versus long-term, Low-dose corticocomes in adults aged ≥75 years: a randomized clinical trial. JAMA. steroid therapy. Ann Surg. 2008; 248: 56477. 2016; 315: 267382. S9. 3. 1-10.",
    "word_count": 596,
    "char_count": 3933,
    "sentence_count": 130,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 137,
      "total_chunks": 166,
      "position": "138/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "albuminuria",
        "potassium",
        "antihypertensive",
        "dialysis",
        "kidney transplant",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 138,
    "text": "JAMA. steroid therapy. Ann Surg. 2008; 248: 56477. 2016; 315: 267382. S9. 3. 1-10. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, mulS9. 3-32. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in ticenter study of steroid avoidance, early steroid withdrawal or estimated glomerular estimated glomerular filtration rate during treatment with losartan standard steroid therapy in Kidney transplant recipients. Am J predicts a slower decrease in long-term renal function. Kidney Int. Transplant. 2008; 8: 30716. 2011; 80: 2827. S9. 3. 1-11. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure S9. 3-33. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery maintains efficacy and safety at 5 years: results from the long-term stenoses or renal-artery stenosis in a solitary Kidney. N Engl J Med. extension of the BENEFIT study. Am J Transplant. 2013; 13: 287583. 1983; 308: 3736. S9. 3. 1-12. Opelz G, Dohler B; Collaborative Transplant Study. Improved S9. 3-34. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, caplong-term outcomes after renal transplantation associated with topril, or both in myocardial infarction complicated by Heart Blood Hypertension control. Am J Transplant. 2005; 5: 272531. failure, left ventricular dysfunction, or both. N Engl J Med. S9. 3. 1-13. Hillebrand U, Suwelack BM, Loley potassium, et al. Blood Hypertension, anti2003; 349: 1893906. hypertensive treatment, and graft survival in Kidney transplant S9. 3-35. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients. Transpl Int. 2009; 22: 107380. patients at High risk for vascular events. ONTARGET Investigators. S9. 3. 1-14. Wadei HM, Amer H, Taler SJ, et al. Diurnal Blood Hypertension changes N Engl J Med. 2008; 358: 154759. one year after Kidney transplantation: relationship to allograft S9. 3-36. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin function, histology, and resistive index. J Am Soc Nephrol. inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2007; 18: 160715. 2013; 369: 1892903. S9. 3. 1-15. Ambrosi P, Kreitmann B, Habib G. Home Blood Hypertension moniS9. 3-37. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end toring in Heart transplant recipients: comparison with ambulatory points in a trial of aliskiren for type 2 Diabetes. N Engl J Med. Blood Hypertension monitoring. Transplantation. 2014; 97: 3637. 2012; 367: 220413. S9. 3. 1-16. Haydar AA, Covic A, Jayawardene S, et al. Insights from ambulaS9. 3-38. Peterson JC, Adler S, Burkart JM, et al. Blood Hypertension control, tory Blood Hypertension monitoring: diagnosis of hypertension and diurproteinuria, and the progression of renal disease. The Modification nal Blood Hypertension in renal transplant recipients. Transplantation. of Diet in Renal Disease Study. Ann Intern Med. 1995; 123: 75462. 2004; 77: 84953. S9. 3-39. Appel LJ, Wright JT Jr, Greene T, et al. Intensive Blood-Hypertension S9. 3. 1-17. Jennings DL, Taber DJ. Use of renin-angiotensin-aldosterone syscontrol in hypertensive chronic Kidney disease. N Engl J Med. tem inhibitors within the first eight to twelve weeks after renal 2010; 363: 91829. transplantation. Ann Pharmacother. 2008; 42: 11620. Downloaded from by on December 30, 2025 e98 Hypertension June 2018 9. 4. Cerebrovascular Disease S9. 4. 2-11. Leonardi-Bee J, Rice PM, Phillips SJ, et al. Blood Hypertension and clinical outcomes in the International Stroke Trial. Stroke. S9. 4-1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and 2002; 33: 131520. stroke statistics2017 update: a report from the American Heart S9. 4. 2-12. Castillo J, Leira R, Garcia MM, et al. Blood Hypertension decrease Association. Circulation. 2017; 135: e146603.",
    "word_count": 589,
    "char_count": 3834,
    "sentence_count": 123,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 138,
      "total_chunks": 166,
      "position": "139/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal function",
        "nephropathy",
        "potassium",
        "diet",
        "kidney transplant",
        "monitoring"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 139,
    "text": "4. 2-12. Castillo J, Leira R, Garcia MM, et al. Blood Hypertension decrease Association. Circulation. 2017; 135: e146603. during the acute phase of ischemic stroke is associated with brain S9. 4-2. Boan AD, Lackland DT, Ovbiagele B. Lowering of Blood Hypertension injury and poor stroke outcome. Stroke. 2004; 35: 5206. for recurrent stroke prevention. Stroke. 2014; 45: 250613. S9. 4. 2-13. Vemmos KN, Tsivgoulis G, Spengos potassium, et al. U-shaped relation9. 4. 1. Acute Intracerebral Hemorrhage ship between mortality and admission Blood Hypertension in patients with acute stroke. J Intern Med. 2004; 255: 25765. S9. 4. 1-1. Anderson CS, Heeley E, Huang Y, et al. Rapid Blood-Hypertension S9. 4. 2-14. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early lowering in patients with acute intracerebral hemorrhage. N Engl management of patients with acute ischemic stroke: a guideline J Med. 2013; 368: 235565. for healthcare professionals from the American Heart Association/ S9. 4. 1-2. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-presAmerican Stroke Association. Stroke. 2013; 44: 870947. sure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016; 375: 103343. 9. 4. 3. Secondary Stroke Prevention S9. 4. 1-3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and S9. 4. 3-1. Liu L, Wang Z, Gong L, et al. Blood Hypertension reduction for the stroke statistics2017 update: a report from the American Heart secondary prevention of stroke: a Chinese trial and a systematic Association. Circulation. 2017; 135: e146603. review of the literature. Hypertens Res. 2009; 32: 103240. S9. 4. 1-4. Zhang Y, Reilly KH, Tong W, et al. Blood Hypertension and clinical outS9. 4. 3-2. Lakhan SE, Sapko MT. Blood Hypertension lowering treatment for precome among patients with acute stroke in Inner Mongolia. China J venting stroke recurrence: a systematic review and meta-analysis. Hypertens. 2008; 26: 144652. Int Arch Med. 2009; 2: 30. S9. 4. 1-5. Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of Blood S9. 4. 3-3. PROGRESS Collaborative Group. Randomised trial of a perinHypertension changes and course on hematoma growth in acute intracedopril-based Blood-Hypertension-lowering regimen among 6 105 indirebral hemorrhage. Eur J Neurol. 2013; 20: 127783. viduals with previous stroke or transient ischaemic attack. Lancet. S9. 4. 1-6. Sakamoto Y, Koga M, Yamagami H, et al. Systolic Blood Hypertension 2001; 358: 103341. after intravenous antihypertensive treatment and clinical outcomes in S9. 4. 3-4. PATS Collaborating Group. Post-stroke antihypertensive treatment hyperacute intracerebral hemorrhage: the Stroke Acute Management study. A preliminary result. Chin Med J. 1995; 108: 7107. With Urgent Risk-Factor Assessment and Improvement-Intracerebral S9. 4. 3-5. Lee M, Saver JL, Hong potassium-S, et al. Renin-angiotensin system moduHemorrhage Study. Stroke. 2013; 44: 184651. lators modestly reduce vascular risk in persons with prior stroke. S9. 4. 1-7. Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive Blood Stroke. 2012; 43: 1139. Hypertension reduction in acute intracerebral hemorrhage: a meta-analS9. 4. 3-6. Wang W-T, You L-potassium, Chiang C-E, et al. Comparative effectiveness ysis. Neurology. 2014; 83: 15239. of Blood Hypertension-lowering drugs in patients who have already sufS9. 4. 1-8. Antihypertensive Treatment of Acute Cerebral Hemorrhage fered from stroke: traditional and Bayesian network meta-analysis (ATACH) investigators. Antihypertensive treatment of acute cereof randomized trials. Medicine (Baltimore). 2016; 95: e3302. bral hemorrhage. Crit Care Med. 2010; 38: 63748. S9. 4. 3-7. Katsanos AH, Filippatou A, Manios E, et al. Blood Hypertension reducS9. 4. 1-9. Anderson CS, Huang Y, Wang JG, et al. Intensive Blood Hypertension tion and secondary stroke prevention: a systematic review and reduction in acute cerebral haemorrhage trial (INTERACT): a ranmetaregression analysis of randomized clinical trials. Hypertension. domised pilot trial.",
    "word_count": 599,
    "char_count": 4036,
    "sentence_count": 138,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 139,
      "total_chunks": 166,
      "position": "140/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "antihypertensive",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 140,
    "text": "Hypertension. domised pilot trial. Lancet Neurol. 2008; 7: 3919. 2017; 69: 1719. 9. 4. 2. Acute Ischemic Stroke S9. 4. 3-8. Benavente OR, Coffey CS, Conwit R, et al. Blood-Hypertension targets in patients with recent lacunar stroke: the SPS3 randomised trial. S9. 4. 2-1. National Institute of Neurological Disorders and Stroke rt-PA SPS3 Study Group. Lancet. 2013; 382: 50715. Stroke Study Group. Tissue plasminogen activator for acute ischS9. 4. 3-9. Arima H, Chalmers J, Woodward M, et al. Lower target Blood presemic stroke. N Engl J Med. 1995; 333: 15817. sures are safe and effective for the prevention of recurrent stroke: S9. 4. 2-2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase the PROGRESS trial. J Hypertens. 2006; 24: 12018. 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. S9. 4. 3-10. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and 2008; 359: 131729. stroke statistics2017 update: a report from the American Heart S9. 4. 2-3. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of Blood Association. Circulation. 2017; 135: e146603. Hypertension, antihypertensive therapy, and outcome in ischemic stroke S9. 4. 3-11. Dhamoon MS, Sciacca respiratory rate, Rundek T, et al. Recurrent stroke and treated with intravenous thrombolysis: retrospective analysis from cardiac risks after first ischemic stroke: the Northern Manhattan Safe Implementation of Thrombolysis in Stroke-International Stroke Study. Neurology. 2006; 66: 6416. Thrombolysis Register (SITS-ISTR). Stroke. 2009; 40: 24429. S9. 4. 3-12. Hardie potassium, Hankey GJ, Jamrozik potassium, et al. Ten-year risk of first S9. 4. 2-4. Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertenrecurrent stroke and disability after first-ever stroke in the Perth sive treatment after acute stroke in the Continue or Stop Post-Stroke Community Stroke Study. Stroke. 2004; 35: 7315. Antihypertensives Collaborative Study (COSSACS): a prospective, ranS9. 4. 3-13. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by domised, open, blinded-endpoint trial. Lancet Neurol. 2010; 9: 76775. subtype of ischemic stroke in population-based incidence studies. S9. 4. 2-5. He J, Zhang Y, Xu T, et al. Effects of immediate Blood Hypertension reducNeurology. 2004; 62: 56973. tion on death and major disability in patients with acute ischemic S9. 4. 3-14. Toschke AM, Gulliford MC, Wolfe CDA, et al. Antihypertensive stroke: the CATIS randomized clinical trial. JAMA. 2014; 311: 47989. treatment after first stroke in primary care: results from the General S9. 4. 2-6. Wang H, Tang Y, Rong X, et al. Effects of early Blood Hypertension Practitioner Research Database. J Hypertens. 2011; 29: 15460. lowering on early and long-term outcomes after acute stroke: an S9. 4. 3-15. Kernan WN, Ovbiagele B, Black heart rate, et al. Guidelines for the prevenupdated meta-analysis. PLoS ONE. 2014; 9: e97917. tion of stroke in patients with stroke and transient ischemic attack: S9. 4. 2-7. Zhao R, Liu F-D, Wang S, et al. Blood Hypertension reduction in the a guideline for healthcare professionals from the American Heart acute phase of an ischemic stroke does not improve shortor longAssociation/American Stroke Association. Stroke. 2014; 45: 2160236. term dependency or mortality: a meta-analysis of current literature. S9. 4. 3-16. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of carMedicine (Baltimore). 2015; 94: e896. diovascular diseases in people with Diabetes mellitus: a scientific S9. 4. 2-8. Rice PM, Krishnan potassium. Interventions for deliberately altering statement from the American Heart Association and the American Blood Hypertension in acute stroke. Cochrane Database Syst Rev. Diabetes Association. Diabetes Care. 2007; 30: 16272. 2014; 10: CD000039. S9. 4. 2-9. Sandset EC, Rice PMW, Boysen G, et al. The angiotensin-recep9. 5.",
    "word_count": 595,
    "char_count": 3868,
    "sentence_count": 128,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 140,
      "total_chunks": 166,
      "position": "141/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "antihypertensive",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 141,
    "text": "2007; 30: 16272. 2014; 10: CD000039. S9. 4. 2-9. Sandset EC, Rice PMW, Boysen G, et al. The angiotensin-recep9. 5. Peripheral Artery Disease tor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. S9. 5-1. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in 2011; 377: 74150. patients with evidence of clinical or subclinical peripheral arterial S9. 4. 2-10. Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated disease. Eur Heart J. 2004; 25: 1724. Blood Hypertension in 563 704 adult patients with stroke presenting to S9. 5-2. Thompson AM, Hu T, Eshelbrenner chloride, et al. Antihypertensive the ED in the United States. Am J Emerg Med. 2007; 25: 328. treatment and secondary prevention of cardiovascular disease Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e99 events among persons without hypertension: a meta-analysis. S9. 6-18. Do DV, Wang X, Vedula SS, et al. Blood Hypertension control for diaJAMA. 2011; 305: 91322. betic retinopathy. Cochrane Database Syst Rev. 2015; 1: CD006127. S9. 5-3. Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertenS9. 6-19. Estacio RO, Jeffers BW, Gifford N, et al. Effect of Blood Hypertension consive patients with concomitant peripheral and coronary artery distrol on diabetic microvascular complications in patients with hypertenease: findings from the INternational VErapamil-SR/Trandolapril sion and type 2 Diabetes. Diabetes Care. 2000; 23(suppl 2): B5464. STudy. Hypertension. 2010; 55: 4853. S9. 6-20. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine S9. 5-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups as compared with enalapril on cardiovascular outcomes in patients of hypertensive patients treated with regimens based on valsartan with non-insulin-dependent Diabetes and hypertension. N Engl J and amlodipine: an analysis of findings from the VALUE trial. J Med. 1998; 338: 64552. Hypertens. 2006; 24: 21638. S9. 6-21. Tight Blood Hypertension control and risk of macrovascular and S9. 5-5. Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and longmicrovascular complications in type 2 Diabetes: UKPDS 38. UK term follow-up of participants with peripheral arterial disease durProspective Diabetes Study Group. BMJ. 1998; 317: 70313. ing ALLHAT. J Gen Intern. Med. 2014; 29: 147583. S9. 6-22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive Blood-Hypertension lowering and Low-dose aspirin in patients with hyperten9. 6. Diabetes Mellitus sion: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 175562. S9. 6-1. Emdin calcium, Rahimi potassium, Neal B, et al. Blood Hypertension lowering in S9. 6-23. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive Blood type 2 Diabetes: a systematic review and meta-analysis. JAMA. Hypertension reduction on myocardial infarction and stroke in Diabetes: 2015; 313: 60315. a meta-analysis in 73 913 patients. J Hypertens. 2011; 29: 125369. S9. 6-2. Arguedas JA, Leiva V, Wright JM. Blood Hypertension targets for S9. 6-24. Ettehad D, Emdin calcium, Kiran A, et al. Blood Hypertension lowering for hypertension in people with Diabetes mellitus. Cochrane Database prevention of cardiovascular disease and death: a systematic review Syst Rev. 2013; 10: CD008277. and meta-analysis. Lancet. 2016; 387: 95767. S9. 6-3. Cushman WC, Evans GW, Byington RP, et al. Effects of intenS9. 6-25. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at sive Blood-Hypertension control in type 2 Diabetes mellitus. ACCORD different Blood Hypertension levels in patients with Diabetes mellitus: Study. N Engl J Med. 2010; 362: 157585. systematic review and meta-analyses. BMJ. 2016; 352: i717. S9. 6-4. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension S9.",
    "word_count": 600,
    "char_count": 3957,
    "sentence_count": 117,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 141,
      "total_chunks": 166,
      "position": "142/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "potassium",
        "calcium",
        "chloride",
        "insulin",
        "antihypertensive",
        "cardiovascular disease",
        "retinopathy",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 142,
    "text": "BMJ. 2016; 352: i717. S9. 6-4. Xie X, Atkins E, Lv J, et al. Effects of intensive Blood Hypertension S9. 6-26. Perkovic V, Rodgers A. Redefining Blood-Hypertension targetsSPRINT lowering on cardiovascular and renal outcomes: updated systematic starts the marathon. N Engl J Med. 2015; 373: 21758. review and meta-analysis. Lancet. 2016; 387: 43543. S9. 6-27. Mancia G, Schumacher H, Redon J, et al. Blood Hypertension targets S9. 6-5. Margolis KL, OConnor PJ, Morgan TM, et al. Outcomes of combined recommended by guidelines and incidence of cardiovascular and cardiovascular risk factor management strategies in type 2 Diabetes: renal events in the Ongoing Telmisartan Alone and in Combination the ACCORD randomized trial. Diabetes Care. 2014; 37: 17218. With Ramipril Global Endpoint Trial (ONTARGET). Circulation. S9. 6-6. Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive 2011; 124: 172736. Blood Hypertension lowering on left ventricular hypertrophy in patients S9. 6-28. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findwith Diabetes mellitus: Action to Control Cardiovascular Risk in ings revisited in the context of subsequent analyses, other trials, Diabetes Blood Hypertension Trial. Hypertension. 2015; 66: 11239. and meta-analyses. Arch Intern Med. 2009; 169: 83242. S9. 6-7. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive Blood pressure lowering on the progression of chronic Kidney disease: a sys9. 7. Metabolic Syndrome tematic review and meta-analysis. CMAJ. 2013; 185: 94957. S9. 6-8. Bress AP, King JB, Kreider KE, et al. Effect of intensive versus S9. 7-1. Lim S, Eckel RH. Pharmacological treatment and therapeutic standard Blood Hypertension treatment according to baseline prediabeperspectives of metabolic syndrome. Rev Endocr Metab Disord. tes status: a post hoc analysis of a randomized trial. Diabetes Care. 2014; 15: 32941. 2017; 40: 14018. S9. 7-2. Owen JG, Reisin E. Anti-hypertensive drug treatment of patients S9. 6-9. Turnbull F, Neal B, Algert C, et al. Effects of different Blood with and the metabolic syndrome and obesity: a review of eviHypertension-lowering regimens on major cardiovascular events in dence, meta-analysis, post hoc and guidelines publications. Curr individuals with and without Diabetes mellitus: results of prospecHypertens Rep. 2015; 17: 558. tively designed overviews of randomized trials. Arch Intern Med. S9. 7-3. Ruderman NB, Shulman GI. Metabolic syndrome. Jameson JL. 2005; 165: 14109. Endocrinology: Adult Pediatric. 2015; Elsevier Saunders: S9. 6-10. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes Philadelphia, PA: 7529. in antihypertensive treatment of type 2 Diabetes, impaired fastS9. 7-4. Mozumdar A, Liguori G. Persistent increase of prevalence of metaing glucose concentration, and normoglycemia: Antihypertensive bolic syndrome among U. S. adults: NHANES III to NHANES and Lipid-Lowering Treatment to Prevent Heart Attack Trial 19992006. Diabetes Care. 2011; 34: 2169. (ALLHAT). Arch Intern Med. 2005; 165: 14019. S9. 7-5. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome S9. 6-11. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and and chronic Kidney disease in U. S. adults. Ann Intern Med. safety of Blood Hypertension-lowering agents in adults with Diabetes and 2004; 140: 16774. Kidney disease: a network meta-analysis. Lancet. 2015; 385: 204756. S9. 7-6. Chen J, Gu D, Chen C-S, et al. Association between the metabolic S9. 6-12. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin syndrome and chronic Kidney disease in Chinese adults. Nephrol system and cardiovascular risk. Lancet. 2007; 369: 120819. Dial Transplant. 2007; 22: 11006. S9. 6-13. Reboussin diabetes mellitus, Allen NB, Griswold ME, et al. Systematic review for S9. 7-7. Barzilay JI, Davis BR, Whelton PK. The glycemic effects of antithe 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ hypertensive medications. Curr Hypertens Rep. 2014; 16: 410.",
    "word_count": 592,
    "char_count": 3976,
    "sentence_count": 113,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 142,
      "total_chunks": 166,
      "position": "143/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "antihypertensive"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 143,
    "text": "The glycemic effects of antithe 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ hypertensive medications. Curr Hypertens Rep. 2014; 16: 410. NMA/PCNA guideline for the prevention, detection, evaluation, and S9. 7-8. Kostis JB, Wilson before meals, Freudenberger RS, et al. Long-term effect of management of Hypertension in adults: a report of the American diuretic-based therapy on fatal outcomes in subjects with isolated College of Cardiology/American Heart Association Task Force on systolic hypertension with and without Diabetes. Am J Cardiol. Clinical Practice Guidelines. Hypertension. 2018; 71: e116e135. 2005; 95: 2935. S9. 6-14. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired S9. 7-9. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes glucose tolerance and hypertension. Am Heart J. 1991; 121: 126873. by race in hypertensive patients with and without the metabolic synS9. 6-15. Tarnow L, Rossing P, Gall MA, et al. Prevalence of arterial hyperdrome: Antihypertensive and Lipid-Lowering Treatment to Prevent tension in diabetic patients before and after the JNC-V. Diabetes Heart Attack Trial (ALLHAT). Arch Intern Med. 2008; 168: 20717. Care. 1994; 17: 124751. S9. 7-10. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findS9. 6-16. Adler AI, Stratton IM, Neil HA, et al. Association of systolic Blood ings revisited in the context of subsequent analyses, other trials, Hypertension with macrovascular and microvascular complications of and meta-analyses. Arch Intern Med. 2009; 169: 83242. type 2 Diabetes (UKPDS 36): prospective observational study. S9. 7-11. Black heart rate, Davis B, Barzilay J, et al. Metabolic and clinical outBMJ. 2000; 321: 4129. comes in nondiabetic individuals with the metabolic syndrome S9. 6-17. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk assigned to chlorthalidone, amlodipine, or lisinopril as initial factors, and 12-yr cardiovascular mortality for men screened treatment for hypertension: a report from the Antihypertensive in the Multiple Risk Factor Intervention Trial. Diabetes Care. and Lipid-Lowering Treatment to Prevent Heart Attack Trial 1993; 16: 43444. (ALLHAT). Diabetes Care. 2008; 31: 35360. Downloaded from by on December 30, 2025 e100 Hypertension June 2018 S9. 7-12. Laurent S, Boutouyrie P; Vascular Mechanism Collaboration. S9. 9-6. Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator Dose-dependent arterial destiffening and inward remodeling therapy in patients with severe aortic regurgitation. N Engl J Med. after olmesartan in hypertensives with metabolic syndrome. 2005; 353: 13429. Hypertension. 2014; 64: 70916. S9. 7-13. Reisin E, Owen J. Treatment: special conditions. Metabolic 9. 10. Aortic Disease syndrome: obesity and the hypertension connection. J Am Soc S9. 101. Genoni M, Paul M, Jenni R, et al. Chronic beta-blocker therHypertens. 2015; 9: 15659; quiz 160. apy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg. 2001; 19: 9. 8. Atrial Fibrillation 60610. S9. 8-1. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial S9. 102. Suzuki T, Isselbacher EM, Nienaber calcium, et al. Type-selective benfibrillation with angiotensin-converting enzyme inhibitors and efits of medications in treatment of acute aortic dissection (from angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. the International Registry of Acute Aortic Dissection IRAD). Am 2005; 45: 18329. J Cardiol. 2012; 109: 1227. S9. 8-2. Zhao D, Wang Z-M, Wang L-S. Prevention of atrial fibrillation S9. 103. Masuda Y, Yamada Z, Morooka N, et al. Prognosis of patients with renin-angiotensin system inhibitors on essential hypertensive with medically treated aortic dissections. Circulation. 1991; 84: patients: a meta-analysis of randomized controlled trials. J Biomed III713. Res. 2015; 29: 47585. S9. 104. Rampoldi V, Trimarchi S, Eagle ketoanalogue, et al. Simple risk models S9. 8-3. Kistler PM, Sanders P, Fynn SP, et al.",
    "word_count": 591,
    "char_count": 4017,
    "sentence_count": 106,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 143,
      "total_chunks": 166,
      "position": "144/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "calcium",
        "angiotensin receptor blockers",
        "antihypertensive",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 144,
    "text": "Simple risk models S9. 8-3. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and to predict surgical mortality in acute type A aortic dissection: electroanatomic changes in the human atrium associated with age. the International Registry of Acute Aortic Dissection score. Ann J Am Coll Cardiol. 2004; 44: 10916. Thorac Surg. 2007; 83: 5561. S9. 8-4. January computed tomography, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS S9. 105. Suzuki T, Mehta RH, Ince H, et al. Clinical profiles and outcomes guideline for the management of patients with atrial fibrillation: of acute type B aortic dissection in the current European Renal Association: lessons from the a report of the American College of Cardiology/American Heart International Registry of Aortic Dissection (IRAD). Circulation. Association Task Force on Practice Guidelines and the Heart 2003; 108(suppl 1): II312I317. Rhythm Society. Circulation. 2014; 130: e199267. S9. 106. Mehta RH, OGara patient, Bossone E, et al. Acute type A aortic S9. 8-5. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the dissection in the elderly: clinical characteristics, management, CHA2DS2-VASc score for refining stroke risk stratification in and outcomes in the current European Renal Association. J Am Coll Cardiol. 2002; 40: patients with atrial fibrillation with a CHADS2 score 01: a nation68592. wide cohort study. Thromb Haemost. 2012; 107: 11729. S9. 107. Chan KK, Lai P, Wright JM. First-line beta-blockers versus other S9. 8-6. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causantihypertensive medications for chronic type B aortic dissection. ative agent, risk factor for complications, and potential therapeutic Cochrane Database Syst Rev. 2014; 2: CD010426. target. Am J Cardiol. 2003; 91: 9G14G. S9. 108. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/ S9. 8-7. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old AATS/albumin-creatinine ratio/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the and new antihypertensive drugs in elderly patients: cardiovascular diagnosis and management of patients with thoracic aortic dismortality and morbidity. The Swedish Trial in Old Patients with ease. a report of the American College of Cardiology Foundation/ Hypertension-2 study. Lancet. 1999; 354: 17516. American Heart Association Task Force on Practice Guidelines, S9. 8-8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive American Association for Thoracic Surgery, American College of patients at High cardiovascular risk treated with regimens based Radiology, American Stroke Association, Society of Cardiovascular on valsartan or amlodipine: the VALUE randomised trial. Lancet. Anesthesiologists, Society for Cardiovascular Angiography and 2004; 363: 202231. Interventions, Society of Interventional Radiology, Society of S9. 8-9. Wachtell potassium, Lehto M, Gerdts E, et al. Angiotensin II receptor Thoracic Surgeons, and Society for Vascular Medicine. Circulation. blockade reduces new-onset atrial fibrillation and subsequent 2010; 121: e266369. stroke compared to atenolol: the Losartan Intervention For End S9. 109. Gaddum NR, Keehn L, Guilcher A, et al. Altered dependence of Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. aortic pulse wave velocity on transmural Hypertension in hyperten2005; 45: 7129. sion revealing structural change in the aortic wall. Hypertension. S9. 8-10. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline 2015; 65: 3629. and during follow-up in ALLHAT (Antihypertensive and LipidS9. 10-10. Zhang L, Tian W, Feng R, et al. Prognostic impact of Blood presLowering Treatment to Prevent Heart Attack Trial). J Am Coll sure variability on aortic dissection patients after endovascular Cardiol. 2009; 54: 202331. therapy. Medicine (Baltimore). 2015; 94: e1591. S9. 8-11. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy 10. Special Patient Groups on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet.",
    "word_count": 600,
    "char_count": 4139,
    "sentence_count": 92,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 144,
      "total_chunks": 166,
      "position": "145/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "creatinine",
        "potassium",
        "antihypertensive",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 145,
    "text": "Special Patient Groups on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 10. 1. Race and Ethnicity 1999; 353: 6116. S10. 1-1. Yoon SSS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 20112014. NCHS Data 9. 9. Valvular Heart Disease Brief. 2015: 18. S9. 9-1. Rieck ÅE, Cramariuc D, Boman potassium, et al. Hypertension in aortic S10. 1-2. Margolis KL, Piller LB, Ford CE, et al. Blood Hypertension constenosis: implications for left ventricular structure and cardiovastrol in Hispanics in the antihypertensive and lipid-lowering cular events. Hypertension. 2012; 60: 907. treatment to prevent Heart attack trial. Hypertension. 2007; 50: S9. 9-2. Eleid MF, Nishimura RA, Sorajja P, et al. Systemic hypertension in 85461. Low-gradient severe aortic stenosis with preserved ejection fraction. S10. 1-3. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, et al. Blood presCirculation. 2013; 128: 134953. sure control and cardiovascular outcomes in High-risk Hispanic S9. 9-3. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, patientsfindings from the International Verapamil SR/Trandolapril randomized controlled trial of the angiotensin-converting enzyme Study (INVEST). Am Heart J. 2006; 151: 10729. inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J S10. 1-4. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and Cardiovasc Imaging. 2015; 16: 83441. stroke statistics2017 update: a report from the American Heart S9. 9-4. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and Association. Circulation. 2017; 135: e146603. efficacy of angiotensin-converting enzyme inhibitors in symptomS10. 1-5. Centers for Disease Control and Prevention. Compressed Mortality atic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot File: Underlying Cause-of-Death 19992013. 2014. Available at: Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J. Accessed November 2, 2017. 2004; 147: E19. S10. 1-6. Guzman NJ. Epidemiology and management of hypertension S9. 9-5. Scognamiglio R, Rahimtoola social history, Fasoli G, et al. Nifedipine in in the Hispanic population: a review of the available literature. asymptomatic patients with severe aortic regurgitation and normal Am J Cardiovasc Drugs. Am J Cardiovasc Drugs. 2012; 12: left ventricular function. N Engl J Med. 1994; 331: 68994. 16578. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e101 S10. 1-7. Sorlie peritoneal dialysis, Allison MA, Aviles-Santa ML, et al. Prevalence of S10. 1. 1-14. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: hypertension, awareness, treatment, and control in the Hispanic antihypertensive drug therapy in black patients. Ann Intern Med. Community Health Study/Study of Latinos. Am J Hypertens. 2004; 141: 61427. 2014; 27: 793800. S10. 1. 1-15. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups S10. 1-8. Rodriguez CJ, Allison M, Daviglus ML, et al. Status of cardioof hypertensive patients treated with regimens based on valsartan vascular disease and stroke in Hispanics/Latinos in the United and amlodipine: an analysis of findings from the VALUE trial. J States: a science advisory from the American Heart Association. Hypertens. 2006; 24: 21638. Circulation. 2014; 130: 593625. S10. 1. 1-16. Jamerson potassium, Weber MA, Bakris GL, et al. Benazepril plus S10. 1-9. Parsa A, Kao WHL, Xie D, et al. APOL1 risk variants, race, amlodipine or hydrochlorothiazide for hypertension in High-risk and progression of chronic Kidney disease. N Engl J Med. patients. N Engl J Med. 2008; 359: 241728. 2013; 369: 218396. S10. 1. 1-17. Woo KS, Nicholls magnesium. High prevalence of persistent cough with S10. 1-10. Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein angiotensin converting enzyme inhibitors in Chinese. Br J Clin L1 gene variants associate with hypertension-attributed nephropaPharmacol.",
    "word_count": 589,
    "char_count": 4028,
    "sentence_count": 117,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 145,
      "total_chunks": 166,
      "position": "146/166",
      "section": "Special Patient Groups on cardiovascular morbidity and mortality in hypertension:",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "magnesium",
        "angiotensin converting enzyme inhibitors",
        "antihypertensive",
        "dialysis",
        "peritoneal dialysis",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 146,
    "text": "Apolipoprotein angiotensin converting enzyme inhibitors in Chinese. Br J Clin L1 gene variants associate with hypertension-attributed nephropaPharmacol. 1995; 40: 1414. thy and the rate of Kidney function decline in African Americans. S10. 1. 1-18. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of Blood Kidney Int. 2013; 83: 11420. Hypertension reduction and of different Blood Hypertension-lowering S10. 1-11. Langefeld CD, Divers J, Pajewski NM, et al. Apolipoprotein L1 regimens on major cardiovascular events according to baseline gene variants associate with prevalent Kidney but not prevalent Blood Hypertension: meta-analysis of randomized trials. J Hypertens. cardiovascular disease in the Systolic Blood Hypertension Intervention 2011; 29: 416. Trial. Kidney Int. 2015; 87: 16975. S10. 1. 1-19. Fretheim A, Odgaard-Jensen J, Brors O, et al. Comparative effecS10. 1-12. Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 risk, and tiveness of antihypertensive medication for primary prevention of estimated glomerular filtration rate decline in the general population. J Am Soc Nephrol. cardiovascular disease: systematic review and multiple treatments 2016; 27: 284250. meta-analysis. BMC Med. 2012; 10: 33. S10. 1. 1-20. Jafar TH, Stark after meals, Schmid CH, et al. Progression of chronic kid10. 1. 1. Racial and Ethnic Differences in Treatment ney disease: the role of Blood Hypertension control, proteinuria, and S10. 1. 1-1. Leenen FHH, Nwachuku CE, Black heart rate, et al. Clinical events angiotensin-converting enzyme inhibition: a patient-level metain High-risk hypertensive patients randomly assigned to calcium analysis. Ann Intern Med. 2003; 139: 24452. channel blocker versus angiotensin-converting enzyme inhibitor S10. 1. 1-21. Law MR, Morris JK, Wald NJ. Use of Blood Hypertension lowerin the antihypertensive and lipid-lowering treatment to prevent ing drugs in the prevention of cardiovascular disease: metaHeart attack trial. Hypertension. 2006; 48: 37484. analysis of 147 randomised trials in the context of expectations S10. 1. 1-2. W right JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findfrom prospective epidemiological studies. BMJ. 2009; 338: ings revisited in the context of subsequent analyses, other trials, b1665. and meta-analyses. Arch Intern Med. 2009; 169: 83242. S10. 1. 1-3. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive 10. 2. Sex-Related Issues black and nonblack patients treated with chlorthalidone, amlodipS10. 2-1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and ine, and lisinopril. JAMA. 2005; 293: 1595608. stroke statistics2017 update: a report from the American Heart S10. 1. 1-4. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outAssociation. Circulation. 2017; 135: e146603. comes by race in hypertensive patients with and without the metaS10. 2-2. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertenbolic syndrome: Antihypertensive and Lipid-Lowering Treatment sive drug treatment on cardiovascular outcomes in women and to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. men. A meta-analysis of individual patient data from randomized, 2008; 168: 20717. controlled trials. The INDANA Investigators. Ann Intern Med. S10. 1. 1-5. ALLHAT Officers and Coordinators for the ALLHAT 1997; 126: 7617. Collaborative Research Group. Major outcomes in High-risk S10. 2-3. Turnbull F, Woodward M, Neal B, et al. Do men and women hypertensive patients randomized to angiotensin-converting respond differently to Blood Hypertension-lowering treatment? Results enzyme inhibitor or calcium channel blocker vs diuretic: The of prospectively designed overviews of randomized trials. Eur Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Heart J. 2008; 29: 266980. Attack Trial (ALLHAT). JAMA. 2002; 288: 298197. S10. 1. 1-6. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized 10. 2. 1. Women trial of intensive versus standard Blood-Hypertension control. SPRINT S10. 2. 1-1. Turnbull F, Woodward M, Neal B, et al. Do men and women Research Group.",
    "word_count": 599,
    "char_count": 4091,
    "sentence_count": 114,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 146,
      "total_chunks": 166,
      "position": "147/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "calcium",
        "angiotensin converting enzyme inhibitors",
        "antihypertensive",
        "cardiovascular disease"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 147,
    "text": "SPRINT S10. 2. 1-1. Turnbull F, Woodward M, Neal B, et al. Do men and women Research Group. N Engl J Med. 2015; 373: 210316. respond differently to Blood Hypertension-lowering treatment? Results S10. 1. 1-7. Wright JT Jr, Bakris G, Greene T, et al. Effect of Blood presof prospectively designed overviews of randomized trials. Eur sure lowering and antihypertensive drug class on progression of Heart J. 2008; 29: 266980. hypertensive Kidney disease: results from the AASK trial. JAMA. S10. 2. 1-2. Wenger NK, Ferdinand KC, Bairey Merz CN, et al. Women, 2002; 288: 242131. hypertension, and the Systolic Blood Hypertension Intervention Trial. S10. 1. 1-8. Odedosu T, Schoenthaler A, Vieira DL, et al. Overcoming barriers Am J Med. 2016; 129: 10306. to hypertension control in African Americans. Cleve Clin J Med. S10. 2. 1-3. Fletcher A, Beevers DG, Bulpitt C, et al. Beta adrenoceptor block2012; 79: 4656. ade is associated with increased survival in male but not female S10. 1. 1-9. Ferdinand KC. Management of Hypertension in African hypertensive patients: a report from the DHSS Hypertension Care Americans and the 2010 ISHIB consensus statement: meetComputing Project (DHCCP). J Hum Hypertens. 1988; 2: 21927. ing an unmet need. J Clin Hypertens (Greenwich). 2010; 12: S10. 2. 1-4. Jansen J, Bonner C, McKinn S, et al. General practitioners 2379. use of absolute risk versus individual risk factors in cardiovasS10. 1. 1-10. Flack JM, Sica DA, Bakris G, et al. Management of High Blood cular disease prevention: an experimental study. BMJ OPEN. Hypertension in blacks: an update of the International Society on 2014; 4: e004812. Hypertension in Blacks consensus statement. Hypertension. S10. 2. 1-5. Lewis CE, Grandits A, Flack J, et al. Efficacy and tolerance 2010; 56: 780800. of antihypertensive treatment in men and women with stage S10. 1. 1-11. Jamerson potassium, DeQuattro V. The impact of ethnicity on response to 1 diastolic hypertension. Results of the Treatment of Mild antihypertensive therapy. Am J Med. 1996; 101: 22S32. Hypertension Study. Arch Intern Med. 1996; 156: 37785. S10. 1. 1-12. Saunders E, Weir MR, Kong BW, et al. A comparison of the effiS10. 2. 1-6. Kloner RA, Sowers JR, DiBona GF, et al. Sexand age-related anticacy and safety of a beta-blocker, a calcium channel blocker, and hypertensive effects of amlodipine. The Amlodipine Cardiovascular a converting enzyme inhibitor in hypertensive blacks. Arch Intern Community Trial Study Group. Am J Cardiol. 1996; 77: 71322. Med. 1990; 150: 170713. S10. 2. 1-7. Igho Pemu P, Ofili E. Hypertension in women: part I. J Clin S10. 1. 1-13. Cushman WC, Reda DJ, Perry HM, et al. Regional and racial difHypertens (Greenwich). 2008; 10: 40610. ferences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United 10. 2. 2. Pregnancy States. Department of Veterans Affairs Cooperative Study Group S10. 2. 2-1. James PR, Nelson-Piercy C. Management of hypertension before, on Antihypertensive Agents. Arch Intern Med. 2000; 160: 82531. during, and after pregnancy. Heart. 2004; 90: 1499504. Downloaded from by on December 30, 2025 e102 Hypertension June 2018 S10. 2. 2-2. American College of Obstetricians and Gynecologists, Task S10. 3. 1-3. Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, Force on Hypertension in Pregnancy. Hypertension in pregMedicare charges, and nursing home admissions in the year when nancy. Report of the American College of Obstetricians and older persons become severely disabled. JAMA. 1997; 277: 72834. Gynecologists Task Force on Hypertension in Pregnancy. Obstet S10. 3. 1-4. den Ouden MEM, Schuurmans MJ, Mueller-Schotte S, et al. Do Gynecol. 2013; 122: 112231. subclinical vascular abnormalities precede impaired physical abilS10. 2. 2-3.",
    "word_count": 598,
    "char_count": 3815,
    "sentence_count": 121,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 147,
      "total_chunks": 166,
      "position": "148/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "calcium",
        "antihypertensive"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 148,
    "text": "Do Gynecol. 2013; 122: 112231. subclinical vascular abnormalities precede impaired physical abilS10. 2. 2-3. National Clinical Guideline Centre (UK). Hypertension: The ity and ADL disability? Exp Gerontol. 2014; 58: 17. Clinical Management of Primary Hypertension in Adults: Update S10. 3. 1-5. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk of Clinical Guidelines 18 and 34. London, UK: Royal College of factors and global and regional burden of disease. Lancet. Physicians (UK); 2011. 2002; 360: 134760. S10. 2. 2-4. Pucci M, Sarween N, Knox E, et al. Angiotensin-converting S10. 3. 1-6. Duprez DA. Systolic hypertension in the elderly: addressing an enzyme inhibitors and angiotensin receptor blockers in women unmet need. Am J Med. 2008; 121: 17984. e3. of childbearing age: risks versus benefits. Expert Rev Clin S10. 3. 1-7. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United Pharmacol. 2015; 8: 22131. States, 1999 to 2012: progress toward Healthy People 2020 goals. S10. 2. 2-5. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angioCirculation. 2014; 130: 16929. tensin converting enzyme inhibitors and angiotensin II receptor S10. 3. 1-8. Liu X, Rodriguez CJ, Wang potassium. Prevalence and trends of isolated blockers. Obstet Gynecol Int. 2012; 2012: 658310. systolic hypertension among untreated adults in the United States. S10. 2. 2-6. Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild J Am Soc Hypertens. 2015; 9: 197205. chronic hypertension during pregnancy: a review. Obstet S10. 3. 1-9. Prevention of stroke by antihypertensive drug treatment in older Gynecol. 2000; 96: 84960. persons with isolated systolic hypertension. Final results of the S10. 2. 2-7. Garovic VD, August P. Preeclampsia and the future risk of Systolic Hypertension in the Elderly Program (SHEP). SHEP hypertension: the pregnant evidence. Curr Hypertens Rep. Cooperative Research Group. JAMA. 1991; 265: 325564. 2013; 15: 11421. S10. 3. 1-10. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind S10. 2. 2-8. Kessous R, Shoham-Vardi I, Pariente G, et al. Long-term matercomparison of placebo and active treatment for older patients nal atherosclerotic morbidity in women with pre-eclampsia. with isolated systolic hypertension. The Systolic Hypertension in Heart. 2015; 101: 4426. Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350: 75764. S10. 2. 2-9. Veerbeek JHW, Hermes W, Breimer AY, et al. Cardiovascular disS10. 3. 1-11. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and ease risk factors after early-onset preeclampsia, late-onset preplacebo in older Chinese patients with isolated systolic hyperteneclampsia, and pregnancy-induced hypertension. Hypertension. sion. Systolic Hypertension in China (Syst-China) Collaborative 2015; 65: 6006. Group. J Hypertens. 1998; 16: 18239. S10. 2. 2-10. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy S10. 3. 1-12. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyperfor mild to moderate hypertension during pregnancy. Cochrane tension in patients 80 years of age or older. N Engl J Med. Database Syst Rev. 2014; 2: CD002252. 2008; 358: 188798. S10. 2. 2-11. Nabhan atrial fibrillation, Elsedawy MM. Tight control of mild-moderate preS10. 3. 1-13. Tinetti ME, Han L, Lee DSH, et al. Antihypertensive medications existing or non-proteinuric gestational hypertension. Cochrane and serious fall injuries in a nationally representative sample of Database Syst Rev. 2011: CD006907. older adults. JAMA Intern Med. 2014; 174: 58895. S10. 2. 2-12. Magee LA, Duley L. Oral beta-blockers for mild to moderate S10. 3. 1-14. Warwick J, Falaschetti E, Rockwood potassium, et al. No evidence that hypertension during pregnancy. Cochrane Database Syst Rev. frailty modifies the positive impact of antihypertensive treatment 2003: CD002863. in very elderly people: an investigation of the impact of frailty S10. 2. 2-13.",
    "word_count": 597,
    "char_count": 3934,
    "sentence_count": 140,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 148,
      "total_chunks": 166,
      "position": "149/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "angiotensin receptor blockers",
        "antihypertensive",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 149,
    "text": "in very elderly people: an investigation of the impact of frailty S10. 2. 2-13. Magee LA, von Dadelszen P, Rey E, et al. Less-tight verupon treatment effect in the HYpertension in the Very Elderly sus tight control of hypertension in pregnancy. N Engl J Med. Trial (HYVET) study, a double-blind, placebo-controlled study of 2015; 372: 40717. antihypertensives in people with hypertension aged 80 and over. S10. 2. 2-14. Duley L, Meher S, Jones L. Drugs for treatment of very High BMC Med. 2015; 13: 78. Blood Hypertension during pregnancy. Cochrane Database Syst Rev. S10. 3. 1-15. Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic 2013; 7: CD001449. hypotension, and the risk of falls in a community-dwelling elderly S10. 2. 2-15. Gulati M. Early identification of pregnant women at risk for population: the maintenance of balance, independent living, intelpreeclampsia: USPSTF recommendations on screening for prelect, and zest in the elderly of Boston study. J Am Geriatr Soc. eclampsia. JAMA Cardiol. 2017; 2: 5935. 2011; 59: 3839. S10. 2. 2-16. Henderson JT, Thompson JH, Burda BU, et al. Preeclampsia S10. 3. 1-16. Margolis KL, Palermo L, Vittinghoff E, et al. Intensive Blood screening: evidence report and systematic review for the ultrasound Hypertension control, falls, and fractures in patients with type 2 diabePreventive Services Task Force. JAMA. 2017; 317: 166883. tes: the ACCORD trial. J Gen Intern Med. 2014; 29: 1599606. S10. 2. 2-17. Regitz-Zagrosek V, Blomstrom LC, Borghi C, et al. ESC S10. 3. 1-17. Bavishi C, Bangalore S, Messerli family history. Outcomes of intensive Guidelines on the management of cardiovascular diseases during Blood Hypertension lowering in older hypertensive patients. J Am Coll pregnancy: the Task Force on the Management of Cardiovascular Cardiol. 2017; 69: 48693. Diseases during Pregnancy of the European Society of Cardiology S10. 3. 1-18. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations (ESC). Eur Heart J. 2011; 32: 314797. of a consensus panel for the screening, diagnosis, and treatment of S10. 2. 2-18. Committee on Obstetric Practice. Committee Opinion No. 623: neurogenic orthostatic hypotension and associated supine hyperEmergent therapy for acute-onset, severe hypertension durtension. J Neurol. 2017; 264: 156782. ing pregnancy and the postpartum period. Obstet Gynecol. 2015; 125: 5215. 10. 3. 2. Children and Adolescents S10. 2. 2-19. Shimada C, Akaishi R, Cho potassium, et al. Outcomes of 83 fetuses S10. 3. 2-1. Moser M, Roccella EJ. The treatment of hypertension: a remarkexposed to angiotensin receptor blockers during the secable success story. J Clin Hypertens (Greenwich). 2013; 15: 8891. ond or third trimesters: a literature review. Hypertens Res. S10. 3. 2-2. Integrated Guidelines for Cardiovascular Health and Risk Reduction 2015; 38: 30813. in Children and Adolescents: Summary Report. 2012; National Heart, Lung, and Blood Institute, U. S. Department of Health and Human 10. 3. Age-Related Issues Services: Bethesda, MD: S1S44; NIH Publication No. 127486. S10. 3. 2-3. Expert Panel on Integrated Guidelines for Cardiovascular Health 10. 3. 1. Older Persons and Risk Reduction in Children and Adolescents, National Heart, S10. 3. 1-1. Williamson JD, Supiano MA, Applegate WB, et al. Intensive Lung, and Blood Institute. Integrated guidelines for cardiovascuvs standard Blood Hypertension control and cardiovascular disease lar health and risk reduction in children and adolescents: summary outcomes in adults aged ≥75 years: a randomized clinical trial. report. Pediatrics. 2011; 128(suppl 5): S21356. JAMA. 2016; 315: 267382. S10. 3. 2-4. Chobanian AV, Bakris GL, Black heart rate, et al; the National High S10. 3. 1-2. Ettinger WH Jr, Fried LP, Harris T, et al. Self-reported causes Blood Hypertension Education Program Coordinating Committee.",
    "word_count": 588,
    "char_count": 3854,
    "sentence_count": 116,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 149,
      "total_chunks": 166,
      "position": "150/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "angiotensin receptor blockers",
        "cardiovascular disease",
        "screening"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 150,
    "text": "3. 1-2. Ettinger WH Jr, Fried LP, Harris T, et al. Self-reported causes Blood Hypertension Education Program Coordinating Committee. of physical disability in older people: the Cardiovascular Health Seventh Report of the Joint National Committee on Prevention, Study. CHS Collaborative Research Group. J Am Geriatr Soc. Detection, Evaluation, and Treatment of Hypertension. 1994; 42: 103544. Hypertension. 2003; 42: 120652. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e103 S10. 3. 2-5. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory 11. 2. Hypertensive CrisesEmergencies Blood Hypertension monitoring in children and adolescents: a scientific and Urgencies statement from the American Heart Association. Hypertension. 2014; 63: 111635. S11. 2-1. Farias S, Peacock WF, Gonzalez M, et al. Impact of initial Blood S10. 3. 2-6. OBrien E, Parati G, Stergiou G, et al. European Society of Hypertension on antihypertensive response in patients with acute hyperHypertension position paper on ambulatory Blood Hypertension monitension. Am J Emerg Med. 2014; 32: 8336. toring. J Hypertens. 2013; 31: 173168. S11. 2-2. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute S10. 3. 2-7. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice Heart failure: results of the A Study of Blood Hypertension Control guideline for screening and management of Hypertension in in Acute Heart FailureA Pilot Study (PRONTO). Am Heart J. children and adolescents. Pediatrics. 2017; 140: e20171904. 2014; 167: 52936. S11. 2-3. Papadopoulos DP, Sanidas EA, Viniou sodium, et al. Cardiovascular hypertensive emergencies. Curr Hypertens Rep. 2015; 17: 5. 11. Other Considerations S11. 2-4. Manning L, Robinson TG, Anderson CS. Control of Blood Hypertension in hypertensive neurological emergencies. Curr. Hypertens Rep. 11. 1. Resistant Hypertension 2014; 16: 436. S11. 2-5. Rhoney D, Peacock WF. Intravenous therapy for hypertensive S11. 1-1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagemergencies, part 1. Am J Health Syst Pharm. 2009; 66: 134352. nosis, evaluation, and treatment: a scientific statement from the S11. 2-6. Rhoney D, Peacock WF. Intravenous therapy for hypertenAmerican Heart Association Professional Education Committee sive emergencies, part 2. Am J Health Syst Pharm. 2009; 66: of the Council for Hypertension Research. Hypertension. 144857. 2008; 51: 140319. S11. 2-7. Keith NM, Wagener HP, Barker NW. Some different types of S11. 1-2. Persell SD. Prevalence of resistant hypertension in the United essential hypertension: their course and prognosis. Am J Med Sci. States, 20032008. Hypertension. 2011; 57: 107680. 1974; 268: 33645. S11. 1-3. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analyS11. 2-8. Perez myocardial infarction, Musini VM. Pharmacological interventions for hypertensis of the prevalence of resistant hypertension in treated hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens. sive populations. Am J Hypertens. 2015; 28: 35561. 2008; 22: 596607. S11. 1-4. Smith SM, Huo T, Delia Johnson B, et al. Cardiovascular and morS11. 2-9. Gifford RW Jr. Current practices in general medicine. 7. Treatment tality risk of apparent resistant hypertension in women with susof hypertensive emergencies including use of Sodium nitroprusside. pected myocardial ischemia: a report from the NHLBI-sponsored Proc Staff Meet Mayo Clin. 1959; 34: 38794. WISE Study. J Am Heart Assoc. 2014; 3: e000660. S11. 2-10. Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized S11. 1-5. Tanner RM, Calhoun DA, Bell EK, et al. Incident end-stage renal disease and comparative effectiveness trial of IV nicardipine versus labetalol treatment-resistant hypertension: the reasons for geographic and use in the emergency department. Crit Care. 2011; 15: R157. racial differences in stroke (REGARDS) study. Am J Kidney Dis. S11. 2-11. Cannon CM, Levy P, Baumann BM, et al.",
    "word_count": 594,
    "char_count": 3991,
    "sentence_count": 125,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 150,
      "total_chunks": 166,
      "position": "151/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "end-stage renal disease",
        "sodium",
        "antihypertensive",
        "heart failure",
        "screening",
        "monitoring",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 151,
    "text": "racial differences in stroke (REGARDS) study. Am J Kidney Dis. S11. 2-11. Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine 2014; 63: 7818. and labetalol use in hypertensive patients with signs or symptoms S11. 1-6. Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, suggestive of end-organ damage in the emergency department: a and outcomes in treatment-resistant hypertension in patients with subgroup analysis of the CLUE trial. BMJ OPEN. 2013; 3: e002338. coronary disease. Am J Med. 2014; 127: 7181. e1. S11. 2-12. Varon J, Soto-Ruiz KM, Baumann BM, et al. The management of S11. 1-7. Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertenacute hypertension in patients with renal dysfunction: labetalol or sion: determination of prevalence, risk factors, and comorbidinicardipine? Postgrad Med. 2014; 126: 12430. ties in a large, population-based cohort. Hypertension. 2014; 63: S11. 2-13. Anderson CS, Heeley E, Huang Y, et al. Rapid Blood-Hypertension 4518. lowering in patients with acute intracerebral hemorrhage. N Engl S11. 1-8. Rosa J, Widimsky P, Waldauf P, et al. Role of adding spironolacJ Med. 2013; 368: 235565. tone and renal denervation in true resistant hypertension: oneyear outcomes of randomized PRAGUE-15 Study. Hypertension. 11. 3. Cognitive Decline and Dementia 2016; 67: 397403. S11. 1-9. Bhatt DL, Kandzari DE, ONeill WW, et al. A controlled trial S11. 3-1. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of of renal denervation for resistant hypertension. N Engl J Med. isolated systolic hypertension on behavioral variables. Results from 2014; 370: 1393401. the systolic hypertension in the elderly program. Arch Intern Med. S11. 1-10. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activa1994; 154: 215460. tion therapy lowers Blood Hypertension in patients with resistant S11. 3-2. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in hypertension: results from the double-blind, randomized, plarandomised double-blind placebo-controlled Systolic Hypertension cebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011; 58: in Europe (Syst-Eur) trial. Lancet. 1998; 352: 134751. 76573. S11. 3-3. Forette F, Seux M-L, Staessen JA, et al. The prevention of dementia S11. 1-11. Stergiou GS, Makris T, Papavasiliou M, et al. Comparison of antiwith antihypertensive treatment: new evidence from the Systolic hypertensive effects of an angiotensin-converting enzyme inhibitor, Hypertension in Europe (Syst-Eur) study. Arch Intern Med. a calcium antagonist and a diuretic in patients with hypertension 2002; 162: 204652. not controlled by angiotensin receptor blocker monotherapy. S11. 3-4. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and J Hypertens. 2005; 23: 8839. Prognosis in the Elderly (SCOPE): principal results of a randomS11. 1-12. Liu G, Zheng XX, Xu YL, et al. Effect of aldosterone antagonists ized double-blind intervention trial. J Hypertens. 2003; 21: 87586. on Blood Hypertension in patients with resistant hypertension: a metaS11. 3-5. Tzourio C, Anderson C, Chapman N, et al. Effects of Blood presanalysis. J Hum Hypertens. 2015; 29: 15966. sure lowering with perindopril and indapamide therapy on demenS11. 1-13. Williams B, MacDonald TM, Morant S, et al. Spironolactone tia and cognitive decline in patients with cerebrovascular disease. versus placebo, bisoprolol, and doxazosin to determine the optiArch Intern Med. 2003; 163: 106975. mal treatment for drug-resistant hypertension (PATHWAY-2): S11. 3-6. Peters R, Beckett N, Forette F, et al. Incident dementia and Blood a randomised, double-blind, crossover trial. Lancet. 2015; 386: Hypertension lowering in the Hypertension in the Very Elderly Trial 205968. cognitive function assessment (HYVET-COG): a double-blind, S11. 1-14. Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and placebo controlled trial. Lancet Neurol. 2008; 7: 6839. doxazosin treatment in patients with resistant hypertension. Rev S11. 3-7.",
    "word_count": 597,
    "char_count": 4015,
    "sentence_count": 102,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 151,
      "total_chunks": 166,
      "position": "152/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "calcium",
        "antihypertensive"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 152,
    "text": "Spironolactone and placebo controlled trial. Lancet Neurol. 2008; 7: 6839. doxazosin treatment in patients with resistant hypertension. Rev S11. 3-7. Prince M, Wimo A, Guerchet M, et al. World Alzheimer Esp Cardiol. 2009; 62: 15866. Report 2015: The Global Impact of Dementia: An Analysis of S11. 1-15. Dahal potassium, Kunwar S, Rijal J, et al. The effects of aldosterone Prevalence, Incidence, Cost and Trends. 2015; Alzheimers Disease antagonists in patients with resistant hypertension: a meta-analyInternational: London, UK: 1027. sis of randomized and nonrandomized studies. Am J Hypertens. S11. 3-8. Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following 2015; 28: 137685. a diagnosis of Alzheimer disease. Arch Neurol. 2002; 59: 17647. S11. 1-16. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amloS11. 3-9. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of dipine on renal outcomes in hypertensive nephrosclerosis: a ranBlood Hypertension to cognitive function and dementia. Lancet Neurol. domized controlled trial. JAMA. 2001; 285: 271928. 2005; 4: 48799. Downloaded from by on December 30, 2025 e104 Hypertension June 2018 S11. 3-10. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk 11. 5. Patients Undergoing Surgical Procedures factors and late-life mild cognitive impairment: a population-based S11. 5-1. Lindenauer PK, Pekow P, Wang potassium, et al. Perioperative beta-blocker study. Neurology. 2001; 56: 16839. therapy and mortality after major noncardiac surgery. N Engl J S11. 3-11. Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular Med. 2005; 353: 34961. dementia in the Cardiovascular Health Cognition Study. Neurology. S11. 5-2. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker 2005; 64: 154852. withdrawal and mortality in vascular surgical patients. Am Heart J. S11. 3-12. Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral 2001; 141: 14853. white matter lesions and hypertension, its treatment, and its conS11. 5-3. Wallace AW, Au S, Cason BA. Association of the pattern of trol. The ARIC Study. Atherosclerosis Risk in Communities Study. use of perioperative β-blockade and postoperative mortality. Stroke. 1996; 27: 226270. Anesthesiology. 2010; 113: 794805. S11. 3-13. Longstreth weight Jr, Manolio TA, Arnold A, et al. Clinical correlates S11. 5-4. Andersson C, Merie C, Jorgensen M, et al. Association of of white matter findings on cranial magnetic resonance imaging β-blocker therapy with risks of adverse cardiovascular events and of 3301 elderly people. The Cardiovascular Health Study. Stroke. deaths in patients with ischemic Heart disease undergoing noncar1996; 27: 127482. diac surgery: a Danish nationwide cohort study. JAMA Intern Med. S11. 3-14. ORourke MF, Safar ME. Relationship between aortic stiffening 2014; 174: 33644. and microvascular disease in brain and Kidney: cause and logic of S11. 5-5. Hoeks SE, Scholte OpReimer WJM, van Urk H, et al. Increase therapy. Hypertension. 2005; 46: 2004. of 1-year mortality after perioperative beta-blocker withdrawal in S11. 3-15. Skoog I. A review on Blood Hypertension and ischaemic white matter endovascular and vascular surgery patients. Eur J Vasc Endovasc lesions. Dement Geriatr Cogn Disord. 1998; 9(suppl 1): 139. Surg. 2007; 33: 139. S11. 3-16. Hughes TM, Sink KM. Hypertension and its role in cognitive S11. 5-6. Barrett TW, Mori M, De Boer D. Association of ambulatory use of function: current evidence and challenges for the future. Am J statins and beta-blockers with long-term mortality after vascular Hypertens. 2016; 29: 14957. surgery. J Hosp Med. 2007; 2: 24152. S11. 3-17. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind S11. 5-7. London MJ, Hur potassium, Schwartz GG, et al.",
    "word_count": 579,
    "char_count": 3796,
    "sentence_count": 110,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 152,
      "total_chunks": 166,
      "position": "153/166",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "statins"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 153,
    "text": "Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind S11. 5-7. London MJ, Hur potassium, Schwartz GG, et al. Association of perioperacomparison of placebo and active treatment for older patients tive β-blockade with mortality and cardiovascular morbidity folwith isolated systolic hypertension. The Systolic Hypertension in lowing major noncardiac surgery. JAMA. 2013; 309: 170413. Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350: 75764. S11. 5-8. Turan A, You J, Shiba A, et al. Angiotensin converting enzyme S11. 3-18. Czernichow S, Ninomiya T, Huxley R, et al. Impact of Blood presinhibitors are not associated with respiratory complications or morsure lowering on cardiovascular outcomes in normal weight, overtality after noncardiac surgery. Anesth Analg. 2012; 114: 55260. weight, and obese individuals: the Perindopril Protection Against S11. 5-9. Rosenman DJ, McDonald FS, Ebbert JO, et al. Clinical conseRecurrent Stroke Study trial. Hypertension. 2010; 55: 11938. quences of withholding versus administering renin-angiotensinS11. 3-19. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing aldosterone system antagonists in the preoperative period. J Hosp stroke: double blind randomised trial. BMJ. 2002; 324: 699702. Med. 2008; 3: 31925. S11. 3-20. Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function S11. 5-10. Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus conand brain structure in persons with type 2 Diabetes mellitus after tinuing angiotensin-converting enzyme inhibitors or angiotensin intensive lowering of Blood Hypertension and lipid levels: a randomized II receptor blockers before noncardiac surgery: an analysis of the clinical trial. JAMA Intern Med. 2014; 174: 32433. Vascular events In noncardiac Surgery patIents cOhort evaluatioN S11. 3-21. Anderson C, Teo potassium, Gao P, et al. Renin-angiotensin system blockProspective Cohort. Anesthesiology. 2017; 126: 1627. ade and cognitive function in patients at High risk of cardiovascular S11. 5-11. Fleisher LA. Preoperative evaluation of the patient with hypertendisease: analysis of data from the ONTARGET and TRANSCEND sion. JAMA. 2002; 287: 20436. studies. Lancet Neurol. 2011; 10: 4353. S11. 5-12. Howell SJ, Sear JW, Foex P. Hypertension, hypertensive S11. 3-22. Diener H-C, Sacco RL, Yusuf S, et al. Effects of aspirin plus Heart disease and perioperative cardiac risk. Br J Anaesth. extended-release dipyridamole versus clopidogrel and telmisartan 2004; 92: 57083. on disability and cognitive function after recurrent stroke in patients S11. 5-13. Hart GR, Anderson RJ. Withdrawal syndromes and the cessawith ischaemic stroke in the Prevention Regimen for Effectively tion of antihypertensive therapy. Arch Intern Med. 1981; 141: Avoiding Second Strokes (PRoFESS) trial: a double-blind, active 11257. and placebo-controlled study. Lancet Neurol. 2008; 7: 87584. S11. 5-14. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery 11. 4. Sexual Dysfunction and Hypertension (POISE trial): a randomised controlled trial. POISE Study Group. S11. 4-1. Nunes KP, Labazi H, Webb RC. New insights into hypertensionLancet. 2008; 371: 183947. associated erectile dysfunction. Curr Opin Nephrol Hypertens. S11. 5-15. Charlson ME, MacKenzie creatinine, Gold JP, et al. The preoperative and 2012; 21: 16370. intraoperative hemodynamic predictors of postoperative myocarS11. 4-2. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dial infarction or ischemia in patients undergoing noncardiac surdysfunction in men 40 to 69 years old: longitudinal results from the gery. Ann Surg. 1989; 210: 63748. Massachusetts male aging study. J Urol. 2000; 163: 4603. S11. 5-16. Cheung AT. Exploring an optimum intra/postoperative manageS11. 4-3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase ment strategy for acute hypertension in the cardiac surgery patient. in erectile dysfunction between 1995 and 2025 and some possible J Card Surg. 2006; 21(suppl 1): S814. policy consequences. BJU Int. 1999; 84: 506. S11. 5-17.",
    "word_count": 597,
    "char_count": 4134,
    "sentence_count": 109,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 153,
      "total_chunks": 166,
      "position": "154/166",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "creatinine",
        "potassium",
        "antihypertensive"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 154,
    "text": "2006; 21(suppl 1): S814. policy consequences. BJU Int. 1999; 84: 506. S11. 5-17. Dix P, Howell S. Survey of cancellation rate of hypertensive S11. 4-4. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dyspatients undergoing anaesthesia and elective surgery. Br J Anaesth. function and subsequent cardiovascular disease. JAMA. 2001; 86: 78993. 2005; 294: 29963002. S11. 5-18. Haas CE, LeBlanc JM. Acute postoperative hypertension: a S11. 4-5. Shin D, Pregenzer G Jr, Gardin JM. Erectile dysfunction: a disease review of therapeutic options. Am J Health Syst Pharm. 2004; 61: marker for cardiovascular disease. Cardiol Rev. 2011; 19: 511. 166173. S11. 4-6. Martin SA, Atlantis E, Lange potassium, et al. Predictors of sexual dysS11. 5-19. Aronson S, Dyke CM, Stierer ketoanalogue, et al. The ECLIPSE trials: comfunction incidence and remission in men. J Sex Med. 2014; 11: parative studies of clevidipine to nitroglycerin, Sodium nitroprus113647. side, and nicardipine for acute hypertension treatment in cardiac S11. 4-7. Vasquez EC, Gava AL, Graceli JB, et al. Novel therapeutic tarsurgery patients. Anesth Analg. 2008; 107: 111021. gets for phosphodiesterase 5 inhibitors: current state-of-the-art S11. 5-20. Espinosa A, Ripolles-Melchor J, Casans-Frances R, et al. on systemic arterial hypertension and atherosclerosis. Curr Pharm Perioperative use of clevidipine: a systematic review and metaBiotechnol. 2016; 17: 34764. analysis. PLoS ONE. 2016; 11: e0150625. S11. 4-8. Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in S11. 5-21. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/ essential hypertension. Curr Hypertens Rep. 2008; 10: 527. AHA guideline on perioperative cardiovascular evaluation and S11. 4-9. Al Khaja KAJ, Sequeira RP, Alkhaja AK, et al. Antihypertensive management of patients undergoing noncardiac surgery: execudrugs and male sexual dysfunction: a review of adult hypertentive summary: a report of the American College of Cardiology/ sion guideline recommendations. J Cardiovasc Pharmacol Ther. American Heart Association Task Force on Practice Guidelines. 2016; 21: 23344. Circulation. 2014; 130: 221545. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e105 S11. 5-22. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF S12. 1. 1-10. Berra E, Azizi M, Capron A, et al. Evaluation of adherence secondary prevention and risk reduction therapy for patients should become an integral part of assessment of patients with with coronary and other atherosclerotic vascular disease: 2011 apparently treatment-resistant hypertension. Hypertension. update: a guideline from the American Heart Association and 2016; 68: 297306. American College of Cardiology Foundation. Circulation. S12. 1. 1-11. Gwadry-Sridhar family history, Manias E, Lal L, et al. Impact of interven2011; 124: 245873. tions on medication adherence and Blood Hypertension control in S11. 5-23. The sixth report of the Joint National Committee on prevention, patients with essential hypertension: a systematic review by the detection, evaluation, and treatment of Hypertension. Arch ISPOR medication adherence and persistence special interest Intern Med. 1997; 157: 241346. group. Value Health. 2013; 16: 86371. S11. 5-24. Wolfsthal SD. Is Blood Hypertension control necessary before surgery? S12. 1. 1-12. Petrilla AA, Benner JS, Battleman DS, et al. Evidence-based Med Clin North Am. 1993; 77: 34963. interventions to improve patient compliance with antihyS11. 5-25. Goldman L, Caldera DL. Risks of general anesthesia and elecpertensive and lipid-lowering medications. Int J Clin Pract. tive operation in the hypertensive patient. Anesthesiology. 2005; 59: 144151. 1979; 50: 28592. S12. 1. 1-13. Brown MT, Bussell JK. Medication adherence: WHO cares? S11. 5-26. Towne JB, Bernhard VM. The relationship of postoperative Mayo Clin Proc. 2011; 86: 30414. hypertension to complications following carotid endarterectomy. S12. 1. 1-14. Krousel-Wood MA, Muntner P, Islam T, et al. Barriers to and Surgery.",
    "word_count": 591,
    "char_count": 4067,
    "sentence_count": 121,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 154,
      "total_chunks": 166,
      "position": "155/166",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "sodium",
        "potassium",
        "antihypertensive",
        "cardiovascular disease",
        "adherence",
        "guideline"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 155,
    "text": "S12. 1. 1-14. Krousel-Wood MA, Muntner P, Islam T, et al. Barriers to and Surgery. 1980; 88: 57580. determinants of medication adherence in hypertension manageS11. 5-27. Aronson S, Boisvert D, Lapp W. Isolated systolic hyperment: perspective of the cohort study of medication adherence tension is associated with adverse outcomes from coroamong older adults. Med Clin North Am. 2009; 93: 75369. nary artery bypass grafting surgery. Anesth Analg. 2002; 94: S12. 1. 1-15. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for 107984. enhancing medication adherence. Cochrane Database Syst Rev. S11. 5-28. Foex P, Meloche R, Prys-Roberts C. Studies of anaesthesia in rela2014; 11: CD000011. tion to hypertension. 3. Pulmonary gas exchange during spontaneS12. 1. 1-16. Viswanathan M, Golin CE, Jones CD, et al. Closing the quality ous ventilation. Br J Anaesth. 1971; 43: 64461. gap: revisiting the state of the science (vol. 4: medication adherS11. 5-29. Gerber JG, Nies AS. Abrupt withdrawal of cardiovascular drugs. ence interventions: comparative effectiveness). Evid RepTechnol N Engl J Med. 1979; 301: 12345. Assess (Full Rep). 2012: 1685. S11. 5-30. Rangno RE, Langlois S. Comparison of withdrawal phenomS12. 1. 1-17. Kim MT, Hill membranous nephropathy, Bone LR, et al. Development and testing of ena after propranolol, metoprolol, and pindolol. Am Heart J. the Hill-Bone Compliance to Hypertension Therapy Scale. 1982; 104: 4738. Prog Cardiovasc Nurs. 2000; 15: 906. S11. 5-31. Walker PR, Marshall AJ, Farr S, et al. Abrupt withdrawal of atenolol in patients with severe angina. Comparison with the effects of 12. 1. 2. Strategies to Promote Lifestyle Modification treatment. Br Heart J. 1985; 53: 27682. S12. 1. 2-1. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from 12. Strategies to Improve Hypertension the American Heart Association. Circulation. 2010; 122: 40641. Treatment and Control S12. 1. 2-2. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of 12. 1. Adherence Strategies for Treatment the American College of Cardiology/American Heart Association of Hypertension Task Force on Practice Guidelines. Circulation. 2014; 129(suppl 2): S7699. 12. 1. 1. Antihypertensive Medication Adherence Strategies S12. 1. 1-1. Claxton AJ, Cramer J, Pierce C. A systematic review of the asso12. 1. 3. Improving Quality of Care for Resourceciations between dose regimens and medication compliance. Clin Constrained Populations Ther. 2001; 23: 1296310. S12. 1. 3-1. Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk S12. 1. 1-2. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship and outcomes for cardiovascular disease: a scientific statement from between daily dose frequency and adherence to antihypertenthe American Heart Association. Circulation. 2015; 132: 87398. sive pharmacotherapy: evidence from a meta-analysis. Clin Ther. S12. 1. 3-2. Institute of Medicine (U. S. ) Committee on Public Health Priorities 2002; 24: 30216. to Reduce and Control Hypertension. A Population-Based S12. 1. 1-3. Schroeder potassium, Fahey T, Ebrahim S. How can we improve adherPolicy and Systems Change Approach to Prevent and Control ence to Blood Hypertension-lowering medication in ambulatory care? Hypertension. 2010; National Academies Press: Washington, DC. Systematic review of randomized controlled trials. Arch Intern S12. 1. 3-3. Margolius D, Bodenheimer T, Bennett H, et al. Health coaching to Med. 2004; 164: 72232. improve hypertension treatment in a Low-income, minority popuS12. 1. 1-4. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose comlation. Ann Fam Med. 2012; 10: 199205. binations improve medication compliance: a meta-analysis. Am J S12. 1. 3-4. Polgreen LA, Han J, Carter BL, et al. Cost-effectiveness of a Med.",
    "word_count": 597,
    "char_count": 3995,
    "sentence_count": 128,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 155,
      "total_chunks": 166,
      "position": "156/166",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "nephropathy",
        "potassium",
        "antihypertensive",
        "cardiovascular disease",
        "physical activity",
        "adherence",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 156,
    "text": "Am J S12. 1. 3-4. Polgreen LA, Han J, Carter BL, et al. Cost-effectiveness of a Med. 2007; 120: 7139. physician-pharmacist collaboration intervention to improve Blood S12. 1. 1-5. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effecHypertension control. Hypertension. 2015; 66: 114551. tiveness of fixed-dose combinations of antihypertensive agents: a S12. 1. 3-5. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness meta-analysis. Hypertension. 2010; 55: 399407. of community health workers in the care of people with hypertenS12. 1. 1-6. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivasion. Am J Prev Med. 2007; 32: 43547. lent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 12. 2. Structured, Team-Based Care Interventions 2011; 13: 898909. for Hypertension Control S12. 1. 1-7. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill S12. 2-1. Carter BL, Rogers M, Daly J, et al. The potency of team-based vs. free combination antihypertensives. Curr Med Res Opin. care interventions for hypertension: a meta-analysis. Arch Intern 2010; 26: 206576. Med. 2009; 169: 174855. S12. 1. 1-8. Franklin SS, Thijs L, Hansen TW, et al. Significance of whiteS12. 2-2. Clark CE, Smith LFP, Taylor RS, et al. Nurse led interventions to coat hypertension in older persons with isolated systolic hyperimprove control of Blood Hypertension in people with hypertension: tension: a meta-analysis using the International Database systematic review and meta-analysis. BMJ. 2010; 341: c3995. on Ambulatory Blood Hypertension Monitoring in Relation to S12. 2-3. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved Cardiovascular Outcomes population. Hypertension. 2012; 59: Blood Hypertension control: a community guide systematic review. Am 56471. J Prev Med. 2014; 47: 8699. S12. 1. 1-9. Holland N, Segraves D, Nnadi VO, et al. Identifying barriers to S12. 2-4. Santschi V, Chiolero A, Colosimo AL, et al. Improving Blood preshypertension care: implications for quality improvement initiasure control through pharmacist interventions: a meta-analysis of tives. Dis Manag. 2008; 11: 7177. randomized controlled trials. J Am Heart Assoc. 2014; 3: e000718. Downloaded from by on December 30, 2025 e106 Hypertension June 2018 S12. 2-5. Shaw RJ, McDuffie JR, Hendrix CC, et al. Effects of nurse-manS12. 3. 2-5. Burke Blood, Ma J, Azar KMJ, et al. Current science on consumer aged protocols in the outpatient management of adults with chronic use of mobile health for cardiovascular disease prevention: a scienconditions: a systematic review and meta-analysis. Ann Intern tific statement from the American Heart Association. Circulation. Med. 2014; 161: 11321. 2015; 132: 1157213. S12. 2-6. Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change S12. 3. 2-6. Li JS, Barnett TA, Goodman E, et al. Approaches to the prevention it: a community-based, multifaceted intervention to improve and management of childhood obesity: the role of social networks Blood Hypertension control. Circ Cardiovasc Qual Outcomes. 2014; 7: and the use of social media and related electronic technolo82834. gies: a scientific statement from the American Heart Association. S12. 2-7. Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of Circulation. 2013; 127: 2607. a physician/pharmacist collaborative model to improve Blood presS12. 3. 2-7. Omboni S, Ferrari R. The role of telemedicine in hypertension mansure control. Circ Cardiovasc Qual Outcomes. 2015; 8: 23543. agement: focus on Blood Hypertension telemonitoring. Curr Hypertens S12. 2-8. Himmelfarb CRD, Commodore-Mensah Y, Hill membranous nephropathy. Expanding Rep. 2015; 17: 535. the role of nurses to improve hypertension care and control globally. Ann Glob Health. 2016; 82: 24353. 12. 4. Improving Quality of Care for Patients S12. 2-9.",
    "word_count": 597,
    "char_count": 3967,
    "sentence_count": 115,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 156,
      "total_chunks": 166,
      "position": "157/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "nephropathy",
        "antihypertensive",
        "cardiovascular disease",
        "adherence",
        "monitoring"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 157,
    "text": "Ann Glob Health. 2016; 82: 24353. 12. 4. Improving Quality of Care for Patients S12. 2-9. The Guide to Community Preventive Services (The Community With Hypertension Guide). Cardiovascular Disease: Team-Based Care to Improve Blood Hypertension Control. 2012. Available at: Performance Measures munityguide. org/findings/cardiovascular-disease-team-based-careS12. 4. 1-1. Svetkey LP, Pollak KI, Yancy WS Jr, et al. Hypertension improvement improve-Blood-Hypertension-control. Accessed June 1, 2017. project: randomized trial of quality improvement for physicians and S12. 2-10. Centers for Disease Control and Prevention. Task Force recomlifestyle modification for patients. Hypertension. 2009; 54: 122633. mends team-based care for improving Blood Hypertension control. Press S12. 4. 1-2. de Lusignan S, Gallagher H, Jones S, et al. Audit-based educaRelease. May 15, 2012. Available at: tion lowers systolic Blood Hypertension in chronic Kidney disease: the releases/2012/p0515_bp_control. html. Accessed September 17, Quality Improvement in chronic kidney disease (QICKD) trial results. Kidney Int. 2017. 2013; 84: 60920. S12. 2-11. Tsuyuki RT, Al Hamarneh YN, Jones calcium, et al. The effectiveness S12. 4. 1-3. Jaffe magnesium, Lee GA, Young JD, et al. Improved Blood Hypertension conof pharmacist interventions on cardiovascular risk: The Multicenter trol associated with a large-scale hypertension program. JAMA. Randomized Controlled RxEACH Trial. J Am Coll Cardiol. 2013; 310: 699705. 2016; 67: 284654. S12. 4. 1-4. Performance Management and Measurement. U. S. Department S12. 2-12. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of of Health and Human Services, Health Resources and Services community health workers in the care of people with hypertension. Administration; 2011. Available at: Am J Prev Med. 2007; 32: 43547. default/files/quality/toolbox/508pdfs/performancemanagementand S12. 2-13. Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health measurement. pdf. Accessed October 30, 2017. policy statement on cardiovascular team-based care and the role S12. 4. 1-5. Bardach NS, Wang JJ, De Leon SF, et al. Effect of pay-for-perof advanced practice providers. J Am Coll Cardiol. 2015; 65: formance incentives on quality of care in small practices with electronic 211836. health records: a randomized trial. JAMA. 2013; 310: 10519. S12. 2-14. Patient-Centered Primary Care Collaborative. The PatientS12. 4. 1-6. Navar-Boggan AM, Shah BR, Boggan JC, et al. Variability in perCentered Medical Home: Integrating Comprehensive Medication formance measures for assessment of hypertension control. Am Management to Optimize Patient Outcomes: Resource Guide. Heart J. 2013; 165: 8237. 2010. Available at: S12. 4. 1-7. D rozda J Jr, Messer JV, Spertus J, et al. ACCF/AHA/AMA-PCPI 2011 medmanagement. pdf. Accessed June 15, 2017. performance measures for adults with coronary artery disease and hyperS12. 2-15. Dunn SP, Birtcher KK, Beavers CJ, et al. The role of the clinical tension: a report of the American College of Cardiology Foundation/ pharmacist in the care of patients with cardiovascular disease. J Am American Heart Association Task Force on Performance Measures Coll Cardiol. 2015; 66: 212939. and the American Medical Association-Physician Consortium for Performance Improvement. Circulation. 2011; 124: 24870. 12. 3. Health Information TechnologyBased S12. 4. 1-8. Powers BJ, Olsen MK, Smith VA, et al. Measuring Blood Hypertension Strategies to Promote Hypertension Control for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011; 154: 7818; W-28990. 12. 3. 1. EHR and Patient Registries S12. 4. 1-9. Bonow RO, Douglas PS, Buxton AE, et al. ACCF/AHA methodS12. 3. 1-1. Rakotz MK, Ewigman BG, Sarav M, et al. A technology-based ology for the development of quality measures for cardiovascuquality innovation to identify undiagnosed hypertension among lar technology: a report of the American College of Cardiology active primary care patients. Ann Fam Med. 2014; 12: 3528. Foundation/American Heart Association Task Force on Performance S12. 3. 1-2. Borden WB, Maddox TM, Tang F, et al.",
    "word_count": 598,
    "char_count": 4165,
    "sentence_count": 122,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 157,
      "total_chunks": 166,
      "position": "158/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "calcium",
        "magnesium",
        "cardiovascular disease"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 158,
    "text": "Foundation/American Heart Association Task Force on Performance S12. 3. 1-2. Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 expert Measures. Circulation. 2011; 124: 1483502. panel recommendations for management of Hypertension on contemporary cardiovascular practice: insights from the NCDR 12. 4. 2. Quality Improvement Strategies PINNACLE registry. J Am Coll Cardiol. 2014; 64: 2196203. S12. 4. 2-1. Walsh JME, McDonald KM, Shojania KG, et al. Quality improveS12. 3. 1-3. Jaffe magnesium, Lee GA, Young JD, et al. Improved Blood Hypertension conment strategies for hypertension management: a systematic review. trol associated with a large-scale hypertension program. JAMA. Med Care. 2006; 44: 64657. 2013; 310: 699705. S12. 4. 2-2. Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 12. 3. 2. Telehealth Interventions to Improve 2009; 169: 174855. Hypertension Control S12. 4. 2-3. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to S12. 3. 2-1. Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness improve control of Blood Hypertension in patients with hypertension. and cost effectiveness of home Blood Hypertension telemonitoring: Cochrane Database Syst Rev. 2010: CD005182. meta-analysis of randomized controlled studies. J Hypertens. S12. 4. 2-4. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved 2013; 31: 45567; discussion 4678. Blood Hypertension control: a community guide systematic review. Am S12. 3. 2-2. Verberk WJ, Kessels AGH, Thien T. Telecare is a valuable tool for J Prev Med. 2014; 47: 8699. hypertension management, a systematic review and meta-analysis. S12. 4. 2-5. Anchala R, Pinto MP, Shroufi A, et al. The role of Decision Support Blood Press Monit. 2011; 16: 14955. System (DSS) in prevention of cardiovascular disease: a systematic S12. 3. 2-3. Agarwal R, Bills JE, Hecht TJW, et al. Role of home Blood presreview and meta-analysis. PLoS ONE. 2012; 7: e47064. sure monitoring in overcoming therapeutic inertia and improvS12. 4. 2-6. Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: ing hypertension control: a systematic review and meta-analysis. a community-based, multifaceted intervention to improve Blood Hypertension. 2011; 57: 2938. Hypertension control. Circ Cardiovasc Qual Outcomes. 2014; 7: 82834. S12. 3. 2-4. Liu S, Dunford SD, Leung YW, et al. Reducing Blood Hypertension S12. 4. 2-7. Jaffe magnesium, Lee GA, Young JD, et al. Improved Blood Hypertension conwith Internet-based interventions: a meta-analysis. Can J Cardiol. trol associated with a large-scale hypertension program. JAMA. 2013; 29: 61321. 2013; 310: 699705. Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e107 S12. 4. 2-8. Agarwal R, Bills JE, Hecht TJW, et al. Role of home Blood presS13-2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary sure monitoring in overcoming therapeutic inertia and improvprevention and risk reduction therapy for patients with coronary and ing hypertension control: a systematic review and meta-analysis. other atherosclerotic vascular disease: 2011 update: a guideline from Hypertension. 2011; 57: 2938. the American Heart Association and American College of Cardiology S12. 4. 2-9. Go AS, Bauman MA, Coleman King SM, et al. An effective Foundation. Circulation. 2011; 124: 245873. approach to Hypertension control: a science advisory S13-3. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/ from the American Heart Association, the American College of PCNA/SCAI/STS focused update of the guideline for the diagnosis and Cardiology, and the Centers for Disease Control and Prevention. management of patients with stable ischemic Heart disease: a report Hypertension. 2014; 63: 87885. of the American College of Cardiology/American Heart Association S12. 4. 2-10. Walsh J, McDonald KM, Shojania KG, et al.",
    "word_count": 599,
    "char_count": 3963,
    "sentence_count": 119,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 158,
      "total_chunks": 166,
      "position": "159/166",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "magnesium",
        "cardiovascular disease",
        "monitoring",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 159,
    "text": "4. 2-10. Walsh J, McDonald KM, Shojania KG, et al. Closing the Quality Task Force on Practice Guidelines, and the American Association Gap: A Critical Analysis of Quality Improvement Strategies (Vol. for Thoracic Surgery, Preventive Cardiovascular Nurses Association, 3: Hypertension Care). Rockville, MD: Agency for Healthcare Society for Cardiovascular Angiography and Interventions, and Research and Quality (U. S. ); 2005. Society of Thoracic Surgeons. Circulation. 2014; 130: 174967. S12. 4. 2-11. Center for Medicare and Medicaid Services. Million Hearts: S13-4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ Cardiovascular Disease Risk Reduction Model. 2016. Available at: PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic Heart disease: a report of the American Accessed October 30, 2017. College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of 12. 5. Financial Incentives Physicians, American Association for Thoracic Surgery, Preventive S12. 5-1. Hysong SJ, Simpson potassium, Pietz potassium, et al. Financial incentives and Cardiovascular Nurses Association, Society for Cardiovascular physician commitment to guideline-recommended hypertension Angiography and Interventions, and Society of Thoracic Surgeons. management. Am J Manag Care. 2012; 18: e37891. Circulation. 2012; 126: e354471. S12. 5-2. Petersen LA, Simpson potassium, Pietz potassium, et al. Effects of individual phyS13-5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline sician-level and practice-level financial incentives on hypertension for the management of Heart failure: a report of the American College care: a randomized trial. JAMA. 2013; 310: 104250. of Cardiology Foundation/American Heart Association Task Force on S12. 5-3. Karunaratne potassium, Stevens P, Irving J, et al. The impact of pay for perforPractice Guidelines. Circulation. 2013; 128: e240327. mance on the control of Blood Hypertension in people with chronic Kidney S13-6. Standards of Medical Care in Diabetes2016: Summary of Revisions. disease stage 35. Nephrol Dial Transplant. 2013; 28: 210716. Diabetes Care. 2016; 39(suppl 1): S45. S12. 5-4. Maimaris W, Paty J, Perel P, et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic 15. Evidence Gaps and Future Directions literature review. PLoS Med. 2013; 10: e1001490. S15-1. Moser M, Brown CM, Rose CH, et al. Hypertension in pregnancy: S12. 5-5. Center for Medicare and Medicaid Services. Million Hearts: is it time for a new approach to treatment? J Hypertens. 2012; 30: Cardiovascular Disease Risk Reduction Model. 2016. Available at: 1092100. Accessed October 30, 2017. Key Words: AHA Scientific Statements ambulatory care antihypertensive 13. The Plan of Care for Hypertension agents behavior modification Blood Hypertension chronic Kidney disease Diabetes hypertension hypertension emergency lifestyle measures S13-1. Jaffe magnesium, Young JD. The Kaiser Permanente Northern California measurement nonpharmacologic treatment resistant hypertension story: improving hypertension control from 44% to 90% in 13 years risk reduction secondary hypertension systems of care treatment (2000 to 2013). J Clin Hypertens (Greenwich). 2016; 18: 2601. adherence treatment outcomes Downloaded from by on December 30, 2025 e108 Hypertension June 2018 Appendix 1. Author Relationships With Industry and Other Entities (Relevant)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of Hypertension in Adults (October 2017) Institutional, Ownership/ Organizational, Speakers Partnership/ Personal or Other Expert Committee Member Employment Consultant Bureau Principal Research Financial Benefit Witness Salary Paul potassium.",
    "word_count": 529,
    "char_count": 3877,
    "sentence_count": 74,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 159,
      "total_chunks": 166,
      "position": "160/166",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "magnesium",
        "antihypertensive",
        "cardiovascular disease",
        "heart failure",
        "adherence",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 160,
    "text": "Whelton, Chair Tulane University School of Hygiene and None None None None None None None Tropical MedicineShow Chwan Professor of Global Public Health Robert M. Carey, Vice University of Virginia School of Medicine None None None Daiichi None None None Chair Dean, Emeritus, and Professor of Medicine Sankyo Inc Wilbert S. Aronow Westchester Medical Center and New York None None None None None None None Medical CollegeProfessor of Medicine Donald E. Casey, Jr Thomas Jefferson College of Population None None None None None None None HealthAdjunct Faculty; Alvarez Marsal Ipo4healthPrincipal and Founder Karen J. Collins Collins CollaborationPresident None None None None None None None Cheryl Dennison John Hopkins UniversityProfessor of None None None None None None None Himmelfarb Nursing and Medicine, Institute for Clinical and Translational Research Sondra M. DePalma PinnacleHealth CardioVascular Institute None None None None None None None Physician Assistant; American Academy of PAsDirector, Regulatory and Professional Practice Samuel Gidding Alfred I. Dupont Hospital for Children None None None None None None None Chief, Division of Pediatric Cardiology, Nemours Cardiac Center David C. Goff, Jr Colorado School of Public Health None None None None None None None Professor and Dean, Department of Epidemiology Kenneth A. Jamerson University of Michigan Health System None None None None None None None Professor of Internal Medicine and Frederick G. L. Huetwell Collegiate Professor of Cardiovascular Medicine Daniel W. Jones University of Mississippi Medical Center None None None None None None None Professor of Medicine and Physiology; Metabolic Diseases and Nutrition University Sanderson Chair in Obesity Mississippi Center for Obesity Research Director, Clinical and Population Science Eric J. MacLaughlin Texas Tech University Health Sciences None None None None None None None CenterProfessor and Chair, Department of Pharmacy Practice, School of Pharmacy Paul Muntner University of Alabama at Birmingham None None None None None None None Professor, Department of Epidemiology Bruce Ovbiagele Medical University of South CarolinaPihl None Boehringer None None None None None Professor and Chairman of Neurology Ingelheim Korea Ltd Sidney C. Smith, Jr University of North Carolina at Chapel None None None None None None None HillProfessor of Medicine; Center for Cardiovascular Science and Medicine Director Crystal C. Spencer Spencer Law, PAAttorney at Law None None None None None None None (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e109 Appendix 1. Continued Institutional, Ownership/ Organizational, Speakers Partnership/ Personal or Other Expert Committee Member Employment Consultant Bureau Principal Research Financial Benefit Witness Salary Randall S. Stafford Stanford Prevention Research Center None None None None None None None Professor of Medicine; Program on Prevention OutcomesDirector Sandra J. Taler Mayo ClinicProfessor of Medicine, None None None None None None None College of Medicine Randal J. Thomas Mayo ClinicMedical Director, Cardiac None None None None None None None Rehabilitation Program Kim A. Williams, Sr Rush University Medical CenterJames B. None None None None None None None Herrick Professor; Division of Cardiology Chief Jeff D. Williamson Wake Forest Baptist Medical Center None None None None None None None Professor of Internal Medicine; Section on Gerontology and Geriatric MedicineChief Jackson T. Wright, Jr Case Western Reserve University None Amgen None None None None None Professor of Medicine; William T. Dahms MD Clinical Research UnitProgram Director; University Hospitals Case Medical CenterDirector, Clinical Hypertension Program This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process.",
    "word_count": 591,
    "char_count": 4103,
    "sentence_count": 4,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 160,
      "total_chunks": 166,
      "position": "161/166",
      "content_type": "reference",
      "content_type_confidence": 3,
      "medical_entities": [
        "nutrition",
        "guideline"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 161,
    "text": "The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the persons gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the persons household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. We gratefully acknowledge the contributions of Dr. Lawrence Appel, who served as a member of the Writing Committee from November 2014 to September 2015. Dr. David C. Goff resigned from the writing committee in December 2016 because of a change in employment before the recommendations were balloted. The writing committee thanks him for his contributions, which were extremely beneficial to the development of the draft. Significant relationship. AAPA indicates American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; NMA, National Medical Association; and PCNA, Preventive Cardiovascular Nurses Association. Downloaded from by on December 30, 2025 e110 Hypertension June 2018 Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of Hypertension in Adults (October 2017) Institutional, Ownership/ Organizational, or Partnership/ Other Financial Reviewer Representation Employment Consultant Speakers Bureau Principal Personal Research Benefit Expert Witness Salary Kim potassium.",
    "word_count": 384,
    "char_count": 2662,
    "sentence_count": 12,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 161,
      "total_chunks": 166,
      "position": "162/166",
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "medical_entities": [
        "potassium",
        "guideline"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 162,
    "text": "Official University of Houston Jones Bartlett None None None Accreditation None Walgreens Birtcher Reviewer College of Pharmacy Learning Council for Clinical TFPG Lead Clinical Professor, Lipidology Reviewer Department of Pharmacy Practice and Translational Research Roger Official Johns Hopkins None None None None None None None Blumenthal Reviewer HospitalKenneth Prevention Jay Pollin Professor of Subcommittee Cardiology; Ciccarone Center for the Prevention of Heart DiseaseDirector Anna Official University of None None None None None None None Dominiczak Reviewer GlasgowRegius AHA Professor of Medicine; Vice-Principal and Head of College of Medical, Veterinary and Life Sciences Carlos M. Official Wake Forest School of None None None None None None None Ferrario Reviewer MedicineProfessor, AHA of Physiology and Pharmacology; Hypertension and Vascular Disease CenterDirector Eugene Official University of RubiconMD None None Amgen Inc. None Third party, None Yang Reviewer Washington School of Regeneron Gilead Sciences, coronary artery disease, 2016 ACC-BOG MedicineAssociate Inc. (DSMB) Clinical Professor of Medicine; UW Medicine Eastside Specialty CenterMedical Director Robert Jay Organizational Massachusetts General None None None None None Defendant, None Amrien Reviewer HospitalClinical aortic AAPA Physician Assistant, dissection, Chelsea Health Center; 2016 Bryant University Physician Assistant Program Greg Organizational Montana Department None None None None American None None Holzman Reviewer of Public Health and Academy of Family ACPM Human Services Medicine State Medical Officer American College of Preventive Medicine Martha Organizational University of None None None None REATA (spouse) None None Gulati Reviewer Arizona College of ASPC MedicineProfessor of Medicine; Chief, Division of Cardiology; University Medicine Cardiovascular Institute in Phoenix Physician Executive Director, Banner Wallace Organizational University of Maryland None None None Amgen None None None Johnson Reviewer Medical Center NMA Assistant Professor of Medicine Nancy Organizational The Lifecare Moving Analytics None None None None None None Houston Reviewer CompanyAssociate Miller PCNA Director (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e111 Appendix 2. Continued Institutional, Ownership/ Organizational, or Partnership/ Other Financial Reviewer Representation Employment Consultant Speakers Bureau Principal Personal Research Benefit Expert Witness Salary Aldo J. Organizational Yale University Lundbeck Inc. None None Bayer Healthcare Bayer Healthcare None None Peixoto Reviewer School of Medicine Pharmaceuticals Pharmaceuticals ASH Professor of Medicine (Nephrology); Associate Chair for Ambulatory Services Operations and Quality, Department of Internal Medicine; Clinical Chief, Section of Nephrology Carlos Organizational Wake Forest Amgen Inc. None None None None None None Rodriguez Reviewer UniversityProfessor, ABC Epidemiology and Prevention Joseph Organizational University of Colorado None None None None National Lipid Defendant, None Saseen Reviewer Anschutz Medical Association statin use, APhA CampusVice-Chair, 2016 Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences Mark Organizational University of Utah School None None None None American None None Supiano Reviewer of MedicineD. Keith Geriatrics Society AGS Barnes, MD, and Dottie Division Chief Barnes Presidential McGraw-Hill Endowed Chair in Medical Medicine; Chief, Division of Geriatrics; VA Salt Lake City Geriatric ResearchDirector, Education, and Clinical Center; University of Utah Center on Aging ExecutiveDirector Sana M. Content Duke Clinical Research None None None AHRQ Elsevier Third party, None Al-Khatib Reviewer InstituteProfessor of FDA NIH, NHLBI implantable ACC/AHA Medicine PCORI cardioverter Task Force VA Health System defibrillators, on Clinical (DSMB) 2017 Practice Guidelines George Content University of Chicago None None None AbbVie, Inc. None None None Bakris Reviewer MedicineProfessor Janssen, Bayer, of Medicine; Director, Relypsa Hypertensive Diseases Unit Jan Basile Content Medical University None Amgen Inc. None Eli Lilly and None None None Reviewer of South Carolina Arbor Company Professor of Medicine, Janssen NHLBI Seinsheimer Pharmaceuticals, Cardiovascular Health Inc Program; Ralph H Johnson VA Medical CenterInternist Joshua A.",
    "word_count": 590,
    "char_count": 4473,
    "sentence_count": 4,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 162,
      "total_chunks": 166,
      "position": "163/166",
      "content_type": "reference",
      "content_type_confidence": 3,
      "medical_entities": [
        "guideline"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 163,
    "text": "Content Vanderbilt University AstraZeneca None EMX Bristol Myers Vascular None 2015 Defendant; Beckman Reviewer Medical Center: Merck JanaCare Squibb Interventional Venous ACC/AHA Director, Cardiovascular SANOFI Advances thromboembolism Task Force Fellowship Program, on Clinical Practice Guidelines John Content University of Rochester CVRx None None CVRx None None None Bisognano Reviewer Medical Center NIH Cardiologist Biykem Content Baylor College of None None None Novartis None None None Bozkurt Reviewer MedicineMedical Corporation ACC/AHA Care Line Executive, Task Force on Cardiology Chief, Gordon Clinical Practice Cain Chair, Professor of Guidelines Medicine, Debakey (Continued ) Downloaded from by on December 30, 2025 e112 Hypertension June 2018 Appendix 2. Continued Institutional, Ownership/ Organizational, or Partnership/ Other Financial Reviewer Representation Employment Consultant Speakers Bureau Principal Personal Research Benefit Expert Witness Salary David Content University of Alabama, Novartis None None MEDTRONIC None None None Calhoun Reviewer Birmingham School of Valencia ReCor Medical MedicineProfessor, Technologies Department of Cardiovascular Disease Joaquin E. Content Oregon Health and None None None NIH ACC/AHA Taskforce Defendant, None Cigarroa Reviewer Science University on Clinical Practice coronary artery disease, 2011 ACC/AHA Clinical Professor of Guidelines Defendant, Task Force Medicine AHA, Board of sudden death/ on Clinical Directors, Western coronary artery disease, 2010 Practice Affiliate Guidelines American Stroke Association, Cryptogenic Stroke Initiative Advisory Committee Catheterization and Cardiovascular Intervention SCAI Quality Interventional Council William Content Memphis VA Medical None None None Lilly Novartis None None Cushman Reviewer CenterChief, Corporation Preventive Medicine Takeda Section; University of Tennessee College of MedicineProfessor, Medicine, Preventive Medicine, and Physiology Anita Content Baylor College of None None None NIH Aurora Health None None Deswal Reviewer Medicine Associate Care Inc. ACC/AHA Professor of Medicine American Heart Task Force Association on Clinical AHA Committee on Practice Heart Failure and Guidelines Transplantation Chair Heart Failure Society of America Dave Dixon Content Virginia Commonwealth None None None None None None None Reviewer University School of Cardiovascular PharmacyAssociate Team Professor Ross Content Winnipeg Regional GSK None None None None None None Feldman Reviewer Health Authority Servier Medical Director, Cardiac Valeant Sciences Program; Pharmaceuticals University of Manitoba International Professor of Medicine Keith Content Tulane University Amgen Inc. None None None Novartis None None Ferdinand Reviewer School of Medicine Boehringer Professor of Clinical Ingelheim Medicine Eli Lilly Sanofi-Aventis Novartis Quantum Genomics Sanofi-Aventis Stephan Content University of None None None None University of None None Fihn Reviewer WashingtonProfessor Washington of Medicine, Heath Services; Division Head, General Internal Medicine; Director, Office of Analytics and Business Intelligence for the Veterans Health Administration; VA Puget Sound Health Care SystemGeneral Internist (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e113 Appendix 2.",
    "word_count": 436,
    "char_count": 3369,
    "sentence_count": 2,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 163,
      "total_chunks": 166,
      "position": "164/166",
      "content_type": "reference",
      "content_type_confidence": 2,
      "medical_entities": [
        "cardiovascular disease",
        "heart failure",
        "guideline"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 164,
    "text": "Continued Institutional, Ownership/ Organizational, or Partnership/ Other Financial Reviewer Representation Employment Consultant Speakers Bureau Principal Personal Research Benefit Expert Witness Salary Lawrence Content National Heart, None None None None NIH None None Fine Reviewer Lung and Blood InstituteChief, Clinical Applications and Prevention Branch, Division of Prevention and Population Sciences John Flack Content Southern Illinois Regeneron None None Bayer Healthcare American Journal None None Reviewer University School of NuSirt Pharmaceuticals of Hypertension MedicineChair and GSK CardioRenal Professor Department Medicine of Internal Medicine; International Chief, Hypertension Journal of Specialty Services Hypertension Southern Illinois University Department of Medicine Joseph Content Seattle Childrens Ultragenyx, Inc. None None None UpToDate, None None Flynn Reviewer HospitalChief (DSMB) Springer of the Division of Nephrology; University of Washington School of MedicineProfessor of Pediatrics Federico Content Centro Cardiologico None None None None None None None Gentile Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Joel Content Kaiser Permanente None None None None None None None Handler Reviewer Physician; National Kaiser Permanente HypertensionClinical Leader Hani Jneid Content Baylor College of None None None None None None None Reviewer MedicineAssociate ACC/AHA Professor of Medicine, Task Force on MEDVAMC Clinical Data Standards José A. Content UT Southwestern None None None None None None None Joglar Reviewer Medical Center ACC/AHA Professor of Task Force Internal Medicine; on Clinical Cardiovascular Clinical Practice Research Center Guidelines Director Amit Khera Content University of Texas None None None None None None None Reviewer Southwestern Medical CenterAssistant Professor of Medicine Glenn N. Content Baylor College of None None None None None Defendant, None Levine Reviewer MedicineProfessor catheterization ACC/AHA of Medicine; Director, laboratory Task Force Cardiac Care Unit procedure, on Clinical 2016 Practice Defendant, Guidelines interpretation of ECG of a patient, 2014 Defendant, interpretation of angiogram (non-ACS), 2014 Defendant, out-of-hospital death, 2016 (Continued ) Downloaded from by on December 30, 2025 e114 Hypertension June 2018 Appendix 2. Continued Institutional, Ownership/ Organizational, or Partnership/ Other Financial Reviewer Representation Employment Consultant Speakers Bureau Principal Personal Research Benefit Expert Witness Salary Giuseppe Content University of Milan- Boehringer None None None Novartis None None Mancia Reviewer BicoccaProfessor of Ingelheim Medicine; Chairman, CVRx Department of Ferrer Clinical Medicine, MEDTRONIC Prevention and Applied Menarini Biotechnologies International Recordati Servier International Actavis Andrew Content Cardiovascular None None None Novartis Bristol-Myers None None Miller Reviewer Associates Corporation Squibb Company Geriatric Cardiologist Pfizer Inc Janssen Cardiology Pharmaceuticals, Section Inc. NIH Pamela Content Seinsheimer Amgen Inc. None None Amgen Inc. None None None Morris Reviewer Cardiovascular AstraZeneca Prevention Health Program Sanofi Regeneron Council, Chair Director; Womens Heart CareMedical University of South Carolina Co-Director Martin Content Sunnybrook Health Ideal Life Inc None None None None None None Myers Reviewer Sciences Centre Affiliate Scientist; University of Toronto Professor, Cardiology Rick Content Mayo Clinic College None None None None None None None Nishimura Reviewer of MedicineJudd and Mary Morris Leighton Professor of Medicine; Mayo ClinicDivision of Cardiovascular Diseases Patrick T. Content Harvard Medical None None None None MEDTRONIC None None OGara Reviewer SchoolProfessor NIH ACC/AHA of Medicine; Brigham Task Force and Womens on Clinical HospitalDirector, Practice Strategic Planning, Guidelines Cardiovascular Division Suzanne Content University of Alabama Actelion None None AstraZeneca (Duke NIH/NHLBI, None None Oparil Reviewer at Birmingham Lundbeck University) Takeda WHF/ Distinguished Professor Novo Nordisk, Inc. Bayer Healthcare ESH/EPH of Medicine; Professor Pharmaceuticals, of Cell, Developmental Inc. and Integrative Biology, Novartis Division of Cardiology NIH Carl Pepine Content Shands Hospital at None None None Capricor, Inc. None None None ReviewerCV University of Florida NIH Disease Professor of Medicine, Cytori in Women Chief of Cardiovascular Therapeutics, Inc. Committee Medicine Sanofi-Aventis InVentive Health Clinical.",
    "word_count": 590,
    "char_count": 4576,
    "sentence_count": 3,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 164,
      "total_chunks": 166,
      "position": "165/166",
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "medical_entities": [],
      "entity_count": 0
    }
  },
  {
    "chunk_id": 165,
    "text": "LLC Mahboob Content Case Western Reserve None None None None None None None Rahman Reviewer University School of MedicineProfessor of Medicine Vankata Content UT Southwestern None None None None None None None Ram Reviewer Medical Center; Apollo Institute for Blood Hypertension Clinics Barbara Content University of None None None Co-Investigator- Novartis Corp None None Riegel Reviewer Pennsylvania School of mentor ACC/AHA NursingProfessor Co-investigator NIH Task Force on NIH grant Clinical Practice PCORI Guidelines (Continued ) Downloaded from by on December 30, 2025 Whelton et al 2017 Hypertension Clinical Practice Guideline e115 Appendix 2. Continued Institutional, Ownership/ Organizational, or Partnership/ Other Financial Reviewer Representation Employment Consultant Speakers Bureau Principal Personal Research Benefit Expert Witness Salary Edward Content National Heart, Lung, Medical None None None American Society None None Roccella Reviewer and Blood Institute University of of Hypertension Coordinator, National South Carolina Consortium Hypertension for Southeast Education Program Hypertension Control Consortium Southeast Hypertension Control Inter American Society of Hypertension Ernesto Content Jewish General Novartis Novartis None Servier CME Medical None None Schiffrin Reviewer HospitalPhysician- Servier Canadian Institutes Grand Rounds in-Chief, Chief of for Health the Department of Research Medicine and Director of the Cardiovascular Prevention Centre; McGill University Professor, Department of Medicine, Division of Experimental Medicine Raymond Content University of MEDTRONIC None None NIH American Society of Nephrology None None Townsend Reviewer Pennsylvania School of UpToDate MedicineProfessor of Medicine; Director, Hypertension Section, Department of Internal Medicine/ Renal; Institute for Translational Medicine and Therapeutics Member Michael Content SUNY Downstate Ablative Menarini None None None None None Weber Reviewer College of Medicine Solutions Merck Co. , Inc. Professor of Medicine Allergan, Inc Astellas Pharma ultrasound Boston Scientific Eli Lilly and Company MEDTRONIC Novartis Recor This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥5 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the persons gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. Significant relationship. No financial benefit. AHRQ indicates Agency for Healthcare Research and Quality; AAPA, American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; BOG, Board of Governors; CME, continuing medical education; DSMB, Data and Safety Monitoring Board; FDA, ultrasound Food and Drug Administration; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NMA, National Medical Association; PCNA, Preventive Cardiovascular Nurses Association; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiovascular Angiography and Interventions; SUNY, State University of New York; TFPG, Task Force on Practice Guidelines; and UT, University of Texas. Downloaded from by on December 30, 2025",
    "word_count": 587,
    "char_count": 4273,
    "sentence_count": 13,
    "metadata": {
      "source_file": "whelton-et-al-2017-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection.pdf",
      "extraction_date": "2025-12-31T14:51:41.505167",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2017",
      "keywords": [],
      "chunk_index": 165,
      "total_chunks": 166,
      "position": "166/166",
      "content_type": "reference",
      "content_type_confidence": 3,
      "medical_entities": [
        "monitoring",
        "guideline"
      ],
      "entity_count": 2
    }
  }
]